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Iron has various functions in the body, including the metabolism of oxygen in a 
variety of biochemical processes. Iron, as either heme or in its “nonheme” form, 
plays an important role in key reactions of DNA synthesis and energy production. 
However, low solubility of iron in body fluids and the ability to form toxic hydroxyl 
radicals in presence of oxygen make iron uptake, use and storage a serious challenge. 
The discovery of new metal transporters, receptors and peptides and as well as the 
discovery of new cross-interactions between known proteins are now leading to a 
breakthrough in the understanding of systemic iron metabolism. The objective of this 
book is to review and summarize recent developments in our understanding of iron 
transport and storage in living systems.
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Preface 
Iron is the most abundant element on earth representing nearly 90% of the mass in the 
earth’s core, yet only trace elements are present in living cells. Most of the iron in the
body is located within the porphyrin ring of heme, which is incorporated into proteins 
such as hemoglobin, myoglobin, cytochromes, catalases and peroxidases. Although 
iron appears in a variety of oxidation states, in particular as hexavalent ferrate, the
ferrous and ferric forms are of most importance. The transition from ferrous to ferric 
iron and vice versa occurs readily, meaning that Fe(II) acts as a reducing agent and
Fe(III) as an oxidant. Iron is closely involved with the metabolism of oxygen in a
variety of biochemical processes. Iron, as either heme or in its “nonheme” form, plays 
an important role in cell growth and metabolism because of its involvement in key 
reactions of DNA synthesis and energy production.  
However, low solubility of iron in body fluids and the ability to form toxic hydroxyl
radicals in presence of oxygen make iron uptake, use and storage a serious challenge.
Iron metabolism in complex organisms involves two levels of regulation. The lower 
level is cellular and comprises the mechanisms of cellular uptake and storage as well
as the intracellular use of iron in enzymes. In this regard, two principles effectively
control iron uptake, the use of cell surface receptors for iron-containing proteins or 
direct iron import by metal transporters. This aspect has been studied in detail during
the last three decades with a special focus on the mechanisms and regulation of 
receptor-mediated cellular iron uptake and storage. In contrast, the knowledge about
the upper level of iron metabolism, the systemic level, was inadequate up to the end of 
the last century. This involves various unsolved questions pertaining to the regulation 
of intestinal iron uptake, various signalling pathways involved in the iron demand of 
individual cells and how these signals are transmitted to the iron stores and the 
intestine. The discovery of new metal transporters, receptors and peptides and as well 
as the discovery of new cross-interactions between known proteins are now leading to 
a breakthrough in the understanding of systemic iron metabolism. The objective of this
book is to review and summarize recent developments in our understanding of iron 
transport and storage in living systems and how iron metabolism may be affected in 
anemias associated with chronic diseases and hemodialysis patients. It begins with a 
focus on normal systemic iron metabolism in humans focusing on the role of various 
iron containing proteins and the mechanisms involved in iron absorption and
utilization. It then progresses to a detailed review on Cellular Iron metabolism with a 
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special focus on the IRP/IRE regulatory network. One of the major roles of iron is in 
erythropoiesis which has been appropriately covered in one of the chapters. Though 
the emphasis is on human iron metabolism in physiological and pathological states, 
further knowledge is derived from the chapter on iron metabolism in pathogenic 
trypanosomes. These parasites have developed distinct strategies to scavenge 
efficiently iron from the surrounding medium and support their metabolic needs, 
which differ between trypanosomatid species and life stages.  
This book provides knowledge about iron metabolism and related diseases in 6 
coordinated Chapters which can also be read as stand-alone. The new and essential 
path breaking insights into iron metabolism have been addressed in this book. 
Together with the efforts of experienced and committed authors who spent their time 
and fundamentally contributed to the success of this book, I hope that a number of 
readers will enjoy the review Chapters and find a lot of information to develop new 
ideas in this rapidly ongoing field of investigation.  
 
Dr Sarika Arora 
Department of Biochemistry 
ESI Postgraduate Institute of Medical Sciences & Research 
Basaidarapur, New Delhi 
India 
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Iron Metabolism in Humans:  
An Overview 
Sarika Arora and Raj Kumar Kapoor 
Department of Biochemistry, ESI Postgraduate Institute of Medical Sciences, 
Basaidarapur, New Delhi,  
India 
1. Introduction 
Iron is the most abundant element on earth, yet only trace elements are present in living 
cells. The four major reasons leading to limited availability of iron in living cells despite 
environmental abundance would be: 
1. When iron was available some 10 billion years ago, it was available as Fe (II), but Fe (II) 
is not a very strong Lewis acid. Thus, it does not bind strongly to most small molecules 
or activate them strongly toward reaction. 
2. Today iron is not readily available from sea or water solutions due to oxidation and 
hydrolysis. 
3. Iron in ferrous state is not easily retained by proteins since it does not bind very 
strongly to them. 
4. Free Fe (II) is mutagenic, especially in the presence of dioxygen. 
To overcome, the above problems with availability of iron, specific ligands have evolved for 
its transport and storage because of its limited solubility at near neutral pH under aerobic 
conditions [1]. 
Iron is involved in many enzymatic reactions of a cell; hence it is believed that the presence 
of iron was obligatory for the evolution of aerobic life on earth. Furthermore, the propensity 
of iron to catalyze the oxygen radicals in aerobic and facultative anaerobic species indicates 
that the intracellular concentration and chemical form of the element must be kept under 
tight control. 
2. Overview of iron metabolism  
2.1 Oxidation states 
The common oxidation states are either ferrous (Fe2+) or ferric (Fe3+); higher oxidation levels 
occur as short-lived intermediates in certain redox processes. Iron has affinity for 
electronegative atoms such as oxygen, nitrogen and sulfur, which provide the electrons that 
form the bond with iron, hence these atoms are found at the heart of the iron-binding 
centers of macromolecules. When favorably oriented on the macromolecules, these anions 
can bind iron with high affinity.  During formation of complexes, no bonding electrons are 
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derived from iron. The non bonding electrons in the outer shell of iron (the incompletely 
filled 3d orbitals) can exist in two states. When bonding interactions with iron are weak, the 
outer non-bonding electrons will avoid pairing and distribute throughout the 3d orbitals. 
When bonding electrons interact strongly with iron, there will be pairing of the outer non-
bonding electrons, favoring lower energy 3d orbitals. These two different distributions for 
each oxidation state of iron can be determined by electron spin resonance measurements. 
Dispersion of 3d electrons to all orbitals leads to the high-spin state, whereas restriction of 3d 
electrons to lower energy orbitals, because of electron pairing, leads to a low-spin state.    
3. Distribution and function 
The total body iron in an adult male is 3000 to 4000 mg. In contrast, the average adult 
woman has only 2000-3000 mg of iron in her body. This difference may be attributed to 
much smaller iron reserves in women, lower concentration of hemoglobin and a smaller 
vascular volume than men. 
Iron is distributed in six compartments in the body. 
i. Hemoglobin   
Iron is a key functional component of this oxygen transporting molecule. About 65% to 70% 
total body iron is found in heme group of hemoglobin. A heme group consists of iron (Fe2+) 
ion held in a heterocyclic ring, known as aporphyrin. This porphyrin ring consists of four 
pyrrole molecules cyclically linked together (by methene bridges) with the iron ion bound in 
the center [Figure 1] [2]. The nitrogen atoms of the pyrrole molecules form coordinate 
covalent bonds with four of the iron's six available positions which all lie in one plane. The 
iron is bound strongly (covalently) to the globular protein via the imidazole ring of the 
F8 histidine residue (also known as the proximal histidine) below the porphyrin ring. A 
sixth position can reversibly bind oxygen by a coordinate covalent bond, completing the  
 
Fig. 1. Structure of heme showing the four coordinate bonds between ferrous ion and four 
nitrogen bases of the porphyrin rings. 
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octahedral group of six ligands [Figure 2]. This site is empty in the nonoxygenated forms of 
hemoglobin and myoglobin. Oxygen binds in an "end-on bent" geometry where one oxygen 
atom binds Fe and the other protrudes at an angle. When oxygen is not bound, a very 
weakly bonded water molecule fills the site, forming a distorted octahedron. 
 
Fig. 2. Structure of heme showing the square planar tetrapyrrole along with the proximal 
and the distal histidine. 
Even though carbon dioxide is also carried by hemoglobin, it does not compete with oxygen 
for the iron-binding positions, but is actually bound to the protein chains of the structure. 
The iron ion may be either in the Fe2+ or in the Fe3+ state, but ferrihemoglobin also called 
methemoglobin (Fe3+) cannot bind oxygen [3]. In binding, oxygen temporarily and 
reversibly oxidizes (Fe2+) to (Fe3+) while oxygen temporarily turns into superoxide, thus iron 
must exist in the +2 oxidation state to bind oxygen. If superoxide ion associated to Fe3+ is 
protonated the hemoglobin iron will remain oxidized and incapable to bind oxygen. In such 
cases, the enzyme methemoglobin reductase will be able to eventually reactivate 
methemoglobin by reducing the iron center. 
ii. Storage Iron- Ferritin and Hemosiderin 
Ferritin is the major protein involved in the storage of iron. The protein consists of an outer 
polypeptide shell (also termed apoferritin) composed of 24 symmetrically placed protein 
chains (subunits), the average outside diameter is approximately 12.0 nm in hydrated state. 
The inner core (approximately 6.0 nm) contains an electron-dense and chemically inert 
inorganic ferric “iron-core” made of ferric oxyhydroxyhydroxide phosphate 
[(FeOOH)8(FeO-OPO3H2)]. [Figure 3]. The ferritins are extremely large proteins (450kDa)  
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Fig. 3. Structure of ferritin showing the outer polypeptide shell with inner iron-core 
containing iron stored as mineral –ferric oxyhydroxyhydroxide phosphate 
[(FeOOH)8 (FeO-OPO3H2)]. 
which can store upto 4500 iron atoms as hydrous ferric oxide. The ratio of iron to 
polypeptide is not constant, since the protein has the ability to gain and release iron 
according to physiological needs. Channels from the surface permit the accumulation and 
release of iron. All iron-containing organisms including bacteria, plants, vertebrates and 
invertebrates have ferritin [4,5].  
Ferritin from humans, horses, pigs and rats and mice consists of two different types of 
subunits- H subunit (heavy; 178 amino acids) and L (Light, 171 amino acids) that provide 
various isoprotein forms. H subunits predominate in nucleated blood cells and heart. L –
subunits in liver and spleen.  H-rich ferritins take up iron faster than L-rich in –vitro and 
may function more in iron detoxification than in storage [6]. Synthesis of the subunits is 
regulated mainly by the concentration of free intracellular iron. The bulk of the iron storage 
occurs in hepatocytes, reticuloendothelial cells and skeletal muscle. When iron is in excess, 
the storage capacity of newly synthesized apoferritin may be exceeded. This leads to iron 
deposition adjacent to ferritin spheres. This amorphous deposition of iron is called 
hemosiderin and the clinical condition is termed as hemosiderosis. 
Multiple genes encode the ferritin proteins, at least in animals, which are expressed in a cell-
specific manner. All cells synthesize ferritin at some point in the cell cycle, though the 
amount may vary depending on the role of the cell in iron storage, i.e housekeeping for 
intracellular use or specialized for use by other cells. 
Expression of ferroportin (FPN) results in export of cytosolic iron and ferritin degradation. 
FPN-mediated iron loss from ferritin occurs in the cytosol and precedes ferritin degradation 
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by the proteasome. Depletion of ferritin iron induces the monoubiquitination of ferritin 
subunits. Ubiquitination is not required for iron release but is required for disassembly of 
ferritin nanocages, which is followed by degradation of ferritin by the proteasome [7]. 
iii. Myoglobin 
Myoglobin is an iron- and oxygen-binding protein found in the muscle tissue of vertebrates 
in general and in almost all mammals. It is a single-chain globular protein of 153 or 
154 amino acids [8,9], containing a heme prosthetic group in the center around which the 
remaining apoprotein folds. It has eight alpha helices and a hydrophobic core. It has a 
molecular weight of 17,699 daltons (with heme), and is the primary oxygen-carrying 
pigment of muscle tissues [9]. Unlike the blood-borne hemoglobin, to which it is structurally 
related [10], this protein does not exhibit cooperative binding of oxygen, since positive 
cooperativity is a property of   multimeric /oligomeric proteins only. Instead, the binding of 
oxygen by myoglobin is unaffected by the oxygen pressure in the surrounding tissue. 
Myoglobin is often cited as having an "instant binding tenacity" to oxygen given its 
hyperbolic oxygen dissociation curve [Figure 4]. 
 
Fig. 4. Iron dissociation curve of hemoglobin and myoglobin. 
iv. Transport Iron- Transferrin 
Transferrin is a protein involved in the transport of iron. The transferrins are glycoproteins 
with molecular weight of approximately 80, 000 Da, consisting of a single polypeptide chain 
of 680 to 700 amino acids and no subunits. The transferrins consist of two non cooperative 
iron- binding lobes of approximately equal size. Each lobe is an ellipsoid of approximate 
dimensions 55 x35 x 35Aº and contains a metal binding site buried below the surface of the 
protein in a hydrophilic environment [Figure 5]. The two binding sites are separated by 42 
Aº [11].  There is approximately 40% identity in the amino acid sequence between the two  
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hyperbolic oxygen dissociation curve [Figure 4]. 
 
Fig. 4. Iron dissociation curve of hemoglobin and myoglobin. 
iv. Transport Iron- Transferrin 
Transferrin is a protein involved in the transport of iron. The transferrins are glycoproteins 
with molecular weight of approximately 80, 000 Da, consisting of a single polypeptide chain 
of 680 to 700 amino acids and no subunits. The transferrins consist of two non cooperative 
iron- binding lobes of approximately equal size. Each lobe is an ellipsoid of approximate 
dimensions 55 x35 x 35Aº and contains a metal binding site buried below the surface of the 
protein in a hydrophilic environment [Figure 5]. The two binding sites are separated by 42 
Aº [11].  There is approximately 40% identity in the amino acid sequence between the two  
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Fig. 5. Bilobar structure of Human transferrin 
lobes [12, 13]. The protein is a product of gene duplication derived from a putative ancestral 
gene coding for a protein binding only one atom of iron.  
The transferrins are highly cross-linked proteins, the number of disulfide bridges varying 
between proteins and between domains within each protein. There are six disulfide bonds 
conserved in each of the two-domains of all the transferrins, plus additional ones for the 
individual proteins. Human serum transferrin is the most cross- linked, having 8 and 11 
disulfide bridges in the N- and C- terminal metal-binding lobes. The transferrins, with the 
exception of lactoferrin, are acidic proteins, having an isoelectric point (pI) value around 5.6 
to 5.8. 
Several metals bind to transferrin; the highest affinity is for Fe3+; Fe2+ ion is not bound. 
Various spectroscopic and chemical modification studies have implicated histidine, tyrosine, 
water (or hydroxide) and (bi) carbonate as ligands to the Fe3+ in the metal-protein complex. 
The transferrins are unique among proteins in their requirement of coordinate binding of an 
anion (bicarbonate) for iron binding [14,15]. Several studies suggest that the bicarbonate is 
directly coordinated to the iron, presumably forming a bridge between the metal and a 
cationic group on the protein. In the normal physiological state, approximately one-ninth of 
all the transferrin molecules are   saturated with iron at both sides; four-ninths of transferrin 
molecules have iron at either site; and four-ninth of transferrin molecules are free of iron.  
Transferrin delivers iron to cells by binding to specific cell surface receptors (TfR) that 
mediate the internalization of the protein. The TfR is a transmembrane protein consisting of 
two subunits of 90,000 Da each, joined by a disulfide bond. Each subunit contains one 
transmembrane segment and about 670 residues that are extracellular and bind a transferrin 
molecule, favoring the diferric form. Internalization of the receptor- transferrin complex is 
dependent on receptor phosphorylation by a Ca2+- Calmodulin- protein kinase C complex. 
Release of the iron atoms occurs within the acidic milieu of the lysososme after which the 
receptor- apotransferrin complex returns to the cell surface where the apotransferrin is 
released to be reutilized in the plasma [Figure 6]. Inside the cell, iron is used for heme 
synthesis within the mitochondria, or is stored as ferritin. 
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Fig. 6. Cellular uptake of iron by transferrin receptor 
v. Labile iron Pool 
The uptake and storage of iron is carried out by different proteins, hence a pool of accessible 
iron ions, called labile iron pool (LIP) exists, that constitutes crossroads of the metabolic 
pathways of iron containing compounds [16]. The LIP is localized primarily but not 
exclusively, within the cytoplasm of the cells. It is bound to low-affinity ligands [17] and is 
accessible to permeant chelators and contains the cells' metabolically and catalytically 
reactive iron. LIP is maintained by a balanced movement of iron from extra- and 
intracellular sources [18].  
The trace amounts of "free" iron can catalyse production of a highly toxic hydroxyl radical 
via Fenton/Haber-Weiss reaction cycle. The critical factor appears to be the availability and 
abundance of cellular labile iron pool (LIP) that constitutes a crossroad of metabolic 
pathways of iron-containing compounds and is midway between the cellular need of iron, 
its uptake and storage. To avoid an excess of harmful "free" iron, the LIP is kept at the 
lowest sufficient level by transcriptional and posttranscriptional control of the expression of 
principal proteins involved in iron homeostasis [19]. 
vi. Other heme proteins and flavoproteins 
Certain enzymes also contain heme as part of their prosthetic group (e.g. catalase, 
peroxidases, tryptophan pyrrolase, guanylate cyclase, Nitric oxide synthase and 
mitochondrial cytochromes). 
Iron readily forms clusters linked to the polypeptide chain by thiol groups of cysteine 
residues or to non-proteins by inorganic sulphide and cysteine thiols leading to generation 
of iron- sulphur clusters. Examples of iron-sulphur proteins are the ferredoxins, 
hydrogenases,  nitrogenases, NADH dehydrogenases and aconitases. Structure of most of 
these proteins dictates their function. 
4. Physiological turnover of iron in the body  
Daily requirements for iron vary depending on the person’s age, sex and physiological 
status. Although iron is not excreted in the conventional sense, about 1 mg is lost daily 
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through the normal shedding of skin epithelial cells and cells that line the gastrointestinal 
and urinary tracts. Small numbers of erythrocytes are lost in urine and feces as well. 
Humans and other vertebrates strictly conserve iron by recycling it from senescent 
erythrocytes and from other sources. The loss of iron in a typical adult male is so small that 
it can be met by absorbing approximately 1 mg of iron per day [20] [Figure 7]. In 
comparison, the daily iron requirement for erythropoiesis is about 20 mg. Such conservation 
of iron is essential because many human diets contain just enough iron to replace the small 
losses. However, the blood lost in each menstrual cycle drains 20 to 40 mg of iron, so women 
in their reproductive years need to absorb approximately 2 mg of iron per day. 
However, when dietary iron is more abundant, absorption is appropriately attenuated. 
 
Fig. 7. Diagram showing the physiological turnover of iron in the body 
5. Mechanisms regulating Iron absorption 
The iron stores in the body are regulated by intestinal absorption. Intestinal absorption of 
iron is itself a regulated process and the efficacy of absorption increases or decreases 
depending on the body requirements of iron.  
The dietary iron, which exists mostly in the ferric form, is converted to the more soluble 
ferrous form, which is readily absorbed. The ferric form is reduced to ferrous by the action 
of acids in stomach, reducing agents such as ascorbic acid, cysteine and –SH groups of 
proteins. Entry of Fe3+ into the mucosal cells may be aided by an enzyme on the brush- 
border of the enterocyte (the enzyme possesses ferric reductase activity also). The ferrous 
ion is then transported in the cell by a divalent metal transporter (DMT1) [Figure 8]. 
In the intestinal cell, the iron may be (a) stored by incorporation into ferritin in those 
individuals who have adequate plasma iron concentration. A ferroxidase converts the 
absorbed ferrous iron to the ferric form, which then combines with apoferritin to form 
ferritin, or (b) transported to a transport protein at the basolateral cell membrane and 
released into the circulation. However, the basolateral-transport protein has not yet been 
identified, It is believed to work in combination with hephaestin, a copper-containing 
protein, which oxidizes Fe2+ back to Fe3+ . 
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Fig. 8. Mechanism of intestinal Iron absorption 
The intestinal cells internalize more iron than the amount that will eventually enter the 
circulation. The surplus, incorporated into ferritin for storage, is subsequently mobilized, if 
necessary. The ferritin stores are gradually built up, but most are lost when the mucosal cells 
are shed.  
Thus during the dietary iron absorption, iron needs to traverse both the apical and basolateral 
membranes of absorptive epithelial cells in the duodenum to reach the blood, where it is 
incorporated into transferrin. The transport of non-heme iron across the apical membrane 
occurs via the divalent metal transporter 1 (DMT1), the only known intestinal iron importer. 
Dietary non-heme iron exists mainly in ferric form (Fe+3) and must be reduced prior to 
transport. Duodenal cytochrome B (DcytB) is one of the major reductases localized in the apical 
membrane of intestinal enterocytes [21]. A heme protein, Dcytb, is upregulated by conditions 
that stimulate iron absorption, including iron deficiency, chronic anaemia and hypoxia. The 
mechanism by which its expression is upregulated in these conditions is unclear, as there are 
no obvious IREs in the mRNA of Dcytb. Nevertheless, the localization of Dcytb on the brush 
border of duodenal enterocytes closely mirrors that of DMT1, supporting the concept that 
Dcytb supplies ferrous iron to DMT1. 
In addition, iron is also absorbed as heme. The transporter responsible for heme uptake at 
the apical membrane has not yet been conclusively identified. Cytosolic iron in intestinal 
enterocytes can be either stored in ferritin or exported into plasma by the basolateral iron 
exporter ferroportin (FPN). FPN is most likely the only cellular iron exporter in the 
duodenal mucosa as well as in macrophages, hepatocytes and the syncytial trophoblasts of 
the placenta. The export of iron by FPN depends on two multicopper oxidases, 
ceruloplasmin (Cp) in the circulation and hephaestin on the basolateral membrane of 
enterocytes, which convert Fe+2 to Fe+3 for incorporation of iron into transferrin (Tf). 
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Intestinal iron absorption is dependent on the body iron needs and is a tightly controlled 
process. Recent studies indicate that this process is accomplished by modulating the 
expression levels of DMT1, DcytB and FPN by multiple pathways. 
Iron regulatory proteins (IRPs) are essential for intestinal iron absorption. DMT1 mRNA has 
an iron responsive element (IRE) at the 3'UTR and is stabilized upon IRP binding. In 
contrast, FPN mRNA has IRE at the 5'UTR and IRP binding inhibits translation. 
Specific intestinal depletion of both IRP1 and IRP2 in mice markedly decreases the DMT1 
and increases FPN, resulting in the death of the intestinal epithelial cells [22]. The mice die of 
malnutrition within two weeks of birth, underscoring the importance of these proteins. 
These results demonstrate the critical role of IRPs in the control of DMT1 and FPN 
expression. A novel isoform of FPN lacking an IRE was recently identified in enterocytes 
[23]. This FPN isoform is hypothesized to allow intestinal cells to export iron into the body 
under low iron conditions. DMT1 also expresses multiple isoforms with and without 3'IRE. 
The IRP/IRE regulatory network is described in detail in the subsequent chapters. 
Secondly, the hypoxia-inducible factor (HIF)-mediated signaling plays a critical role in 
regulating iron absorption. Two studies [24,25] show that acute iron deficiency induces HIF 
signaling via HIF-2  in the duodenum, which upregulates DcytB and DMT1 expression and 
increases iron absorption. A conditional knockdown of intestinal HIF-2  in mice abolishes 
this response. In addition to DMT1 and FPN, both HIF signaling and IRP1 activation 
are associated with the regulation of iron absorption [26, 27]. HIF-2  mRNA contains an IRE 
within its 5'-UTR [26]. Under conditions of cellular hypoxia, HIF-2  is derepressed through 
the inhibition of IRP-1–dependent translational repression [27].  
Thirdly, FPN protein is negatively regulated by hepcidin, a critical and one of the most 
important iron regulatory hormones, predominantly secreted by liver hepatocytes. Thus, 
intestinal iron absorption is coordinately regulated by several signaling pathways and is 
sensitive to hypoxia by HIF-2 , enterocyte iron levels by IRP/IRE and bodily iron levels by 
hepcidin. 
Although iron uptake into the body is tightly controlled, iron loss does not appear to be 
regulated. Under normal conditions iron is excreted through blood loss, sweat, and the 
sloughing of epithelial cells. These losses amount to approximately 1 to 2 mg of iron per day. 
Under certain pathological states, Tf, and therefore iron, can be lost when the kidney fails 
to reabsorb proteins from the urinary filtrate. These proteinurea syndromes result from the 
lack of functional cubulin, megalin, or ClC-5 [28]. Cubulin and megalin are protein 
scavenging receptors, whose function in the proximal renal tubule is the reuptake of 
nutrients from the urinary filtrate. ClC-5, a voltage-gated chloride channel, is required for 
the acidification of endocytic vesicles and the release of iron from Tf. 
6. Mechanisms of cellular iron transport and uptake  
(This section is only briefly described here. The topic is discussed in detail in subsequent 
chapter by Dr Sanchez etal).  
The abundance and availability of transferrin receptor for cellular iron uptake is regulated 
by cellular iron status. Cellular iron content determines the composition of a cytosolic 
protein termed iron regulatory protein 1 (IRP1). Under iron-replete conditions, IRP1 
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contains a 4Fe–4S cluster that is unable to bind to iron-responsive elements (IRE) in the 
mRNAs of TfR1 and ferritin. When cellular iron content is low, the iron–sulphur cluster is 
disassembled, liberating an apo-IRP that binds to specific stem–loop structures in the 3′ or 5′ 
untranslated regions (UTRs) of the mRNAs encoding these proteins. In the case of TfR1, the 
IREs are located in the 3′ UTR, and binding of IRP1 increases the stability of the message 
and enhances the synthesis of TfR1. 
Conversely, binding of IRP1 to the IREs in the 5′ UTR of ferritin mRNA mediates translation 
repression. Thus, under iron replete conditions, there is more rapid turnover of TfR1 
mRNA, leading to diminished translation and cell-surface expression of TfR1, reduced 
uptake of transferrin-bound iron and an expanded capacity for iron storage through 
increased synthesis of ferritin. Hepatic transferrin receptor (TfR2) expression is not 
downregulated by iron overload [29]. Given that the liver is a major site for iron storage, the 
high level of expression of TfR2 and its lack of responsiveness to iron status might be 
viewed as a protective mechanism, selectively diverting iron to hepatocytes under 
conditions in which circulating levels of transferrin bound iron are high and peripheral iron 
stores are replete. 
In normal individuals, nearly all cellular acquisition of iron from blood occurs via 
transferrin receptor-mediated uptake, since most of the iron in circulation is bound to 
transferrin. In circumstances in which the binding capacity of transferrin becomes saturated, 
as in case of iron loading disorders, iron forms low-molecular-weight complexes, the most 
abundant being iron citrate. It has been known for years that hepatic clearance of this non-
transferrin-bound iron (NTBI) is rapid and highly efficient. Furthermore, studies in isolated 
perfused rat livers and cultured hepatocytes indicated that hepatic uptake of NTBI involves 
a membrane carrier protein whose iron transport function is subject to competition by other 
divalent metal ions. Based on these characteristics, it appears that the recently discovered 
divalent metal transporter 1 (DMT1; also known as DCT1 and Nramp-2) is the major 
transporter accounting for hepatic uptake of NTBI. Using a cDNA library prepared from 
iron-deficient rat intestine, the DMT1 transcript was identified by its ability to increase iron 
uptake in Xenopus oocytes [30]. DMT1 has subsequently been shown to transport various 
divalent metal ions in a manner that is coupled to the transport of protons. Although DMT1 
mRNA is broadly expressed in mammalian tissues including liver, its highest level of 
expression is found in the proximal intestine, consistent with its role in the absorption of 
dietary non-heme iron. Two isoforms of DMT1 have been described. The form of DMT1 that 
predominates in the intestine has an IRE in its 3′ UTR, indicating that the stability of this 
transcript is regulated by cellular iron status in a manner similar to that of TfR1. Reciprocal 
changes in duodenal DMT1 expression vis-àvis iron status have been demonstrated in iron-
deficient rats and in humans with iron deficiency and iron overload [31]. 
Collectively, these data provide evidence for a negative feedback loop in which iron status 
regulates intestinal DMT1 expression, which in turn controls iron uptake. 
7. Mechanism of iron mobilization and export from storage sites 
Liver is the main site of iron storage under physiological conditions, hence various 
mechanisms regulate the mobilization and export of stored iron from liver to extrahepatic 
tissues. Under normal physiological circumstances, Kupffer cells play a prominent role in 
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deficient rats and in humans with iron deficiency and iron overload [31]. 
Collectively, these data provide evidence for a negative feedback loop in which iron status 
regulates intestinal DMT1 expression, which in turn controls iron uptake. 
7. Mechanism of iron mobilization and export from storage sites 
Liver is the main site of iron storage under physiological conditions, hence various 
mechanisms regulate the mobilization and export of stored iron from liver to extrahepatic 
tissues. Under normal physiological circumstances, Kupffer cells play a prominent role in 
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inter organ iron trafficking. One of the primary sites of erythrocyte turnover, Kupffer cells, 
along with the reticuloendothelial cells of the spleen and bone marrow, ingest senescent or 
damaged red blood cells, catabolize the haemoglobin and release the iron. Collectively, the 
quantity of iron that is recycled from erythrocytes through the macrophage compartment on 
a daily basis is several fold greater than that taken up through the intestine. Hence, the 
contribution of Kupffer cells to total body iron economy is both qualitatively and 
quantitatively important. It is therefore not surprising that Kupffer cells are the major type 
of liver cell that express a recently described iron exporter, FPN (also known as Ireg1 and 
MTP1) [32-34]. Consistent with its role in iron absorption, FPN is expressed at high levels 
along the basolateral membrane in mature enterocytes of the duodenal villi. In the intestine, 
FPN expression is upregulated by iron deficiency and anaemia.  In addition, FPN transcripts 
are also detected in liver, spleen, kidney and placenta. In murine liver, hepatocytes as well 
as Kupffer cells show immunoreactivity for FPN, albeit less intense. The quantitative PCR 
study on isolated cells from rat livers discussed above reported similar levels of FPN 
transcripts in hepatocytes, Kupffer cells and stellate cells, and lower levels in sinusoidal 
endothelial cells [35]; however, FPN protein has not been demonstrated in the last two cell 
types. Interestingly, the subcellular localization of FPN appears to differ between 
hepatocytes and Kupffer cells, being localized to the plasma membrane along the sinusoidal 
border in the former and cytoplasmic in the latter [34]. It has been proposed that the 
intracellular localization of FPN in Kupffer cells (which is also observed in RAW267.4 cells, 
a murine macrophage cell line) indicates that FPN does not directly export iron across the 
plasma membrane in these cells but, rather, that it may participate in intracellular trafficking 
of iron, perhaps through the secretory pathway. Further studies are needed to determine 
whether FPN is involved in multiple pathways of iron export. 
Like cellular uptake of iron, efflux of iron from cells requires ferroxidase activity. It has been 
known for some time that ceruloplasmin, a copper-containing plasma ferroxidase 
synthesized by hepatocytes, plays an important role in iron homeostasis. 
Aceruloplasminaemia results in a form of iron overload that is recapitulated in mice with a 
targeted disruption of the ceruloplasmin gene [36]. Interestingly, although the 
ceruloplasmin knockout mice accumulate iron in both hepatocytes and Kupffer cells, 
intestinal iron absorption is unaffected by ceruloplasmin deficiency. This observation could 
probably be explained by the recent demonstration of ceruloplasmin homologue, termed 
hephaestin in the intestinal villi. Despite their similarities, the function of hephaestin is 
distinct from that of ceruloplasmin,as mutations in hephaestin lead to iron deficiency rather 
than iron overload.  
In this context, it is interesting to contrast hepatocytes, which have low levels of FPN protein 
and lack detectable hephaestin transcripts, with Kupffer cells, which have higher levels of 
FPN and express hephaestin transcripts, at levels that are considerably lower than the 
intestine [35]. Taken together, these observations suggest that the ferroxidase activity of 
ceruloplasmin can indeed substitute for hephaestin in FPN-expressing cells in the liver (but 
not in the intestine). Another possibility is that hepatocytes and Kupffer cells may employ 
additional means to promote iron export, such as upregulation of hephaestin in response to 
iron loading and/or the expression of alternative exporters or ferroxidases. 
A major advance in the understanding of iron metabolism was the discovery of the iron 
regulatory hormone hepcidin nearly 10 years ago. Hepcidin was originally identified as an 
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antimicrobial peptide isolated from human urine [37]. The liver is the predominant source of 
hepcidin, where the 84-amino-acid prepropeptide is synthesized and cleaved to yield 20- 
and 25-amino-acid peptides that are released into the circulation and filtered by the kidney. 
Consistent with release into the blood from hepatocytes, hepcidin immunoreactivity is 
observed along the sinusoidal borders of hepatocyte membranes, with accentuated staining 
of periportal (zone 1) hepatocytes which decreases towards the central vein and sinusoids 
[38].  
Hepcidin acts as a systemic iron-regulatory hormone as it controls iron transport from iron-
exporting tissues into plasma [39]. [Figure 9] Studies have demonstrated that hepcidin 
knockout mice develop a form of iron overload reminiscent of hereditary haemochromatosis 
[40], while mice with over expression of hepcidin have severe iron-deficiency anaemia [41]. 
Hepcidin inhibits the intestinal absorption [37,41], macrophage release [42,43] and placental 
passage [41] of iron. A pharmacodynamic study of the effects of a radiolabelled hepcidin 
injection in mice, showed that a single 50 µg dose resulted in 80% drop in serum iron within 
1 h which did not return to normal until 96 hours [44]. This time course is consistent with 
the blockage of recycled iron from macrophages and previous reports of the rapid hepcidin 
response to IL-6 administration [45]. The rapid disappearance of plasma iron was followed 
by a delayed recovery, possibly due to the slow resynthesis of membrane FPN. Tissue 
concentrations revealed that hepcidin preferentially accumulates in the proximal duodenum 
and spleen, reecting the high expression of FPN in these areas. 
Hepatocytes evaluate body iron status and release or downregulate hepcidin according to 
the iron status of the body [Figure 9]. An oral load of 65 mg of iron in healthy volunteers 
caused > 5-fold increase in hepcidin within 1 day [45]. Hepcidin mRNA moves with the  
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body's iron levels, increasing as they increase and decreasing as they decrease [46]. Hepcidin 
regulates iron uptake constantly on a daily basis, to maintain sufficient iron stores for 
erythropoiesis [47], as well as its feedback mechanism to prevent iron overload. Hepcidin 
negatively regulates the uptake of iron by Tf, the major iron transport protein in the blood. 
Since Tf is the major source of iron for hemoglobin synthesis by red blood cell precursors, 
increased hepcidin limits erythropoiesis and is a major contributor to the anemia of chronic 
disease [48]. In humans, patients with large hepatic adenomas found to overexpress 
hepcidin, had a severe iron refractory microcytic anaemia, which was corrected by removal 
of the adenoma [49]. 
Recent studies have provided insight into the mechanisms by which hepcidin modulates 
iron absorption. Within a week of being placed on a low-iron diet, rats show a twofold 
increase in intestinal iron absorption that is temporally associated with a significant drop in 
hepatic hepcidin expression, and increases in duodenal mRNAs for Dcytb, DMT1 and FPN 
[50]. Although the increase in FPN mRNA under these circumstances is of relatively small 
magnitude, the increase in FPN protein is more substantial. A similar pattern is seen in the 
intestine of hepcidin knockout mice, providing additional evidence that hepcidin suppresses 
the expression of these iron transporters. While the role of hepcidin in the regulation of 
Dcytb and DMT1 has not been characterized, several reports have established that FPN is a 
major target of hepcidin’s action. As suggested by the observations discussed above, 
hepcidin appears to regulate FPN expression by two distinct mechanisms. The first is at the 
level of FPN transcripts, which are decreased following stimulation of endogenous hepcidin 
production or administration of recombinant hepcidin [51]. The second involves binding of 
hepcidin to FPN at the cell membrane, causing internalization and degradation of FPN, thus 
diminishing iron transfer [39, 52,53]. These mechanisms are clearly not mutually exclusive 
and, either or both may probably contribute to the decrease in intestinal iron absorption in 
response to hepcidin. However, it is unclear at present whether FPN expression in liver cells 
is regulated in the same manner. In mice treated with iron, intestinal FPN expression is low, 
consistent with the known effects of hepcidin. In the liver, however, FPN is increased, 
particularly in Kupffer cells [34]. This may result from enhanced translation due to the 
presence of the IRE in the 5′ UTR of FPN mRNA. If so, this effect must predominate over the 
hepcidin-induced increase in FPN turnover. Alternatively, the distinctive intracellular 
pattern of FPN in Kupffer cells implies that FPN may not physically interact with hepcidin 
in macrophages, again raising the possibility of differential regulation of FPN in liver vs. 
intestine.  
Hepcidin inhibits the release of iron by macrophages and lessens the iron uptake in the gut 
by diminishing the effective number of iron exporters on the membrane of enterocytes or 
macrophages. In FPN mutations it has been observed that iron accumulates mainly in 
macrophages and is often combined with anemia [54]. 
The development of iron overload in hepcidin knockout mice [40] and humans with 
mutations in the hepcidin gene [55] is clearly explicable by the effects of hepcidin on 
intestinal iron absorption. Since the discovery of hepcidin, several authors have reported 
that hepcidin expression fails to increase in response to increased iron stores in other disease 
states characterized by iron loading. For example, hepcidin expression is inappropriately 
low in iron-loaded subjects with hereditary haemochromatosis [56] and haemojuvelin (HJV) 
mutations [57]. Similar findings are reported in a variety of iron-loading anaemias [58]. 
Under physiological conditions, hepatic hepcidin expression is regulated by a cohort of 
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proteins that are expressed in hepatocytes, including the hereditary hemochromatosis 
(HH) protein called HFE, transferrin receptor 2 (TfR2), hemojuvelin (HJV), bone 
morphogenetic protein 6 (BMP6), matriptase-2 and Tf. Hepcidin expression can also be 
robustly regulated by erythroid factors, hypoxia, and inflammation, regardless of body 
iron levels. The inappropriately low levels of hepcidin production in HFE-associated 
Hereditary Hemochromatosis (HH) suggest that HFE is upstream of hepcidin in the 
molecular regulation of hepcidin production [59]. Similarly, the HJV gene, which is mutated 
in Juvenile Hemochromatosis [JH] , is associated with low hepcidin levels [60], suggesting 
regulation proximal to hepcidin. Type 3 haemochromatosis is due to homozygous mutations 
in TfR2, a membrane glycoprotein that mediates cellular iron uptake from transferrin. TfR2 
mutant mice have low levels of hepcidin mRNA expression, even after massive 
intraperitoneal iron loading also suggestive of iron modulation proximal to hepcidin [61]  
It is possible that hepcidin is the common pathway modulating iron absorption via HFE, 
TfR2 and HJV, mutations of which all result in an iron overload phenotype. Mutations in 
these proteins, or their genetic ablation, result in diminished hepcidin expression, indicating 
that they positively regulate hepcidin production. Signaling through the BMP pathway has 
been shown to be a central axis for hepcidin regulation. BMPs (such as BMP2, 4, 6, or 9) are 
secreted soluble factors that interact with cell-surface BMP receptors, initiating an 
intracellular signaling cascade that activates hepcidin transcription [62].  
In vivo, BMP6 seems especially important for iron homeostasis; because Bmp6-null mice 
display reduced hepcidin expression and iron overload [63]. Efficient BMP signaling 
through BMP receptor requires HJV, a 50-kDa protein with a glycosylphosphatidylinositol 
(GPI) anchor that tethers the protein to the extracellular surface of the plasma membrane. 
This membrane-bound hemojuvelin (m-HJV) is capable of binding BMPs, facilitating their 
association with the BMP receptor [64]. As such, m-HJV is often referred to as a BMP co-
receptor. The potent contribution of m-HJV to BMP-mediated hepcidin activation is 
illustrated by mutations in HJV that abrogate cell surface expression. Individuals with such 
mutations develop juvenile hemochromatosis, characterized by exceedingly low serum 
hepcidin concentrations (<5 ng/mL) [65] and severe hepatic iron overload. 
Several studies have proved that there is local production of hepcidin by macrophages [74], 
cardiomyocytes [66] and fat cells [67], suggesting that hepcidin is involved in different 
regulatory mechanisms to control iron imbalance. Apart from this, few studies have 
proposed that hepcidin might also directly inhibit erythroid-progenitor proliferation and 
survival [68]. At the same time hepcidin synthesis is increased by iron loading and 
decreased by anemia and hypoxia [69]. Anemia and hypoxia are associated with a dramatic 
decrease in liver hepcidin gene expression, which may account for the increase in iron 
release from reticuloendothelial cells and increase in iron absorption frequently observed in 
these situations [47]. 
HFE is highly expressed in the liver as well as the intestine and is involved in regulation of 
iron metabolism. Originally identified on the basis of a high frequency of HFE mutations in 
patients with genetic haemochromatosis, wild-type HFE protein forms a complex at the 
plasma membrane with TfR1 and β2-microglobulin [Figure 8]. Studies in transfected cells 
indicate that the stoichiometry of these components influences the rate of recycling of TfR1, 
thus modulating iron uptake [70]. Nonetheless, the precise mechanism whereby HFE 
mutations lead to iron loading remains speculative. While immunohistochemistry for HFE 
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demonstrates a distinctive pattern of intracellular perinuclear staining in the epithelial cells 
of the small intestine [71], immunoreactivity for HFE in liver has been variously ascribed to 
bile ducts, sinusoidal lining cells, Kupffer cells and endothelial cells. Furthermore, these 
studies are at variance with results of PCR and Western blot analysis of isolated liver cells 
demonstrating that hepatocytes are the major source of HFE in rat liver, with a minor 
contribution from Kupffer cells [35]. Additional studies are needed to resolve this 
discrepancy and provide further insight into the function of HFE.  
While the function of HJV is unknown, it has been proposed that HJV is ‘upstream’ of 
hepcidin in the pathways controlling iron metabolism, as both patients with iron overload 
resulting from HJV mutations and HJV knockout mice fail to respond to their iron burden 
with an appropriate increase in hepcidin. On treatment with parenteral iron in mice, hepatic 
expression of HJV is not altered despite an increase in hepcidin mRNA indicating that a 
direct interaction between these two proteins is unlikely. Thus, currently available studies 
demonstrate lack of responsiveness of HJV to iron as well as divergent regulation of HJV 
and hepcidin in normal animals treated with iron. 
8. Conclusion 
Iron is an essential element in the body but its effect in the body is like a two-edged sword. 
At one end it is essential for maintaining most of the body functions and at the other end it 
becomes potentially toxic if in excess. Thus, elaborate physiological mechanisms have 
evolved for regulation of uptake and disposition of iron.  The earlier concept of regulation of 
iron levels by absorption could not explain several clinical conditions like hemochromatosis 
and severe anemias associated with chronic diseases and malignancies. However, a newer 
insight into the understanding of iron metabolism has been provided in the past few years, 
mainly as a result of the discovery of hepcidin, a key regulator of whole-body iron 
homeostasis.   
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demonstrates a distinctive pattern of intracellular perinuclear staining in the epithelial cells 
of the small intestine [71], immunoreactivity for HFE in liver has been variously ascribed to 
bile ducts, sinusoidal lining cells, Kupffer cells and endothelial cells. Furthermore, these 
studies are at variance with results of PCR and Western blot analysis of isolated liver cells 
demonstrating that hepatocytes are the major source of HFE in rat liver, with a minor 
contribution from Kupffer cells [35]. Additional studies are needed to resolve this 
discrepancy and provide further insight into the function of HFE.  
While the function of HJV is unknown, it has been proposed that HJV is ‘upstream’ of 
hepcidin in the pathways controlling iron metabolism, as both patients with iron overload 
resulting from HJV mutations and HJV knockout mice fail to respond to their iron burden 
with an appropriate increase in hepcidin. On treatment with parenteral iron in mice, hepatic 
expression of HJV is not altered despite an increase in hepcidin mRNA indicating that a 
direct interaction between these two proteins is unlikely. Thus, currently available studies 
demonstrate lack of responsiveness of HJV to iron as well as divergent regulation of HJV 
and hepcidin in normal animals treated with iron. 
8. Conclusion 
Iron is an essential element in the body but its effect in the body is like a two-edged sword. 
At one end it is essential for maintaining most of the body functions and at the other end it 
becomes potentially toxic if in excess. Thus, elaborate physiological mechanisms have 
evolved for regulation of uptake and disposition of iron.  The earlier concept of regulation of 
iron levels by absorption could not explain several clinical conditions like hemochromatosis 
and severe anemias associated with chronic diseases and malignancies. However, a newer 
insight into the understanding of iron metabolism has been provided in the past few years, 
mainly as a result of the discovery of hepcidin, a key regulator of whole-body iron 
homeostasis.   
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1. Introduction 
General Overview of iron homeostasis 
Iron is the most abundant transition metal in cellular systems and is an essential 
micronutrient required for many cellular processes including DNA synthesis, oxidative cell 
metabolism, haemoglobin synthesis and cell respiration. Despite iron being an absolute 
requirement for almost all organisms, caution should be taken with an inappropriate 
disequilibrium in iron levels because excess iron is toxic and a lack of it leads to anaemia. 
As a transition metal, iron can exist in various oxidation states (from -2 to +6). Usually, iron 
exists and switches between two different ionic states (Fe+2 and Fe+3). Iron in the reduced 
state is known as ferrous iron and has a net positive charge of two (Fe+2). In the oxidized 
state it is known as ferric iron and has a net positive charge of three (Fe+3). This electron 
switch property of iron as a metal element allows it to be used as a cofactor by many 
enzymes involved in oxidation-reduction reactions and also confers its toxicity. Iron toxicity 
relates to the intracellular labile iron pool (LIP), a pool of transitory, chelatable (i.e. free) and 
redox-active iron that can catalyze the formation of oxygen-derived free radicals via the 
Fenton reaction. Iron-catalyzed oxidative stress causes lipid peroxidation, protein 
modifications, DNA damage (promoting mutagenesis) and depletion of antioxidant 
defences.  
Iron containing proteins can be classified into 3 groups (for an extensive revision see 
(Crichton, 2009)): 
Haemoproteins, in which iron is bound to four ring nitrogen atoms of a porphyrin molecule 
called haem and one or two axial ligands from the protein. Examples of haemoproteins are 
the oxygen transport protein haemoglobin, the muscle oxygen storage protein myoglobin, 
peroxidases, catalases and electron transport proteins such as the cytochromes a, b and c. 
Iron-sulphur proteins are proteins that contain iron atoms bound to sulphur forming a 
cluster linked to the polypeptide chain by thiol groups of cysteine residues or to non-protein 
structures by inorganic sulphide and cysteine thiols. Examples of iron-sulphur proteins are 
the ferredoxins, hydrogenases, nitrogenases, NADH dehydrogenases and aconitases. 
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Non-haem non iron-sulphur proteins, these proteins can be of three types:  
Mononuclear non-haem iron enzymes such as catechol or Rieske dioxygenases, alpha-keto 
acid dependent enzymes, pterin-dependent hydrolases, lipoxygenases and bacterial 
superoxide dismutases 
Dinuclear non-haem iron enzymes, also known as diiron proteins, like the H-ferritin chain, 
haemerythrins, ribonucleotide redictase R2 subunit, stearoyl-CoA desaturases and 
bacterial monoxygenases 
Proteins involved in ferric iron transport, for instance the transferrin family that includes 
serotransferrin, lactotransferrin, ovotransferrin and melanotransferrin and are found in 
physiological fluids of many vertebrates. 
As previously mentioned, many proteins involved in very different cellular pathways 
contain iron. Therefore, cells require iron to function properly. However, mammals have no 
physiological excretion mechanisms to release an excess of iron and consequently, iron 
homeostasis must be tightly controlled on both the systemic and cellular levels to provide 
just the right amounts of iron at all times. If an adequate balance of iron is not achieved, it 
will cause a clinical disorder. Iron is therefore crucial for health. Iron deficiency leads to 
anaemia —a major world-wide public health problem— and iron overload is toxic and 
increases the oxidative stress of body tissues leading to inflammation, cell death, system 
organ dysfunction, and cancer (Hentze et al., 2010).  
Systemic iron homeostasis is regulated by the hepcidin/ferroportin system in vertebrates 
(Ganz & Nemeth, 2011). Hepcidin is a liver-specific hormone secreted in response to iron 
loading and inflammation and is the master regulator of systemic iron homeostasis. 
Increased hepcidin levels result in anaemia while decreased expression is a causative feature 
in most primary iron overload diseases. Transcription of hepcidin in hepatocytes is 
regulated by a variety of stimuli including cytokines (TNF-α, IL-6), erythropoiesis, iron 
stores and hypoxia (De Domenico et al., 2007). At the molecular level, the binding of 
hepcidin to the iron exporter ferroportin (FPN) induces its internalization and degradation; 
and thus prevents iron entry into plasma (Nemeth et al., 2004).  
Cellular iron homeostasis is mainly controlled by a system composed of RNA binding 
proteins and RNA binding elements that constitutes a post-transcriptional gene expression 
regulation system known as the Iron Regulatory Protein (IRP) / Iron-Responsive Element 
(IRE) regulatory network (Hentze et al., 2010; Muckenthaler et al., 2008; Recalcati et al., 
2010). This chapter will focus on the IRP/IRE regulatory network, addressing in depth, its 
role in the regulation of cellular iron homeostasis, its alterations in diseases and new 
research lines to be explored in the future. 
2. Cellular iron homeostasis 
Cellular iron maintenance involves the coordination of iron uptake, utilization, and storage 
to ensure appropriate levels of iron inside the cell. Although transcriptional regulation of 
iron metabolism has been reported in the literature; cellular iron homeostasis is mainly 
controlled at the post-transcriptional level (Muckenthaler et al., 2008). In general, post-
transcriptional regulation ensures a faster and easier way of controlling protein expression 
levels in mammalians by changing the rate of specific mRNA synthesis using repressor or 
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stabilizer proteins. Particularly in iron metabolism, this system involves the so-called 
IRP/IRE regulatory network. 
2.1 The IRP/IRE regulatory network 
The Iron Regulatory Protein (IRP) / Iron-Responsive Element (IRE) regulatory network is 
a post-transcriptional gene expression regulation system that controls cellular iron 
homeostasis. This network comprises two RNA binding proteins called Iron Regulatory 
Proteins (IRP1 and IRP2) and cis-regulatory RNA elements, named Iron-Responsive 
Elements, or IRE, that are present in mRNAs encoding for important proteins of iron 
homeostasis. 
IRP/IRE interactions regulate the expression of the mRNAs encoding proteins for iron 
acquisition (transferrin receptor 1, TFR1; divalent metal transporter 1, Slc11a2), iron storage 
(H-ferritin, Fth1; L-ferritin, Ftl), iron utilization (erythroid 5-aminolevulinic acid synthase, 
Alas2), energy (mitochondrial aconitase, Aco2; Drosophila succinate dehydrogenase, Sdh), 
and iron export (ferroportin, Fpn-Slc40a1) (Figure 1) (Muckenthaler et al., 2008). Less well 
known is the role of the IRP/IRE regulatory network in the control of other pathways (for 
details see section 2.1.3.5).  
The IRE binding activities of IRP1 and IRP2 are regulated by intracellular iron levels and 
other stimuli (including nitric oxide, oxidative stress, and hypoxia) through distinct 
mechanisms (for details see sections 2.1.2.1 and 2.1.2.2). IRP/IRE binding activity is high in 
iron-deficient cells and low in iron-replete cells. When iron levels inside the cells are 
increased the IRPs are unable to bind the IREs, because IRP1 in these conditions assemble an 
iron-sulphur cluster (Fe-S cluster) and it is transformed into a cytosolic aconitase; while IRP2 
is degraded by a mechanism that involves the proteosome (see section 2.1.2.1). Therefore, 
only in iron-starved cells, the IRPs became an IRE binding protein (Figure 1). 
Depending on the location of the IRE in the untranslated regions (UTR), IRP binding 
regulates gene expression differentially. Both IRPs inhibit translation initiation when bound 
to IREs at the 5’UTR by preventing the recruitment of the small ribosomal subunit to the 
mRNA (Muckenthaler et al., 1998). Although the cap binding complex eIF4F can assemble 
when IRP1 is bound to a cap-proximal IRE, the small ribosomal subunit cannot be 
established in the presence of IRP1, which interferes with the bridging interactions that need 
to be established between eIF4F and the small ribosomal subunit. The IRPs association with 
the 3’IREs of the TRF1 mRNA decreases its turnover by preventing an endonucleolytic 
cleavage and its mRNA degradation (Binder et al., 1994). This mechanism of IRP mRNA 
stabilization has not been fully probed for other 3’ IRE-containing mRNAs such as DMT1 
and CDC14A, which only have a single 3’IRE and may require additional factors for their 
regulation. Overall, the regulation of the IRE-binding activities of IRP1 and IRP2 assures the 
appropriate expression of IRP target mRNAs and cellular iron balance. 
The IRP/IRE regulatory system was initially described as a simple post-transcriptional 
regulatory gene expression circuit controlling the production of the ferritins and Transferrin 
Receptor 1. The identification of other mRNAs associated with this system has added 
considerable complexity and has extended the role of the IRPs to interconnect different 
cellular pathways, which should be regulated by iron metabolism in a coordinated way.  
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Fig. 1. The iron-regulatory protein/iron-responsive element (IRP/IRE) regulatory system. 
IRP1 and IRP2 bind to IREs in iron-deficient conditions (-Fe). This binding mediates 
translation repression in those mRNAs with an IRE at the 5’ UTR, decreasing their protein 
levels. If the IRE is in the 3’ UTR the IRP binding enhances mRNA stabilization by 
preventing an endonucleotic cleavage in TFR1 mRNA. The exact mechanism of IRP 
regulation in DMT1 and CDC14A mRNA is not yet well known. H-Fer: H-ferritin, L-Fer: L-
ferritin, ALAS2: erythroid-specific delta-aminolevulinate synthase, FPN: Ferroportin, ACO2: 
mitochondrial aconitase 2, HIF2α: Hypoxia inducible factor 2 alpha, TFR1: Transferrin 
Receptor 1, DMT1: divalent metal transporter 1, CDC14A: Cell Division Cycle 14, S. 
Cerevisiae, homolog A. 
2.1.1 Iron-Responsive Elements (IRE) 
Iron-responsive elements or IREs are conserved cis-regulatory mRNA motifs of 25-30 
nucleotides located in the untranslated regions (UTR) of mRNAs that encode proteins 
involved in iron metabolism.  
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The mRNAs of H-ferritin (FTH1), L-ferritin (FTL), erythroid-specific delta-aminolevulinate 
synthase (ALAS2), ferroportin (FPN), mitochondrial aconitase 2 (ACO2), and others (see 
section 2.1.3.5) contain one single IRE in their 5´UTRs (Figure 1 and 2). The mRNA encoding 
for Transferrin Receptor 1 (TFR1) is so far the only known mRNA with multiple (five) IREs, 
all of them located in its 3´UTR. The mRNA encoding for DMT1 protein (gene SLC11A2) 
also contains a single IRE in its 3´UTR (Figure 1 and 2). In addition, a single 3’ IRE has been 
reported in other not so well documented mRNAs (see section 2.1.3.5). 
 
Fig. 2. Functional Iron-Responsive Elements (IREs) and the role of their encoded protein. Note 
all motifs contain the characteristic C-bulge (C8) present in the stem motif and a 6-nucleotide –
CAGAGU/C- apical loop both circled in blue. 5’ IREs are shown at the top of the figure and 3’ 
IREs at the bottom. The 5 IREs from TFR1 mRNAs are depicted and named as IRE-A to IRE-E. 
Nucleotides shown in blue represent changes in mouse with respect to the human sequence. 
The function of the encoded protein is shown in red. FTL: L-Ferritin, FTH:H- Ferritin, e-
ALAS2: erythroid-specific delta-aminolevulinate synthase, ACO2: mitochondrial aconitase 2, 
dSdhB: Drosophila succinate dehydrogenase B, FPN: Ferroportin, HIF2α: Hypoxia inducible 
factor 2 alpha, TFR1: Transferrin Receptor 1, DMT1: divalent metal transporter 1.  
The canonical IRE hairpin-loop is composed of a six-nucleotide apical loop (5’-CAGWGH-3’; 
whereby W stands for A or U and H for A, C or U) on a stem of five paired nucleotides, a 
small asymmetrical bulge with an unpaired cytosine on the 5’strand of the stem, and an 
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whereby W stands for A or U and H for A, C or U) on a stem of five paired nucleotides, a 
small asymmetrical bulge with an unpaired cytosine on the 5’strand of the stem, and an 
additional lower stem of variable length (see Figure 2 for IREs examples). The IRE stem 
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forms base pairs of moderate stability, and folds into an α-helix (Figure 3B) distorted by the 
presence of a small 5’ bulge (an unpaired C8 nucleotide) in the middle of the IRE. IRE base 
pairs can be Watson-Crick bonding or wobble pairs (U.G or G.U). The IRE (CAGWGH) 
terminal loop forms a pseudotriloop (AGW) isolated by a conserved base pair (C14:G18) 
and followed by an unpaired nucleotide (N19, Figure 3A). The base pair C14:G18 and the 
unpaired nucleotide do not make contact with the protein, which suggests that the bridge 
C14:G18 serves only a structural role for IRP1 recognition (Walden et al., 2006). The 
pseudotriloop and the C8 nucleotide make multiple contacts with IRP1 (for more details see 
section 2.1.2.1). It is most likely that all these important structural details, revealed in the 2.8 
angstrom resolution crystal structure of the IRP1:H-ferritin IRE complex reported by 




Fig. 3. SIREs, Searching for Iron-Responsive Elements, the bioinformatic program for the 
prediction of IREs. A. Schematic representation of an IRE motif, rectangular region indicates 
the IRE core region predicted by SIREs software. C-bulge (C8) and 6 nucleotide apical loop 
are shown within a blue circle. The presence of possible 3’ bulge nucleotides are represented 
as N20b, N21b, N22b and N23b. B. SIREs freely available web-server home page at 
http://ccbg.imppc.org/sires/index.html.  
The differential regulation of the IRPs on the different 5’ and 3’ IREs is discussed in the 
section above. Mutations in the Iron-Responsive Elements disrupt the IRP/IRE regulatory 
system and cause iron-related disorders in humans (for details see sections 3). 
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2.1.1.1 Bioinfomatic predictions of iron-responsive elements 
One of the biggest challenges facing researchers in the study of IREs is the availability of 
fast, reliable approaches to recognising possible IREs in known RNA sequences. Existing 
software tools to predict this type of cis-regulatory element (RNA Analyzer, UTRScan and 
RNAMotif) (Bengert & Dandekar, 2003; Macke et al., 2001; Mignone et al., 2005) are not 
sufficiently accurate to find atypical IREs due to their strict constraints for pattern matching 
searches. Therefore, these programs fail to identify mRNAs that have an atypical IRE with 
an unpaired 3’ bulged nucleotide in the upper stem, such as the HIF2α IRE (see Figure 2). In 
addition, previous SELEX (systematic evolution of ligands by exponential enrichment) 
experiments have reported that the six-nucleotide apical loop of an IRE can differ from the 
canonical CAG(U/A)GN sequence and still bind efficiently to IRPs in vitro (Butt et al., 1996; 
Henderson et al., 1996). Furthermore, current IRE prediction programs do not allow for the 
presence of a mismatch pair of nucleotides in the upper stem, although the IRE reported in 
the Gox mRNA contains one such mismatch (Kohler et al., 1999) (see Figure 5).  
To overcome these limitations, the laboratory of Dr. Mayka Sanchez has created new 
software for the prediction of IREs which is implemented as a user-friendly web server tool. 
The SIREs (Search for iron-responsive elements) web server uses a simple data input 
interface and provides structural analysis, predicts RNA folds, folding energy data and an 
overall quality flag based on properties of well characterized IREs. The SIREs algorithm is 
implemented on a Perl script that screens for a 19 or 20 nucleotide sequence motif 
corresponding to the core sequence of an IRE (positions n07–n25) that includes the hexa-
apical hairpin loop (n14–n19), the upper stem, the cytosine bulge (C8) and the lower base 
pair (n07–n25) (see Figure 3A). This core IRE region is sufficient to identify known IREs 
assigning them an equal RNA binding hierarchy as recently reported between IRP1 and 5’ 
IREs (Goforth et al., 2010). The SIREs results are displayed in a tabular format and as a 
schematic visual representation that highlights important features of the IRE. The major 
advantage of the SIREs program is that it is able to detect canonical and non-canonical IREs 
because it integrates and allows the combination of several experimentally reported IRE 
structures without losing stringency in its predictions. Therefore, with this new 
bioinformatic software one can screen an input sequence for the existence of IRE structures 
and will receive a scored output (as a high, medium or low) of the predicted IRE for 
prioritization of further studies (see Figure 3B for the home page of the SIREs website).  
Overall, the SIREs web server represents a significant improvement on currently available 
programs to predict IREs, providing the scientific community with an easy-to-use 
bioinformatics platform to identify putative IRE motifs that can then be subjected to further 
experimental testing in vitro and in vivo. The SIREs web server is freely available on the web 
at: http://ccbg.imppc.org/sires/index.html (Figure 3) and was published by Campillos and 
collaborators (Campillos et al., 2010). 
2.1.2 Iron regulatory proteins: IRP1 and IRP2 
Iron regulatory proteins 1 and 2 (IRP1 and IRP2) are proteins sensitive to cytosolic iron 
concentrations that post-transcriptionally regulate the expression of iron metabolism genes 
to optimize cellular iron availability. IRP1 is encoded by the gene ACO1 found in 
chromosome 9p21.1 and IRP2 by the gene IREB2 found in chromosome 15q25.1. In iron-
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forms base pairs of moderate stability, and folds into an α-helix (Figure 3B) distorted by the 
presence of a small 5’ bulge (an unpaired C8 nucleotide) in the middle of the IRE. IRE base 
pairs can be Watson-Crick bonding or wobble pairs (U.G or G.U). The IRE (CAGWGH) 
terminal loop forms a pseudotriloop (AGW) isolated by a conserved base pair (C14:G18) 
and followed by an unpaired nucleotide (N19, Figure 3A). The base pair C14:G18 and the 
unpaired nucleotide do not make contact with the protein, which suggests that the bridge 
C14:G18 serves only a structural role for IRP1 recognition (Walden et al., 2006). The 
pseudotriloop and the C8 nucleotide make multiple contacts with IRP1 (for more details see 
section 2.1.2.1). It is most likely that all these important structural details, revealed in the 2.8 
angstrom resolution crystal structure of the IRP1:H-ferritin IRE complex reported by 




Fig. 3. SIREs, Searching for Iron-Responsive Elements, the bioinformatic program for the 
prediction of IREs. A. Schematic representation of an IRE motif, rectangular region indicates 
the IRE core region predicted by SIREs software. C-bulge (C8) and 6 nucleotide apical loop 
are shown within a blue circle. The presence of possible 3’ bulge nucleotides are represented 
as N20b, N21b, N22b and N23b. B. SIREs freely available web-server home page at 
http://ccbg.imppc.org/sires/index.html.  
The differential regulation of the IRPs on the different 5’ and 3’ IREs is discussed in the 
section above. Mutations in the Iron-Responsive Elements disrupt the IRP/IRE regulatory 
system and cause iron-related disorders in humans (for details see sections 3). 
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2.1.1.1 Bioinfomatic predictions of iron-responsive elements 
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software tools to predict this type of cis-regulatory element (RNA Analyzer, UTRScan and 
RNAMotif) (Bengert & Dandekar, 2003; Macke et al., 2001; Mignone et al., 2005) are not 
sufficiently accurate to find atypical IREs due to their strict constraints for pattern matching 
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Henderson et al., 1996). Furthermore, current IRE prediction programs do not allow for the 
presence of a mismatch pair of nucleotides in the upper stem, although the IRE reported in 
the Gox mRNA contains one such mismatch (Kohler et al., 1999) (see Figure 5).  
To overcome these limitations, the laboratory of Dr. Mayka Sanchez has created new 
software for the prediction of IREs which is implemented as a user-friendly web server tool. 
The SIREs (Search for iron-responsive elements) web server uses a simple data input 
interface and provides structural analysis, predicts RNA folds, folding energy data and an 
overall quality flag based on properties of well characterized IREs. The SIREs algorithm is 
implemented on a Perl script that screens for a 19 or 20 nucleotide sequence motif 
corresponding to the core sequence of an IRE (positions n07–n25) that includes the hexa-
apical hairpin loop (n14–n19), the upper stem, the cytosine bulge (C8) and the lower base 
pair (n07–n25) (see Figure 3A). This core IRE region is sufficient to identify known IREs 
assigning them an equal RNA binding hierarchy as recently reported between IRP1 and 5’ 
IREs (Goforth et al., 2010). The SIREs results are displayed in a tabular format and as a 
schematic visual representation that highlights important features of the IRE. The major 
advantage of the SIREs program is that it is able to detect canonical and non-canonical IREs 
because it integrates and allows the combination of several experimentally reported IRE 
structures without losing stringency in its predictions. Therefore, with this new 
bioinformatic software one can screen an input sequence for the existence of IRE structures 
and will receive a scored output (as a high, medium or low) of the predicted IRE for 
prioritization of further studies (see Figure 3B for the home page of the SIREs website).  
Overall, the SIREs web server represents a significant improvement on currently available 
programs to predict IREs, providing the scientific community with an easy-to-use 
bioinformatics platform to identify putative IRE motifs that can then be subjected to further 
experimental testing in vitro and in vivo. The SIREs web server is freely available on the web 
at: http://ccbg.imppc.org/sires/index.html (Figure 3) and was published by Campillos and 
collaborators (Campillos et al., 2010). 
2.1.2 Iron regulatory proteins: IRP1 and IRP2 
Iron regulatory proteins 1 and 2 (IRP1 and IRP2) are proteins sensitive to cytosolic iron 
concentrations that post-transcriptionally regulate the expression of iron metabolism genes 
to optimize cellular iron availability. IRP1 is encoded by the gene ACO1 found in 
chromosome 9p21.1 and IRP2 by the gene IREB2 found in chromosome 15q25.1. In iron-
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deficient cells, IRPs bind to iron-responsive elements (IREs) found in the mRNAs of ferritin, 
transferrin receptor and other iron metabolism transcripts, enhancing iron uptake and 
decreasing iron sequestration. IRP1 registers cytosolic iron status mainly through an iron-
sulphur cluster switch mechanism, alternating between an active cytosolic aconitase form 
with an iron-sulphur cluster ligated to its active site and an apo-protein form that binds 
IREs. Although IRP2 is 60 to 70% identical to IRP1 (one of the major difference is an extra 73 
amino acid insertion present in IRP2), both proteins are differentially regulated. IRP2 does 
not have an aconitase function and its activity is regulated primarily by iron-dependent 
degradation through a ubiquitin-proteasomal system in iron-replete cells (see next section).  
Constitutive deletion of both IRPs is embryonic lethal, demonstrating that the IRP/IRE 
regulatory system is essential for life (Galy et al., 2008; Smith et al., 2006). The groups of 
Matthias W. Hentze (EMBL) and Tracey Rouault (NIH) have reported knock-out targeted 
deletion strategies for IRP1 and/or IRP2 in whole animals or tissue specific. Their 
publications show that adult mice that constitutively lack IRP1 develop no overt 
abnormalities under standard laboratory conditions; however, IRP2 KO mice developed 
microcytic anaemia, elevated red cell protoporphyrin IX levels, high serum ferritin, and 
adult-onset neurodegeneration. When mice are missing both copies of IRP2 and one copy of 
IRP1 they develop a more severe anaemia and neurodegeneration compared with mice with 
deletion of IRP2 alone (Smith et al., 2006). At the cellular level, Galy and collaborators 
reported that mitochondrial iron supply and function also require IRPs for cellular ATP, 
haem and iron-sulphur cluster production (Galy et al., 2010). 
Both IRPs are expressed in all tissues, however IRP1 is particularly abundant in kidney and 
brown fat, and IRP2 expression is higher in brain, intestine, and cells of the 
reticuloendothelial system (reviewed in (Cairo & Pietrangelo, 2000)).  
2.1.2.1 Structure and regulation of IRPs by iron 
IRP1 is a dual-functional protein with a key role in the control of iron metabolism as an IRE-
binding protein and with an additional function as a cytoplasmic isoform of the aconitase 
enzyme (Figure 4). Aconitases are a group of iron-sulphur enzymes that require a 4Fe-4S 
cluster (iron-sulphur cluster, ISC) for their function. The ISC is essential to catalyse the 
conversion of citrate to isocitrate via the intermediate cis-aconitate during the citric acid 
cycle. Three iron atoms are attached to cysteine residues of the active site, whereas a fourth 
iron remains free and mediates catalytic chemistry (reviewed in (Eisenstein, 2000)). IRP1, as 
cytosolic aconitase (c-aconitase), catalyses the citrate to isocitrate conversion in the cytosol 
and shares 30% amino acid sequence homology with mitochondrial aconitase (m-aconitase), 
which catalyzes the same reaction in the mitochondrial matrix. In contrast with m-aconitase, 
IRP1 only retains its ISC and enzymatic function in iron-replete cells, and thus only 
functions as a cytosolic aconitase when cells have high levels of iron. Under iron scarcity, 
the ISC dissemble from holo-IRP1 and the protein is converted into IRP1 apo-protein, 
acquiring IRE-binding ability. Hence, IRP1 is reversibly regulated by this unusual ISC 
switch (Wallander et al., 2006).  
The IRP1 protein is composed of four globular domains. In its c-aconitase form, domains 1–3 
are compact and join domain 4 through a polypeptide linker and the ISC is central at the 
interface of the four domains. The ISC structure and surrounding environment are fairly 
well conserved between c- and m-aconitases. Nevertheless, the overall structure of holo-
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IRP1 (a 889 amino acid protein), shows differences to m-aconitase, which is smaller (780 
amino acids). The short IRP1 fragments that do not superimpose with m-aconitase are 
exposed on the surface of the protein. As a result, the shapes and surface topologies of holo-
IRP1 and m-aconitase diverge substantially, which may explain the fact that IRP1 is the only 
aconitase that can acquire IRE binding activity.  
 
Fig. 4. Iron regulation of Iron-Regulatory Proteins IRP1 and IRP2. Under iron depleted 
conditions (-Fe) IRP1 and IRP2 bind to IREs. IRP1 is a bi-functional protein acting as an 
aconitase when it assembles an iron-sulphur cluster (4Fe-4S) or as an IRE binding protein. 
IRP2 undergoes proteosomal degradation via ubiquitinization (Ub) when iron (Fe) and 
oxygen (O2) levels are high. FBXL5: F-Box and leucine rich repeat protein 5, SKP1: S-Phase 
kinase-associated protein 1, CUL1: Cullin 1.  
IRP1 apo-protein shows an open conformation compared with that of cytosolic aconitase, 
allowing its interactions with IREs and controlling the gene expression of key proteins of 
iron metabolism. IRP1: H-ferritin IRE crystal structural complex has been resolved at a 
resolution of 2.8Å and the details of its reorganization upon loss of its ISC has been 
described by Walden and collaborators (Walden et al., 2006). IRP1 conformational changes 
after loss of its ISC reveals a rotation of domain 4 and an extensive rearrangement of domain 
3, creating a hydrophilic cavity that allows access to the IRE (Figure 4). The RNA–protein 
interaction requires two important segments at the interface of domain 2 (residues 436–442) 
and domain 3 (residues 534–544). Thr438 and Asn439 make direct contact with the IRE. The 
terminal residues of the IRE motif, A15, G16 and U17 (see figure 3A), interact with Ser371, 
Lys379 and Arg269 respectively within a cavity between domains 2 and 3. A second binding 
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deficient cells, IRPs bind to iron-responsive elements (IREs) found in the mRNAs of ferritin, 
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decreasing iron sequestration. IRP1 registers cytosolic iron status mainly through an iron-
sulphur cluster switch mechanism, alternating between an active cytosolic aconitase form 
with an iron-sulphur cluster ligated to its active site and an apo-protein form that binds 
IREs. Although IRP2 is 60 to 70% identical to IRP1 (one of the major difference is an extra 73 
amino acid insertion present in IRP2), both proteins are differentially regulated. IRP2 does 
not have an aconitase function and its activity is regulated primarily by iron-dependent 
degradation through a ubiquitin-proteasomal system in iron-replete cells (see next section).  
Constitutive deletion of both IRPs is embryonic lethal, demonstrating that the IRP/IRE 
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Matthias W. Hentze (EMBL) and Tracey Rouault (NIH) have reported knock-out targeted 
deletion strategies for IRP1 and/or IRP2 in whole animals or tissue specific. Their 
publications show that adult mice that constitutively lack IRP1 develop no overt 
abnormalities under standard laboratory conditions; however, IRP2 KO mice developed 
microcytic anaemia, elevated red cell protoporphyrin IX levels, high serum ferritin, and 
adult-onset neurodegeneration. When mice are missing both copies of IRP2 and one copy of 
IRP1 they develop a more severe anaemia and neurodegeneration compared with mice with 
deletion of IRP2 alone (Smith et al., 2006). At the cellular level, Galy and collaborators 
reported that mitochondrial iron supply and function also require IRPs for cellular ATP, 
haem and iron-sulphur cluster production (Galy et al., 2010). 
Both IRPs are expressed in all tissues, however IRP1 is particularly abundant in kidney and 
brown fat, and IRP2 expression is higher in brain, intestine, and cells of the 
reticuloendothelial system (reviewed in (Cairo & Pietrangelo, 2000)).  
2.1.2.1 Structure and regulation of IRPs by iron 
IRP1 is a dual-functional protein with a key role in the control of iron metabolism as an IRE-
binding protein and with an additional function as a cytoplasmic isoform of the aconitase 
enzyme (Figure 4). Aconitases are a group of iron-sulphur enzymes that require a 4Fe-4S 
cluster (iron-sulphur cluster, ISC) for their function. The ISC is essential to catalyse the 
conversion of citrate to isocitrate via the intermediate cis-aconitate during the citric acid 
cycle. Three iron atoms are attached to cysteine residues of the active site, whereas a fourth 
iron remains free and mediates catalytic chemistry (reviewed in (Eisenstein, 2000)). IRP1, as 
cytosolic aconitase (c-aconitase), catalyses the citrate to isocitrate conversion in the cytosol 
and shares 30% amino acid sequence homology with mitochondrial aconitase (m-aconitase), 
which catalyzes the same reaction in the mitochondrial matrix. In contrast with m-aconitase, 
IRP1 only retains its ISC and enzymatic function in iron-replete cells, and thus only 
functions as a cytosolic aconitase when cells have high levels of iron. Under iron scarcity, 
the ISC dissemble from holo-IRP1 and the protein is converted into IRP1 apo-protein, 
acquiring IRE-binding ability. Hence, IRP1 is reversibly regulated by this unusual ISC 
switch (Wallander et al., 2006).  
The IRP1 protein is composed of four globular domains. In its c-aconitase form, domains 1–3 
are compact and join domain 4 through a polypeptide linker and the ISC is central at the 
interface of the four domains. The ISC structure and surrounding environment are fairly 
well conserved between c- and m-aconitases. Nevertheless, the overall structure of holo-
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IRP1 (a 889 amino acid protein), shows differences to m-aconitase, which is smaller (780 
amino acids). The short IRP1 fragments that do not superimpose with m-aconitase are 
exposed on the surface of the protein. As a result, the shapes and surface topologies of holo-
IRP1 and m-aconitase diverge substantially, which may explain the fact that IRP1 is the only 
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aconitase when it assembles an iron-sulphur cluster (4Fe-4S) or as an IRE binding protein. 
IRP2 undergoes proteosomal degradation via ubiquitinization (Ub) when iron (Fe) and 
oxygen (O2) levels are high. FBXL5: F-Box and leucine rich repeat protein 5, SKP1: S-Phase 
kinase-associated protein 1, CUL1: Cullin 1.  
IRP1 apo-protein shows an open conformation compared with that of cytosolic aconitase, 
allowing its interactions with IREs and controlling the gene expression of key proteins of 
iron metabolism. IRP1: H-ferritin IRE crystal structural complex has been resolved at a 
resolution of 2.8Å and the details of its reorganization upon loss of its ISC has been 
described by Walden and collaborators (Walden et al., 2006). IRP1 conformational changes 
after loss of its ISC reveals a rotation of domain 4 and an extensive rearrangement of domain 
3, creating a hydrophilic cavity that allows access to the IRE (Figure 4). The RNA–protein 
interaction requires two important segments at the interface of domain 2 (residues 436–442) 
and domain 3 (residues 534–544). Thr438 and Asn439 make direct contact with the IRE. The 
terminal residues of the IRE motif, A15, G16 and U17 (see figure 3A), interact with Ser371, 
Lys379 and Arg269 respectively within a cavity between domains 2 and 3. A second binding 
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site is present around the unpaired-C-bulge residue (C8 bulge, Figure 3A) located between 
the upper and lower stem, which occupies a pocket within domain 4, involving residues 
between Arg713 and Arg780. The IRE–IRP1 complex is also stabilized by additional ionic 
interactions. The evolutionary origin and selective advantage of the IRP1 dramatic 
conformational plasticity and dual functionality remains to be determined. 
A second IRE-binding protein first named IRFB and lately renamed as IRP2 was isolated 
and characterized in rodents in 1993 (Henderson et al., 1993). This manuscript also reports 
that IRP1 IRE binding activity is predominant in liver, intestine, and kidney, while IRP2 
revealed highest binding activity in intestine and brain. Human IRP2 has a molecular mass 
of 105 kD, slightly larger than human IRP1 (87kD) due to an extra 73 amino acid insertion. 
Human IRP2 shares 57% homology with human IRP1. Despite this homology, IRP2 is 
unable to assemble an iron-sulphur cluster and thus has no aconitase activity. IRP1 and 
IRP2’s role in controlling mRNA translation and stabilization in IRE-containing mRNAs is 
similar, that is both proteins carry out a translational repression in 5’ IREs and mRNA 
stabilization in 3’ IREs. However unlike IRP1, IRP2 is rapidly targeted for degradation in 
iron-replete cells (Recalcati et al., 2010). It seems that the mechanism by which IRP2 
undergoes iron-dependent degradation may involve different aspects. The 73 cysteine rich 
amino acid domain of IRP2 may be responsible for this degradation due to its ability to 
facilitate iron-dependent oxidation, ubiquitination, and proteasomal degradation (Wang & 
Pantopoulos, 2011). Recently, two groups have independently identified the protein FBXL5 
as part of the ubiquitin ligase complex that promotes iron-dependent polyubiquitination 
and degradation of IRP2 (Salahudeen et al., 2009; Vashisht et al., 2009) (see Figure 4). As the 
stability of FBXL5 itself is controlled by iron and/or oxygen levels through an iron-binding 
hemerythrin-like domain located in the N-terminus, FBXL5 accumulates when iron is 
plentiful and is degraded upon iron depletion. By this mechanism the presence of FBXL5 in 
iron rich conditions works as a key sensor in the regulation of IRP2 degradation. No crystal 
structure of IRP2 is available as of yet, and forthcoming experiments will allow us to 
elucidate the role (if any) of the extra amino acid residues in IRP2 IRE binding specificity 
and/or their role in protein degradation. Ultimately, the crystallization of IRP2, especially in 
a complex with IRE, will be necessary to precisely map the RNA–protein interactions and 
further shed light on its mechanistic properties (Wang & Pantopoulos, 2011). 
2.1.2.2 Regulation of IRPs by other stimuli than iron 
Iron was the first identified regulator of the IRP/IRE network however various other 
stimuli, drugs and pathological agents have been reported to affect IRP activity. 
Hypoxia  
IRP1 and IRP2 are regulated by oxygen levels (reviewed in (Rouault, 2006)) which control their 
binding activity. Hypoxia has been shown to decrease the binding to IREs in IRP1 by 
favouring the assembly of the ISC and causing IRP1 to acquire aconitase activity, but 
increasing IRP2 activity (Meyron-Holtz et al., 2004). Other studies also reported an opposite 
regulatory effect of hypoxia on IRP1 and IRP2 IRE binding activities, though not all studies 
agree on the direction of this divergent modulation. As described in section 2.1.2.1 IRP2 
degradation is controlled by FBXL5 in an iron- and oxygen-dependent manner, which 
suggests one possible explanation for the differential regulation of the two IRPs by hypoxia. At 
low oxygen concentrations, which favour the assembly of an ISC of IRP1 and stabilise IRP2, 
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the latter regulates iron homeostasis but, at high oxygen concentrations, FBXL5 is stabilised, 
interacts with IRP2 and induces its degradation, whereas the apoform of IRP1 can bind and 
regulate the mRNAs encoding proteins of iron metabolism. These mechanisms may therefore 
allow cells to regulate iron metabolism effectively over a broad range of oxygen availability.  
Hypoxia has also been shown to reduce IRP1 binding to HIF-2α mRNA via a newly 
identified 5’ IRE (see section 2.1.3.5), while slightly increasing binding to IRP2 (Zimmer et 
al., 2008). Interestingly, these authors describe a major effect of IRP1 on de-repression of 
HIF-2α translation in hypoxic conditions, and they suggest that IRP1 acts as a direct or 
indirect sensor of hypoxia, which is somehow contradictory to the previous reported 
predominant role of IRP2 at physiologically low oxygen levels (3%-5%). This work was done 
in the context of renal cells in which IRP1 is particularly abundant, and this may explain the 
main regulatory role of IRP1 in HIF translation during hypoxia. 
Oxidative stress 
Both IRP1 and IRP2 are sensitive to ROS (Reactive Oxygen Species) and RNS (Reactive 
Nitrogen Species) (reviewed in (Cairo & Pietrangelo, 2000)). As explained earlier, the redox 
regulation of IRP1 is mediated by its iron-sulphur cluster (ISC) switch. Exposure of cells to 
H2O2 leads to the removal of ISC and conversion of IRP1 into a null protein lacking both 
RNA binding and aconitase activities. This conversion can be reversed by myeloperoxidase-
derived hypochlorite (Mutze et al., 2003). 
Early studies of exogenous H2O2 exposure to cell lines were shown to increase IRP1 
expression (Cairo & Pietrangelo, 2000) though this was later shown to be a consequence of 
signalling pathway effects rather than direct oxidative stress on IRP1 (Caltagirone et al., 
2001). Successive studies in various cell models have reported a number of agents 
(superoxide, phorone, quinone) (reviewed in (Recalcati et al., 2010)) with the ability to 
increase cellular H2O2 and O2- and reversibly inactivate IRP1. This opens up the question of 
whether IRP1 inactivation (and subsequent TFR1 down-regulation, ferritins up-regulation 
and therefore decreasing LIP) is a homeostatic response to subdue ROS formation.  
ROS studies on IRP2 have revealed seemingly contradictory results to date. Iwai and 
collaborators suggested that ROS triggers down-regulation of IRP2 by alterations to 
“sensitive” amino acid residues leading to ubiquitin-dependent proteasomal degradation 
(Iwai et al., 1998). However, a more recent study reported that treatment of murine 
macrophage cells with exogenous H2O2 protects IRP2 against iron and increases its IRE-
binding activity (Hausmann et al., 2011). Moreover, they also showed that IRP2 is stabilized 
during menadione-induced oxidative stress suggesting that the degradation of IRP2 in iron-
replete cells is not only oxygen-dependent but also sensitive to redox perturbations. Overall, 
further in-depth analysis of the exact role of oxidative stress is needed to properly evaluate 
its specific role in iron homeostasis. 
Nitric Oxide 
Nitric Oxide (NO) is a vital signalling and effector molecule that can rapidly switch IRP1 
from its holo- to the apo-form (Drapier, 1997). NO is produced by NO synthases and once 
released, attacks the ISC of IRP1 promoting its gradual disassembly and complete removal 
suggesting this NO-mediated switch could represent a homoeostatic response to iron 
starvation. NO has also been implicated in promoting iron efflux from cells (Drapier, 1997). 
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site is present around the unpaired-C-bulge residue (C8 bulge, Figure 3A) located between 
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that IRP1 IRE binding activity is predominant in liver, intestine, and kidney, while IRP2 
revealed highest binding activity in intestine and brain. Human IRP2 has a molecular mass 
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as part of the ubiquitin ligase complex that promotes iron-dependent polyubiquitination 
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stability of FBXL5 itself is controlled by iron and/or oxygen levels through an iron-binding 
hemerythrin-like domain located in the N-terminus, FBXL5 accumulates when iron is 
plentiful and is degraded upon iron depletion. By this mechanism the presence of FBXL5 in 
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structure of IRP2 is available as of yet, and forthcoming experiments will allow us to 
elucidate the role (if any) of the extra amino acid residues in IRP2 IRE binding specificity 
and/or their role in protein degradation. Ultimately, the crystallization of IRP2, especially in 
a complex with IRE, will be necessary to precisely map the RNA–protein interactions and 
further shed light on its mechanistic properties (Wang & Pantopoulos, 2011). 
2.1.2.2 Regulation of IRPs by other stimuli than iron 
Iron was the first identified regulator of the IRP/IRE network however various other 
stimuli, drugs and pathological agents have been reported to affect IRP activity. 
Hypoxia  
IRP1 and IRP2 are regulated by oxygen levels (reviewed in (Rouault, 2006)) which control their 
binding activity. Hypoxia has been shown to decrease the binding to IREs in IRP1 by 
favouring the assembly of the ISC and causing IRP1 to acquire aconitase activity, but 
increasing IRP2 activity (Meyron-Holtz et al., 2004). Other studies also reported an opposite 
regulatory effect of hypoxia on IRP1 and IRP2 IRE binding activities, though not all studies 
agree on the direction of this divergent modulation. As described in section 2.1.2.1 IRP2 
degradation is controlled by FBXL5 in an iron- and oxygen-dependent manner, which 
suggests one possible explanation for the differential regulation of the two IRPs by hypoxia. At 
low oxygen concentrations, which favour the assembly of an ISC of IRP1 and stabilise IRP2, 
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the latter regulates iron homeostasis but, at high oxygen concentrations, FBXL5 is stabilised, 
interacts with IRP2 and induces its degradation, whereas the apoform of IRP1 can bind and 
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allow cells to regulate iron metabolism effectively over a broad range of oxygen availability.  
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Oxidative stress 
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whether IRP1 inactivation (and subsequent TFR1 down-regulation, ferritins up-regulation 
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“sensitive” amino acid residues leading to ubiquitin-dependent proteasomal degradation 
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Nitric Oxide 
Nitric Oxide (NO) is a vital signalling and effector molecule that can rapidly switch IRP1 
from its holo- to the apo-form (Drapier, 1997). NO is produced by NO synthases and once 
released, attacks the ISC of IRP1 promoting its gradual disassembly and complete removal 
suggesting this NO-mediated switch could represent a homoeostatic response to iron 
starvation. NO has also been implicated in promoting iron efflux from cells (Drapier, 1997). 
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The effect of NO on IRP2 has also been studied, although with contradictory results. Wang 
and collaborators claimed that IRP2 was activated under NO exposure (Wang et al., 2005), 
whereas Kim and collaborators demonstrated that IRP2 degradation was NO-dependent (S. 
Kim et al., 2004). Mulero and collaborators showed that IRP2 had a lack of regulation by NO 
(Mulero & Brock, 1999). Furthermore, it has been reported that endogenous and exogenous 
NO increases (S. Kim & Ponka, 2002) or decreases (Pantopoulos & Hentze, 1995) ferritin 
levels and further discrepant results of TfR1 regulation by NO has been described 
(Pantopoulos & Hentze, 1995). As a result, the role of the IRP/IRE system in NO-mediated 
regulation of cellular iron metabolism still remains unknown.  
Other antioxidants, such as ascorbate, α-tocopherol and N-acetylcysteine have also been 
shown to disturb the IRE/IRP regulation system by promoting the proteasomal turnover of 
IRP2 (Wang et al., 2004).  
Other stimuli that affect IRP regulation: Hormones and viruses 
A number of hormones and viruses have been documented as interacting with IRPs and 
regulating iron metabolism. In an extensive report, in vitro and in vivo studies of the thyroid 
hormone showed that it functionally regulates the IRE binding activity of the IRPs to ferritin 
mRNA (Leedman et al., 1996). Estrogens modulate the RNA binding of IRP1 in adipose 
tissue and consequently the expression of ferritin and TfR1 (Mattace Raso et al., 2009).  
Given the importance of iron in viral infections and replication (Drakesmith & Prentice, 
2008) several studies have outlined the impact of viruses on iron homeostasis. In the case of 
Herpes Virus-1 infection of Madin-Darby bovine kidney cells, IRP RNA binding activity 
was reported to be reduced (Maffettone et al., 2008). However, this effect may be due to 
different factors, as shown in studies on the hepatitis B virus X protein that produced an 
increase in ROS and thus IRP1 down modulation (Gu et al., 2008). Similarly, in a cell culture 
model of hepatitis C virus replication, the down-regulation of TfR1, increased FPN levels 
and reduced LIP were associated with concomitant induction of IRE-binding activity and 
IRP2 expression (Fillebeen et al., 2007). 
Other stimuli that affect IRP regulation: Xenobiotics 
Many studies of xenobiotic effects on the IRP/IRE regulatory system have been performed 
with Doxorubicin (DOX). DOX is an anti-cancer anthracycline that causes a severe form of 
chronic cardiomyopathy. The alcohol metabolite of DOX (DOXol) breaks iron away from the 
iron-sulphur cluster of cytoplasmic aconitase and the O2 free radicals and H2O2 derived 
from the redox activation of DOX convert IRP1 to a null protein (Brazzolotto et al., 2003). In 
another study it was shown that this null protein does not actually rely on the action of 
DOXol but on anthracycline-iron complexes attacking both aconitase and IRP1 (Kwok & 
Richardson, 2002). IRP2 protein does not contain an ISC and is not affected by DOXol, but is 
degraded by the action of the ROS that is produced (Minotti et al., 2001). The ability of DOX 
to regulate the RNA binding activity of IRP1 and IRP2 may also be due to its anti-tumoral 
and cardiotoxic activities. The possibility of combining DOX with other anti-neoplastic 
drugs is currently being tested for clinical applications. 
Other stimuli that affect IRP regulation: Cell growth  
Iron homeostasis and cell growth are interrelated because iron is essential for cell 
proliferation and is especially required in neoplastic cells as they proliferate faster and thus 
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require elevated iron supplies. This is demonstrated by a higher expression of TfR1 and 
higher transferrin iron uptake in cancer cells. In addition, iron is required for the function of 
many proteins involved in cell cycle and DNA synthesis (e.g. Ribonucleotide Reductase). 
Moreover, iron appears to play a critical role in the expression and regulation of a number of 
molecules that control cell cycle progression e.g. p53, GADD45 and WAF1/p21 (Gao et al., 
1999). In fact, without iron, cells are unable to proceed from G1 to the S phase of the cell 
cycle due to post-transcriptional regulation caused by iron depletion in cyclin D1 expression 
(a protein that plays a critical role in G1 progression) (Nurtjahja-Tjendraputra et al., 2007).  
The cell cycle further manipulates the IRP/IRE regulatory system as IRP2 is phosphorylated 
at Ser 157, independently of iron levels, by Cdk1/cyclin B1 during the G2/M phase of the 
cell cycle, and in turn dephosphorylated by CDC14A after mitosis. This reduces IRP2 RNA 
binding activity in the G2/M phase of the cell cycle, increasing ferritin synthesis and 
impairing TfR1 mRNA stability (Wallander et al., 2008). Therefore, it seems that this 
reversible phosphorylation of IRP2 facilitates cell cycle progression. It has been shown that 
IRP activity is high in a classical model of non-neoplastic cell growth such as liver 
regeneration (Cairo & Pietrangelo, 1994). Cell proliferation induces IRP2 activity possibly 
because of the combined effect of high iron consumption in growing cells and IRP2’s 
preferential sensitivity to iron deprivation (Recalcati et al., 1999). However, the fact that 
IRP2 transcription is specifically stimulated by a c-myc oncogene (Wu et al., 1999) suggests 
that the induction of IRP2 activity (with consequent ferritin repression and TfR1 up-
regulation) may be specifically aimed at ensuring sufficient iron for the metabolic 
requirement of proliferating cells.  
In 2006, Sanchez and collaborators reported a novel IRE located in the 3' UTR of the cell 
division cycle 14A (CDC14A) mRNA that efficiently binds both IRP1 and IRP2 (Sanchez et 
al., 2006) (see also section 2.1.3.5). Differential splicing of CDC14A produces IRE- and 
non-IRE-containing mRNA isoforms. Interestingly, only the expression of the IRE-
containing mRNA isoforms is selectively increased by cellular iron deficiency. This 
uncovered a previously unrecognized regulatory link between iron metabolism and the 
cell cycle. 
2.1.3.1 The IRP/IRE regulatory network in iron uptake 
The main cellular iron uptake pathway is mediated by Transferrin Receptor 1 (TFR1, gene 
located on chromosome 3q29), which internalises iron-bound transferrin (TF) via a receptor-
mediated endocytosis mechanism (Ponka et al., 1998). Iron-loaded transferrin binds with 
high affinity to TFR1 on the surface of cells, and the complex undergoes endocytosis via 
clathrin-coated pits. Once inside the endosome, a proton pump lowers the pH to 5.5, 
resulting in the release of Fe3+ from transferrin. Subsequently, the affinity of transferrin to 
TFR1 falls about 500-fold, resulting in its de-attachment of the TFR1-TF complex. In the final 
step of the cycle, non-iron bound transferrin is secreted into the bloodstream to recapture 
more Fe3+ and the transferrin receptor 1 protein is again relocated in the cell surface for 
another round of endocytosis. 
TFR1 is expressed in many cells and plays a relevant function in erythroid iron acquisition 
for haem synthesis and haemoglobinization. Its expression parallels the maturation of 
erythroid progenitors and is involved in the development of erythrocytes and the nervous 
system (Levy et al., 1999). 
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require elevated iron supplies. This is demonstrated by a higher expression of TfR1 and 
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Moreover, iron appears to play a critical role in the expression and regulation of a number of 
molecules that control cell cycle progression e.g. p53, GADD45 and WAF1/p21 (Gao et al., 
1999). In fact, without iron, cells are unable to proceed from G1 to the S phase of the cell 
cycle due to post-transcriptional regulation caused by iron depletion in cyclin D1 expression 
(a protein that plays a critical role in G1 progression) (Nurtjahja-Tjendraputra et al., 2007).  
The cell cycle further manipulates the IRP/IRE regulatory system as IRP2 is phosphorylated 
at Ser 157, independently of iron levels, by Cdk1/cyclin B1 during the G2/M phase of the 
cell cycle, and in turn dephosphorylated by CDC14A after mitosis. This reduces IRP2 RNA 
binding activity in the G2/M phase of the cell cycle, increasing ferritin synthesis and 
impairing TfR1 mRNA stability (Wallander et al., 2008). Therefore, it seems that this 
reversible phosphorylation of IRP2 facilitates cell cycle progression. It has been shown that 
IRP activity is high in a classical model of non-neoplastic cell growth such as liver 
regeneration (Cairo & Pietrangelo, 1994). Cell proliferation induces IRP2 activity possibly 
because of the combined effect of high iron consumption in growing cells and IRP2’s 
preferential sensitivity to iron deprivation (Recalcati et al., 1999). However, the fact that 
IRP2 transcription is specifically stimulated by a c-myc oncogene (Wu et al., 1999) suggests 
that the induction of IRP2 activity (with consequent ferritin repression and TfR1 up-
regulation) may be specifically aimed at ensuring sufficient iron for the metabolic 
requirement of proliferating cells.  
In 2006, Sanchez and collaborators reported a novel IRE located in the 3' UTR of the cell 
division cycle 14A (CDC14A) mRNA that efficiently binds both IRP1 and IRP2 (Sanchez et 
al., 2006) (see also section 2.1.3.5). Differential splicing of CDC14A produces IRE- and 
non-IRE-containing mRNA isoforms. Interestingly, only the expression of the IRE-
containing mRNA isoforms is selectively increased by cellular iron deficiency. This 
uncovered a previously unrecognized regulatory link between iron metabolism and the 
cell cycle. 
2.1.3.1 The IRP/IRE regulatory network in iron uptake 
The main cellular iron uptake pathway is mediated by Transferrin Receptor 1 (TFR1, gene 
located on chromosome 3q29), which internalises iron-bound transferrin (TF) via a receptor-
mediated endocytosis mechanism (Ponka et al., 1998). Iron-loaded transferrin binds with 
high affinity to TFR1 on the surface of cells, and the complex undergoes endocytosis via 
clathrin-coated pits. Once inside the endosome, a proton pump lowers the pH to 5.5, 
resulting in the release of Fe3+ from transferrin. Subsequently, the affinity of transferrin to 
TFR1 falls about 500-fold, resulting in its de-attachment of the TFR1-TF complex. In the final 
step of the cycle, non-iron bound transferrin is secreted into the bloodstream to recapture 
more Fe3+ and the transferrin receptor 1 protein is again relocated in the cell surface for 
another round of endocytosis. 
TFR1 is expressed in many cells and plays a relevant function in erythroid iron acquisition 
for haem synthesis and haemoglobinization. Its expression parallels the maturation of 
erythroid progenitors and is involved in the development of erythrocytes and the nervous 
system (Levy et al., 1999). 
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Knockout mice homozygous for a null mutation in the transferrin receptor 1 (Tfr1) gene die 
after 12.5 days from severe anaemia and neurological abnormalities during embryonic 
development (Levy et al., 1999). These mice have a more severe phenotype than 
homozygous hypotransferrinaemic (hpx/hpx) mice that carry a mutation in the transferrin 
gene and have a severe reduction of transferrin expression. Haploinsufficiency for Tfr1 
(Trfr+/–) results in impaired erythroid development with microcytic, hypochromic 
erythrocytes and abnormal iron homeostasis with mild tissue iron depletion in liver and 
spleen. In this regard, Trfr+/– mice differ from hpx/hpx and +/hpx mice, which have 
increased intestinal iron absorption leading to tissue iron overload.  
TFR1 expression is controlled by iron and oxygen status amongst other factors (Cairo & 
Pietrangelo, 2000). At the transcriptional level, TFR1 is regulated by the hypoxia-inducible 
factor HIF1 in response to low oxygen levels and iron starvation (Bianchi et al., 1999). In 
addition, the TFR1 promoter region contains potential binding sites for transcription factors 
such as c-myc (O'Donnell et al., 2006). Nevertheless, in most cells TFR1 expression is mainly 
controlled post-transcriptionally by cellular iron levels through binding of IRP1 and IRP2 to 
five IREs located in the 3’ UTR of the TFR1 mRNA (see Figure 2). TFR1 mRNA is stabilized 
by the binding of IRPs under iron-starved conditions by a mechanism that involves the 
protection of the mRNA degradation by a cleavage of a putative, as yet unidentified, 
endonuclease (Figure 1). This mechanism will ensure an increased expression of TFR1 in the 
cell surface to stimulate the acquisition of iron from plasma transferrin, and it will be 
blocked in iron-replete cells. However, the IRP/IRE regulation of TFR1 mRNA is overridden 
in specialized cells such as the erythroid progenitor cells, where TFR1 mRNA stability is 
uncoupled from iron supply and IRP regulation to ensure efficient massive iron uptake 
needed in these cells for haem synthesis and haemoglobinisation. In these cells TFR1 
expression is regulated transcriptionally by a promoter erythroid active element (Lok & 
Ponka, 2000). 
The SLC11A2 gene, located on chromosome 12q13, encodes a member of the solute carrier 
11 protein family named Divalent Metal Transporter 1 (DMT1) or natural resistance-
associated macrophage protein 2 (Nramp2). DMT1 is a glycoprotein that consists of twelve 
transmembrane domains and transports reduced ferrous iron (Fe+2) and other divalent 
metals (manganese, cobalt, nickel, cadmium, lead, copper, and zinc) to the inside of 
duodenal enterocytes, where it is highly expressed at the apical (luminal) site (Mackenzie & 
Garrick, 2005).  
Inorganic iron absorption via DMT1 is an important iron uptake pathway, as observed in 
homozygous mk/mk mice that have microcytic, hypochromic anaemia due to severe defects 
in intestinal iron absorption and erythroid iron utilization. By positional cloning, Fleming 
and collaborators discovered in 1997 that a missense mutation in the gene Nramp2 was 
responsible for the mk mouse phenotype (Fleming et al., 1997). One year later the same 
group also reported that a similar phenotype present in Belgrade (b) rats was due to the 
same missense mutation, a glycine-to-arginine missense mutation (G185R), in the Nramp2 
gene (Fleming et al., 1998). Functional studies of the protein encoded by the mutated b allele 
of rat Nramp2 demonstrated that the mutation disrupted iron transport. Therefore, the 
phenotypic characteristics of mk mouse and Belgrade rats indicate that Nramp2 is not only 
essential for normal intestinal iron absorption but also for transport of iron out of the 
transferrin cycle endosome. 
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DMT1 is a conserved transporter in vertebrates and the phenotype called chardonnay (cdy) 
in zebrafish mutants with hypochromic, microcytic anaemia is due to a nonsense mutation 
in DMT1. The truncated DMT1 protein expressed in cdy mutants is not functional (Donovan 
et al., 2002). In humans, mutations in this gene are associated with hypochromic microcytic 
anaemia with iron overload. This is a very rare disease so far described in only five subjects 
(OMIM 206100).  
The SLC11A2 gene encodes four transcripts that are the result of alternative splicing at the 5’ 
or 3’ end, yielding DMT-1A-IRE, DMT-1B-IRE, DMT-1A-nonIRE, and DMT-1B-nonIRE 
isoforms. The different isoforms of DMT1 are differentially expressed in tissues, increasing 
somewhat the complexity of the study of this gene (Hubert & Hentze, 2002). One of the two 
3’ splicing forms (the IRE isoform) contains an IRE structure in its 3’ UTR (see Figure 2) and 
is up-regulated by iron deficiency via the IRPs (Mackenzie & Garrick, 2005); however, the 
regulation of DMT1 is very complex and both transcriptional and post-transcriptional 
regulations may be involved in its gene expression regulation. The ablation of both IRPs in 
intestinal epithelial cells reduces the levels of IRE-containing DMT1 mRNA and DMT1-
dependent intestinal iron uptake (Galy et al., 2008), but transcriptional regulation may be 
important, as is also suggested by recent studies showing that HIF2α–dependent DMT1 
transcription plays a role in intestinal iron uptake (Mastrogiannaki et al., 2009).  
2.1.3.2 The IRP/IRE regulatory network in iron storage 
In addition to iron recycling and absorption, the storage and potential release of (excess) 
iron are critical determinants of circulating iron levels. Under physiological conditions, 
approximately 20% (0.5 to 1g) of the body’s total iron content is stocked in the storage 
compartment, and only 1 to 2mg of iron is lost each day. The iron stores become depleted 
when iron absorption does not meet the body’s needs or in cases of excessive iron loss (e.g. 
bleeding, pregnancy); conversely, tissue iron overload occurs when intestinal iron 
absorption surpasses iron utilization and loss (Andrews, 2010). Iron storage should be 
therefore tightly controlled to avoid an iron imbalance that will lead to a disease stage. 
Ferritins are the major iron storage protein, and are found in the cytoplasm, mitochondria, 
and nucleus of the cells (Arosio et al., 2009). In vertebrates, cytoplasmic ferritin is expressed 
in almost all tissues and plays an important role in the control of intracellular iron 
distribution. Ferritin consists of a 24-subunit heteromultimer of light (L) and heavy (H) 
chains (174 and 182 amino acids respectively) that form a spherical shell around a cavity 
where iron (as ferric oxide) is stored. Each subunit has a distinct role in iron metabolism: L-
ferritin facilitates iron-core formation and H-ferritin subunit generates ferroxidase activity 
(converting Fe+2 to Fe+3) to incorporate iron into the protein shell. Plant and bacteria ferritins 
have only a single type of subunit which probably fulfils both functions. L- and H-ferritin 
subunits are synthesized by two different genes located on chromosomes 19q13.2 and 11q13, 
respectively. Although both genes are ubiquitously expressed, post-transcriptional 
regulation mediates tissue-specific changes in the H/L mRNA ratio.  
The best characterized system regulating ferritin expression is the post-transcriptional, iron-
dependent machinery based on the interaction between the IRPs and IREs localized in the 5’ 
untranslated region of H- and L-ferritin mRNA (Muckenthaler et al., 2008) (see Figure 1 and 
2). Iron deficient cells need to rapidly mobilize the iron storage pool and in these conditions 
there is no need for the production of ferritins. This is achieved through the formation of 
 
Iron Metabolism 38
Knockout mice homozygous for a null mutation in the transferrin receptor 1 (Tfr1) gene die 
after 12.5 days from severe anaemia and neurological abnormalities during embryonic 
development (Levy et al., 1999). These mice have a more severe phenotype than 
homozygous hypotransferrinaemic (hpx/hpx) mice that carry a mutation in the transferrin 
gene and have a severe reduction of transferrin expression. Haploinsufficiency for Tfr1 
(Trfr+/–) results in impaired erythroid development with microcytic, hypochromic 
erythrocytes and abnormal iron homeostasis with mild tissue iron depletion in liver and 
spleen. In this regard, Trfr+/– mice differ from hpx/hpx and +/hpx mice, which have 
increased intestinal iron absorption leading to tissue iron overload.  
TFR1 expression is controlled by iron and oxygen status amongst other factors (Cairo & 
Pietrangelo, 2000). At the transcriptional level, TFR1 is regulated by the hypoxia-inducible 
factor HIF1 in response to low oxygen levels and iron starvation (Bianchi et al., 1999). In 
addition, the TFR1 promoter region contains potential binding sites for transcription factors 
such as c-myc (O'Donnell et al., 2006). Nevertheless, in most cells TFR1 expression is mainly 
controlled post-transcriptionally by cellular iron levels through binding of IRP1 and IRP2 to 
five IREs located in the 3’ UTR of the TFR1 mRNA (see Figure 2). TFR1 mRNA is stabilized 
by the binding of IRPs under iron-starved conditions by a mechanism that involves the 
protection of the mRNA degradation by a cleavage of a putative, as yet unidentified, 
endonuclease (Figure 1). This mechanism will ensure an increased expression of TFR1 in the 
cell surface to stimulate the acquisition of iron from plasma transferrin, and it will be 
blocked in iron-replete cells. However, the IRP/IRE regulation of TFR1 mRNA is overridden 
in specialized cells such as the erythroid progenitor cells, where TFR1 mRNA stability is 
uncoupled from iron supply and IRP regulation to ensure efficient massive iron uptake 
needed in these cells for haem synthesis and haemoglobinisation. In these cells TFR1 
expression is regulated transcriptionally by a promoter erythroid active element (Lok & 
Ponka, 2000). 
The SLC11A2 gene, located on chromosome 12q13, encodes a member of the solute carrier 
11 protein family named Divalent Metal Transporter 1 (DMT1) or natural resistance-
associated macrophage protein 2 (Nramp2). DMT1 is a glycoprotein that consists of twelve 
transmembrane domains and transports reduced ferrous iron (Fe+2) and other divalent 
metals (manganese, cobalt, nickel, cadmium, lead, copper, and zinc) to the inside of 
duodenal enterocytes, where it is highly expressed at the apical (luminal) site (Mackenzie & 
Garrick, 2005).  
Inorganic iron absorption via DMT1 is an important iron uptake pathway, as observed in 
homozygous mk/mk mice that have microcytic, hypochromic anaemia due to severe defects 
in intestinal iron absorption and erythroid iron utilization. By positional cloning, Fleming 
and collaborators discovered in 1997 that a missense mutation in the gene Nramp2 was 
responsible for the mk mouse phenotype (Fleming et al., 1997). One year later the same 
group also reported that a similar phenotype present in Belgrade (b) rats was due to the 
same missense mutation, a glycine-to-arginine missense mutation (G185R), in the Nramp2 
gene (Fleming et al., 1998). Functional studies of the protein encoded by the mutated b allele 
of rat Nramp2 demonstrated that the mutation disrupted iron transport. Therefore, the 
phenotypic characteristics of mk mouse and Belgrade rats indicate that Nramp2 is not only 
essential for normal intestinal iron absorption but also for transport of iron out of the 
transferrin cycle endosome. 
 
Cellular Iron Metabolism – The IRP/IRE Regulatory Network 39 
DMT1 is a conserved transporter in vertebrates and the phenotype called chardonnay (cdy) 
in zebrafish mutants with hypochromic, microcytic anaemia is due to a nonsense mutation 
in DMT1. The truncated DMT1 protein expressed in cdy mutants is not functional (Donovan 
et al., 2002). In humans, mutations in this gene are associated with hypochromic microcytic 
anaemia with iron overload. This is a very rare disease so far described in only five subjects 
(OMIM 206100).  
The SLC11A2 gene encodes four transcripts that are the result of alternative splicing at the 5’ 
or 3’ end, yielding DMT-1A-IRE, DMT-1B-IRE, DMT-1A-nonIRE, and DMT-1B-nonIRE 
isoforms. The different isoforms of DMT1 are differentially expressed in tissues, increasing 
somewhat the complexity of the study of this gene (Hubert & Hentze, 2002). One of the two 
3’ splicing forms (the IRE isoform) contains an IRE structure in its 3’ UTR (see Figure 2) and 
is up-regulated by iron deficiency via the IRPs (Mackenzie & Garrick, 2005); however, the 
regulation of DMT1 is very complex and both transcriptional and post-transcriptional 
regulations may be involved in its gene expression regulation. The ablation of both IRPs in 
intestinal epithelial cells reduces the levels of IRE-containing DMT1 mRNA and DMT1-
dependent intestinal iron uptake (Galy et al., 2008), but transcriptional regulation may be 
important, as is also suggested by recent studies showing that HIF2α–dependent DMT1 
transcription plays a role in intestinal iron uptake (Mastrogiannaki et al., 2009).  
2.1.3.2 The IRP/IRE regulatory network in iron storage 
In addition to iron recycling and absorption, the storage and potential release of (excess) 
iron are critical determinants of circulating iron levels. Under physiological conditions, 
approximately 20% (0.5 to 1g) of the body’s total iron content is stocked in the storage 
compartment, and only 1 to 2mg of iron is lost each day. The iron stores become depleted 
when iron absorption does not meet the body’s needs or in cases of excessive iron loss (e.g. 
bleeding, pregnancy); conversely, tissue iron overload occurs when intestinal iron 
absorption surpasses iron utilization and loss (Andrews, 2010). Iron storage should be 
therefore tightly controlled to avoid an iron imbalance that will lead to a disease stage. 
Ferritins are the major iron storage protein, and are found in the cytoplasm, mitochondria, 
and nucleus of the cells (Arosio et al., 2009). In vertebrates, cytoplasmic ferritin is expressed 
in almost all tissues and plays an important role in the control of intracellular iron 
distribution. Ferritin consists of a 24-subunit heteromultimer of light (L) and heavy (H) 
chains (174 and 182 amino acids respectively) that form a spherical shell around a cavity 
where iron (as ferric oxide) is stored. Each subunit has a distinct role in iron metabolism: L-
ferritin facilitates iron-core formation and H-ferritin subunit generates ferroxidase activity 
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The best characterized system regulating ferritin expression is the post-transcriptional, iron-
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IRP/IRE complexes in the 5’UTR of ferritins that inhibits translation in iron-starved cells. 
Mechanistically, this translational block is due to the IRP interference in the recruitment of 
the small ribosomal subunit to the mRNA by preventing the interactions between the cap 
binding complex eIF4F and the small ribosomal subunit (Muckenthaler et al., 1998). The rate 
of de novo synthesis and abundance of ferritin can change over a 50-fold range in response to 
variations in iron availability mainly via the IRP/IRE regulatory system and thus the 
transcripts of the H- and L-ferritin chains are the prototypes of IRP-mediated translational 
control. 
In vivo disruption of the H-ferritin gene by homologous recombination (Fth-/- mice) is early 
embryonic lethal (Ferreira et al., 2000). Fth -/- embryos die between 3.5 and 9.5 days of 
development, suggesting that there is no functional redundancy between the two ferritin 
subunits and that, in the absence of H subunits, L-ferritin homopolymers are not able to 
maintain iron in a bioavailable and nontoxic form. Fth +/- mice are healthy, fertile, and do 
not differ significantly from their control littermates. To overcome this embryonic lethality 
of Fth -/- mice, the group of Dr. Lukas Kuhn has recently created an intestine-specific H-
ferritin knock-out mouse model (Vanoaica et al., 2010), which shows that not only is 
hepcidin required for an accurate control of iron absorption, but H-ferritin is also critical for 
limiting iron efflux from intestinal cells. These mice with an intestinal H-ferritin gene 
deletion show increased body iron stores and transferrin saturation that resembles 
Hereditary Hemochromatosis (HH). 
In humans defects in the L-ferritin gene are associated with a neurodegenerative disease 
(NBIA3, neurodegeneration with brain iron accumulation 3, OMIM #606159), genetic 
hyperferritinemia without iron overload (Kannengiesser et al., 2009) and hyperferritinemia-
cataract syndrome (HHCS). A mutation in the H-ferritin gene causes the autosomal 
dominant Iron overload syndrome. The hyperferritinemia-cataract syndrome (HHCS, 
OMIM #600886) and the autosomal dominant Iron overload syndrome (OMIM +134770) are 
due to specific mutations in the IRE motif of H- and L-ferritin, respectively and are 
extensively discussed in sections 3.1 and 3.2. 
2.1.3.3 The IRP/IRE regulatory network in iron release 
The transmembrane protein Ferroportin (FPN) is encoded by the SLC40A1 gene 
(chromosome 2q32.2) and this protein is the only known cellular iron exporter (Donovan et 
al., 2005). FPN is ubiquitously expressed, but is more abundant on the basolateral 
membrane of enterocytes in the duodenum and in reticuloendothelial cells. Ferroportin 
plays an important role in iron absorption (i.e. iron transport from enterocytes into the 
plasma) and iron reuse (i.e. iron released out of macrophages and coming from 
erythrophagocytosis of senescent or damaged red blood cells) (Hentze et al., 2010). 
FPN is post-translationally regulated by hepcidin, which plays a central role in controlling 
systemic iron levels. On hepcidin binding, FPN is internalized and degraded (Ganz & 
Nemeth, 2011), thus inhibiting iron efflux from enterocytes, macrophages, and other cells.  
FPN is also regulated at the post-transcriptional level by the IRP/IRE regulatory system 
(Figure 1). FPN mRNA bears a functional IRE motif in its 5’UTR (see Figure 2) that allows it 
to respond to iron manipulations in hepatic, intestinal, and monocytic cells (Lymboussaki et 
al., 2003). Similarly to ferritin IRP control, in iron deprivation the IRP binding to the 
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ferroportin 5’ IRE will inhibit its translation. The simultaneous ablation of IRP1 and IRP2 in 
mice markedly increases intestinal FPN expression, despite the increase in hepatic hepcidin 
expression, indicating that IRPs are as critical as hepcidin for physiological FPN expression 
in the intestine (Galy et al., 2008). The IRP-dependent translational control of FPN 
expression has been found in response to nitric oxide (NO) (X. B. Liu et al., 2002) and 
erythrophagocytosis (Delaby et al., 2008). Duodenal epithelial and erythroid precursor cells 
utilize an alternative upstream promoter to express a FPN1 transcript, FPN1B, which lacks 
the IRE and therefore this FPN isoform will escape the IRP repression in iron-deficient 
conditions (Zhang et al., 2009).   
SLC40A1 gene mutations are associated with an autosomal inherited genetic iron disorders 
described as ferroportin disease. Indeed, ferroportin disease is phenotypically 
heterogeneous with two sub-types. Classical ferroportin disease is the usual form and is 
characterized by hyperferritinemia, normal or low transferrin saturation, and iron overload 
in macrophages. This form is generally asymptomatic with no tissue damage and is due to 
ferroportin mutations that lead to a loss of function. The non-classical ferroportin form is 
rarer and resembles Hereditary Hemochromatosis with hepatocellular iron deposits and 
high transferrin saturation. In this form, ferroportin mutations are responsible for a gain of 
function with full iron export capability but resistance to down-regulation by hepcidin, 
which leads to a phenotype similar to hepcidin deficiency-related HH (i.e. types 1, 2, and 3). 
In fact, the non-classical ferroportin form is also known as Hereditary Hemochromatosis 
type 4. Most of the described mutations in ferroportin are located in the coding region or in 
exon-intron boundaries, only one patient with iron-overload Hereditary Hemochromatosis 
type 4 has been described with a point mutation close to the FPN IRE. This mutation could 
alter the IRE structure and the IRP regulation of FPN, but this was not studied further (Liu 
et al., 2005). In addition, radiation-induced polycythaemia (Pcm) mice were shown to have a 
ferroportin promoter microdeletion that also eliminates the iron-responsive element (IRE) in 
the 5' untranslated region (Mok et al., 2004) (see section 3.3). 
2.1.3.4 The IRP/IRE regulatory network in iron utilization and energy metabolism 
The erythroid iron utilization is also controlled by the IRP/IRE system through the 
interaction with ALAS2 mRNA. ALAS2 (erythroid-specific 5-aminolevulinic acid synthase) 
mRNA encodes for the first and rate-limiting enzyme in the haem biosynthesis pathway. 
This mRNA contains a 5’ UTR IRE (see Figure 1) identified using an in silico approach, and it 
is translationally repressed by the binding of the IRPs in iron-deficient conditions 
preventing the accumulation of toxic intermediates of the haem biosynthesis pathways such 
as protoporphyrin IX (Dandekar et al., 1991). The regulation of the Alas2 mRNA by the IRPs 
is affected in the zebrafish mutant shiraz, which presents severe hypochromic anaemia and 
early embryonic lethality due to defects in the Grx5 gene (Wingert et al., 2005). Grx5 protein 
is required for iron-sulphur cluster assembly and its abrogation shifts IRP1 conformation to 
an IRE-binding protein that leads to Alas2 repression and cytosolic iron depletion that also 
activates IRP2, which will further contribute to the repression of Alas2. A patient with iron 
overload and mild sideroblastic anaemia was described as bearing a homozygous mutation 
that interferes with intron 1 splicing and drastically reduces GLRX5 mRNA levels 
(Camaschella et al., 2007). Surprisingly, in this patient the anaemia was worsened by blood 
transfusions but partially reversed by iron chelation, presumably because iron chelation will 
redistribute iron to the cytosol, which might decrease IRP2 excess, improving haem 
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synthesis and anaemia. These intricate mechanisms reveal the control of the IRP/IRE 
regulatory system in haem biosynthesis during erythroid differentiation, as well as the 
coordination of the regulation of haemoglobin with the iron-sulphur cluster assembly 
machinery. 
The IRP/IRE system also controls energy metabolism by the regulation of two iron-sulphur 
containing enzymes of the tricarboxylic acid cycle (TCA cycle), the mitochondrial aconitase 
Aco2 and the Drosophila succinate dehydrogenase B, SdhB. These two mRNAs contain a 
single 5’ UTR IRE that were identified using the same IRE bio-computational searching 
approach as previously mentioned (Gray et al., 1996) (see Figure 1). The translational 
regulation of these mRNAs by the IRPs may co-ordinate their expression with iron 
availability since these are iron-containing enzymes, and altogether influence energy 
metabolism. 
There is evidence that the translational repression exerted by the IRPs varies depending on 
the targeted mRNA. For instance, IRP regulation of ferritin transcripts is stronger than IRP 
Aco2 repression (Schalinske et al., 1998), this is in part due to differences in binding 
affinities of the IRPs for each particular transcript (Goforth et al., 2010).  
2.1.3.5 The IRP/IRE regulatory network in other pathways 
Apart from the IREs found in transferrin receptor 1, DMT1, H- and L-ferritins, ferroportin, 
Alas2, Aco2 and DSdhB already discussed, it seems that the IRP/IRE regulatory network is 
wider than previously thought and may regulate pathways not directly related to iron 
homeostasis (Sanchez et al., 2011). 
Several groups have reported new IRE-containing mRNAs using different approaches 
By computational searches, an IRE was described in the 3’ UTR of the human MRCKα, also 
known as CDC42 binding protein kinase alpha (CDC42BPA) (Cmejla et al., 2006) (see Figure 
5). This kinase is the effector of a small Rho GTPase Cdc42 and promotes cytoskeletal 
reorganization. The authors claim that the mRNA of MRCKα is regulated by iron in a 
similar but less intense way to TFR1 mRNA and they proposed a novel molecular link 
between iron metabolism and the cellular cytoskeleton. 
Members of our group have found a conserved and functional 3’ UTR IRE in a splicing 
mRNA isoform coding for CDC14A, a highly evolutionarily conserved cell-cycle 
phosphatase (Sanchez et al., 2006) (see Figure 5). The CDC14A mRNA and other mRNAs 
were bioinformatically predicted to bear a conserved IRE and subsequently spotted on a 
home-made iron-specific microarray. The CDC14A and HIF2α mRNAs (see below) were 
isolated by IRP immunoprecipitation, using total RNA derived from human cell lines, and 
identified using this same iron-specific microarray. The mRNA levels of the human 
CDC14A IRE isoform were shown to be specifically increased upon iron deprivation and it 
is possible that the regulation of CDC14A by the IRPs participates in the cell-cycle arrest 
observed during iron scarcity in cells. This finding opens up new interesting links between 
iron metabolism and cell cycle regulation. 
The approach described above also revealed an atypical IRE in the 5’ UTR of HIF2α mRNA, 
which encodes for a key transcription factor induced by lack of oxygen (hypoxia) or iron 
(Sanchez et al., 2007). The IREs of HIF2α and DMT1 mRNAs have an additional bulge on the 
 
Cellular Iron Metabolism – The IRP/IRE Regulatory Network 43 
3’ strand of the upper stem (see Figure 2). Under normoxic conditions, IRPs bind to the 5’ 
IRE of HIF2α mRNA and repress its translation, whereas hypoxia de-represses HIF2α 
mRNA translation by impairing IRP binding activity and prevents HIF2α degradation by 
inhibiting prolyl hydroxylase activity. This mechanism was proposed to modulate the levels 
of erythropoietin, a major target of HIF2α, adjusting the rate of red blood cell production to 
iron availability. Therefore, we discovered a negative feedback control of the HIF-mediated 
response under conditions of limited iron availability. HIF2α also regulates the expression 
of genes involved in angiogenesis and vascularisation (i.e. VEGF, PDGF), but the effect of 
the IRP/IRE system on these HIF2α targets has yet to be studied. To investigate the 
physiological and pathophysiological role of HIF2α IRE in vivo and the effect of its ablation 
on haematopoiesis and cancer development it would be necessary to generate a knock-in 
mouse model, in which the IRE-IRP interaction is selectively disrupted.  
 
Fig. 5. Other poorly conserved IREs and the role of their encoded proteins. Apical loops and 
C-bulges are circled in blue. 5’ or 3’ location of the IRE and the specie where it is found are 
shown. The function of the encoded protein is shown in red. MRCKα: CDC42-binding 
protein kinase alpha, CDC14A: Cell division cycle 14A, Gox: Glycolate oxidase, AHSP: 
Erythroid-associated factor, NDUFS1: NADH-ubiquinone oxidoreductase Fe-S protein, β-
APP: Amyloid beta A4 precursor protein. 
Additional non-canonical and poorly conserved IREs have been described in different 
mRNAs.  
An IRE-like structure is present in the 3’UTR of mouse glycolate oxidase (Gox), a liver-
specific mRNA (Kohler et al., 1999) (see Figure 5). This novel IRE-containing mRNA was 
detected by enrichment of mRNAs using an affinity IRP1 matrix; positive mRNAs were then 
cloned in a cDNA library and screened by RNA-protein band shift assays. The main 
difference from a canonical IRE was the presence of a mismatched (A:A) nucleotide pair in 
the middle of the upper stem. This IRE-like sequence exhibited strong binding to IRPs at 
room temperature but not at 37 degrees and translational regulation in response to iron 
deprivation was not observed when the 3’IRE was cloned at a 5’ position of a reported 
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deprivation was not observed when the 3’IRE was cloned at a 5’ position of a reported 
 
Iron Metabolism 44
construct. These observations brought the authors to claim that such an IRE is not functional 
in cells. 
In primate sequences of the mRNA encoding for the alpha-haemoglobin-stabilizing protein 
(AHSP), a molecular chaperone that binds and stabilizes free alpha-globin during 
haemoglobin synthesis, a 3’ UTR IRE-like sequence was detected using an RNA folding 
program (Meehan & Connell, 2001) (see Figure 5). The main difference between this and a 
canonical IRE is the presence of an A8 bulge nucleotide instead of a C8 and in 2 additional 
unpaired nucleotides (UG) at the 3’ end of a typical CAGUGH apical loop. Although this 
IRE-like structure binds IRPs poorly in electrophoretic mobility shift assays, in cytoplasmic 
extracts the AHSP mRNA co-immunoprecipitates with IRPs via this element and this 
interaction is inhibited by iron. The IRP- AHSP interaction enhances AHSP mRNA stability 
in erythroid and heterologous cells.  
The human 75-KDa subunit of mitochondrial complex I (NDUFS1) is regulated by iron at 
the protein but not at the mRNA level (Lin et al., 2001). In the 5’ UTR of this mRNA a motif 
element that resembles an IRE was identified; however this element does not contain a C8 
bulged nucleotide and in it the apical loop (CAGAG) is formed by only five nucleotides 
instead of six (see Figure 5). Interestingly, this element is bound by a specific cytoplasmic 
protein, which is neither IRP1 nor IRP2 and the binding interaction can be competed with 
ferritin IRE and was affected by iron status. It has been suggested that NDUFS1 may be 
regulated by a novel IRP/IRE system.  
A type II IRE motif was found in the 5’ UTR of the human mRNA encoding the Alzheimer’s 
beta amyloid precursor protein (β-APP), which functions as a translational control element 
via interaction with IRP1 (Rogers et al., 2002) (see Figure 5). This IRE is structurally different 
from the one presented earlier. Also, a very atypical IRE motif was predicted in the 5’UTR of 
the human α-synuclein mRNA involved in Parkinson’s disease (see Figure 5); however, no 
functional characterization was reported (Friedlich et al., 2007). As brain iron homeostasis is 
disrupted in a number of neurodegenerative disorders, a deeper understanding of the 
functional IRP regulation of mRNAs involved in these diseases is of great interest.  
IRE-like structures were reported in the Bacillus subtilis genome and the aconitase of this 
gram-positive bacterium was described as an RNA-binding protein (Alen & Sonenshein, 
1999). B. subtilis aconitase mutants demonstrate that its non-enzymatic activity is important 
for sporulation, an iron-dependent process. The authors suggest that bacterial aconitases, 
like their eukaryotic homologues, are bi-functional proteins, showing aconitase activity in 
the presence of iron and RNA binding activity in iron-deprived conditions.  
A recent genome-wide study was carried out by our group to identify the whole repertoire 
of mRNAs that can interact with the IRPs (Sanchez et al., 2011). IRP1/IRE and IRP2/IRE 
mRNP complexes were immunoselected and the mRNA composition of the IRP-binding 
transcripts was determined using whole-genome microarrays. In this strategy we used total 
mRNA from five different mouse tissues relevant for iron metabolism (liver, duodenum, 
spleen, bone marrow and brain). Using this approach novel mRNAs that can bind to both 
IRPs (n=35), as well as specific-IRP1 mRNAs (n=101) and specific-IRP2 mRNAs (n=113) 
were detected for the first time. Bioinformatic analysis to predict IRE motifs in the novel IRP 
target mRNAs was carried out using the newly developed software called SIREs (Searching 
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for IREs, (Campillos et al., 2010), see section 2.1.1.1) also designed by our group. Some of the 
novel IRP target mRNAs were tested in vitro in IRP1 competitive binding assays. We also 
undertook a proteomic approach to identify iron and/or IRP-modulated proteins in an iron-
regulated mouse hepatic cell line and in bone marrow derived macrophages from IRP1- and 
IRP2-deficient mice. We are currently proceeding with the functional characterization (iron 
and IRP regulation) of these novel mRNAs to discover and connect known and new cellular 
functions that need to respond to changes in iron metabolism.  
3. Diseases affecting the IRP/IRE regulatory network 
In humans, several diseases are caused by the disturbance of systemic or cellular iron 
homeostasis. In particular for cellular iron misregulation involving the IRP/IRE regulatory 
system several diseases have been reported and are described in the sections below.  
3.1 Hyperferritinemia-cataract syndrome (OMIM #600886) 
“Hereditary Hyperferritinemia-Cataract Syndrome” (HHCS) was first described in 1995 
(Bonneau et al., 1995; Girelli et al., 1995) as an autosomal dominant inherited disorder 
characterised by markedly elevated serum ferritin levels (≥1000 ng/ml) without iron 
overload and congenital early onset bilateral cataract.  
The absence of iron overload in HHCS patients suggested that the elevated serum ferritin 
resulted from misregulation of L-ferritin expression. Analysis of the L-ferritin genetic locus 
in HHCS patients led to the identification of heterozygous mutations occurring within the 
IRE of the L-ferritin gene. An inability to block ferritin translation in this disorder has been 
demonstrated by experiments using cultured lymphoblastoid cells from affected patients: 
the mutation abolishes the binding of IRPs and leads to constitutively high levels of L-
ferritin synthesis (Cazzola et al., 1997). The clinical phenotype of these mutations is only the 
presence of bilateral congenital cataracts. Although the mechanism of cataract formation is 
not clear, the deposit of excess L-ferritin in the lens seems to be responsible. A 
comprehensive study of cataract features in several families affected by HHCS has been 
performed by Craig and colleagues (Craig et al., 2003). 
Since 1995, numerous mutations affecting the 5’ IRE of L-ferritin have been described, 
including deletions and point mutations (Millonig et al., 2010). A comprehensive revision of 
the described mutations in HHCS is shown in Figure 6. Most of the mutations discovered so 
far are located in the upper stem and the conserved hexa-nucleotide apical loop of the IRE. 
Historically, the L-ferritin IRE mutations have been described with the name of the city in 
which mutations were identified followed by the nucleotide position and change (i.e. 
Verona 1 (+41) C). Up to now, less than 90 families have been diagnosed with the disease 
around the world, so it appears to be uniformly widespread. Prevalence of this disease still 
needs to be precisely determined but it is estimated to be at least 1 in 200,000 according to 
the Orphanet database.  
Our group have recently diagnosed four Spanish families (ten individuals) affected by 
HHCS that present four previously described single point mutations in the IRE of the L-
ferritin (unpublished data, Figure 7). All our cases present high levels of serum ferritin and 
cataracts that were detected at a young age. 
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construct. These observations brought the authors to claim that such an IRE is not functional 
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Fig. 6. Predicted secondary structure of the IRE motif in the 5’ UTR of the L-ferritin mRNA 
and reported mutations causing HHCS (name and position in blue and nucleotide change in 
red). The apical loop and the C8-bulge are circled in blue. The transcriptional start site is 
shown as (+1), and the first 77 nucleotides are shown in an extended stem-loop structure. 
Single nucleotide changes are depicted by arrows and nucleotide deletions are represented 
by brackets. 
In HHCS patients there is a marked phenotypic variability with regard to ocular 
involvement, serum ferritin levels and age of cataract onset, even between subjects sharing 
the same mutation in the same family. This suggests that other environmental factors could 
be involved in the development of clinical symptoms in each person (Girelli et al., 2001). 
Although HHCS is an autosomal dominant disorder, a patient without family history has 
recently been reported (Cao et al., 2010). 
Because of the high levels of serum ferritin, some HHCS patients have been misdiagnosed 
with the iron-overload genetic disease Hereditary Hemochromatosis. These HHCS patients 
have been studied by liver biopsy and have developed iron-deficiency anemia after repeated 
venesections. A correct genetic diagnosis in HHCS patients is very important, as it will 
prevent unnecessary clinical tests and the implementation of inadequate treatments. For this 
reason, it is important to increase awareness of this rare pathology among pediatricians, 
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ophthalmologists, gastroenterologists, haematologists and general practitioners. Patients 
diagnosed with HHCS should be counselled regarding the relative harmlessness of this 
genetic disease, with early cataract surgery as the only clinical consequence. 
 
Fig. 7. Four Spanish families affected by hyperferritinemia-cataract syndrome reported in 
our laboratory. Family pedigrees are shown together with histograms reporting the 
nucleotide change and the mutation name and position. In the pedigrees, squares and circles 
symbolize males and females, respectively, and black symbols denote affected patients with 
hyperferritinemia and cataracts. Serum ferritin (ng/ml) values are indicated in affected 
individuals. Dashed symbols represent deceased individuals. Roman numerals indicate 
generations. Point mutations are located in the IRE structure of L-ferritin. 
3.2 Autosomal dominant Iron overload syndrome (OMIM +134770) 
An autosomal dominant iron overload syndrome has been described in a unique Japanese 
family by Kato and colleagues (Kato et al., 2001). In this family a point mutation (A49U) in 
the IRE of the H-ferritin gene was found. However, no other mutations in the IRE of the H-
Ferritin that affects the IRP/IRE binding have been reported by any other researchers, 
including a large study with subjects presenting abnormal serum ferritin values and 
abnormal iron status (Cremonesi et al., 2003). 
The proband described by Kato and collaborators was a woman showing high serum 
ferritin levels, iron overload and increased transferrin saturation. Authors also studied 
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family by Kato and colleagues (Kato et al., 2001). In this family a point mutation (A49U) in 
the IRE of the H-ferritin gene was found. However, no other mutations in the IRE of the H-
Ferritin that affects the IRP/IRE binding have been reported by any other researchers, 
including a large study with subjects presenting abnormal serum ferritin values and 
abnormal iron status (Cremonesi et al., 2003). 
The proband described by Kato and collaborators was a woman showing high serum 
ferritin levels, iron overload and increased transferrin saturation. Authors also studied 
seven family members and found that three of them showed an iron overload phenotype 
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defined by elevated serum iron values and excessive iron deposition in liver and bone 
marrow evidenced by magnetic resonance imaging. Two of these three relatives also had 
elevated serum ferritin levels, but the proband’s daughter did not (Figure 8A).  
After excluding other causes of iron overload, they sequenced H- and L-ferritin cDNAs in 
the proband. A heterozygous single A-to-U conversion at position 49 inside the IRE was 
found in the sequence of the H-ferritin gene (see Figure 8B and 8C).  
 
Fig. 8. A mutation in the IRE of H-ferritin mRNA causes autosomal dominant iron overload. 
A. Pedigree of a family with dominant primary iron overload. Black symbols denote 
individuals showing the A49T genotype. Serum ferritin (ng/ml) values are indicated. The 
arrow indicates the proband (II-4). B. Histograms for a normal relative and the proband 
showing the sequence of H-ferritin where the mutation (+49A>T) was found in 
heterozygous state. C. Predicted secondary structure of the 5’ IRE in H-ferritin subunit 
mRNA. The mutation position (+49) is based on the human H-ferritin chain mRNA 
sequence L20941. The A49U mutation affects the second nucleotide of the IRE loop. Adapted 
from Kato et. al. 2001. 
The A49U mutation affects the second base of the IRE apical loop (CAGUG), a nucleotide 
that was reported to have direct protein contact with IRP1 in the IRP1/IRE crystallography 
structure (Walden et al., 2006). This mutation was also detected in the genomic DNA of the 
four relatives who had iron overload, but not in the genomic DNA of 42 unrelated control 
subjects. The segregation of the mutation and iron overload in the family members was 
consistent with an autosomal dominant pattern of inheritance. The +49A>T mutation was 
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considered a novel cause of hereditary iron overload, most likely related to an impairment 
of the ferroxidase activity generated by H subunit (Kato et al., 2001).  
3.3 Mutations in the ferroportin 5’ IRE 
A radiation-induced mouse model with a 58 bp deletion in the 5’ UTR of ferroportin gene, 
including the IRE motif, has been described (Mok et al., 2004). These mice present 
erythropoietin-dependent polycythaemia when the mutation is in the heterozygous state 
and microcytic hypochromic anaemia in homozygosity. Both defects in erythropoiesis were 
transient and corrected in early adulthood by the action of hepcidin.  
A 5’ UTR mutation has been detected in a patient with iron overload due to Hereditary 
Hemochromatosis type 4, also known as ferroportin disease (Liu et al., 2005). The mutation 
is located seven nucleotides downstream of the ferroportin IRE and may alter the IRE-IRP 
recognition, although this has not been proven.  
3.4 IRPs in iron-sulphur cluster deficiency anaemias 
As mentioned in section 2.1.2.1, IRP1 has a dual function; firstly as a cytosolic aconitase 
when it incorporates an iron-sulphur cluster, and secondly as an RNA-binding protein 
when this cluster is removed in iron-deprived conditions. The formation and assembly of 
iron-sulphur clusters in the cell is therefore very important for the regulation of IRP1 
activity. 
A novel disorder affecting the iron/sulphur cluster biogenesis has been described in a 
patient with a recessive form of inherited sideroblastic anaemias and a zebrafish model with 
severe hypochromic anaemia, the shiraz mutant (Camaschella et al., 2007; Wingert et al., 
2005). Both phenotypes are due to a mutation in the GLRX5 gene, which encodes for a 
mitochondrial protein important for iron/sulphur cluster biogenesis. The observed anaemia 
is the result of GLRX5 deficiency that increases IRP1 activity in the absence of iron/sulfur 
clusters which hampers its conversion to an aconitase. Increased IRP1 IRE binding activity 
leads to Alas2 translational repression and cytosolic iron depletion that also activates IRP2, 
which further contributes to Alas2 blocking. The described patient bears a homozygous 
mutation that interferes with intron 1 splicing and drastically reduces GLRX5 mRNA levels. 
Clinically this patient presents with iron overload and mild sideroblastic anaemia 
(Camaschella et al., 2007). Surprisingly, the anaemia in the patient was worsened by blood 
transfusions but partially reversed by iron chelation, presumably because iron chelation will 
redistribute iron to the cytosol, which might decrease IRP2 excess, improving haem 
synthesis and anaemia. The discovery of this disease establishes a link between two 
pathways of mitochondria iron utilization: haem biosynthesis and iron/sulphur cluster 
biogenesis. 
X-linked sideroblastic anaemia with ataxia (XLSA/A) is another disease affecting the 
iron/sulphur cluster (ISC) pathway. XLSA/A is a rare inherited disorder characterized by 
mild anaemia and ataxia and is caused by mutations in the ABCB7 gene, which encodes a 
member of the ATP-binding cassette transporter family involved in the transport of ISC 
from the mitochondria to the cytoplasm. The liver-specific conditional knockout of Abcb7 
results in strong decrease of cytosolic aconitase activity and a 6-fold reciprocal increase in 
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considered a novel cause of hereditary iron overload, most likely related to an impairment 
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IRP1 RNA binding activity, with concomitant increase in TFR1 expression and hepatic iron 
overload (Pondarre et al., 2006). However, increased levels of TFR1 proteins were attributed 
to IRP2 stabilizing effects rather than IRP1, as surprisingly it was found that IRP1 protein 
levels were reduced in these mice due to an iron-dependent IRP1 protein degradation. RNA 
binding activity and protein levels of IRP2 were found to increase, despite the apparent 
cellular iron overload that does not seem to be appropriately sensed by IRP2.  
In conclusion, ISC deficiency leads to dysregulated activation of IRP1 and IRP2 and it seems 
that IRP RNA binding activity may respond more to the flux of iron through a specific 
metabolic pathway, such as the ISC assembly, than to the absolute levels of cellular iron. 
Therefore, major problems associated with these disorders seem to be a consequence of 
inappropriate regulation of downstream targets of cytosolic IRPs, rather than ISC deficiency 
per se. 
3.5 Other pathophysiological roles for IRPs 
Brain homeostasis of trace metals such as copper and iron is dysregulated in neurological 
disorders such as Alzheimer's disease, where increased iron and decreased copper levels are 
observed. Young mice with targeted deletion of IRP2 have significantly less brain copper 
and the expression of β-APP is significantly up-regulated in the hippocampus (Mueller et 
al., 2009). In humans, polymorphisms in the promoter region of IRP2 gene are statistically 
associated with Alzheimer’s disease (Coon et al., 2006). This finding awaits further 
confirmation in independent and larger studies, and also the functional significance of these 
polymorphisms needs to be clarified. Mouse work on the role of IRP2 in neuropathology is 
somewhat controversial. One group have reported that aging IRP2 KO mice develop a 
progressive neurodegenerative disorder (LaVaute et al., 2001), while the IRP2 KO mice 
generated by an independent group using a different targeting strategy do not manifest 
severe neurodegeneration, despite performing poorly in neurobehavioural tests (Galy et al., 
2006). In spite of the observed iron accumulation in the neurons of the substantia nigra of 
Parkinson’s patients, ferritin levels are not up-regulated. This effect was attributed to high 
levels of IRP1-IRE binding activity, which is insensitive to iron concentration, probably 
because of a different compartmentalization of the iron (Faucheux et al., 2002). IRP-1 and -2 
activities were found to be increased in brain cells in a Transmissible Spongiform 
Encephalopathy mouse model (Kim et al., 2007). 
Genome-wide association studies in combination with expression profiling implicate IRP2 
as a susceptibility gene in chronic obstructive pulmonary disease (COPD) (DeMeo et al., 
2009). This study also found that IRP2 protein and mRNA were increased in lung-tissue 
samples from COPD subjects in comparison with controls. The association of IRP2 SNPs 
with COPD has been recently replicated by a second group (Chappell et al., 2011). 
IRPs have been involved in cancer biology. The over-expression of IRP1 suppresses growth 
of tumour xenografts in nude mice (Chen et al., 2007). In these experiments, stable 
transfected and tetracycline inducible (tet-off system) H1299 lung cancer cells with IRP1 
wild-type or a mutated IRP1 version that constitutively binds IRE were used; these cells and 
control cells were then transplanted into nude mice to study their tumourogenic effects. 
Interestingly, similar experiments with IRP2 showed the opposite behaviour, a pro-
oncogenic activity of the over-expression of IRP2 that was attributed to an IRP2-specific 
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domain of 73 amino acids (Maffettone et al., 2010). In both systems the expression of ferritin 
and TFR1 was similar; however, tumours over-expressing IRP1 and IRP2 exhibited distinct 
gene-expression profiles, suggesting that IRPs may differentially modulate cancer growth 
by regulating a different subset of genes, which could be related or not to iron homeostasis. 
Indeed, the IRP2 pro-oncogenic activity was associated with an increase in the 
phosphorylation of ERK ½, an extracellular signal-regulated kinase, and with high levels of 
the proto-oncogene c-myc that was previously implicated in the transcriptional activation of 
IRP2 (Wu et al., 1999). The understanding of the molecular pathways that involves IRPs in 
cancer biology is very incipient and further work is required. 
4. Small molecules and drugs affecting the IRP/IRE regulatory network 
Small-molecules that selectively bind to and modulate the IRP-IRE interaction, by inhibiting 
or enhancing it, have been described in two studies. 
By chemical footprinting assay the natural product yohimbine was found to selectively 
interfere with the ferritin IRE and inhibit IRP-ferritin IRE binding, increasing the rate of 
ferritin biosynthesis in cell-free extracts (Tibodeau et al., 2006). The selective effect of this 
compound proved that small-molecules can distinguish between different members of the 
IRE family. Further development of therapeutic approaches, with this or similar 
compounds, could be used to increase iron-storage capacity in pathological conditions that 
require it, such as iron-overload diseases.  
Using a cell-based screen method several small molecules that decrease HIF2α translation 
by enhancing the binding of preferentially IRP1 to the 5’ IRE present in HIF2α were 
described by Zimmer and collaborators (Zimmer et al., 2008). An enhancer effect of these 
compounds on the IRP-IRE binding was also observed for transferrin receptor 1 (TFR1), 
increasing its mRNA stability. As hypoxia inducible factors (HIFs) are linked to cancer 
progression, angiogenesis and inflammation, HIF inhibitors (like these compounds) could 
be used in antineoplastic and anti-inflammatory therapies. 
Other small molecules and drugs that interfere with iron uptake via DMT1 or transferrin 
receptor 1 have been reported but their mechanism of action does not seem to be related 
with the modulation of the IRP-IRE regulatory system (Brown et al., 2004; Horonchik & 
Wessling-Resnick, 2008; Wetli et al., 2006). 
5. Conclusions and future perspectives 
In recent years, impressive progress has been made in unraveling the control of iron 
homeostasis by the IRP/IRE regulatory system. However, many details remain unanswered 
and require further investigation. For instance, a recent high-throughput screening study 
has considerably enlarged the number of known IRP-binding mRNAs, extending the IRP 
functions to multiple pathways, including cancer biology (Sanchez et al., 2011). Now the 
challenge is to uncover the role and mechanisms of action of these new mRNAs regulated 
by IRPs with studies ranging from basic research to medical and applied physiology.  
Additional IRP mouse models with cell-specific ablation or over-expression in an inducible 
or non-inducible system will provide valuable information concerning the 
pathophysiological role of IRPs. To elucidate the specific role of mRNA isoforms containing 
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IRP1 RNA binding activity, with concomitant increase in TFR1 expression and hepatic iron 
overload (Pondarre et al., 2006). However, increased levels of TFR1 proteins were attributed 
to IRP2 stabilizing effects rather than IRP1, as surprisingly it was found that IRP1 protein 
levels were reduced in these mice due to an iron-dependent IRP1 protein degradation. RNA 
binding activity and protein levels of IRP2 were found to increase, despite the apparent 
cellular iron overload that does not seem to be appropriately sensed by IRP2.  
In conclusion, ISC deficiency leads to dysregulated activation of IRP1 and IRP2 and it seems 
that IRP RNA binding activity may respond more to the flux of iron through a specific 
metabolic pathway, such as the ISC assembly, than to the absolute levels of cellular iron. 
Therefore, major problems associated with these disorders seem to be a consequence of 
inappropriate regulation of downstream targets of cytosolic IRPs, rather than ISC deficiency 
per se. 
3.5 Other pathophysiological roles for IRPs 
Brain homeostasis of trace metals such as copper and iron is dysregulated in neurological 
disorders such as Alzheimer's disease, where increased iron and decreased copper levels are 
observed. Young mice with targeted deletion of IRP2 have significantly less brain copper 
and the expression of β-APP is significantly up-regulated in the hippocampus (Mueller et 
al., 2009). In humans, polymorphisms in the promoter region of IRP2 gene are statistically 
associated with Alzheimer’s disease (Coon et al., 2006). This finding awaits further 
confirmation in independent and larger studies, and also the functional significance of these 
polymorphisms needs to be clarified. Mouse work on the role of IRP2 in neuropathology is 
somewhat controversial. One group have reported that aging IRP2 KO mice develop a 
progressive neurodegenerative disorder (LaVaute et al., 2001), while the IRP2 KO mice 
generated by an independent group using a different targeting strategy do not manifest 
severe neurodegeneration, despite performing poorly in neurobehavioural tests (Galy et al., 
2006). In spite of the observed iron accumulation in the neurons of the substantia nigra of 
Parkinson’s patients, ferritin levels are not up-regulated. This effect was attributed to high 
levels of IRP1-IRE binding activity, which is insensitive to iron concentration, probably 
because of a different compartmentalization of the iron (Faucheux et al., 2002). IRP-1 and -2 
activities were found to be increased in brain cells in a Transmissible Spongiform 
Encephalopathy mouse model (Kim et al., 2007). 
Genome-wide association studies in combination with expression profiling implicate IRP2 
as a susceptibility gene in chronic obstructive pulmonary disease (COPD) (DeMeo et al., 
2009). This study also found that IRP2 protein and mRNA were increased in lung-tissue 
samples from COPD subjects in comparison with controls. The association of IRP2 SNPs 
with COPD has been recently replicated by a second group (Chappell et al., 2011). 
IRPs have been involved in cancer biology. The over-expression of IRP1 suppresses growth 
of tumour xenografts in nude mice (Chen et al., 2007). In these experiments, stable 
transfected and tetracycline inducible (tet-off system) H1299 lung cancer cells with IRP1 
wild-type or a mutated IRP1 version that constitutively binds IRE were used; these cells and 
control cells were then transplanted into nude mice to study their tumourogenic effects. 
Interestingly, similar experiments with IRP2 showed the opposite behaviour, a pro-
oncogenic activity of the over-expression of IRP2 that was attributed to an IRP2-specific 
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domain of 73 amino acids (Maffettone et al., 2010). In both systems the expression of ferritin 
and TFR1 was similar; however, tumours over-expressing IRP1 and IRP2 exhibited distinct 
gene-expression profiles, suggesting that IRPs may differentially modulate cancer growth 
by regulating a different subset of genes, which could be related or not to iron homeostasis. 
Indeed, the IRP2 pro-oncogenic activity was associated with an increase in the 
phosphorylation of ERK ½, an extracellular signal-regulated kinase, and with high levels of 
the proto-oncogene c-myc that was previously implicated in the transcriptional activation of 
IRP2 (Wu et al., 1999). The understanding of the molecular pathways that involves IRPs in 
cancer biology is very incipient and further work is required. 
4. Small molecules and drugs affecting the IRP/IRE regulatory network 
Small-molecules that selectively bind to and modulate the IRP-IRE interaction, by inhibiting 
or enhancing it, have been described in two studies. 
By chemical footprinting assay the natural product yohimbine was found to selectively 
interfere with the ferritin IRE and inhibit IRP-ferritin IRE binding, increasing the rate of 
ferritin biosynthesis in cell-free extracts (Tibodeau et al., 2006). The selective effect of this 
compound proved that small-molecules can distinguish between different members of the 
IRE family. Further development of therapeutic approaches, with this or similar 
compounds, could be used to increase iron-storage capacity in pathological conditions that 
require it, such as iron-overload diseases.  
Using a cell-based screen method several small molecules that decrease HIF2α translation 
by enhancing the binding of preferentially IRP1 to the 5’ IRE present in HIF2α were 
described by Zimmer and collaborators (Zimmer et al., 2008). An enhancer effect of these 
compounds on the IRP-IRE binding was also observed for transferrin receptor 1 (TFR1), 
increasing its mRNA stability. As hypoxia inducible factors (HIFs) are linked to cancer 
progression, angiogenesis and inflammation, HIF inhibitors (like these compounds) could 
be used in antineoplastic and anti-inflammatory therapies. 
Other small molecules and drugs that interfere with iron uptake via DMT1 or transferrin 
receptor 1 have been reported but their mechanism of action does not seem to be related 
with the modulation of the IRP-IRE regulatory system (Brown et al., 2004; Horonchik & 
Wessling-Resnick, 2008; Wetli et al., 2006). 
5. Conclusions and future perspectives 
In recent years, impressive progress has been made in unraveling the control of iron 
homeostasis by the IRP/IRE regulatory system. However, many details remain unanswered 
and require further investigation. For instance, a recent high-throughput screening study 
has considerably enlarged the number of known IRP-binding mRNAs, extending the IRP 
functions to multiple pathways, including cancer biology (Sanchez et al., 2011). Now the 
challenge is to uncover the role and mechanisms of action of these new mRNAs regulated 
by IRPs with studies ranging from basic research to medical and applied physiology.  
Additional IRP mouse models with cell-specific ablation or over-expression in an inducible 
or non-inducible system will provide valuable information concerning the 
pathophysiological role of IRPs. To elucidate the specific role of mRNA isoforms containing 
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an IRE and the physiological role that IRPs exert on them in vivo, the generation of animal 
models with a particular disrupted IRE would be of great interest. A deeper study into 
several research fields affecting iron and IRP misregulation (such as iron brain homeostasis, 
iron in cancer biology and iron implication in immunity and infection) will have 
implications for the development of therapies for common and rare disorders related to the 
IRP/IRE regulatory system. 
6. Acknowledgements 
Dr. Mayka Sanchez's group is supported by by ‘Instituto de Salud Carlos III’, Spanish 
Health Program (Ministry of Science and Innovation; PS09/00341); Spanish Ministry of 
Science and Innovation (RYC−2008−02352 research contract under the Ramon y Cajal 
program). Dr. Mayka Sanchez’s group was also awarded with a European Union 
programme for research in rare diseases (ERA-Net on rare diseases) project, ERARE-115, 
HMA-IRON, co-ordinated by Dr. Carole Beaumont. 
7. References 
Alen, C., & Sonenshein, A. L. (1999). Bacillus subtilis aconitase is an RNA-binding protein. 
Proc Natl Acad Sci U S A, 96(18), 10412-10417. 
Andrews, N. C. (2010). Ferrit(in)ing out new mechanisms in iron homeostasis. Cell Metab, 
12(3), 203-204. 
Arosio, P., Ingrassia, R., & Cavadini, P. (2009). Ferritins: a family of molecules for iron 
storage, antioxidation and more. Biochim Biophys Acta, 1790(7), 589-599. 
Bengert, P., & Dandekar, T. (2003). A software tool-box for analysis of regulatory RNA 
elements. Nucleic Acids Res, 31(13), 3441-3445. 
Bianchi, L., Tacchini, L., & Cairo, G. (1999). HIF-1-mediated activation of transferrin receptor 
gene transcription by iron chelation. Nucleic Acids Res, 27(21), 4223-4227. 
Binder, R., Horowitz, J. A., Basilion, J. P., et al. (1994). Evidence that the pathway of 
transferrin receptor mRNA degradation involves an endonucleolytic cleavage 
within the 3' UTR and does not involve poly(A) tail shortening. EMBO J, 13(8), 
1969-1980. 
Bonneau, D., Winter-Fuseau, I., Loiseau, M. N., et al. (1995). Bilateral cataract and high 
serum ferritin: a new dominant genetic disorder? J Med Genet, 32(10), 778-779. 
Brazzolotto, X., Andriollo, M., Guiraud, P., et al. (2003). Interactions between doxorubicin 
and the human iron regulatory system. Biochim Biophys Acta, 1593(2-3), 209-218. 
Brown, J. X., Buckett, P. D., & Wessling-Resnick, M. (2004). Identification of small molecule 
inhibitors that distinguish between non-transferrin bound iron uptake and 
transferrin-mediated iron transport. Chem Biol, 11(3), 407-416. 
Butt, J., Kim, H. Y., Basilion, J. P., et al. (1996). Differences in the RNA binding sites of iron 
regulatory proteins and potential target diversity. Proc Natl Acad Sci U S A, 93(9), 
4345-4349. 
Cairo, G., & Pietrangelo, A. (1994). Transferrin receptor gene expression during rat liver 
regeneration. Evidence for post-transcriptional regulation by iron regulatory 
factorB, a second iron-responsive element-binding protein. J Biol Chem, 269(9), 6405-
6409. 
Cairo, G., & Pietrangelo, A. (2000). Iron regulatory proteins in pathobiology. Biochem J, 352 
Pt 2, 241-250. 
 
Cellular Iron Metabolism – The IRP/IRE Regulatory Network 53 
Caltagirone, A., Weiss, G., & Pantopoulos, K. (2001). Modulation of cellular iron metabolism 
by hydrogen peroxide. Effects of H2O2 on the expression and function of iron-
responsive element-containing mRNAs in B6 fibroblasts. J Biol Chem, 276(23), 
19738-19745. 
Camaschella, C., Campanella, A., De Falco, L., et al. (2007). The human counterpart of 
zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. 
Blood, 110(4), 1353-1358. 
Campillos, M., Cases, I., Hentze, M. W., et al. (2010). SIREs: searching for iron-responsive 
elements. Nucleic Acids Res, 38 Suppl, W360-367. 
Cao, W., McMahon, M., Wang, B., et al. (2010). A case report of spontaneous mutation 
(C33>U) in the iron-responsive element of L-ferritin causing hyperferritinemia-
cataract syndrome. Blood Cells Mol Dis, 44(1), 22-27. 
Cazzola, M., Bergamaschi, G., Tonon, L., et al. (1997). Hereditary hyperferritinemia-cataract 
syndrome: relationship between phenotypes and specific mutations in the iron-
responsive element of ferritin light-chain mRNA. Blood, 90(2), 814-821. 
Cmejla, R., Petrak, J., & Cmejlova, J. (2006). A novel iron responsive element in the 3'UTR of 
human MRCKalpha. Biochem Biophys Res Commun, 341(1), 158-166. 
Coon, K. D., Siegel, A. M., Yee, S. J., et al. (2006). Preliminary demonstration of an allelic 
association of the IREB2 gene with Alzheimer's disease. J Alzheimers Dis, 9(3), 225-
233. 
Craig, J. E., Clark, J. B., McLeod, J. L., et al. (2003). Hereditary hyperferritinemia-cataract 
syndrome: prevalence, lens morphology, spectrum of mutations, and clinical 
presentations. Arch Ophthalmol, 121(12), 1753-1761. 
Cremonesi, L., Foglieni, B., Fermo, I., et al. (2003). Identification of two novel mutations in 
the 5'-untranslated region of H-ferritin using denaturing high performance liquid 
chromatography scanning. Haematologica, 88(10), 1110-1116. 
Crichton, R. R. (2009). Iron metabolism : from molecular mechanisms to clinical consequences (3rd 
ed.). Chichester, UK: John Wiley & Sons. 
Chappell, S. L., Daly, L., Lotya, J., et al. (2011). The role of IREB2 and transforming growth 
factor beta-1 genetic variants in COPD: a replication case-control study. BMC Med 
Genet, 12, 24. 
Chen, G., Fillebeen, C., Wang, J., et al. (2007). Overexpression of iron regulatory protein 1 
suppresses growth of tumor xenografts. Carcinogenesis, 28(4), 785-791. 
Dandekar, T., Stripecke, R., Gray, N. K., et al. (1991). Identification of a novel iron-
responsive element in murine and human erythroid delta-aminolevulinic acid 
synthase mRNA. EMBO J, 10(7), 1903-1909. 
De Domenico, I., Ward, D. M., & Kaplan, J. (2007). Hepcidin regulation: ironing out the 
details. J Clin Invest, 117(7), 1755-1758. 
Delaby, C., Pilard, N., Puy, H., et al. (2008). Sequential regulation of ferroportin expression 
after erythrophagocytosis in murine macrophages: early mRNA induction by 
haem, followed by iron-dependent protein expression. Biochem J, 411(1), 123-131. 
DeMeo, D. L., Mariani, T., Bhattacharya, S., et al. (2009). Integration of genomic and genetic 
approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet, 85(4), 
493-502. 
Donovan, A., Brownlie, A., Dorschner, M. O., et al. (2002). The zebrafish mutant gene 




an IRE and the physiological role that IRPs exert on them in vivo, the generation of animal 
models with a particular disrupted IRE would be of great interest. A deeper study into 
several research fields affecting iron and IRP misregulation (such as iron brain homeostasis, 
iron in cancer biology and iron implication in immunity and infection) will have 
implications for the development of therapies for common and rare disorders related to the 
IRP/IRE regulatory system. 
6. Acknowledgements 
Dr. Mayka Sanchez's group is supported by by ‘Instituto de Salud Carlos III’, Spanish 
Health Program (Ministry of Science and Innovation; PS09/00341); Spanish Ministry of 
Science and Innovation (RYC−2008−02352 research contract under the Ramon y Cajal 
program). Dr. Mayka Sanchez’s group was also awarded with a European Union 
programme for research in rare diseases (ERA-Net on rare diseases) project, ERARE-115, 
HMA-IRON, co-ordinated by Dr. Carole Beaumont. 
7. References 
Alen, C., & Sonenshein, A. L. (1999). Bacillus subtilis aconitase is an RNA-binding protein. 
Proc Natl Acad Sci U S A, 96(18), 10412-10417. 
Andrews, N. C. (2010). Ferrit(in)ing out new mechanisms in iron homeostasis. Cell Metab, 
12(3), 203-204. 
Arosio, P., Ingrassia, R., & Cavadini, P. (2009). Ferritins: a family of molecules for iron 
storage, antioxidation and more. Biochim Biophys Acta, 1790(7), 589-599. 
Bengert, P., & Dandekar, T. (2003). A software tool-box for analysis of regulatory RNA 
elements. Nucleic Acids Res, 31(13), 3441-3445. 
Bianchi, L., Tacchini, L., & Cairo, G. (1999). HIF-1-mediated activation of transferrin receptor 
gene transcription by iron chelation. Nucleic Acids Res, 27(21), 4223-4227. 
Binder, R., Horowitz, J. A., Basilion, J. P., et al. (1994). Evidence that the pathway of 
transferrin receptor mRNA degradation involves an endonucleolytic cleavage 
within the 3' UTR and does not involve poly(A) tail shortening. EMBO J, 13(8), 
1969-1980. 
Bonneau, D., Winter-Fuseau, I., Loiseau, M. N., et al. (1995). Bilateral cataract and high 
serum ferritin: a new dominant genetic disorder? J Med Genet, 32(10), 778-779. 
Brazzolotto, X., Andriollo, M., Guiraud, P., et al. (2003). Interactions between doxorubicin 
and the human iron regulatory system. Biochim Biophys Acta, 1593(2-3), 209-218. 
Brown, J. X., Buckett, P. D., & Wessling-Resnick, M. (2004). Identification of small molecule 
inhibitors that distinguish between non-transferrin bound iron uptake and 
transferrin-mediated iron transport. Chem Biol, 11(3), 407-416. 
Butt, J., Kim, H. Y., Basilion, J. P., et al. (1996). Differences in the RNA binding sites of iron 
regulatory proteins and potential target diversity. Proc Natl Acad Sci U S A, 93(9), 
4345-4349. 
Cairo, G., & Pietrangelo, A. (1994). Transferrin receptor gene expression during rat liver 
regeneration. Evidence for post-transcriptional regulation by iron regulatory 
factorB, a second iron-responsive element-binding protein. J Biol Chem, 269(9), 6405-
6409. 
Cairo, G., & Pietrangelo, A. (2000). Iron regulatory proteins in pathobiology. Biochem J, 352 
Pt 2, 241-250. 
 
Cellular Iron Metabolism – The IRP/IRE Regulatory Network 53 
Caltagirone, A., Weiss, G., & Pantopoulos, K. (2001). Modulation of cellular iron metabolism 
by hydrogen peroxide. Effects of H2O2 on the expression and function of iron-
responsive element-containing mRNAs in B6 fibroblasts. J Biol Chem, 276(23), 
19738-19745. 
Camaschella, C., Campanella, A., De Falco, L., et al. (2007). The human counterpart of 
zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. 
Blood, 110(4), 1353-1358. 
Campillos, M., Cases, I., Hentze, M. W., et al. (2010). SIREs: searching for iron-responsive 
elements. Nucleic Acids Res, 38 Suppl, W360-367. 
Cao, W., McMahon, M., Wang, B., et al. (2010). A case report of spontaneous mutation 
(C33>U) in the iron-responsive element of L-ferritin causing hyperferritinemia-
cataract syndrome. Blood Cells Mol Dis, 44(1), 22-27. 
Cazzola, M., Bergamaschi, G., Tonon, L., et al. (1997). Hereditary hyperferritinemia-cataract 
syndrome: relationship between phenotypes and specific mutations in the iron-
responsive element of ferritin light-chain mRNA. Blood, 90(2), 814-821. 
Cmejla, R., Petrak, J., & Cmejlova, J. (2006). A novel iron responsive element in the 3'UTR of 
human MRCKalpha. Biochem Biophys Res Commun, 341(1), 158-166. 
Coon, K. D., Siegel, A. M., Yee, S. J., et al. (2006). Preliminary demonstration of an allelic 
association of the IREB2 gene with Alzheimer's disease. J Alzheimers Dis, 9(3), 225-
233. 
Craig, J. E., Clark, J. B., McLeod, J. L., et al. (2003). Hereditary hyperferritinemia-cataract 
syndrome: prevalence, lens morphology, spectrum of mutations, and clinical 
presentations. Arch Ophthalmol, 121(12), 1753-1761. 
Cremonesi, L., Foglieni, B., Fermo, I., et al. (2003). Identification of two novel mutations in 
the 5'-untranslated region of H-ferritin using denaturing high performance liquid 
chromatography scanning. Haematologica, 88(10), 1110-1116. 
Crichton, R. R. (2009). Iron metabolism : from molecular mechanisms to clinical consequences (3rd 
ed.). Chichester, UK: John Wiley & Sons. 
Chappell, S. L., Daly, L., Lotya, J., et al. (2011). The role of IREB2 and transforming growth 
factor beta-1 genetic variants in COPD: a replication case-control study. BMC Med 
Genet, 12, 24. 
Chen, G., Fillebeen, C., Wang, J., et al. (2007). Overexpression of iron regulatory protein 1 
suppresses growth of tumor xenografts. Carcinogenesis, 28(4), 785-791. 
Dandekar, T., Stripecke, R., Gray, N. K., et al. (1991). Identification of a novel iron-
responsive element in murine and human erythroid delta-aminolevulinic acid 
synthase mRNA. EMBO J, 10(7), 1903-1909. 
De Domenico, I., Ward, D. M., & Kaplan, J. (2007). Hepcidin regulation: ironing out the 
details. J Clin Invest, 117(7), 1755-1758. 
Delaby, C., Pilard, N., Puy, H., et al. (2008). Sequential regulation of ferroportin expression 
after erythrophagocytosis in murine macrophages: early mRNA induction by 
haem, followed by iron-dependent protein expression. Biochem J, 411(1), 123-131. 
DeMeo, D. L., Mariani, T., Bhattacharya, S., et al. (2009). Integration of genomic and genetic 
approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet, 85(4), 
493-502. 
Donovan, A., Brownlie, A., Dorschner, M. O., et al. (2002). The zebrafish mutant gene 




Donovan, A., Lima, C. A., Pinkus, J. L., et al. (2005). The iron exporter ferroportin/Slc40a1 is 
essential for iron homeostasis. Cell Metab, 1(3), 191-200. 
Drakesmith, H., & Prentice, A. (2008). Viral infection and iron metabolism. Nat Rev Microbiol, 
6(7), 541-552. 
Drapier, J. C. (1997). Interplay between NO and [Fe-S] clusters: relevance to biological 
systems. Methods, 11(3), 319-329. 
Eisenstein, R. S. (2000). Iron regulatory proteins and the molecular control of mammalian 
iron metabolism. Annu Rev Nutr, 20, 627-662. 
Faucheux, B. A., Martin, M. E., Beaumont, C., et al. (2002). Lack of up-regulation of ferritin is 
associated with sustained iron regulatory protein-1 binding activity in the 
substantia nigra of patients with Parkinson's disease. J Neurochem, 83(2), 320-330. 
Ferreira, C., Bucchini, D., Martin, M. E., et al. (2000). Early embryonic lethality of H ferritin 
gene deletion in mice. J Biol Chem, 275(5), 3021-3024. 
Fillebeen, C., Muckenthaler, M., Andriopoulos, B., et al. (2007). Expression of the 
subgenomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells. J 
Hepatol, 47(1), 12-22. 
Fleming, M. D., Romano, M. A., Su, M. A., et al. (1998). Nramp2 is mutated in the anemic 
Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc 
Natl Acad Sci U S A, 95(3), 1148-1153. 
Fleming, M. D., Trenor, C. C., 3rd, Su, M. A., et al. (1997). Microcytic anaemia mice have a 
mutation in Nramp2, a candidate iron transporter gene. Nat Genet, 16(4), 383-386. 
Friedlich, A. L., Tanzi, R. E., & Rogers, J. T. (2007). The 5'-untranslated region of Parkinson's 
disease alpha-synuclein messengerRNA contains a predicted iron responsive 
element. Mol Psychiatry, 12(3), 222-223. 
Galy, B., Ferring-Appel, D., Kaden, S., et al. (2008). Iron regulatory proteins are essential for 
intestinal function and control key iron absorption molecules in the duodenum. 
Cell Metab, 7(1), 79-85. 
Galy, B., Ferring-Appel, D., Sauer, S. W., et al. (2010). Iron regulatory proteins secure 
mitochondrial iron sufficiency and function. Cell Metab, 12(2), 194-201. 
Galy, B., Holter, S. M., Klopstock, T., et al. (2006). Iron homeostasis in the brain: complete 
iron regulatory protein 2 deficiency without symptomatic neurodegeneration in the 
mouse. Nat Genet, 38(9), 967-969; discussion 969-970. 
Ganz, T., & Nemeth, E. (2011). Hepcidin and disorders of iron metabolism. Annu Rev Med, 
62, 347-360. 
Gao, J., Lovejoy, D., & Richardson, D. R. (1999). Effect of iron chelators with potent anti-
proliferative activity on the expression of molecules involved in cell cycle 
progression and growth. Redox Rep, 4(6), 311-312. 
Girelli, D., Bozzini, C., Zecchina, G., et al. (2001). Clinical, biochemical and molecular 
findings in a series of families with hereditary hyperferritinaemia-cataract 
syndrome. Br J Haematol, 115(2), 334-340. 
Girelli, D., Olivieri, O., De Franceschi, L., et al. (1995). A linkage between hereditary 
hyperferritinaemia not related to iron overload and autosomal dominant congenital 
cataract. Br J Haematol, 90(4), 931-934. 
Goforth, J. B., Anderson, S. A., Nizzi, C. P., et al. (2010). Multiple determinants within iron-
responsive elements dictate iron regulatory protein binding and regulatory 
hierarchy. RNA, 16(1), 154-169. 
 
Cellular Iron Metabolism – The IRP/IRE Regulatory Network 55 
Gray, N. K., Pantopoulos, K., Dandekar, T., et al. (1996). Translational regulation of 
mammalian and Drosophila citric acid cycle enzymes via iron-responsive elements. 
Proc Natl Acad Sci U S A, 93(10), 4925-4930. 
Gu, J. M., Lim, S. O., Oh, S. J., et al. (2008). HBx modulates iron regulatory protein 1-
mediated iron metabolism via reactive oxygen species. Virus Res, 133(2), 167-177. 
Hausmann, A., Lee, J., & Pantopoulos, K. (2011). Redox control of iron regulatory protein 2 
stability. FEBS Lett, 585(4), 687-692. 
Henderson, B. R., Menotti, E., & Kuhn, L. C. (1996). Iron regulatory proteins 1 and 2 bind 
distinct sets of RNA target sequences. J Biol Chem, 271(9), 4900-4908. 
Henderson, B. R., Seiser, C., & Kuhn, L. C. (1993). Characterization of a second RNA-binding 
protein in rodents with specificity for iron-responsive elements. J Biol Chem, 
268(36), 27327-27334. 
Hentze, M. W., Muckenthaler, M. U., Galy, B., et al. (2010). Two to tango: regulation of 
Mammalian iron metabolism. Cell, 142(1), 24-38. 
Horonchik, L., & Wessling-Resnick, M. (2008). The small-molecule iron transport inhibitor 
ferristatin/NSC306711 promotes degradation of the transferrin receptor. Chem Biol, 
15(7), 647-653. 
Hubert, N., & Hentze, M. W. (2002). Previously uncharacterized isoforms of divalent metal 
transporter (DMT)-1: implications for regulation and cellular function. Proc Natl 
Acad Sci U S A, 99(19), 12345-12350. 
Iwai, K., Drake, S. K., Wehr, N. B., et al. (1998). Iron-dependent oxidation, ubiquitination, 
and degradation of iron regulatory protein 2: implications for degradation of 
oxidized proteins. Proc Natl Acad Sci U S A, 95(9), 4924-4928. 
Kannengiesser, C., Jouanolle, A. M., Hetet, G., et al. (2009). A new missense mutation in the 
L ferritin coding sequence associated with elevated levels of glycosylated ferritin in 
serum and absence of iron overload. Haematologica, 94(3), 335-339. 
Kato, J., Fujikawa, K., Kanda, M., et al. (2001). A mutation, in the iron-responsive element of 
H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet, 
69(1), 191-197. 
Kim, B. H., Jun, Y. C., Jin, J. K., et al. (2007). Alteration of iron regulatory proteins (IRP1 and 
IRP2) and ferritin in the brains of scrapie-infected mice. Neurosci Lett, 422(3), 158-
163. 
Kim, S., & Ponka, P. (2002). Nitric oxide-mediated modulation of iron regulatory proteins: 
implication for cellular iron homeostasis. Blood Cells Mol Dis, 29(3), 400-410. 
Kim, S., Wing, S. S., & Ponka, P. (2004). S-nitrosylation of IRP2 regulates its stability via the 
ubiquitin-proteasome pathway. Mol Cell Biol, 24(1), 330-337. 
Kohler, S. A., Menotti, E., & Kuhn, L. C. (1999). Molecular cloning of mouse glycolate 
oxidase. High evolutionary conservation and presence of an iron-responsive 
element-like sequence in the mRNA. J Biol Chem, 274(4), 2401-2407. 
Kwok, J. C., & Richardson, D. R. (2002). Unexpected anthracycline-mediated alterations in 
iron-regulatory protein-RNA-binding activity: the iron and copper complexes of 
anthracyclines decrease RNA-binding activity. Mol Pharmacol, 62(4), 888-900. 
LaVaute, T., Smith, S., Cooperman, S., et al. (2001). Targeted deletion of the gene encoding 
iron regulatory protein-2 causes misregulation of iron metabolism and 
neurodegenerative disease in mice. Nat Genet, 27(2), 209-214. 
Leedman, P. J., Stein, A. R., Chin, W. W., et al. (1996). Thyroid hormone modulates the 
interaction between iron regulatory proteins and the ferritin mRNA iron-
responsive element. J Biol Chem, 271(20), 12017-12023. 
 
Iron Metabolism 54
Donovan, A., Lima, C. A., Pinkus, J. L., et al. (2005). The iron exporter ferroportin/Slc40a1 is 
essential for iron homeostasis. Cell Metab, 1(3), 191-200. 
Drakesmith, H., & Prentice, A. (2008). Viral infection and iron metabolism. Nat Rev Microbiol, 
6(7), 541-552. 
Drapier, J. C. (1997). Interplay between NO and [Fe-S] clusters: relevance to biological 
systems. Methods, 11(3), 319-329. 
Eisenstein, R. S. (2000). Iron regulatory proteins and the molecular control of mammalian 
iron metabolism. Annu Rev Nutr, 20, 627-662. 
Faucheux, B. A., Martin, M. E., Beaumont, C., et al. (2002). Lack of up-regulation of ferritin is 
associated with sustained iron regulatory protein-1 binding activity in the 
substantia nigra of patients with Parkinson's disease. J Neurochem, 83(2), 320-330. 
Ferreira, C., Bucchini, D., Martin, M. E., et al. (2000). Early embryonic lethality of H ferritin 
gene deletion in mice. J Biol Chem, 275(5), 3021-3024. 
Fillebeen, C., Muckenthaler, M., Andriopoulos, B., et al. (2007). Expression of the 
subgenomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells. J 
Hepatol, 47(1), 12-22. 
Fleming, M. D., Romano, M. A., Su, M. A., et al. (1998). Nramp2 is mutated in the anemic 
Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc 
Natl Acad Sci U S A, 95(3), 1148-1153. 
Fleming, M. D., Trenor, C. C., 3rd, Su, M. A., et al. (1997). Microcytic anaemia mice have a 
mutation in Nramp2, a candidate iron transporter gene. Nat Genet, 16(4), 383-386. 
Friedlich, A. L., Tanzi, R. E., & Rogers, J. T. (2007). The 5'-untranslated region of Parkinson's 
disease alpha-synuclein messengerRNA contains a predicted iron responsive 
element. Mol Psychiatry, 12(3), 222-223. 
Galy, B., Ferring-Appel, D., Kaden, S., et al. (2008). Iron regulatory proteins are essential for 
intestinal function and control key iron absorption molecules in the duodenum. 
Cell Metab, 7(1), 79-85. 
Galy, B., Ferring-Appel, D., Sauer, S. W., et al. (2010). Iron regulatory proteins secure 
mitochondrial iron sufficiency and function. Cell Metab, 12(2), 194-201. 
Galy, B., Holter, S. M., Klopstock, T., et al. (2006). Iron homeostasis in the brain: complete 
iron regulatory protein 2 deficiency without symptomatic neurodegeneration in the 
mouse. Nat Genet, 38(9), 967-969; discussion 969-970. 
Ganz, T., & Nemeth, E. (2011). Hepcidin and disorders of iron metabolism. Annu Rev Med, 
62, 347-360. 
Gao, J., Lovejoy, D., & Richardson, D. R. (1999). Effect of iron chelators with potent anti-
proliferative activity on the expression of molecules involved in cell cycle 
progression and growth. Redox Rep, 4(6), 311-312. 
Girelli, D., Bozzini, C., Zecchina, G., et al. (2001). Clinical, biochemical and molecular 
findings in a series of families with hereditary hyperferritinaemia-cataract 
syndrome. Br J Haematol, 115(2), 334-340. 
Girelli, D., Olivieri, O., De Franceschi, L., et al. (1995). A linkage between hereditary 
hyperferritinaemia not related to iron overload and autosomal dominant congenital 
cataract. Br J Haematol, 90(4), 931-934. 
Goforth, J. B., Anderson, S. A., Nizzi, C. P., et al. (2010). Multiple determinants within iron-
responsive elements dictate iron regulatory protein binding and regulatory 
hierarchy. RNA, 16(1), 154-169. 
 
Cellular Iron Metabolism – The IRP/IRE Regulatory Network 55 
Gray, N. K., Pantopoulos, K., Dandekar, T., et al. (1996). Translational regulation of 
mammalian and Drosophila citric acid cycle enzymes via iron-responsive elements. 
Proc Natl Acad Sci U S A, 93(10), 4925-4930. 
Gu, J. M., Lim, S. O., Oh, S. J., et al. (2008). HBx modulates iron regulatory protein 1-
mediated iron metabolism via reactive oxygen species. Virus Res, 133(2), 167-177. 
Hausmann, A., Lee, J., & Pantopoulos, K. (2011). Redox control of iron regulatory protein 2 
stability. FEBS Lett, 585(4), 687-692. 
Henderson, B. R., Menotti, E., & Kuhn, L. C. (1996). Iron regulatory proteins 1 and 2 bind 
distinct sets of RNA target sequences. J Biol Chem, 271(9), 4900-4908. 
Henderson, B. R., Seiser, C., & Kuhn, L. C. (1993). Characterization of a second RNA-binding 
protein in rodents with specificity for iron-responsive elements. J Biol Chem, 
268(36), 27327-27334. 
Hentze, M. W., Muckenthaler, M. U., Galy, B., et al. (2010). Two to tango: regulation of 
Mammalian iron metabolism. Cell, 142(1), 24-38. 
Horonchik, L., & Wessling-Resnick, M. (2008). The small-molecule iron transport inhibitor 
ferristatin/NSC306711 promotes degradation of the transferrin receptor. Chem Biol, 
15(7), 647-653. 
Hubert, N., & Hentze, M. W. (2002). Previously uncharacterized isoforms of divalent metal 
transporter (DMT)-1: implications for regulation and cellular function. Proc Natl 
Acad Sci U S A, 99(19), 12345-12350. 
Iwai, K., Drake, S. K., Wehr, N. B., et al. (1998). Iron-dependent oxidation, ubiquitination, 
and degradation of iron regulatory protein 2: implications for degradation of 
oxidized proteins. Proc Natl Acad Sci U S A, 95(9), 4924-4928. 
Kannengiesser, C., Jouanolle, A. M., Hetet, G., et al. (2009). A new missense mutation in the 
L ferritin coding sequence associated with elevated levels of glycosylated ferritin in 
serum and absence of iron overload. Haematologica, 94(3), 335-339. 
Kato, J., Fujikawa, K., Kanda, M., et al. (2001). A mutation, in the iron-responsive element of 
H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet, 
69(1), 191-197. 
Kim, B. H., Jun, Y. C., Jin, J. K., et al. (2007). Alteration of iron regulatory proteins (IRP1 and 
IRP2) and ferritin in the brains of scrapie-infected mice. Neurosci Lett, 422(3), 158-
163. 
Kim, S., & Ponka, P. (2002). Nitric oxide-mediated modulation of iron regulatory proteins: 
implication for cellular iron homeostasis. Blood Cells Mol Dis, 29(3), 400-410. 
Kim, S., Wing, S. S., & Ponka, P. (2004). S-nitrosylation of IRP2 regulates its stability via the 
ubiquitin-proteasome pathway. Mol Cell Biol, 24(1), 330-337. 
Kohler, S. A., Menotti, E., & Kuhn, L. C. (1999). Molecular cloning of mouse glycolate 
oxidase. High evolutionary conservation and presence of an iron-responsive 
element-like sequence in the mRNA. J Biol Chem, 274(4), 2401-2407. 
Kwok, J. C., & Richardson, D. R. (2002). Unexpected anthracycline-mediated alterations in 
iron-regulatory protein-RNA-binding activity: the iron and copper complexes of 
anthracyclines decrease RNA-binding activity. Mol Pharmacol, 62(4), 888-900. 
LaVaute, T., Smith, S., Cooperman, S., et al. (2001). Targeted deletion of the gene encoding 
iron regulatory protein-2 causes misregulation of iron metabolism and 
neurodegenerative disease in mice. Nat Genet, 27(2), 209-214. 
Leedman, P. J., Stein, A. R., Chin, W. W., et al. (1996). Thyroid hormone modulates the 
interaction between iron regulatory proteins and the ferritin mRNA iron-
responsive element. J Biol Chem, 271(20), 12017-12023. 
 
Iron Metabolism 56
Levy, J. E., Jin, O., Fujiwara, Y., et al. (1999). Transferrin receptor is necessary for 
development of erythrocytes and the nervous system. Nat Genet, 21(4), 396-399. 
Lin, E., Graziano, J. H., & Freyer, G. A. (2001). Regulation of the 75-kDa subunit of 
mitochondrial complex I by iron. J Biol Chem, 276(29), 27685-27692. 
Liu, W., Shimomura, S., Imanishi, H., et al. (2005). Hemochromatosis with mutation of the 
ferroportin 1 (IREG1) gene. Intern Med, 44(4), 285-289. 
Liu, X. B., Hill, P., & Haile, D. J. (2002). Role of the ferroportin iron-responsive element in 
iron and nitric oxide dependent gene regulation. Blood Cells Mol Dis, 29(3), 315-326. 
Lok, C. N., & Ponka, P. (2000). Identification of an erythroid active element in the transferrin 
receptor gene. J Biol Chem, 275(31), 24185-24190. 
Lymboussaki, A., Pignatti, E., Montosi, G., et al. (2003). The role of the iron responsive 
element in the control of ferroportin1/IREG1/MTP1 gene expression. J Hepatol, 
39(5), 710-715. 
Macke, T. J., Ecker, D. J., Gutell, R. R., et al. (2001). RNAMotif, an RNA secondary structure 
definition and search algorithm. Nucleic Acids Res, 29(22), 4724-4735. 
Mackenzie, B., & Garrick, M. D. (2005). Iron Imports. II. Iron uptake at the apical membrane 
in the intestine. Am J Physiol Gastrointest Liver Physiol, 289(6), G981-986. 
Maffettone, C., Chen, G., Drozdov, I., et al. (2010). Tumorigenic properties of iron regulatory 
protein 2 (IRP2) mediated by its specific 73-amino acids insert. PLoS One, 5(4), 
e10163. 
Maffettone, C., De Martino, L., Irace, C., et al. (2008). Expression of iron-related proteins 
during infection by bovine herpes virus type-1. J Cell Biochem, 104(1), 213-223. 
Mastrogiannaki, M., Matak, P., Keith, B., et al. (2009). HIF-2alpha, but not HIF-1alpha, 
promotes iron absorption in mice. J Clin Invest, 119(5), 1159-1166. 
Mattace Raso, G., Irace, C., Esposito, E., et al. (2009). Ovariectomy and estrogen treatment 
modulate iron metabolism in rat adipose tissue. Biochem Pharmacol, 78(8), 1001-
1007. 
Meehan, H. A., & Connell, G. J. (2001). The hairpin loop but not the bulged C of the iron 
responsive element is essential for high affinity binding to iron regulatory protein-
1. J Biol Chem, 276(18), 14791-14796. 
Meyron-Holtz, E. G., Ghosh, M. C., & Rouault, T. A. (2004). Mammalian tissue oxygen levels 
modulate iron-regulatory protein activities in vivo. Science, 306(5704), 2087-2090. 
Mignone, F., Grillo, G., Licciulli, F., et al. (2005). UTRdb and UTRsite: a collection of 
sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs. 
Nucleic Acids Res, 33(Database issue), D141-146. 
Millonig, G., Muckenthaler, M. U., & Mueller, S. (2010). Hyperferritinaemia-cataract 
syndrome: worldwide mutations and phenotype of an increasingly diagnosed 
genetic disorder. Hum Genomics, 4(4), 250-262. 
Minotti, G., Ronchi, R., Salvatorelli, E., et al. (2001). Doxorubicin irreversibly inactivates iron 
regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic 
pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. 
Cancer Res, 61(23), 8422-8428. 
Mok, H., Jelinek, J., Pai, S., et al. (2004). Disruption of ferroportin 1 regulation causes 
dynamic alterations in iron homeostasis and erythropoiesis in polycythaemia mice. 
Development, 131(8), 1859-1868. 
Muckenthaler, M., Gray, N. K., & Hentze, M. W. (1998). IRP-1 binding to ferritin mRNA 
prevents the recruitment of the small ribosomal subunit by the cap-binding 
complex eIF4F. Mol Cell, 2(3), 383-388. 
 
Cellular Iron Metabolism – The IRP/IRE Regulatory Network 57 
Muckenthaler, M. U., Galy, B., & Hentze, M. W. (2008). Systemic iron homeostasis and the 
iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. 
Annu Rev Nutr, 28, 197-213. 
Mueller, C., Magaki, S., Schrag, M., et al. (2009). Iron regulatory protein 2 is involved in 
brain copper homeostasis. J Alzheimers Dis, 18(1), 201-210. 
Mulero, V., & Brock, J. H. (1999). Regulation of iron metabolism in murine J774 
macrophages: role of nitric oxide-dependent and -independent pathways following 
activation with gamma interferon and lipopolysaccharide. Blood, 94(7), 2383-2389. 
Mutze, S., Hebling, U., Stremmel, W., et al. (2003). Myeloperoxidase-derived hypochlorous 
acid antagonizes the oxidative stress-mediated activation of iron regulatory protein 
1. J Biol Chem, 278(42), 40542-40549. 
Nemeth, E., Tuttle, M. S., Powelson, J., et al. (2004). Hepcidin regulates cellular iron efflux by 
binding to ferroportin and inducing its internalization. Science, 306(5704), 2090-
2093. 
Nurtjahja-Tjendraputra, E., Fu, D., Phang, J. M., et al. (2007). Iron chelation regulates cyclin 
D1 expression via the proteasome: a link to iron deficiency-mediated growth 
suppression. Blood, 109(9), 4045-4054. 
O'Donnell, K. A., Yu, D., Zeller, K. I., et al. (2006). Activation of transferrin receptor 1 by c-
Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol, 26(6), 2373-
2386. 
Pantopoulos, K., & Hentze, M. W. (1995). Nitric oxide signaling to iron-regulatory protein: 
direct control of ferritin mRNA translation and transferrin receptor mRNA stability 
in transfected fibroblasts. Proc Natl Acad Sci U S A, 92(5), 1267-1271. 
Pondarre, C., Antiochos, B. B., Campagna, D. R., et al. (2006). The mitochondrial ATP-
binding cassette transporter Abcb7 is essential in mice and participates in cytosolic 
iron-sulfur cluster biogenesis. Hum Mol Genet, 15(6), 953-964. 
Ponka, P., Beaumont, C., & Richardson, D. R. (1998). Function and regulation of transferrin 
and ferritin. Semin Hematol, 35(1), 35-54. 
Recalcati, S., Conte, D., & Cairo, G. (1999). Preferential activation of iron regulatory protein-
2 in cell lines as a result of higher sensitivity to iron. Eur J Biochem, 259(1-2), 304-
309. 
Recalcati, S., Minotti, G., & Cairo, G. (2010). Iron regulatory proteins: from molecular 
mechanisms to drug development. Antioxid Redox Signal, 13(10), 1593-1616. 
Rogers, J. T., Randall, J. D., Cahill, C. M., et al. (2002). An iron-responsive element type II in 
the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. 
J Biol Chem, 277(47), 45518-45528. 
Rouault, T. A. (2006). The role of iron regulatory proteins in mammalian iron homeostasis 
and disease. Nat Chem Biol, 2(8), 406-414. 
Salahudeen, A. A., Thompson, J. W., Ruiz, J. C., et al. (2009). An E3 Ligase Possessing an 
Iron Responsive Hemerythrin Domain Is a Regulator of Iron Homeostasis. Science. 
Sanchez, M., Galy, B., Dandekar, T., et al. (2006). Iron regulation and the cell cycle: 
identification of an iron-responsive element in the 3'-untranslated region of human 
cell division cycle 14A mRNA by a refined microarray-based screening strategy. J 
Biol Chem, 281(32), 22865-22874. 
Sanchez, M., Galy, B., Muckenthaler, M. U., et al. (2007). Iron-regulatory proteins limit 




Levy, J. E., Jin, O., Fujiwara, Y., et al. (1999). Transferrin receptor is necessary for 
development of erythrocytes and the nervous system. Nat Genet, 21(4), 396-399. 
Lin, E., Graziano, J. H., & Freyer, G. A. (2001). Regulation of the 75-kDa subunit of 
mitochondrial complex I by iron. J Biol Chem, 276(29), 27685-27692. 
Liu, W., Shimomura, S., Imanishi, H., et al. (2005). Hemochromatosis with mutation of the 
ferroportin 1 (IREG1) gene. Intern Med, 44(4), 285-289. 
Liu, X. B., Hill, P., & Haile, D. J. (2002). Role of the ferroportin iron-responsive element in 
iron and nitric oxide dependent gene regulation. Blood Cells Mol Dis, 29(3), 315-326. 
Lok, C. N., & Ponka, P. (2000). Identification of an erythroid active element in the transferrin 
receptor gene. J Biol Chem, 275(31), 24185-24190. 
Lymboussaki, A., Pignatti, E., Montosi, G., et al. (2003). The role of the iron responsive 
element in the control of ferroportin1/IREG1/MTP1 gene expression. J Hepatol, 
39(5), 710-715. 
Macke, T. J., Ecker, D. J., Gutell, R. R., et al. (2001). RNAMotif, an RNA secondary structure 
definition and search algorithm. Nucleic Acids Res, 29(22), 4724-4735. 
Mackenzie, B., & Garrick, M. D. (2005). Iron Imports. II. Iron uptake at the apical membrane 
in the intestine. Am J Physiol Gastrointest Liver Physiol, 289(6), G981-986. 
Maffettone, C., Chen, G., Drozdov, I., et al. (2010). Tumorigenic properties of iron regulatory 
protein 2 (IRP2) mediated by its specific 73-amino acids insert. PLoS One, 5(4), 
e10163. 
Maffettone, C., De Martino, L., Irace, C., et al. (2008). Expression of iron-related proteins 
during infection by bovine herpes virus type-1. J Cell Biochem, 104(1), 213-223. 
Mastrogiannaki, M., Matak, P., Keith, B., et al. (2009). HIF-2alpha, but not HIF-1alpha, 
promotes iron absorption in mice. J Clin Invest, 119(5), 1159-1166. 
Mattace Raso, G., Irace, C., Esposito, E., et al. (2009). Ovariectomy and estrogen treatment 
modulate iron metabolism in rat adipose tissue. Biochem Pharmacol, 78(8), 1001-
1007. 
Meehan, H. A., & Connell, G. J. (2001). The hairpin loop but not the bulged C of the iron 
responsive element is essential for high affinity binding to iron regulatory protein-
1. J Biol Chem, 276(18), 14791-14796. 
Meyron-Holtz, E. G., Ghosh, M. C., & Rouault, T. A. (2004). Mammalian tissue oxygen levels 
modulate iron-regulatory protein activities in vivo. Science, 306(5704), 2087-2090. 
Mignone, F., Grillo, G., Licciulli, F., et al. (2005). UTRdb and UTRsite: a collection of 
sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs. 
Nucleic Acids Res, 33(Database issue), D141-146. 
Millonig, G., Muckenthaler, M. U., & Mueller, S. (2010). Hyperferritinaemia-cataract 
syndrome: worldwide mutations and phenotype of an increasingly diagnosed 
genetic disorder. Hum Genomics, 4(4), 250-262. 
Minotti, G., Ronchi, R., Salvatorelli, E., et al. (2001). Doxorubicin irreversibly inactivates iron 
regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic 
pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. 
Cancer Res, 61(23), 8422-8428. 
Mok, H., Jelinek, J., Pai, S., et al. (2004). Disruption of ferroportin 1 regulation causes 
dynamic alterations in iron homeostasis and erythropoiesis in polycythaemia mice. 
Development, 131(8), 1859-1868. 
Muckenthaler, M., Gray, N. K., & Hentze, M. W. (1998). IRP-1 binding to ferritin mRNA 
prevents the recruitment of the small ribosomal subunit by the cap-binding 
complex eIF4F. Mol Cell, 2(3), 383-388. 
 
Cellular Iron Metabolism – The IRP/IRE Regulatory Network 57 
Muckenthaler, M. U., Galy, B., & Hentze, M. W. (2008). Systemic iron homeostasis and the 
iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. 
Annu Rev Nutr, 28, 197-213. 
Mueller, C., Magaki, S., Schrag, M., et al. (2009). Iron regulatory protein 2 is involved in 
brain copper homeostasis. J Alzheimers Dis, 18(1), 201-210. 
Mulero, V., & Brock, J. H. (1999). Regulation of iron metabolism in murine J774 
macrophages: role of nitric oxide-dependent and -independent pathways following 
activation with gamma interferon and lipopolysaccharide. Blood, 94(7), 2383-2389. 
Mutze, S., Hebling, U., Stremmel, W., et al. (2003). Myeloperoxidase-derived hypochlorous 
acid antagonizes the oxidative stress-mediated activation of iron regulatory protein 
1. J Biol Chem, 278(42), 40542-40549. 
Nemeth, E., Tuttle, M. S., Powelson, J., et al. (2004). Hepcidin regulates cellular iron efflux by 
binding to ferroportin and inducing its internalization. Science, 306(5704), 2090-
2093. 
Nurtjahja-Tjendraputra, E., Fu, D., Phang, J. M., et al. (2007). Iron chelation regulates cyclin 
D1 expression via the proteasome: a link to iron deficiency-mediated growth 
suppression. Blood, 109(9), 4045-4054. 
O'Donnell, K. A., Yu, D., Zeller, K. I., et al. (2006). Activation of transferrin receptor 1 by c-
Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol, 26(6), 2373-
2386. 
Pantopoulos, K., & Hentze, M. W. (1995). Nitric oxide signaling to iron-regulatory protein: 
direct control of ferritin mRNA translation and transferrin receptor mRNA stability 
in transfected fibroblasts. Proc Natl Acad Sci U S A, 92(5), 1267-1271. 
Pondarre, C., Antiochos, B. B., Campagna, D. R., et al. (2006). The mitochondrial ATP-
binding cassette transporter Abcb7 is essential in mice and participates in cytosolic 
iron-sulfur cluster biogenesis. Hum Mol Genet, 15(6), 953-964. 
Ponka, P., Beaumont, C., & Richardson, D. R. (1998). Function and regulation of transferrin 
and ferritin. Semin Hematol, 35(1), 35-54. 
Recalcati, S., Conte, D., & Cairo, G. (1999). Preferential activation of iron regulatory protein-
2 in cell lines as a result of higher sensitivity to iron. Eur J Biochem, 259(1-2), 304-
309. 
Recalcati, S., Minotti, G., & Cairo, G. (2010). Iron regulatory proteins: from molecular 
mechanisms to drug development. Antioxid Redox Signal, 13(10), 1593-1616. 
Rogers, J. T., Randall, J. D., Cahill, C. M., et al. (2002). An iron-responsive element type II in 
the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. 
J Biol Chem, 277(47), 45518-45528. 
Rouault, T. A. (2006). The role of iron regulatory proteins in mammalian iron homeostasis 
and disease. Nat Chem Biol, 2(8), 406-414. 
Salahudeen, A. A., Thompson, J. W., Ruiz, J. C., et al. (2009). An E3 Ligase Possessing an 
Iron Responsive Hemerythrin Domain Is a Regulator of Iron Homeostasis. Science. 
Sanchez, M., Galy, B., Dandekar, T., et al. (2006). Iron regulation and the cell cycle: 
identification of an iron-responsive element in the 3'-untranslated region of human 
cell division cycle 14A mRNA by a refined microarray-based screening strategy. J 
Biol Chem, 281(32), 22865-22874. 
Sanchez, M., Galy, B., Muckenthaler, M. U., et al. (2007). Iron-regulatory proteins limit 




Sanchez, M., Galy, B., Schwanhaeusser, B., et al. (2011). Iron regulatory protein-1 and -2: 
transcriptome-wide definition of binding mRNAs and shaping of the cellular 
proteome by IRPs. Blood, In press. 
Schalinske, K. L., Chen, O. S., & Eisenstein, R. S. (1998). Iron differentially stimulates 
translation of mitochondrial aconitase and ferritin mRNAs in mammalian cells. 
Implications for iron regulatory proteins as regulators of mitochondrial citrate 
utilization. J Biol Chem, 273(6), 3740-3746. 
Smith, S. R., Ghosh, M. C., Ollivierre-Wilson, H., et al. (2006). Complete loss of iron 
regulatory proteins 1 and 2 prevents viability of murine zygotes beyond the 
blastocyst stage of embryonic development. Blood Cells Mol Dis, 36(2), 283-287. 
Tibodeau, J. D., Fox, P. M., Ropp, P. A., et al. (2006). The up-regulation of ferritin expression 
using a small-molecule ligand to the native mRNA. Proc Natl Acad Sci U S A, 103(2), 
253-257. 
Vanoaica, L., Darshan, D., Richman, L., et al. (2010). Intestinal ferritin H is required for an 
accurate control of iron absorption. Cell Metab, 12(3), 273-282. 
Vashisht, A. A., Zumbrennen, K. B., Huang, X., et al. (2009). Control of Iron Homeostasis by 
an Iron-Regulated Ubiquitin Ligase. Science. 
Walden, W. E., Selezneva, A. I., Dupuy, J., et al. (2006). Structure of dual function iron 
regulatory protein 1 complexed with ferritin IRE-RNA. Science, 314(5807), 1903-
1908. 
Wallander, M. L., Leibold, E. A., & Eisenstein, R. S. (2006). Molecular control of vertebrate 
iron homeostasis by iron regulatory proteins. Biochim Biophys Acta, 1763(7), 668-689. 
Wallander, M. L., Zumbrennen, K. B., Rodansky, E. S., et al. (2008). Iron-independent 
phosphorylation of iron regulatory protein 2 regulates ferritin during the cell cycle. 
J Biol Chem, 283(35), 23589-23598. 
Wang, J., Chen, G., Muckenthaler, M., et al. (2004). Iron-mediated degradation of IRP2, an 
unexpected pathway involving a 2-oxoglutarate-dependent oxygenase activity. Mol 
Cell Biol, 24(3), 954-965. 
Wang, J., Chen, G., & Pantopoulos, K. (2005). Nitric oxide inhibits the degradation of IRP2. 
Mol Cell Biol, 25(4), 1347-1353. 
Wang, J., & Pantopoulos, K. (2011). Regulation of cellular iron metabolism. Biochem J, 434(3), 
365-381. 
Wetli, H. A., Buckett, P. D., & Wessling-Resnick, M. (2006). Small-molecule screening 
identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron 
uptake. Chem Biol, 13(9), 965-972. 
Wingert, R. A., Galloway, J. L., Barut, B., et al. (2005). Deficiency of glutaredoxin 5 reveals 
Fe-S clusters are required for vertebrate haem synthesis. Nature, 436(7053), 1035-
1039. 
Wu, K. J., Polack, A., & Dalla-Favera, R. (1999). Coordinated regulation of iron-controlling 
genes, H-ferritin and IRP2, by c-MYC. Science, 283(5402), 676-679. 
Zhang, D. L., Hughes, R. M., Ollivierre-Wilson, H., et al. (2009). A ferroportin transcript that 
lacks an iron-responsive element enables duodenal and erythroid precursor cells to 
evade translational repression. Cell Metab, 9(5), 461-473. 
Zimmer, M., Ebert, B. L., Neil, C., et al. (2008). Small-molecule inhibitors of HIF-2a 
translation link its 5'UTR iron-responsive element to oxygen sensing. Mol Cell, 
32(6), 838-848. 
Section 3 
Functional Role of Iron 
 
Iron Metabolism 58
Sanchez, M., Galy, B., Schwanhaeusser, B., et al. (2011). Iron regulatory protein-1 and -2: 
transcriptome-wide definition of binding mRNAs and shaping of the cellular 
proteome by IRPs. Blood, In press. 
Schalinske, K. L., Chen, O. S., & Eisenstein, R. S. (1998). Iron differentially stimulates 
translation of mitochondrial aconitase and ferritin mRNAs in mammalian cells. 
Implications for iron regulatory proteins as regulators of mitochondrial citrate 
utilization. J Biol Chem, 273(6), 3740-3746. 
Smith, S. R., Ghosh, M. C., Ollivierre-Wilson, H., et al. (2006). Complete loss of iron 
regulatory proteins 1 and 2 prevents viability of murine zygotes beyond the 
blastocyst stage of embryonic development. Blood Cells Mol Dis, 36(2), 283-287. 
Tibodeau, J. D., Fox, P. M., Ropp, P. A., et al. (2006). The up-regulation of ferritin expression 
using a small-molecule ligand to the native mRNA. Proc Natl Acad Sci U S A, 103(2), 
253-257. 
Vanoaica, L., Darshan, D., Richman, L., et al. (2010). Intestinal ferritin H is required for an 
accurate control of iron absorption. Cell Metab, 12(3), 273-282. 
Vashisht, A. A., Zumbrennen, K. B., Huang, X., et al. (2009). Control of Iron Homeostasis by 
an Iron-Regulated Ubiquitin Ligase. Science. 
Walden, W. E., Selezneva, A. I., Dupuy, J., et al. (2006). Structure of dual function iron 
regulatory protein 1 complexed with ferritin IRE-RNA. Science, 314(5807), 1903-
1908. 
Wallander, M. L., Leibold, E. A., & Eisenstein, R. S. (2006). Molecular control of vertebrate 
iron homeostasis by iron regulatory proteins. Biochim Biophys Acta, 1763(7), 668-689. 
Wallander, M. L., Zumbrennen, K. B., Rodansky, E. S., et al. (2008). Iron-independent 
phosphorylation of iron regulatory protein 2 regulates ferritin during the cell cycle. 
J Biol Chem, 283(35), 23589-23598. 
Wang, J., Chen, G., Muckenthaler, M., et al. (2004). Iron-mediated degradation of IRP2, an 
unexpected pathway involving a 2-oxoglutarate-dependent oxygenase activity. Mol 
Cell Biol, 24(3), 954-965. 
Wang, J., Chen, G., & Pantopoulos, K. (2005). Nitric oxide inhibits the degradation of IRP2. 
Mol Cell Biol, 25(4), 1347-1353. 
Wang, J., & Pantopoulos, K. (2011). Regulation of cellular iron metabolism. Biochem J, 434(3), 
365-381. 
Wetli, H. A., Buckett, P. D., & Wessling-Resnick, M. (2006). Small-molecule screening 
identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron 
uptake. Chem Biol, 13(9), 965-972. 
Wingert, R. A., Galloway, J. L., Barut, B., et al. (2005). Deficiency of glutaredoxin 5 reveals 
Fe-S clusters are required for vertebrate haem synthesis. Nature, 436(7053), 1035-
1039. 
Wu, K. J., Polack, A., & Dalla-Favera, R. (1999). Coordinated regulation of iron-controlling 
genes, H-ferritin and IRP2, by c-MYC. Science, 283(5402), 676-679. 
Zhang, D. L., Hughes, R. M., Ollivierre-Wilson, H., et al. (2009). A ferroportin transcript that 
lacks an iron-responsive element enables duodenal and erythroid precursor cells to 
evade translational repression. Cell Metab, 9(5), 461-473. 
Zimmer, M., Ebert, B. L., Neil, C., et al. (2008). Small-molecule inhibitors of HIF-2a 
translation link its 5'UTR iron-responsive element to oxygen sensing. Mol Cell, 
32(6), 838-848. 
Section 3 
Functional Role of Iron 
 3 
Relationship Between  
Iron and Erythropoiesis 
Nadia Maria Sposi 
Department of Hematology, Oncology and Molecular Medicine,  
Istituto Superiore di Sanità, Rome, 
Italy 
1. Introduction 
In recent years there has been important advancement in our knowledge of iron metabolism 
regulation that also has implications for understanding the physiopathology of some human 
disorders like beta-thalassemia and other iron overload diseases.  In fact, progressive iron 
overload is the most salient and ultimately fatal complication of beta-thalassemia. Iron 
deposition occurs in visceral organs (mainly in the heart, liver and endocrine glands), 
causing tissue damage and ultimately organ dysfunction and failure. Both transfusional iron 
overload and excess gastrointestinal absorption are contributory. Paradoxically, excess 
gastrointestinal iron absorption persists despite massive increases in total body iron load. 
However, little is known about the relationship among ineffective erythropoiesis, the role of 
iron-regulatory genes, and tissue iron distribution in beta-thalassemia. The focus of this 
chapter is an update about iron homeostasis and erythroid differentiation with a particular 
attention to the molecular mechanisms of iron homeostasis deregulation in thalassemia and 
to the GDF15-BMP-Hepcidin-Ferroportin regulatory pathway in order to understand the 
contribution to iron overload. The chapter describes evidences for these relationships and 
discusses how recent discoveries on iron metabolism and erythropoiesis could lead to new 
therapeutic strategies and better clinical care of these diseases, thereby yielding a much 
better quality of life for the patients.  
2. Overall view on erythroid cells differentiation and importance of iron 
homeostasis 
Iron homeostasis depends on a coordinated regulation of molecules involved in the import 
of this element and those exporting it out of the cells. In some cell types, such as erythroid 
cells, iron import mechanisms are highly expressed, thus allowing massive iron uptake 
(Pietrangelo, 2002; Testa et al.,1995). Excessive iron, however, may be toxic for these cells, 
particularly in view of its capacity to generate superoxide radicals and H2O2, which may 
freely diffuse into the nucleus resulting in cell damage (Karthikeyan, 2002) and it seemed 
therefore of interest to investigate whether erythroid cells possess specific mechanisms for 
iron export. Within the hematopoietic differentiation, the maintenance of iron homeostasis is 
essential for erythroid cells and macrophages. Erythroid cells need to incorporate very high 
amounts of iron to support the continued synthesis of heme and hemoglobin, while the 
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macrophage cells play a key role in iron storage and recycling (Ponka, 1997; Testa et al.,1993; 
Testa, 2002). Human erythropoiesis is a dynamic complex multistep process that involves 
differentiation of pluripotent hematopoietic stem cells (HSCs) and early multipotent 
progenitors (MPP) to generate committed erythroid precursors, the erythroblasts, which then 
give birth to mature erythrocytes, i.e. the red blood cells (RBCs) (Orkin & Zon, 2008; Palis, 
2008; Tsiftsoglou et al., 2009; Weissman, 2000). Briefly, the early erythroid progenitors (BFU-E, 
burst-forming units-erythroid) differentiate into late colony-forming units erythroid (CFU-E) 
and proerythroblasts followed by a progressive wave of erythroblast maturation in 
polychromatic and orthochromatic erythroblasts coupled with a gradual increase of erythroid-
specific markers (Fig.1). As the hematopoietic process progresses from the early stages into 
erythroid cell maturation, cells gradually lose their potential for cell proliferation and become 
mature enucleated cells(Fig.1). Mature erythrocytes are biconcave disks without mithocondria 
and other organelles but full of hemoglobin able to bind and deliver O2 (Ingley et al., 2004; 
Koury et al., 2002; Stamatoyannopoulos, 2005; Tsiftsoglou et al., 2009). The hematopoietic 
differentiation is a highly complex system in which, from a pool of totipotent stem cells, 
originate all the cells of peripheral blood (Golde, 1991; Metcalf, 1989; Orkin, 1996; Smith, 2003). 
The blood has a very important role in the functions of the organism from the earliest 
moments of its development, so that during embryonic life the various stages of the 
hematopoietic process alternate at different sites according to the different stages of 
development (Emerson et al., 1989). The embryonic→fetal hematopoiesis is characterized by 
three fundamental periods of activity progressively involving the yolk sac, liver and bone 
marrow. The first period, during which hematopoiesis is localized at the yolk sac, begins 
between the 14th and 19th days of embryonic life and continues until the completion of 3rd 
month (Emerson et al., 1989). Starting from the third month, the second phase of 
hematopoiesis takes place in the liver where it reaches its maximum during the 3rd-4th month 
and remains active until a few weeks before birth, when the definitive hematopoiesis (third 
phase) is concentrated only in the bone marrow and it will continue throughout adult life 
(Emerson et al., 1989). In this system of hematopoietic differentiation four compartments may 
be identified: stem cells and the progenitors (cellular compartments), precursors and mature 
elements of circulating blood (maturation compartments).  Hematopoietic stem cells are 
characterized by the ability to self-renew (i.e. to generate other totipotent stem cells) and 
differentiate into hematopoietic progenitor cells. Stem cells also show the important property 
to remain for long time in a state of quiescence during adult life (Domen,1999;Metcalf,1989; 
Orkin, 1996; Smith, 2003). Primitive progenitors are able to generate blast colonies (CFU-B), the 
progenitors of high proliferative potential (HPP-CFC, colony-forming cells that power high-
proliferative), and finally the multipotent progenitors that are still capable of generating mixed 
colonies, belonging to the different types of hematopoietic differentiation: erythroid, 
granulocyte, monocyte, and megakaryocytic (the CFU-GEMM) (Orkin, 1996; Ogawa, 1993; 
Grover, 1994). Mature progenitors are committed to the differentiation towards a singular 
hematopoietic lineage and are functionally defined as early burst forming units (BFUs) or 
more differentiated colony forming units (CFUs): erythroid progenitors are BFU-E and CFU-E; 
granulocytic-macrophagic progenitors are CFU-GM, CFU-G and CFU-M; finally 
megakaryocitc progenitors are BFU-Mk and CFU-Mk (Grover, 1994; Ogawa, 1993; Orkin, 1996; 
Smith, 2003). The survival, proliferation and differentiation of hematopoietic stem and 
progenitor cells are regulated by a complex network of hematopoietic growth factors 
collectively known as colony stimulating factors (CSFs), interleukins (ILs) or hemopoietins that 
are released from accessory cells such as fibroblasts, macrophages, lymphocytes and 
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endothelial cells. Depending on their mechanism of action during hematopoietic 
differentiation, these factors can be classified into three categories: the first category includes 
growth factors that exert their action at the earliest stages of hematopoiesis, e.g. the c-kit 
receptor ligand (KL) or stem cell factor (SCF) (Bernstein,1991), FLT-3 ligand (FL) (Gabbianelli, 
1995;Lyman,1994;), the basic fibroblast growth factor (bFGF) (Berardi, 1995; Gabbianelli, 1990) 
and interleukin-6 (IL-6) [Leary, 1988]; in the second category are growth factors acting as 
multilineage, whose prototypes are the IL-3 and GM-CSF that are able to stimulate primitive 
progenitors to proliferate and differentiate into all hematopoietic lineage (Metcalf, 1993); and 
finally in the third category are included the growth factors acting as unilineage, i.e. those that 
stimulate the differentiation and proliferation of a single lineage and include erythropoietin 
(EPO) [Fried, 1995; Krantz, 1991], the granulocytic growth factor (G-CSF) [Demetri & Griffin, 
1991], monocytic growth factor (M-CSF) [Sherr, 1990] and thrombopoietin (TPO) [Kaushanky 
et al., 1994]. These unilineage factors act on progenitors already moving towards 
hematopoietic lineage and promote the production of mature cells in the circulating blood, i.e. 
erythrocytes, neutrophils, eosinophils, monocytes/macrophages and megakaryocytes. During 
the hematopoietic differentiation, the maintenance of iron homeostasis is essential for 
erythrocytes and macrophages. Erythroid cells need to incorporate very high amounts of iron 
to support the continued synthesis of heme and hemoglobin, while the macrophage cells play 
a key role in the storage and recycling of iron (Testa et al., 1993; Testa, 2002; Tsiftsoglou,2009). 
During the differentiation of erythroid progenitors towards mature red cells the following 
morphologically recognizable stages can be distinguished: 1) the earlier stage of 
proerythroblast, that presents a nucleus relatively large in respect to the cytoplasm, and one or 
two nucleoli; 2) the more advanced basophilic erythroblast, characterized by a reduced cellular 
diameter, a nuclear volume reduced more rapidly than the cytoplasm, and a cytoplasm 
uniformly basophilic; 3) the polychromatophilic erythroblast, that shows the initial 
condensation of the nucleus, nucleoli no longer visible and the cytoplasm with acidophilic 
areas; 4) the orthochromatic erythroblast, with a nucleus:cytoplasm ratio of approximately 1:4, 
nucleus darker and subject to pyknotic degeneration, and cytoplasm slightly pink as a 
consequence of the progressive increase in hemoglobin concentration; 5) and finally the 
reticulocyte that has lost its nucleus and, through the complete degradation of ribosomes and 
mitochondria, proceeds to the transformation in mature erythrocyte (Grover, 1994; Loken et 
al., 1987; Okumura et al., 1992; Orkin, 1996) (Fig.1). In adult mammalian bone marrow 
erythroblasts are always associated to the erythroblastic islets, that represent the drive 
amplification stage anatomy of erythropoiesis and consists of 1 or 2 histiocytic crown cells 
surrounded by erythroblasts at all stages of maturation. The histiocytes have thin cytoplasmic 
extensions that insert between erythroblasts suggesting that factors of nutrition can be 
provided by the histiocytic cell, centrally located, to the peripheral maturing erythroblasts 
(Grover, 1994; Orkin, 1996). The circulating red cell mass is maintained constant by a 
homeostatic mechanism regulating erythropoiesis, based on an erythropoietic stimulus which 
ensures that, under physiological conditions, the production of red blood cells equals their 
destruction. Moreover, in response to hypoxia, hemorrhage or hemolysis, this stimulus causes 
increase in the production of red blood cells (Ponka, 1997). The most important factor involved 
in the control of erythropoiesis is erythropoietin, but other substances, particularly hormones, 
contribute to the regulation of this process [Fried, 1995; Ponka, 1997]. Transferrin comes out 
from the bone marrow sinusoids using ample fenestrature exits, and binds to surface receptors 
carried by erythroblasts. The iron transferred from transferrin and transported to the 
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tetrapyrroles heme synthetase (Heme synthetase HS) for the synthesis of heme (Ponka, 1997; 
Testa et al., 1993; Testa, 2002). The reticuloendothelial system is a functional unit that includes 
cells having heterogeneous histologically different identities and a widespread distribution 
throughout the body, which share the common property of phagocytic activity, e.g. 
endothelial cells of blood capillaries of liver, spleen, bone marrow and lymph nodes, tissue 
and circulating macrophages (Andrews, 2000; Ponka, 1997). Reticuloendothelial system is the 
most important source of iron that enters the blood compartment. The flow of iron from 
reticuloendothelial plasma is unidirectional, as the reticuloendothelial cells are not able to pick 
up the metal from transferrin, but receive only hemoglobin or ferritin iron (Ponka, 1997; 
Andrews, 2000).Senescent erythrocytes at the end of their life (approximately 120 days) are 
phagocytized by endothelial cells and represent the largest source of iron entering the 
reticuloendothelial system. About 85% of the iron that enters the reticuloendothelial cells is 
promptly transferred to plasma transferrin and the remaining 15% is stored as intracellular 
ferritin, and transferred to plasma much more slowly [(Andrews, 2000; Grover, 1994; Ponka, 
1997). 
 
Fig. 1. Pathway of the erythropoiesis from progenitors to mature cells. Different stages are 
indicated: hematopoietic stem cell (HSC), burst-forming unit erythroid (BFU-E), colony-
forming unit erythroid (CFU-E), proerythroblast (ProE), basophylic (BasoE), polychromatic 
(PolyE) and orthochromatic erythroblast (OrthoE). Coloured bars indicate timing of FPN1 
alternative transcript expression (bottom) and hemoglobin synthesis referred to stages of 
erythropoiesis (bottom). 
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3. Iron acquisition by erythroid cells 
Most of the iron in the plasma is bound to transferrin, an 80-kDa  glycoprotein with 
homologous N-terminal and C-terminal iron-binding domains that is synthesized in the 
liver(De Domenico et al., 2008). Plasma transferrin has two important roles in iron 
physiology: first, the high iron-binding affinity of transferrin and the presence of a high 
concentration of apotransferrin (the iron-free form of transferrin) ensure that when iron 
enters plasma it is chelated , so limiting the ability of iron to generate toxic radicals; second, 
transferrin also directs iron towards cells that express transferrin receptors(De Domenico et 
al., 2008). Erythroid precursors require efficient iron uptake from Tf so that hemoglobin can 
be produced. TfR1 mediates erythroid iron acquisition, and its expression paralleles the 
maturation of erythroid progenitors (Hentze et al.,2004). The number of TfRs on erythroid 
cell, markedly higher than on other cell types (Sposi et al., 2000) is directly related to 
hemoglobin (Hb) production (Horton, 1983; Iacopetta et al., 1982; Nunez et al., 1977). In 
normal erythropoiesis, the hyperexpression of TfR1, starting from early erythroid HPC 
differentiation, is Epo-dependent and mediated via transcriptional and post-transcriptional 
mechanisms (Sposi et al., 2000). Both the number of TfRs present on the membrane and 
cellular ferritin concentration are regulated by intracellular iron level. Coordinate regulation 
of TfRs and ferritin is one of the most extensively studied mechanisms of post-
transcriptional control of gene expression. In response to iron deprivation, the cytoplasmic 
stability of TfR mRNA is increased and ferritin mRNA translation inhibited (Klausner et al., 
1993). As a consequence, enhanced iron uptake and diminished iron storage compensate for 
the lack of iron. The feedback regulation can be considered as a protective mechanism that 
prevents nutritional starvation and permits the biosynthesis of essential iron or heme-
containing proteins. Under conditions of high iron supply, when cells need to store excess 
iron in order to prevent adverse effects of iron overload, the regulatory balance is inversed: 
TfR mRNA decays more rapidly and ferritin translation is no longer inhibited(Klausner et 
al., 1993). After binding to its receptor, the complex of Fe(III)-transferrin-TfR1 is rapidly 
internalized by receptor-mediated endocytosis through clathrin-coated pits (De Domenico et 
al., 2008 ; Ponka et al,1998). Acidification of the endosome produces a conformational 
change in both transferrin-Fe(III) and TfR1 with the consequent release of iron (Bali et al., 
1991; De Domenico et al., 2008; Sipe & Murphy, 1991). The endosomal Fe(III) is converted 
into Fe(II) by a STEAP3, an erythroid-specific reductase (Ohgami et al., 2005). 
DMT1/Nramp2, a protons and Fe(II) co-transporter present in the endosomal membrane, 
transports iron into the cytosol (De Domenico et al., 2008; Gunshin et al., 2001). 
DMT1/Nramp2 is a member of the natural resistance-associate-macrophage protein 
(Nramp) family (Cellier et al., 1995). Several isoforms of the DMT1/Nramp2 mRNA are 
known, resulting from alternative splicing and/or the use of two alternative upstream 
promoter regions (Hubert & Hentze, 2002; Millot et al., 2009; Tabuchi et al., 2002). The 
isoform I is localized mainly at the apical site of the enterocytes and other epithelial cells 
whereas isoform II is found on the endosomal membrane of peripheral tissues and erythroid 
cells (Canonne-Hergaux et al., 2001; Millot et al., 2009). At acidic pH, apotransferrin remains 
bound to TfR1 and the complex is recycled to the cell surface (De Domenico et al., 2008). At 
the more neutral pH of plasma, apotransferrin dissociates from TfR1 and is free to bind iron 





tetrapyrroles heme synthetase (Heme synthetase HS) for the synthesis of heme (Ponka, 1997; 
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Fig. 1. Pathway of the erythropoiesis from progenitors to mature cells. Different stages are 
indicated: hematopoietic stem cell (HSC), burst-forming unit erythroid (BFU-E), colony-
forming unit erythroid (CFU-E), proerythroblast (ProE), basophylic (BasoE), polychromatic 
(PolyE) and orthochromatic erythroblast (OrthoE). Coloured bars indicate timing of FPN1 
alternative transcript expression (bottom) and hemoglobin synthesis referred to stages of 
erythropoiesis (bottom). 
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3. Iron acquisition by erythroid cells 
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containing proteins. Under conditions of high iron supply, when cells need to store excess 
iron in order to prevent adverse effects of iron overload, the regulatory balance is inversed: 
TfR mRNA decays more rapidly and ferritin translation is no longer inhibited(Klausner et 
al., 1993). After binding to its receptor, the complex of Fe(III)-transferrin-TfR1 is rapidly 
internalized by receptor-mediated endocytosis through clathrin-coated pits (De Domenico et 
al., 2008 ; Ponka et al,1998). Acidification of the endosome produces a conformational 
change in both transferrin-Fe(III) and TfR1 with the consequent release of iron (Bali et al., 
1991; De Domenico et al., 2008; Sipe & Murphy, 1991). The endosomal Fe(III) is converted 
into Fe(II) by a STEAP3, an erythroid-specific reductase (Ohgami et al., 2005). 
DMT1/Nramp2, a protons and Fe(II) co-transporter present in the endosomal membrane, 
transports iron into the cytosol (De Domenico et al., 2008; Gunshin et al., 2001). 
DMT1/Nramp2 is a member of the natural resistance-associate-macrophage protein 
(Nramp) family (Cellier et al., 1995). Several isoforms of the DMT1/Nramp2 mRNA are 
known, resulting from alternative splicing and/or the use of two alternative upstream 
promoter regions (Hubert & Hentze, 2002; Millot et al., 2009; Tabuchi et al., 2002). The 
isoform I is localized mainly at the apical site of the enterocytes and other epithelial cells 
whereas isoform II is found on the endosomal membrane of peripheral tissues and erythroid 
cells (Canonne-Hergaux et al., 2001; Millot et al., 2009). At acidic pH, apotransferrin remains 
bound to TfR1 and the complex is recycled to the cell surface (De Domenico et al., 2008). At 
the more neutral pH of plasma, apotransferrin dissociates from TfR1 and is free to bind iron 





4. Iron utilization by erythroid cells 
Erythroblasts also handle large amounts of iron. In these cells, most of the iron leaving the 
endosome is then transported to the mitochondria for heme synthesis and iron-sulfur cluster 
assembly (Napier et al., 2005). Potentially, iron may be directly transported from endosome 
into mitochondria by a “kiss-and-run mechanism” through a direct contact between both 
organelles, effectively bypassing the cytosol (Sheftel et al., 2007).Mitoferrin (Mfrn1, 
SLC25a37), a protein belonging to the family of mitochondrial solute carrier proteins 
expressed in the inner mitochondrial membrane, is thought to be implicated in shuttling 
iron across mitochondrial membrane (Millot et al., 2009; Shaw et al., 2006). The zebra fish 
mutant frascati with a mutated Mfrn1 gene shows profound hypochromic anaemia due to 
defective iron uptake by mitochondria (Shaw et al., 2006). Mfrn1 has a paralogue in 
mammals, Mrfn2 that is ubiquitously expressed. Silencing of both Mrfn1 and Mrfn2 induces 
reduction in heme synthesis by 90% (Paradkar et al., 2009). Most of heme in the body is 
synthesized in erythroid cells, as a precursor to hemoglobin formation, although heme is 
also the prosthetic group of various types of proteins, such as cytosolic or mitochondrial 
cytochromes, catalase, peroxidase and NO synthase (Millot et al., 2009). The erythroid-
specific first enzyme of protoporphyrin IX synthesis,  5-aminolaevulinate synthase (ALAS), 
is encoded  by two different genes:  ALAS1 which is ubiquitously expressed and ALAS2, 
which is expressed only in erythroid cells (Furuyama et al., 2007). Regulation mechanisms 
differ widely between the two isoforms, i.e ALAS1 expression is negatively regulated by 
heme, whereas ALAS2 expression is only dependent on iron (Furuyama et al., 2007). 
Ferrochelatase, the last enzyme of the pathway, synthesizes heme from Fe(II) and 
protoporphyrin IX (PIX). Heme is then transported out of the mitochondria to be associated 
to globin chains and apocytochromes (Furuyama et al., 2007). Three molecules have been 
identified as possible mitochondrial heme exporters or transporters: the breast cancer 
resistance protein (ABCG2) (Jonker et al., 2002), the ABC-mitochondrial erythroid (ABC-me) 
transporter (Shirihai et al., 2000) and the feline leukemic virus subgroup C receptor 
(FLVCR)(Quigley et al., 2004). Heme export from mitochondria is thought to be mediated by 
ATP-Binding Cassette (ABC) transporters, i.e. ABCG2 and ABC-me (Shirihai et al., 2000), 
although the exact nature of the transporter has not been elucidated. FLVCR could be 
required for differentiation of erythroid precursors into colony forming units, potentially 
protecting cells against heme toxicity by exporting excess heme that can otherwise result in 
oxidative stress (Dunn et al., 2008; Quigley et al., 2004). However, the heme transporters 
responsible for heme release remain unclear. Another important function of iron in the 
mitochondria is to ensure the [Fe-S] cluster synthesis. It has been proposed that frataxin acts 
as a metabolic switch between [Fe-S] cluster and heme synthesis (Becker et al., 2002; Dunn et 
al., 2006). Frataxin expression is much decreased in the disease Friedreich’s ataxia, in which 
iron loading occurs in the mitochondria (Dunn et al., 2006; Puccio et al., 2001). The 
molecular form of this excess iron remains unknown, but it could be unbound iron or iron 
stored in mitochondrial ferritin or other proteins (Dunn et al., 2006). Ferritin mitochondrial 
(FtMt) mRNA does not contain IRE, contrary to the H and L ferritin mRNAs, and therefore 
the FtMt synthesis is not regulated by the IRE/IRP system (Drysdale et al., 2002; Levi et al., 
2001). The role of this FtMt is not fully elucidated but is thought to be a protective molecule 
against iron-mediated oxidative damage rather than an iron-storage molecule (Millot at al., 
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2009). Although erythroid cells consume large amounts of iron, they have to maintain safety 
mechanisms to avoid iron and/or heme excess. It can be stored in ferritin or exported by 
ferroportin. Additionally, erythroblasts also have the capacity to export excess heme by 
FLVCR (Keel et al., 2008). 
5. Iron- and haem-dependent regulation in erythroid cells 
Iron metabolism and cellular heme represent two of the most key regulators of 
erythropoiesis (Andrews, 2008; Nemeth et al., 2008; Tsiftsoglou et al., 2009). The principal 
source of iron for erythrocyte precursors is plasma iron-transferrin (Fe-Tf), whereas heme 
derives from plasma as well as “de novo” biosynthesis inside the mitochondria as 
protoporphyrin IX first and then as iron-protoporphyrin IX (heme) after incorporation of 
iron with ferrochelatase (Tsiftsoglou et al., 2009). Trafficking and storage of iron in the 
mitochondria is tightly regulated as excess free iron promotes the generation of harmful 
reactive oxygen species whereas an inadequate supply of iron prevents haemoglobin 
synthesis leading to microcytic hypochromic anaemia (Martin et al., 2006; Millot et al., 
2009). Cellular iron homeostasis is coordinately regulated posttranscriptionally by 
IRE/IRP system during erythroid differentiation. The analysis of IRP expression in 
hemopoietic cells provided some potentially interesting findings. It is well established 
that two different IRPs, IRP-1 and IRP-2, exist in mammalian cells (Henderson et al., 1993; 
Sposi et al., 2000). Both these proteins interact with the IRE sequence, six nucleotide loops, 
present in the certain mRNA 5′ or 3′ untranslated regions. The binding of IRP to ferritin 
mRNA results in translational block, while the binding to TfR mRNA results in mRNA 
stabilization (Sposi et al., 2000; Thomson et al., 1999). In spite of these similarities, 
however, IRP-1 and IRP-2 exhibit some important differences. In fact IRP-1 is related to 
mitochondrial aconitase, an enzyme of the Krebs cycle. Under high iron conditions IRP-1 
dissociates from the IRE and is converted to a cytoplasmic aconitase through insertion of a 
[4Fe-4S] cluster (Haile et al., 1992). IRP-2 shares 60% amino-acid homology with IRP-1, 
but differs having a 73-amino-acid insertion in its N-terminal region, which confers a 
sensitivity to degradation via the ubiquitin–proteasome pathway in iron loading 
conditions (Guo et al., 1995; Henderson et al., 1993). IRP-2 is unable to assemble a [4Fe-4S] 
cluster and thus lacks aconitase activity. IRP-1 and IRP-2 are differentially expressed in 
hemopoietic cells and their expression is modulated during differentiation/proliferation 
of these cells. Thus, during differentiation of Hemopoietic Progenitor Cells (HPCs) from 
progenitor cells to mature cells it was observed that, during the initial stages 
of hemopoietic cell differentiation both IRP-1 and IRP-2 mRNAs are induced in all 
hemopoietic lineages; however, at later stages of differentiation, IRP-2 is expressed in all 
hemopoietic lineages at different stages of differentiation/maturation, IRP-1 is selectively 
expressed only in erythroid cells, while its expression is lost in all the other hemopoietic 
lineages (Sposi et al., 2000). It is not clear whether both IRP1 and IRP2 contribute to 
stabilization of TfR1 mRNA but several lines of evidence suggest that IRP2 is the main 
iron-sensor in erythroid cells: i.e., heme deficiency stabilizes IRP2 whereas accumulation 
of free heme induces its ubiquitination and degradation by the proteasome (Ishikawa et 
al., 2005; Millot et al., 2009); IRP2 knock-out mice develop microcytic hypochromic 
anaemia with reduced TfR1 expression in bone marrow cells (Cooperman et al. 2005; Galy 
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2009). Although erythroid cells consume large amounts of iron, they have to maintain safety 
mechanisms to avoid iron and/or heme excess. It can be stored in ferritin or exported by 
ferroportin. Additionally, erythroblasts also have the capacity to export excess heme by 
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in IRP2 expression, with a concomitant reduction in TfR1 mRNA and increasing of IRP1 
(Kerenyi et al., 2008). The observation that in differentiating erythroblasts, TfR1 mRNA 
stability and IRP mRNA-binding affinity are no longer modulated by iron supply, has 
recently challenged the implication of the IRE/IRP system in iron homeostasis regulation 
in erythroid cells (Schranzhofer et al., 2006). This would be in agreement with the so 
called “kiss-and-run” hypothesis (Ponka et al., 1997; Richardson et al., 1996). It suggests 
that during terminal erythropoiesis endosomes come into close vicinity/physical contact 
with mitochondria to directly shuttle iron into this organelle for heme synthesis without 
modulating the mRNA-binding activity of the IRPs (Ponka et al., 2002; Zhang et al., 2005). 
This dual mechanism contributes to maintaining the high flux of incoming iron available 
for heme synthesis rather than being sequestered into ferritin (Millot et al., 2009). The 
level of cellular heme is very critical in the regulation of erythropoiesis. Heme 
biosynthesis is increased dramatically during Epo-moderated erythropoiesis to meet extra 
demand for red blood cell production under hypoxic conditions or stress erythropoiesis 
(Tsiftsoglou et al., 2009). Heme is needed for the production of large number of 
hemoproteins involved in cell respiration, O2 tension sensing and metabolism (Tsiftsoglou 
et al., 2009). Heme is also needed to regulate the transcription of globin and nonglobin 
genes, because it has been found to regulate the action of transcription factors at nuclear 
level (Tsiftsoglou et al., 2009). Heme itself functions as a transcriptional regulator. It can 
induce heme oxygenase 1, HO-1, a molecule which reciprocally induces heme 
degradation (Huihui and Ginzburg, 2010). Heme strongly stimulates HO-1 expression by 
inhibiting the transcriptional repressor Bach 1. Binding of a heterodimer of the small maf 
transcription factor and Bach 1 to the multiple MARE (maf recognition element) sites in 
HO-1 enhancer represses HO-1 gene expression (Millot et al., 2009). It has been shown 
that HO-1 mRNA decreases following erythroid differentiation of Friend erythroleukemia 
cells, while mRNAs coding for the enzymes of the heme biosynthetic pathway increase 
(Millot et al., 2009; Fujita and Sassa, 1989). Heme non participating in hemoglobin 
synthesis results in a downregulation of IRP2 which reduces TfR1 expression on the cell 
surface and thus the amount of iron entering cells so preventing excess heme from 
accumulating in erythroid precursors (Huihui and Ginzburg, 2010; Ishikawa et al., 2005). 
In order to prevent excess globin synthesis, heme deficiency represses globin synthesis by 
activating a stress protein kinase named heme regulated inhibitor (HRI) which 
phosphorylates eIF2α (McEwen et al., 2005; Millot et al., 2009). Finally heme export has 
also recently been demonstrated in erythroid precursors. It has been shown that the feline 
leukemia virus, subgroup C, receptor (FLVCR) could function as a heme exporter (Quigly 
et al., 2004; Taylor et al., 1999). FLVCR is a member of the family of MFS (major facilitator 
superfamily) proteins which transport small solutes across membranes by using the 
energy of ion-proton gradient (Millot et al., 2009; Taylor et al., 1999). The absence of 
FLVCR results in arrest of proerythroblast differentiation and apoptosis, likely due to 
heme toxicity, whereas FLCVR overexpression in mice results in a mild microcytic 
hypocromic anemia suggesting that it is needed to maintain heme and globin balance and 
avoid accumulation of free heme or excess globin in the cytoplasm (Huihui and Ginzburg, 
2010; Keel et al., 2008). In conclusion during erythroid differentiation the existence of an 
interplay of positive and negative feedback mechanisms maintains sufficient iron supply 
for heme synthesis and prevents formation or accumulation of heme in excess of globin 
chains. 
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6. Iron deficiency and anemia 
Under physiological conditions, there is a balance between iron absorption, iron transport 
and iron storage in the human body. Iron deficiency anemia may result from the interplay of 
three distinct risk factors: increased iron requirements, limited external supply and 
increased blood loss (Munoz et al., 2010). Likewise, inappropriately high levels of hepcidin 
expression lower plasma iron levels and cause anemia. In this context, the common acquired 
anemia of chronic diseases (ACD) and the genetic iron-refractory iron deficiency anemia 
(IRIDA) are the most interesting examples. Several physiopathological features contribute to 
the anemia of chronic diseases, also known as the anemia of inflammation: impaired 
proliferation of erythroid progenitors and blunted response to erythropoietin, reduced 
erythropoietin synthesis as well as reduced life span of red blood cells (Millot et al., 2009). 
The basis of the disorder is that inflammatory stimuli, such as those caused by bacterial 
infections, cause acute hypoferremia presumably in an attempt to limit the growth of 
bacteria by limiting iron (De Domenico et al., 2008; Schaible and Kaufmann, 2004). During 
inflammation IL-6 seems to be the major pro-inflammatory cytokine implicated in hepcidin 
activation through a Stat3 dependent signaling pathway, so allowing the identification of a 
link between iron homeostasis and inflammation (Millot et al., 2009; Wrighting and 
Andrews. 2006). Hypoferremia develops rapidly as a result of decreased macrophage iron 
release leading to iron-limited erythropoiesis. Increased cellular iron retention is the result 
of decreased levels of cell-surface ferroportin, which, in turn, results from sustained 
secretion of hepcidin (De Domenico et al., 2008). Low or undetectable levels of hepcidin are 
normally observed in patients with iron deficiency. On the contrary, patients with IRIDA 
show very low iron stores and microcytic anemia refractory to iron treatment in 
consequence of inappropriately high hepcidin levels. IRIDA is caused by mutations in 
TMPRSS6 (matriptase-2), a gene that encodes a protease that negatively regulates hepcidin 
expression (Du et al., 2008). Recently it has been observed that genetic variants in TMPRSS6, 
frequent in the general population, may modulate the ability to absorb iron and to 
synthesize hemoglobin for maturing erythroid cells (Andrews, 2009). Recent study suggest 
that TMPRSS6 normally acts to down-regulate hepcidin expression by cleaving membrane-
bound hemojuvelin, HJV, (Silvestri et al., 2008).     
7. Iron overload and hereditary hemochromatosis 
Hereditary hemochromatosis is an iron overload disease characterized by excessive body 
iron that causes tissue damage in the liver, pancreas and heart (Pietrangelo A, 2004).  
Currently four types have been identified in Caucasian populations: type 1 is the common 
form and is an autosomal recessive disorder of low penetrance strongly associated with 
mutations in the HFE gene ; type 2 (juvenile hemochromatosis) is autosomal recessive, of 
high penetrance with causative mutations identified in the HFE2 and HAMP genes; type 3 is 
also autosomal recessive with mutations in the TfR2 gene; type 4, or HFE4 (OMIM 606069), 
or ferroportin disease, is an autosomal dominant condition with heterozygous mutations in 
the ferroportin 1 (FPN1) gene (Worwood, 2005). FPN1(also known as Ireg1 and MTP1), the 
product of the Slc40a1 gene, was independently identified by three groups, using different  
approaches (Abboud & Haile, 2000; Donovan et al, 2000; McKie et al., 2000) and has been 
reported to be expressed and to play a critical role in several different tissue involved in 
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6. Iron deficiency and anemia 
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reported to be expressed and to play a critical role in several different tissue involved in 





the circulation; hepatocytes (storage); syncytiotrophoblasts (transfer to embryo) and 
reticuloendothelial macrophages (iron recycling from senescent red blood cells). FPN1 
appears to act as an iron exporter (Donovan et al., 2000; McKie et al., 2000) and to be 
specifically regulated according to body iron requirements (Donovan et al., 2000; Martini et 
al., 2002; McKie & Barlow, 2004; Mok et al., 2004; Pietrangelo et al., 2004; Yang et al., 2002;  
Zoller et al., 2001) in these tissues. The FPN1 gene has been highly conserved during 
evolution and encodes for a protein composed of 571 aminoacids with a predict mass of 62 
kDa (for review see Cianetti et al., 2010).The presence of a well-conserved IRE in the 5’-UTR 
of FPN1 mRNA indicated the possibility of post-transcriptional control through the IRP-IRE 
systems (Donovan et al., 2000; Liu et al, 2002; Lymboussaki et al., 2003; McKie & Barlow, 
2004) but several recent observation have indicated a more complex regulation  of FPN1 
expression by iron (Cianetti et al., 2010). Hemochromatosis associated with mutations in 
FPN1 can result in two different types of iron loading: one type is phenotypically 
indistinguishable from classical HFE hemochromatosis (or hemochromatosis type 1) 
(Spelling), in that the patients have both an elevated transferrin saturation and serum 
ferritin, while the other type termed “ferroportin disease” is associated with microcytic 
anemia, a raised serum ferritin and iron deposition in macrophages rather than hepatocytes 
(Pietrangelo, 2004). FPN1 mutations have two effects, either causing misfolding of the 
protein and failure to reach the cell surface (“loss of function”)(Schimanski, 2005), or the 
mutant protein is expressed at the cell surface but is not inhibited by hepcidin (“loss of 
regulation”)(Drakesmith, 2005). Briefly it was shown that A77D, V162del, and G490D 
mutations, that are associated with typical pattern of disease in vivo, cause a loss of iron 
export function in vitro, but do not physically or functionally impede wild-type FPN1 
(Drakesmith, 2005; Schimanski, 2005). These mutations may, therefore, lead to disease by 
haploinsufficieny. By contrast the Y64N, N144D, Q248H and C326Y mutations, which can be 
associated with greater transferrin saturation and more prominent iron deposition in liver 
parenchyma in vivo, retained iron export function in vitro (Drakesmith, 2005; Schimanski, 
2005). Because the peptide hormone hepcidin inhibits ferroportin as part of a homeostatic 
negative feedback loop, it was postulated that this group of mutations may resist inhibition 
to hepcidin resulting in a permanently “turned on” iron exporter (Drakesmith, 2005; 
Schimanski, 2005). All these results with A77D, V162del and G490D mutations of FPN1 are 
consistent with the scheme proposed by Montosi et al (Montosi et al., 2001)) to explain the 
macrophage iron loading observed in patients with these mutations (Schimanski et al., 
2005): lower serum iron resulting from iron sequestration in macrophages reduces 
availability to the bone marrow for erythropoiesis thus leading to anemia that was 
effectively observed in some patients with mild anemia in the early stages of disease and 
that respond poorly to phlebotomy (Pietrangelo,2004; Schimanski et al, 2005). So iron 
overload may be a consequence of the erythron signalling to the gut enterocyte to increase 
iron uptake from the diet to compensate for the anemia.  According to recent progress in 
this field it is likely that the erythron signalling is directly working through hepcidin-
ferroportin interaction. By contrast the Y64N, N144D, Q248H and C326Y mutations, which 
can be associated with greater transferrin saturation and more prominent iron deposition in 
liver parenchyma in vivo, retain iron export function in vitro (Schimanski et al., 2005; 
Drakesmith et al., 2005). It was postulated that this group of mutations may resist inhibition 
by hepcidin, so interfering with its homeostatic negative feedback loop and resulting in a 
permanently “turned on” iron exporter (Schimanski et al., 2005; Drakesmith et al., 2005). 
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8. Ineffective erythropoiesis and thalassemia 
In recent years there has been important advancement in our understanding of iron 
metabolism, mainly as a result of the discovery of hepcidin , a key regulator of whole-body 
iron homeostasis (for an exhaustive review see Ganz& Nemeth, 2006; Piperno et al, 2009; 
Lee & Beutler, 2009). Increasing experimental evidence suggested that a single molecule 
could be the “stores”, the “erythropoietic” and the “inflammation” regulator of iron 
absorption and recycling [Cianetti et al., 2010; Fleming & sly, 2001; Nicolas et al., 2002), and 
that hepcidin acted principally or solely by binding to ferroportin, the only known cellular 
iron exporter, causing ferroportin to be phosphorylated, internalized, ubiquitylated, sorted 
(Nemeth et al., 2004) through the multivesicular body pathway and degraded in lysosomes 
(Ganz, 2005; Nemeth et al., 2004). Different stimuli can modulate hepcidin and act as 
positive or negative regulators. Four major regulatory pathways (erythroid, iron store, 
inflammatory and hypoxia-mediated regulation) that act through different signaling 
pathways to control the production of hepcidin are known (Cianetti et al., 2010). It is 
obvious that this complex network of interactions must be subjected to very close control in 
order to ensure that the iron erythropoietic demand is met and, in turn, adequate 
concentrations of iron in the circulation are always present (Cianetti et al., 2010; Piperno et 
al., 2009). Under normal conditions iron store and inflammatory regulation activate 
hepcidin transcription in the hepatocytes through the bone morphogenetic proteins 
(BMPs)/SMAD4 and signal transducer and activator of transcription-3 (STAT-3) pathways, 
respectively (Andrews, 2008; Piperno et al., 2009). The hemochromatosis protein HFE, 
transferrin receptor 2 (TfR2) and the membrane isoform of hemojuvelin (mHJV) are all 
positive modulators of hepcidin transcription and when defective, lead to hemochromatosis 
(HH) in humans (De Domenico et al., 2008; Piperno et al., 2009). Oppositely, hypoxia, 
anemia, increased erythropoiesis and reduced iron stores all negatively regulate hepcidin 
expression(Piperno et al., 2009). Emerging evidence suggests that erythropoiesis modulates 
hepcidin expression, with increased erythropoietic activity suppressing the action of 
hepcidin (Dallalio et al., 2006; Dunn et al., 2007; Kattamis et al., 2006; Pak et al., 2006; 
Vokurka et al., 2006). This in turn facilitates export of iron from the reticuloendothelial 
system and enterocytes, increasing the availability of iron for erythropoiesis (Dunn et al., 
2007; Pak et al., 2006). Anemia and hypoxia also suppress hepcidin expression, although 
recent experiments indicate that functional erythropoiesis is required (Dunn et al., 2007; Pak 
et al., 2006; Vokurka et al., 2006) for these conditions to regulate hepcidin expression. Finally 
it is evident that erythropoiesis and iron metabolism are extremely intertwined in that 
alteration of one of the two may have a major impact on the second (Gardenghi et al., 2007; 
El Rassi et al., 2008; Rivella, 2009; Rund & Rachmilewitz, 2005; Weatherall & Clegg. 2001; 
Weatherall, 2001). That’s the reason why thalassemia intermedia and thalassemia major are 
the best studied human models of hepcidin modulation by ineffective erythropoiesis. Beta-
thalassemias are caused by mutations in the beta-globin gene resulting in reduced or absent 
beta-chain synthesis (for exhaustive reviews see Wetherall, 1998; Olivieri, 1999; Cao & 
Galanello, 2010; Ginzburg & Rivella, 2011). A relative excess of α-globin chain synthesis 
leads to increased erythroid precursor apoptosis, causing ineffective erythropoiesis which 
together with extramedullary expansion, splenomegalia and shortened red blood cells 
survival result in anemia (Huihui & Ginzburg, 2010). Patients either homozygous or 
compound heterozygous for mutation in the β-globin gene present with a broad range of 
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hemoglobinopathies, and additional modifying factors (Ginzburg & Rivella, 2011; Huihui & 
Ginzburg, 2010). Individuals with thalassemia major require regular red blood cell (RBC) 
transfusions to ameliorate anemia and suppress extramedullary erythropoiesis. Patients 
with beta-thalassemia intermedia show a milder clinical picture with more beta-globin 
chains synthesis and require only intermittent transfusions (Huihui & Ginzburg, 2010). 
Patients with beta-thalassemia have increased intestinal iron absorption which, in addition 
to transfusion dependence, contributes to iron overload (Huihui & Ginzburg, 2010). 
Progressive iron overload is the most salient and ultimately fatal complication of beta-
thalassemia. Iron deposition occurs in visceral organs (mainly in the heart, liver and 
endocrine glands), causing tissue damage and ultimately organ dysfunction and failure 
(Fig.2). Both transfusional iron overload and excess gastrointestinal absorption are 
contributory. Paradoxically, excess gastrointestinal iron absorption persists despite massive 
increases in total body iron load (Fleming & Sly, 2001; Gardenghi et al., 2007; Rivella, 
2009)(Fig.3). However, little is known about the relationship among ineffective 
erythropoiesis, the role of iron-regulatory genes, and tissue iron distribution in beta-
thalassemia. If iron were a dominant regulator, patients with beta-thalassemia should 
express very high levels of hepcidin in serum; in contrast, the levels are very low, suggesting 
that the ineffective erythropoiesis alone is able to suppress the synthesis of hepcidin in spite 
of the presence of a severe iron overload (Cianetti et al, 2010; Piperno et al., 2009). 
Furthermore, serum from patients with thalassemia inhibited hepcidin mRNA expression in 
the HepG2 cell line, which suggested the presence of a humoral factor that down-regulates 
hepcidin (Weizer-Stern et al., 2006). The nature of the erythropoietic regulator of hepcidin is 
still uncharacterized, but may include one or more proteins during active erythropoiesis. 
Recent observations in thalassemia patients has suggested that one of these regulators could 
be the cytokine growth differentiation factor-15 (GDF15) (Piperno et al., 2009; Tanno et al., 
2007). GDF15 is a divergent member of the transforming growth factor-beta superfamily 
that is secreted by erythroid precursors and other tissues. It has been identified as an 
oxygen-regulated transcript responding to hypoxia and as a molecule involved in hepcidin 
regulation (Cianetti et al., 2010; Bottner et al., 1999; De Caestecker, 2004; Tanno et al., 2007). 
Serum from thalassemia patients suppressed hepcidin mRNA expression in primary human 
hepatocytes and depletion of GDF15 reversed the hepcidin suppression (Piperno et al., 2009; 
Tanno et al., 2007). It was suggested that GDF15 overexpression arising from an expanded 
erythroid compartment contributed to iron overload in thalassemia syndromes by inhibiting 
hepcidin expression, possibly by antagonizing the BMP pathway. Without going into a 
detailed analysis of the GDF15 regulation mechanisms, we would like to recall the results 
obtained recently, that are in our view important to start reflecting on the existence of 
alternative ways that regulate hepcidin production (Cianetti et al., 2010). Recently a very 
interesting study demonstrated that expression of both GDF15 mRNA and protein was 
strongly and specifically responsive to intracellular iron depletion in a number of human 
cell lines and in vivo in humans (Lakhal et al., 2009; Cianetti et al., 2010). This up-regulation 
is independent of IRP1, IRP2 and the HIF pathway suggesting the involvement of a novel 
iron-regulatory pathway (Lakhal et al., 2009). This study showed that GDF15 was induced 
by over-expression of wild type ferroportin (Lakhal et al., 2009). This observation is very 
intriguing because it connects the iron-mediated regulation of GDF15 concentration to 
patho-physiological levels of iron: despite systemic iron overload, ineffective erythropoiesis 
and associated iron-fluxes in beta-thalassemia might generate an iron deficiency signal in a 
relevant molecular or cellular context and consequent stimulation of GDF15 expression in a 
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particular erythroid compartment (Cianetti et al., 2010; Lakhal et al., 2009). Recent literatures 
provided at least two more molecules potentially involved in the regulation of hepcidin by 
erythropoiesis, i.e. the human twisted gastrulation factor (TWSG1) (Tanno et al., 2009) and 
the Oncostatin M (OsM) (Chung et al., 2010; Kanda et al., 2009). In contrast to GDF15, the 
highest-level expression of TWSG1 was detected at early stages of erythroblast 
differentiation before hemoglobinization of the cells (Tanno et al.,2009). In human cells, 
TWSG1 suppressed hepcidin through a BMP-dependent mechanism (Tanno et al., 2009). In 
vivo studies on thalassemic mice showed that TWSG1 expression was significantly 
increased in the spleen, bone marrow and liver. So it was proposed that TWSG1 might act 
with GDF15 to dysregulate iron homeostasis in beta-thalassemia (Tanno et al., 2009). In 
contrast to GDF15 and TWSG1, recent observations have showed that OsM could induce 
hepcidin expression in human hepatoma cell lines mainly through the JAK/STAT pathways 
(Kanda et al., 2009). Finally, results obtained by HuH7 hepatoma cells cocultured  with 
primary human erythroblasts or erythroleukemic UT7 cells presented a 20- to 35-fold 
increase of hepcidin expression and identified OsM as responsible for increased levels of 
hepcidin (Chung et al., 2010). Furthermore, this study described the biological involvement 
of OsM in iron metabolism “in vivo” through direct transcriptional regulation of hepcidin 
gene expression and suggested a new OsM-hepcidin axis that might be critical in the 
development of hypoferremia in inflammation (Chung et al., 2010). 
 
Fig. 2. A summary of the causes of iron overload. A schematic representation of the main 





hemoglobinopathies, and additional modifying factors (Ginzburg & Rivella, 2011; Huihui & 
Ginzburg, 2010). Individuals with thalassemia major require regular red blood cell (RBC) 
transfusions to ameliorate anemia and suppress extramedullary erythropoiesis. Patients 
with beta-thalassemia intermedia show a milder clinical picture with more beta-globin 
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particular erythroid compartment (Cianetti et al., 2010; Lakhal et al., 2009). Recent literatures 
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gene expression and suggested a new OsM-hepcidin axis that might be critical in the 
development of hypoferremia in inflammation (Chung et al., 2010). 
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Fig. 3. Pathophysiology of beta-thalassemia and corresponding clinical manifestations.  
A summary of the effects of excess production of free alpha-globin chains. Excess unbound 
alpha-globin chains and their degradation products precipitate in red-cell precursors, 
causing defective maturation and ineffective erythropoiesis. 
9. Ferroportin and erythroid cells 
We reported for the first time the expression of FPN1 mRNA and protein in normal human 
erythroid cells at all stages of differentiation (Cianetti et al., 2005). The presence of an iron 
exporter was very surprising because the erythroid cells need to incorporate very high 
amounts of iron to support the continued synthesis of heme and hemoglobin (Cianetti et al., 
2010). The IRE element in the 5’-UTR of FPN1 mRNA was demonstrated to be functional in 
erythroid cells and able to mediate translational modulation by cellular iron levels (Cianetti 
et al., 2005). Nonetheless, FPN1 protein expression appeared to maintain a constant level 
during different steps of erythroid differentiation and after iron treatments (Cianetti et al., 
2005). A solution to this problem could be to use an upstream alternative promoters to 
produce mRNA species in which the 5’-UTR IRE could be spliced out or made non-
functional (Cianetti et al., 2010). We described for the first time the existence of two 
alternative FPN1 transcripts (variant II and III), other than the IRE-containing canonical one 
(variant I), that did not contain the IRE element in their 5’-UT region, did not respond to iron 
treatments and together accounted for more than half of total FPN1 mRNA present in 
erythroid cells (Cianetti et al., 2005; Cianetti et al., 2010). These transcripts arise from the 
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usage of alternative upstream promoters and differential splicing of 5’-UTR sequences. 
Interestingly, these transcripts were expressed mainly during the middle steps (4-11 days) of 
in vitro erythroid differentiation, corresponding to the maturation from late erythroid 
progenitors to polychromatophilic erythroblasts (Cianetti et al., 2005) (Fig.1). At these stages 
of erythroid differentiation TfR1, the receptor responsible for iron import in erythroid cells, 
is strongly and increasingly expressed (Sposi et al., 2000). Therefore, the non-IRE (variant II 
and III) FPN1 transcripts were expressed when erythroid progenitor/precursor cells need to 
accumulate iron into the cells (Cianetti et al.,2005). It was speculated that expression of the 
non-IRE FPN1 transcripts could produce a constant level of the transporter, unresponsive to 
the very high iron levels present in maturing erythroid cell. In contrast, IRE-containing 
FPN1 transcripts were mainly expressed in undifferentiated erythroid progenitors and in 
mature terminal erythroblasts, suggesting a possible role at these particular stages of 
erythroid differentiation (Cianetti et al., 2005; Cianetti et al., 2010). The existence of multiple 
FPN1 alternative transcripts indicated a complex regulation of the FPN1 gene in erythroid 
cells and the possibility that the control of FPN1 expression by iron conditions in different 
cell types might be complex. So in erythroid cells the regulation of FPN1 mRNA translation 
through the 5’-UTR IRE mechanism might be silenced because in this cell type a high level 
of iron uptake is needed to accumulate high amounts of iron required for optimal heme 
synthesis (Cianetti et al., 2005). A solution for this problem might be the utilization of an 
upstream alternative promoter to produce mRNA species in which the 5’-UTR IRE might be 
spliced out or made non functional (Cianetti et al., 2005; Cianetti et al., 2010). The alternative 
FPN1 transcripts are differentially expressed during erythroid differentiation, in particular 
indicating a sequential and specific activation pathway, with an apparently mutual 
exclusion between variant I IRE and variant II/III not containing the IRE transcripts (Cianetti 
et al., 2005) (Fig.1). These observations suggest that erythroid precursor cells need FPN1 
transcript without a IRE to evade translational control by IRP-IRE system in order to export 
iron during the critical period when cells are committed to proliferate and differentiate 
(Cianetti et al., 2010). Once the precursor erythroid cells begin to produce hemoglobin, FPN1 
without a IRE diminishes and FPN1 with a IRE predominates allowing erythroid cells to 
limit iron export through the IRP-IRE system and synthesize heme without developing 
microcytic anemia (Cianetti et al., 2010) (Fig.1).  
10. New potential therapeutic opportunities 
It is increasingly evident that the iron metabolism, heme and cellular erythropoiesis are 
inextricably linked, because iron metabolism (Andrews, 2005; Nemeth, 2008) and cellular 
heme (for exhaustive review see Tsiftsoglou et al., 2006) are two of the most relevant key 
regulators of erythropoiesis (Cianetti et al., 2010). The complex regulation of erythropoiesis 
suggests the existence of several molecular targets that could be exploited therapeutically 
for treatment of RBC disorders like thalassemias and anemias (Tsiftsoglou et al., 2009). We 
must differentiate between primary iron overload, and iron overload that accompanies 
ineffective erythropoiesis: in the latter case the administration of hepcidin might be 
considered as a new potential therapeutic approach to reduce iron overload in thalassemias 
and other forms of anemia associated with ineffective erythropoiesis (Cianetti et al., 2010; 
Tsiftsoglou et al., 2009). The reduced number or the absence of mature erythroid cells in 
beta-thalassemia patients is still very difficult to understand, and it has become one of the 
paradoxes among the most difficult to resolve : when the body has greater need for red 
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probable hypothesis to explain this phenomenon might rely on the existence of intrinsic and 
extrinsic mechanisms that would affect the process of differentiation: for example in cells 
where the synthesis of beta-globin gene is defective to the point that they ensure a 
stoichiometric between alpha and beta globin chains, a security mechanism can block the 
intrinsic maturation or, alternatively, an amount of heme in excess can be an extrinsic signal 
to prevent the differentiation that would lead to clusters of alpha globin chains production 
of reactive oxygen species (ROS) too toxic to survive (Cianetti et al, 2010; Rivella, 2009). 
There is much experimental evidence that oxidative stress may limit the process of 
differentiation. All this of course worsens the anemic outline (Rivella, 2009). So the 
contribution of these mechanisms to ineffective erythropoiesis might be different in each 
patient according to level of beta-globin synthesis and other extrinsic factors such as iron 
overload (Rivella,2009). At this point the question arises: is there a meeting point between 
different signaling pathways, although activated by different signals? Recent discoveries 
indicate that there is a potential for therapeutic intervention in beta-thalassemia by means of 
manipulating iron metabolism (Mabaera et al., 2008; Rivella, 2009; Rund & Rachmilewitz, 
2005). A recent study suggested a link between EpoR/Jak/Stat signaling and iron 
metabolism, showing that in mice that completely lack Stat5 activity the cell surface levels of 
TfR1 on erythroid cells were decreased more than 2-fold (Kerenyi et al., 2008). Another 
study suggested a direct involvement of Epo in hepcidin regulation through the 
transcriptional factor C/EBP alpha (Pinto et al., 2008). In addition a link has been shown 
between Jak 2 and FPN1: Jak2 phosphorylates FPN1 following binding of this protein to 
hepcidin (De Domenico et al., 2009). Phosphorylation of FPN1 then triggers its 
internalization and degradation (De domenico et al., 2009). Therefore Jak2 might represent 
one of the major links at the interface between erythropoiesis and iron metabolism 
suggesting that use of Jak2 inhibitors, antioxidant, and analog of the hepcidin might be used 
to reduce ineffective erythropoiesis and abnormal iron absorption (Cianetti et al., 2010; 
Rivella, 2009). Administration of synthetic hepcidin or of agents that increase its expression, 
may be beneficial in controlling absorption of this metal (Piperno et al., 2009). Hepcidin 
agonists or stimulators of hepcidin production are being developed for the treatment or 
prevention of iron overload in hepcidin deficiency states, including hereditary 
hemochromatosis and beta-thalassemia (Ganz, 2011). In the mouse model of beta-
thalassemia, transgenic hepcidin therapy improved iron overload as well as erythropoiesis 
suggesting that hepcidin deficiency or iron overload may adversely impact erythropoiesis in 
this disease (Ganz.2011). Hepcidin antagonists and inhibitors of hepcidin production may 
find utility in the treatment of iron-restricted anemias, alone or in combination with 
erythropoiesis-stimulating agents (Ganz,2011).  Also GDF15 could be another potential 
therapeutic target for beta-thalassemia syndromes (Tanno et al., 2007). A major goal of 
hemoglobinopathy research is to develop treatments that correct the underlying molecular 
defects responsible for sickle cell disease and beta-thalassemia (Mabaera et al., 2008). One 
approach to achieving this goal is the pharmacologic induction of fetal hemoglobin (HbF). 
Although many of the events controlling the activity of the beta-globin locus are known, the 
details of those regulating normal human hemoglobin switching and reactivation of HbF in 
adult hematopoietic cells remain to be elucidated (Cianetti et al., 2010). If the molecular 
events in hemoglobin switching or gamma-globin gene reactivation were better understood 
and HbF could be fully reactivated in adult cells, the insights obtained might lead to a cure 
for these disorders (Cianetti et al., 2010). Agents that increase human HbF in patients may 
work at one or more levels: for example, hydroxyurea and 5-azacytidine kill dividing cells 
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preferentially and may increase gamma-globin expression indirectly through this effect [for 
complete reviews see Mabaera et al., 2008; Bank, 2006). Butyrate may work both by histone 
deacetylase (HDAC) inhibition and by increasing gamma-globin translation on ribosomes 
(Bank, 2006; Mabaera et al., 2008). The Stem Cell Factor (SCF) induced an “in vitro” 
expansion of effective erythropoiesis and a reactivation of gamma-globin synthesis up to 
fetal levels, paving the way to its potential use in the therapeutic treatment of this disease 
(Gabbianelli et al., 2008). Recently it was reported the ability of thalidomide to increase 
gamma-globin gene expression and the proportion of HbF-containing cells in a human in 
vitro erythroid differentiation system (Aerbajinai et al., 2007) showing that thalidomide 
induced production of ROS that in turn caused p38 MAPK phosphorylation and globally 
increased histone H4 acetylation (Aerbajinai et al., 2007; Mabaera et al., 2008). All these 
experiments present a body of evidence that suggests an important role for intracellular 
signaling in HbF induction (Cianetti et al., 2010). However, the mechanisms of action of 
these agents are not yet defined and their role in beta-thalassemia therapy is still being 
explored in light of its acceptable toxicity profiles adding to their promise as therapeutic 
agents (Ginzburg & Rivella, 2011). Key genes controlling fetal/adult globin switching have 
been identified (e.g. BCL11 and cMYB) and may ultimately serve as direct targets for small 
molecules that would increase HbF levels in this patients (Bauer & Orkin, 2011; Ginzburg & 
Rivella, 2011; Wilber et al., 2011).  Finally recent publications have demonstrated the 
importance of what has been termed the “integrated stress response” pathway in erythroid 
cells that is also activated from a variety of stress stimuli, including viral infection, NO, heat 
shock, ROS, endoplasmic reticulum stress, ultraviolet irradiation, proteosome inhibition, 
inadequate nutrients and, in erythroid cells, limiting amounts of heme (Chen, 2007; Cianetti 
et al., 2010; Mabaera et al., 2008 Wek et al., 2006).  
11. Conclusion 
Our understanding of the pathogenesis of iron-restricted anemias and iron-overload has 
been revolutionized by discovery of hepcidin and its role in iron homeostasis stimulating 
the development of new diagnostic and therapeutic modalities for these disorders. Further 
work is required to understand the mechanisms of hepcidin regulation by iron and 
erythroid activity and to understand the structure, the transport function and the complex 
regulation of the hepcidin receptor ferroportin. In conclusion we are increasingly convinced 
of the importance to study the molecular mechanisms of iron homeostasis dysregulation in 
thalassemia and in particular the GDF15-BMP-Hepcidin-Ferroportin regulatory way in 
order to understanding its contribute to iron overload. 
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1. Introduction 
Chronic kidney disease is a public health problem and one of the outstanding causes of 
death in the industrialized world. The most serious condition is advanced chronic renal 
failure requiring replacement therapy by dialysis or kidney transplantation. In recent years 
the incidence is stabilizing but the prevalence is increasing probably due to the progressive 
aging of the population and increased comorbidity with other chronic disorders such as 
diabetes mellitus, hypertension and obesity (de Francisco et al. 2007). It is also a major cause 
of anemia in developing countries (Maiz, Abderrahim, and Zouaghi 2002) . The long-term 
survival and good quality of life of patients with chronic renal failure depends, among other 
factors, on hemoglobin, iron status and bone marrow response to erythropoiesis stimulating 
agents (ESA). Anemia is an almost constant complication of advanced renal failure which 
may contribute to worsen preexisting heart disease and, as a consequence, accelerate the 
progression of renal dysfunction (Kuwahara et al. 2011), (Silverberg et al. 2009). The 
administration of erythropoietin to patients with kidney and heart failure improves both 
processes, not only increasing hemoglobin but also by a direct effect of erythropoietin on 
cardiac function (Belonje, de Boer, and Voors 2008). In general, anemia is normocytic, 
normochromic and usually well tolerated until the advanced stages of kidney disease. It is 
usually a complication of stage 3 chronic kidney disease (KDOQI and National Kidney 
Foundation 2006). Its etiology is multifactorial: shortening of life span of erythrocytes, 
presence of inhibitors of erythropoiesis in plasma, inadequate production of endogenous 
erythropoietin (EPO) for the degree of anemia, blood loss, and iron and vitamin 
deficiency(Tsubakihara et al. 2010) (Belonje, de Boer, and Voors 2008), (Chamney et al. 2010). 
The outstanding cause is impaired secretion of erythropoietin due to renal disease, while 
other factors may contribute to its establishment, maintenance or aggravation.  
 4 
Iron Deficiency in Hemodialysis Patients –  
Evaluation of a Combined Treatment with  
Iron Sucrose and Erythropoietin-Alpha: 
Predictors of Response, Efficacy and Safety 
Martín Gutiérrez Martín1, Maria Soledad Romero Colás2,  
and José Antonio Moreno Chulilla3  
1Department of Medicine, University of Zaragoza, 
Investigation Group: Multifunctional Molecular Magnetic Materials,  
and INA (Institute of Nanocience of Aragon), 
2Department of Medicine, University Hospital of Zaragoza, 
3University Hospital of Zaragoza, 
Spain 
1. Introduction 
Chronic kidney disease is a public health problem and one of the outstanding causes of 
death in the industrialized world. The most serious condition is advanced chronic renal 
failure requiring replacement therapy by dialysis or kidney transplantation. In recent years 
the incidence is stabilizing but the prevalence is increasing probably due to the progressive 
aging of the population and increased comorbidity with other chronic disorders such as 
diabetes mellitus, hypertension and obesity (de Francisco et al. 2007). It is also a major cause 
of anemia in developing countries (Maiz, Abderrahim, and Zouaghi 2002) . The long-term 
survival and good quality of life of patients with chronic renal failure depends, among other 
factors, on hemoglobin, iron status and bone marrow response to erythropoiesis stimulating 
agents (ESA). Anemia is an almost constant complication of advanced renal failure which 
may contribute to worsen preexisting heart disease and, as a consequence, accelerate the 
progression of renal dysfunction (Kuwahara et al. 2011), (Silverberg et al. 2009). The 
administration of erythropoietin to patients with kidney and heart failure improves both 
processes, not only increasing hemoglobin but also by a direct effect of erythropoietin on 
cardiac function (Belonje, de Boer, and Voors 2008). In general, anemia is normocytic, 
normochromic and usually well tolerated until the advanced stages of kidney disease. It is 
usually a complication of stage 3 chronic kidney disease (KDOQI and National Kidney 
Foundation 2006). Its etiology is multifactorial: shortening of life span of erythrocytes, 
presence of inhibitors of erythropoiesis in plasma, inadequate production of endogenous 
erythropoietin (EPO) for the degree of anemia, blood loss, and iron and vitamin 
deficiency(Tsubakihara et al. 2010) (Belonje, de Boer, and Voors 2008), (Chamney et al. 2010). 
The outstanding cause is impaired secretion of erythropoietin due to renal disease, while 





The specific treatment of choice for anemia of chronic renal failure is recombinant human 
erythropoietin (rHuEPO), a drug considered a historic milestone since the time of its clinical 
use in 1986 (Winearls et al. 1986), and the major therapeutic advance in anemia of chronic 
renal failure. Erythropoietin remains vital in the treatment of anemia of renal failure, but in 
the coming years could be replaced by new erythropoiesis-stimulating agents under 
investigation (Schmid and Schiffl 2010). The use of erythropoietin led to a drastic reduction 
of transfusions and androgen therapy with the consequence of decreasing the complications 
of these treatments. Suitable doses of the drug, as well as the correction of other contributing 
factors to anemia, are necessary to maintain adequate levels of hemoglobin in the range of 
11-12 g / dl (KDOQI 2007). 
Iron is an essential factor to achieve and maintain effective erythropoiesis in patients with 
chronic renal failure treated with rHuEPO, due to frequent losses of blood in the 
hemodialyzer, overstimulation of erythropoiesis induced by erythropoietin and possible 
gastrointestinal bleeding. Moreover, the renal disease itself and chronic inflammation can 
sequester iron in the mononuclear phagocytic system preventing its use for erythropoiesis. 
These factors as a whole significantly increase the demand for iron. Capacity of intestinal 
iron absorption in these patients is not enough to maintain adequate levels of iron stores. On 
the other hand, the supply of iron improves response to rHuEPO and aids to lower its dose 
up to 30%. However, iron administration must be handled with caution, as an excess is not 
safe. The body has mechanisms to regulate iron absorption in the gastro-duodenal tract, but 
lacks a physiological mechanism to remove excess iron. Therefore treatment with 
intravenous iron should be monitored carefully. 
Other causes of anemia in dialysis patients such as: hemolysis, aluminum intoxication, 
infection, chronic inflammation and hyperparathyroidism should not be overlooked; on the 
contrary the anemia of renal failure is not generally characterized by a lack of folic acid or 
vitamin B12 (Bravo, Galindo, and Bienchy 1994). 
For all these reasons, patients need iron administration (usually intravenous) and regular 
monitoring of iron body stores. The diagnosis and treatment protocols should be optimized 
to adjust the cost, improve quality of life and prolong survival, as it has recently been 
reported that patients with hemoglobin above 12 g / dl have a higher survival rate than 
those with lower levels (Pollak et al. 2009). 
The evaluation of anemia and iron status in chronic renal failure has peculiarities that make 
it different from other processes. Therefore we find it useful to include a brief description of 
the normal values in adults, the diagnosis of iron deficiency in general and the peculiarities 
of the diagnosis of iron status in patients with chronic renal failure. The World Health 
Organization specifies the normal range of hemoglobin and defines anemia as a hemoglobin 
decrease below the normal lower limit (Nutritional anaemias (Anonymous1968). 
Hematology analyzers measure the hemoglobin directly, with great precision and accuracy, 
while the hematocrit is a calculated value. Moreover hemoglobin remains constant from the 
extraction of blood until it is analyzed, while the hematocrit increases with time due to 
changes in erythrocyte volume (Tsubakihara et al. 2010). However some publications rely on 
hematocrit as an indicator of anemia, thus we consider both parameters. Red cell indices are 
very useful in the diagnosis of anemia whatever the etiology, and parameters of iron 
metabolism are essential for the diagnosis of iron deficiency anemia. Here we only state the 
normal range for adults of both sexes, excluding infants, children and pregnant women.  
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Below we present laboratory data useful for the study of iron deficiency anemia in general 
and the specific laboratory tests to evaluate iron status in chronic renal failure and 
hemodialysis patients. 
1.1 Red blood cells: Normal values in adults 
Hemoglobin: ♂: 14-17 g / dl; ♀: 12-14 g / dl 
Hematocrit: ♂: 42-52% ♀: 36-46% 
Red cell indices: mean corpuscular volume (MCV) 81-99 fl; 
mean corpuscular hemoglobin (MCH), 27-31 pg; mean corpuscular hemoglobin 
concentration (MCHC) 34 ± 2 g/ dl 
Reticulocytes: ♀: 0.4 to 2.4%, ♂: 0.6 to 2.6%; in absolute numbers: 40 - 100 x 109 / l 
1.2 Assessment of normal iron status in adults 
Serum iron: ♂ and ♀ postmenopausal 50-150 mg/dl; ♀ reproductive age 35-140 mg/ dl 
Transferrin: 200-350 mg/dl 
Transferrin saturation ( serum iron x 100/ transferrin): 30%  
Serum ferritin: ♂ and ♀ postmenopausal 30-400 ng/ml; ♀ reproductive age 15-150 ng/ml 
Absence of iron stores in patients not on dialysis <10-15 ng/ml  
Iron overload > 800 ng/ml. High levels of serum ferritin must be interpreted with caution in 
the clinical setting of tumors, inflammation and chronic conditions because ferritin may be 
elevated even if iron stores are normal or low. In these cases the soluble transferrin receptor 
is useful in estimating iron deposits. Normal levels of soluble transferrin receptor 0.8 to 1.8 
ng /l. 
1.3 Diagnosis of iron deficiency anemia 
In patients without renal impairment, the diagnosis of iron deficiency anemia is based on 
the assessment of Hb (♂ <13 g/ dl and ♀ <12 g/ dl) and hematocrit (♂ <42% ♀ <36%) along 
with a decrease in mean corpuscular volume (MCV <80fl) mean corpuscular hemoglobin 
(MCH <25 pg) and mean corpuscular hemoglobin concentration (MCHC <32g/dl). 
The diagnosis of iron deficiency anemia also requires a reduction of serum iron below the 
following levels: (♂ and ♀ postmenopausal (<50 mg / dl) and ♀ reproductive age (<30 mg / 
dl), increased transferrin (> 360 mg / dl) decrease saturation of transferrin (<20%) and 
decreased serum ferritin (♂ and ♀ postmenopausal <30 ng / ml and ♀ reproductive age <15 
ng / ml), all of them may be complemented by an increase in soluble transferrin receptor (> 
2 ng /l). 
1.4 Diagnosis of iron deficiency in chronic renal failure  
In chronic kidney disease 60-80% of cases have absolute or functional deficiency of iron, 
especially in haemodialysed patients.  
The European Best Practice Guidelines (EBPG) and the Kidney Disease Outcomes Quality 
Initiative (EBPG K / DOQI) have specified slightly different criteria for diagnosis of anemia 
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Below we present laboratory data useful for the study of iron deficiency anemia in general 
and the specific laboratory tests to evaluate iron status in chronic renal failure and 
hemodialysis patients. 
1.1 Red blood cells: Normal values in adults 
Hemoglobin: ♂: 14-17 g / dl; ♀: 12-14 g / dl 
Hematocrit: ♂: 42-52% ♀: 36-46% 
Red cell indices: mean corpuscular volume (MCV) 81-99 fl; 
mean corpuscular hemoglobin (MCH), 27-31 pg; mean corpuscular hemoglobin 
concentration (MCHC) 34 ± 2 g/ dl 
Reticulocytes: ♀: 0.4 to 2.4%, ♂: 0.6 to 2.6%; in absolute numbers: 40 - 100 x 109 / l 
1.2 Assessment of normal iron status in adults 
Serum iron: ♂ and ♀ postmenopausal 50-150 mg/dl; ♀ reproductive age 35-140 mg/ dl 
Transferrin: 200-350 mg/dl 
Transferrin saturation ( serum iron x 100/ transferrin): 30%  
Serum ferritin: ♂ and ♀ postmenopausal 30-400 ng/ml; ♀ reproductive age 15-150 ng/ml 
Absence of iron stores in patients not on dialysis <10-15 ng/ml  
Iron overload > 800 ng/ml. High levels of serum ferritin must be interpreted with caution in 
the clinical setting of tumors, inflammation and chronic conditions because ferritin may be 
elevated even if iron stores are normal or low. In these cases the soluble transferrin receptor 
is useful in estimating iron deposits. Normal levels of soluble transferrin receptor 0.8 to 1.8 
ng /l. 
1.3 Diagnosis of iron deficiency anemia 
In patients without renal impairment, the diagnosis of iron deficiency anemia is based on 
the assessment of Hb (♂ <13 g/ dl and ♀ <12 g/ dl) and hematocrit (♂ <42% ♀ <36%) along 
with a decrease in mean corpuscular volume (MCV <80fl) mean corpuscular hemoglobin 
(MCH <25 pg) and mean corpuscular hemoglobin concentration (MCHC <32g/dl). 
The diagnosis of iron deficiency anemia also requires a reduction of serum iron below the 
following levels: (♂ and ♀ postmenopausal (<50 mg / dl) and ♀ reproductive age (<30 mg / 
dl), increased transferrin (> 360 mg / dl) decrease saturation of transferrin (<20%) and 
decreased serum ferritin (♂ and ♀ postmenopausal <30 ng / ml and ♀ reproductive age <15 
ng / ml), all of them may be complemented by an increase in soluble transferrin receptor (> 
2 ng /l). 
1.4 Diagnosis of iron deficiency in chronic renal failure  
In chronic kidney disease 60-80% of cases have absolute or functional deficiency of iron, 
especially in haemodialysed patients.  
The European Best Practice Guidelines (EBPG) and the Kidney Disease Outcomes Quality 
Initiative (EBPG K / DOQI) have specified slightly different criteria for diagnosis of anemia 





With respect to hemoglobin (Hb): 
♂ Hb <13.5 g / dl (EBPG) and Hb <13.5 g / dl (K / DOQI) 
♀ Hb <11.5 g / dl (EBPG) and Hb   12.0 g / dl (K / DOQI) 
> 70 years old Hb <12 g / dl (EBPG) 
With respect to hematocrit, values differ by sex, race and age, decreasing values with 
increasing age, like hemoglobin. The reference values to define anemia by hematocrit in 
Japanese adult males are <40% and in adult women ♀ <35%(Tsubakihara et al. 2010)  
If MCV is decreased or normal the most probable diagnosis is iron deficiency anemia, 
nevertheless other less frequent diagnoses must be ruled out such as: anemia of chronic 
disease, sideroblastic anemia, thalassemia, hemolytic anemia, aplastic anemia, 
myelodysplastic syndrome and pure red cell aplasia. The latter, though extremely rare has 
been associated with erythropoietin therapy, mainly if administered subcutaneously. On the 
contrary if the MCV is elevated macrocytic anemia should be considered due to deficiency 
of vitamin B12 and / or folic acid, liver disease, hypothyroidism, aplastic anemia, 
myelodysplastic syndrome or drugs that interfere with DNA synthesis.  
The traditional parameters of iron metabolism, which are used for the diagnosis of iron 
deficiency in chronic kidney disease, are: serum iron <40 mg / dl, transferrin saturation < or 
= 20%, ferritin < or = 100 ng / ml and Hb <11 g / dl.(KDOQI and National Kidney 
Foundation 2006).  
1.5 New red cell indices and iron status markers – Advantages over traditional 
markers 
The anemia of chronic renal failure is complex and multifactorial, hence the analysis of 
individual parameters is neither accurate nor does it provide a predictive value to determine 
which patients will respond to therapy. This has led in recent years to the publication of 
numerous studies to find new laboratory tests that can identify patients with absolute or 
functional iron deficiency, in order to individualize and improve treatment. These 
parameters as well as others not related to the diagnosis of anemia have also been used to 
try to predict response to treatment with iron and erythropoietin. 
Serum ferritin is not a good index for estimating iron deposits in the course of chronic 
kidney disease ((Kalantar-Zadeh, Kalantar-Zadeh, and Lee 2006). However on the other 
hands serum ferritin is useful for monitoring iron therapy in chronic kidney disease 
((Nakanishi et al. 2010). To overcome drawbacks of ferritin as an estimator of iron stores 
several authors have studied the usefulness of soluble transferrin receptor with discrepant 
results.(Chang et al. 2007) have found a good correlation between the increase in soluble 
transferrin receptor and decreased iron stores. However (Gupta, Uppal, and Pawar 2009, 96-
100) have not found any utility in transferrin soluble receptor as a marker of iron deficiency 
in patients with renal failure. In this context (Chen, Hung, and Tarng 2006a) studied the TfR-
F index calculated by the ratio of transferrin receptor and the logarithm of serum ferritin, 
concluding that it is more sensitive than transferrin receptor to assess iron stores and may 
guide the IV iron therapy in hemodialysis patients better. 
For over a decade reticulocyte parameters have been used to monitor erythropoiesis in 
various diseases, among which are patients with chronic renal failure and anemia (Remacha 
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et al. 1997). (Agarwal, Davis, and Smith 2008) show that the fraction of immature 
reticulocytes behaves as an indicator of response in the anemia of chronic renal failure. (C.H. 
Fourcade, L. Jary, and and H. Belaouni 1999) have studied the reticulocyte profile under 
both regenerative and hypo regenerative bone marrow conditions. (Maconi et al. 2009) have 
made comparative studies of reticulocyte and erythrocyte parameters in the clinical setting 
of patients with anemia. (Brugnara, Schiller, and Moran 2006) have shown the usefulness of 
hemoglobin content of reticulocytes and red cells: Ret-He and RBC-He (Sysmex XE 2100) 
and CH and CHr (Bayer ADVIA 2120), in the identification of different stages of iron 
deficiency in hemodialysis patients. The correlation of both parameters is good and the 
performance of Ret-He is good for absolute iron deficiency, with an AUC of 0.913 a 
sensitivity of 93.3%, and a specificity of 83.2%. The diagnostic performance of Ret-He is less 
favorable for funcional iron deficiency, as the AUC is low (0.657).  
Others such as (Kalantar-Zadeh et al. 2009), have studied iron metabolism markers and 
parameters of renal osteodystrophy looking for predictors of response to erythropoiesis-
stimulating agents in hemodialysis patients and found that in the long term, low iron stores 
in patients with hyperparathyroidism and high bone marrow turnover are associated with 
hypo-responsiveness to ESA.  
The sensitivity and specificity of some other parameters such as transferrin saturation, 
serum ferritin, hypochromic red cells (% Hypo), reticulocyte hemoglobin content (CHr) and 
soluble transferrin receptor (sTfR) have been published by (Tsubakihara et al. 2010). 
According these authors the most sensitive parameters to detect functional iron deficiency 
are serum ferritin and hypochromic red blood cells while the CHr is more specific. On the 
other hand CHr is the most sensitive parameter to detect iron overload, whereas ferritin (> 
800ng/mL) and hypochromic red blood (<10%) cells are more specific (Tsubakihara et al. 
2010).  
In a multicenter study with participation of 9 hospitals in Europe, ( Zini et al 2006) studied 
the utility of a new analytical parameter, low density hemoglobin, (LDH% Beckman-
Coulter), compared with HCM, in hemodialysis patients with functional iron deficiency and 
concluded that they are useful parameters. The percentage of hypochromic red cells 
(%Hypo) has been incorporated to National Kidney Foundation KDOQI guidelines for 
monitoring recombinant human erythropoietin therapy. (Urrechaga 2010) (Urrechaga 2008) 
find a good correlation between (% Hypo) and low-density hemoglobin (LDH%), Both 
behave as good markers of iron deficiency in different types of anemia (anemia of kidney 
disease, iron deficiency anemia, anemia of chronic disease and beta thalassemia) and are 
equivalent. LDH% is a parameter calculated by a mathematical function based on mean cell 
hemoglobin concentration (MCHC) (Urrechaga 2010) 
The anemia of chronic renal failure is also a chronic disease anemia, and therefore 
parameters such as IL6, TNF-alfa and other proteins such as neopterin, hepcidin and 
hemojuvelin should be evaluated. In this context (van der Putten et al. 2010 recently set out 
the clinical role of changes in hepcidin levels and response to treatment with EPO in patients 
with inflammation and renal and cardiac damage. Previously (Zaritsky et al. 2009) propose 
hepcidin as a new biomarker of iron status in chronic kidney disease. Moreover, pro-
hepcidin has been proposed as a useful parameter in the evaluation of iron status in chronic 
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This trial evaluates a treatment protocol for patients with anemia of chronic kidney disease 
on hemodialysis 
It has two objectives:  
a. To find new predictors of response 
b. To evaluate a combined treatment regimen with EPO and iron in terms of safety, 
stability and efficacy. 
Although planned in advance, this work meets the recommendation of Coyne (Coyne 2010) 
(2010) which specifies: “rather than focus on individual products, we should perform trials 
comparing anemia management strategies to assess safety, efficacy, and cost”. 
Hematological 
parameters Hb Coulter LH750® 
 RBC, WBC Coulter LH750®
 HCT, MCV, MCH, MRV, MCHC, MPV, MSCV Coulter LH750® 
 RET %, RET#, HLR%, HLR# Coulter LH750® 
 IRF Coulter LH750®
 NE %, NE# Coulter LH750®
Iron metabolism Iron COBAS-Integra 400 Roche® Diagnostic  
 Transferrin COBAS-Integra 400 Roche® Diagnostic 
 TSAT COBAS-Integra 400 Roche® Diagnostic 
 Ferritin COBAS-Integra 400 Roche® Diagnostic 
 TfR-F index, sTfR Roche® Diagnostic
 RBC Ferritin, COBAS-Integra 400 Roche® Diagnostic 
 EPO Access 2 Beckman Coulter
 ESR Alifax Beckman Coulter
Inflammation Fibrinogen ACL TOP IL
 CRP High-sensitivity nephelometry. Beckman 
 IL6 Access 2 Beckman Coulter
Vitamins Vit B12, Folate, RBC Folate Access 2 Beckman Coulter
Platelets  Plt Coulter LH750®
 PPV Coulter LH750®
 PDW Coulter LH750®
Liver ALT, GGT, AT III Roche® Diagnostic
Calculated 
parameters RPI calculated : (RET% x HCT)/45  
 RSf® calculated : MRVMCV  /1000 
 Maf® calculated : Hb x MCV/100
 VHDWf® (MCV x Hgb)/(RDW x 10)
Table 1. Column 2 shows the panel of laboratory tests. These are grouped by category in 
column 1. Column 3 shows the instrumentation used. The tests were done with reagents 
supplied by the manufacturers of the devices, strictly following the operating instructions 
Iron Deficiency in Hemodialysis Patients – Evaluation of a Combined Treatment with  
Iron Sucrose and Erythropoietin-Alpha: Predictors of Response, Efficacy and Safety 
 
95 
manual. (CRP= C- reactive protein, EPO= Erythropoietin, ESR = Erythrocyte Sedimentation 
rate) Hb=Hemoglobin, HCT =Hematocrit ,HLR#=High light scatter reticulocytes (absolute), 
HLR%=High light scatter reticulocytes (relative to Hb), IRF=Immature reticulocyte fraction, 
Maf®=Microcytic anemia factor, IL6= Interleukin 6, MCH=Mean corpuscular Hemoglobin, 
MCHC=Mean corpuscular hemoglobin content, MCV=Mean corpuscular volume, 
MPV=Mean platelet volume, MRV=Mean reticulocyte volume, MSCV=Variance of MCV 
measurement, NE#=Neutrophils count (absolute), NE%=Neutrophils %, RBC=Red blood 
cell count, Plt= Platelets count, PPV=Platelet Packed Volume, RET#=Reticulocytes count 
(absolute), RET% = Reticulocytes %, RBC Folate= Intra-Red Blood Cells Folate), RPI= 
Reticulocyte production index , sTfR=soluble Transferrin Receptor, TSAT= Transferrin 
saturation, RBC Ferritin = Intra-Red Blood Cell Ferritin, TfR-F index =Transferrin Receptor-
Ferritin Index (Soluble Transferrin Receptor/log Ferritin), VHDWf= Volumen Hemoglobin 
Distriburion Wide factor, WBC=White Blood Cells count.  
To achieve these goals we used the laboratory data recommended in the 2006 KDOQI guide 
in order to evaluate anemia and iron status: “Complete blood count (CBC) including red blood 
cell indices (mean corpuscular hemoglobin [MCH], mean corpuscular volume [MCV], mean 
corpuscular hemoglobin concentration [MCHC]), white blood cell count, differential and platelet 
count, absolute reticulocyte count, serum ferritin to assess iron stores and serum ferritin and the 
transferrin saturation (TSAT) or content of Hb in reticulocytes (CHr) to assess adequacy of iron for 
erythropoiesis”; as well as other parameters that we feel could be useful in predicting 
response, according to publications mentioned above (see table 1)  
3. Materials, patients and methods 
3.1 Study groups and therapy  
This is a prospective, open, nonrandomized trial. Forty-two patients from the dialysis 
department of the "Hospital Clinico Universitario de Zaragoza" (Spain) have been included. 
Patients were treated by hemodialysis (HD), EPO and Iron. Patients were not transfused 
during the study.  
All patients gave informed consent. We analyzed the parameters specified in Table 1, 
monthly for 6 months. 
In addition hemoglobin, reticulocyte and iron status were evaluated at the 7th month to 
assess response to therapy received during the sixth month. 
3.2 EPO doses 
3.2.1 Initial  
- Pre-dialysis, 40 U / kg once a week 
- Dialysis: 40 U / kg three times a week 
3.2.2 Adjustment  
- Evaluate four weeks later. If Hb increase exceeds 5%: do not change dose, otherwise 
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- Reassess every 4 weeks. Increase 20 U if the rise in hemoglobin is less than 5% 
- Maximum 200 U / kg. 
- Do not abruptly discontinue administration of erythropoietin, unless there is life 
threatening risk. 
The maintenance phase begins when the target is reached (hemoglobin 12g/dl) 
3.2.3 Maintenance 
If the hemoglobin is 12 g / dl or greater decrease the dose of erythropoietin as follows: 
- If the last dose was greater than 80 u / kg, reduced by half. 
- If the last dose was less than 80 U / kg, left as maintenance 30 U / kg. 
3.3 Iron therapy  
3.3.1 Pre-dialysis 
Iron (oral ferrous sulfate) is given to all patients with chronic renal failure non dialyzed with 
hemoglobin less than 11 g / dl or ferritin below 100 ng / mL and transferrin saturation 
below 20%. 
Patients with an inadequate response to oral iron or gastrointestinal intolerance have been 
treated with 200 mg of Intravenous iron sucrose before starting the dialysis program. 
3.3.2 Dialysis 
All patients on dialysis included in this assay were treated with iron sucrose: 100 mg of iron 
sucrose in 100 cc saline in slowly perfusion at the end of each hemodialysis session (three 
times per week) 
3.3.3 Target 
Ferritin levels between 200 – 400 ng/ml and transferrin saturation > 20% 
3.3.4 Adjustment of iron dose  
As shown in table 2 
Conditions Adjustment of iron doses  
If ferritin < 200 ng /ml 100 mg weekly  
If ferritin 200-350 ng / ml 100 mg every 15 days 
If ferritin 350 – 500 ng / ml 100 mg monthly. 
If ferritin > 500 ng /ml Stop iron therapy  
If TfSat > 50% Stop iron therapy regardless of serum ferritin 
Table 2. Schedule for dose adjustment of Iron  
With the exception of 7 patients, 6 laboratory panels per patient (one panel per month) are 
available. Of the 7 patients with missing data 3 died and 4 were transplanted. None of the 
Iron Deficiency in Hemodialysis Patients – Evaluation of a Combined Treatment with  
Iron Sucrose and Erythropoietin-Alpha: Predictors of Response, Efficacy and Safety 
 
97 
deaths were related to the treatment with iron or erythropoietin. The laboratory data of 
these patients until death or transplantation were included in the statistical analysis.  
Hemoglobin and iron status were also analyzed one month after the last (6th) panel in order 
to classify patients as responders or non-responders. Finally 224 laboratory panels were 
analyzed.  
4. Definitions and criteria of response 
Most authors only use hemoglobin as a criterion of response. This is correct when 
evaluating a long period of time, but for short periods the response may have started before 
there was an increase in hemoglobin. Therefore we have chosen a target compound in which 
the main data is the increase or maintenance hemoglobin, but giving the option to evaluate 
earlier data of erythropoiesis (reticulocytes and sTfR (Soluble transferrin receptor)) and the 
rise in hemoglobin over two months, instead of evaluating only the change in hemoglobin 
from one month to the next. 
4.1 Criteria  
Response was assumed if one of the following four conditions was fulfilled.  
1. Increase of Hb ≥ 0.5 g/dl in the next control and/or increase of Hb for the following 
two controls > 0.8 g/dL, under condition that both changes are positive. 
2. Achieve or maintain minimum levels of hemoglobin of 11 g/dl in women and 12 g/dl 
in men with the following two conditions: 
3. Hb increase 
4. Ret# >50 x 109/L  
5. Increase of sTfR > 20%, provided that Hb also increases 
6. Increase of Ret#>40 x 109/L provided that Hb also increases. 
As can be seen to increase or maintain hemoglobin at normal levels is a prerequisite. 
However, we reduce the quantitative criteria for hemoglobin if the increase in reticulocytes 
or soluble transferrin receptor suggests an early recovery. Others consider, like us, the 
increase of reticulocytes as one of the criteria of response to erythropoietin (Brugnara, 2003)  
4.2 Definition and classification of iron deficiency status  
Applying the criteria of (Ng et al. 2009, c247-52) patients were divided into 4 groups, whose 
definitions and frequencies are as follows: 
- Group 1. Absolute Iron deficiency. (Ferritin < 100ng/ml and Transferrin Saturation < 
20%): 5  
- Group 2. Functional Iron deficiency. (Ferritin ≥ 100ng/ml and Transferrin Saturation < 
20%): 33 
- Group 3. Ferritin < 100ng/ml and Transferrin Saturation ≥ 20%: 9 
- Group 4. Iron repletion (Ferritin > 100ng/ml and Transferrin Saturation ≥ 20%): 198 
To avoid confusion between functional iron deficiency and iron deficiency, hereinafter the 





- Reassess every 4 weeks. Increase 20 U if the rise in hemoglobin is less than 5% 
- Maximum 200 U / kg. 
- Do not abruptly discontinue administration of erythropoietin, unless there is life 
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With the exception of 7 patients, 6 laboratory panels per patient (one panel per month) are 
available. Of the 7 patients with missing data 3 died and 4 were transplanted. None of the 
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deaths were related to the treatment with iron or erythropoietin. The laboratory data of 
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5. Statistical analyses  
5.1 Directed at objective A 
All statistical analyses were performed with SPSS.  
All parameters were tested regarding departures from normal distribution by KS-test 
(Kolmogorov-Smirnov). In case of normal distributed parameters, group-wise means and 
standard deviations were calculated. In case of non-normality log transformation or 
description by non-parametric approaches (median, rank-correlation) were used to avoid 
biases related to not normally distributed parameters. All comparisons were performed by 
U-test. For parameters with significant group-wise differences the area under ROC curve 
(AUC) was calculated.  
A correlation matrix (Pearson-correlation, rank-Spearman correlation) of all parameters was 
calculated and evaluated by factor analysis in order to gain information about relationship 
between the parameters and to reach a reduction of dimensions (variables) in subsequent 
statistical analysis (Härdle and Simar 2003) Parameters that were found associated using the 
statistical program were regarded as a parameter-class. 
Bonferroni correction was used to avoid false positive results of significance due to multiple 
testing. The number of components NC resulting from factor analysis was used for 
correction. Starting from a significance level of =0.05, comp=0.05/NC was used for group-
wise comparisons. 
In order to calculate models describing dependence of binary outcome variable (response) 
on parameter values, logistic regression was performed. Parameters ci determined in the 
model can be used in equations of the following type (n-dimensional model for logistic 
regression), where presp is probability of response, Xi is value of blood parameter and ci is 










In practice, ranges of probability of response between 0 (prediction of no response) and 1 
(prediction of response) can be calculated by putting all parameter values Xi into the 
formula.  
Resulting models were evaluated by ROC analysis and calculating AUC, as mentioned 
above. Furthermore, practical issues like robustness of parameters and ability of a simple 
data management (e.g. avoiding usage of mean differences) were considered.  
In addition cases were separated according to iron status classification and compared by 
univariate two-factor ANOVA (factors: iron status group, response) with post-hoc-
comparisons 
5.2 Statistical analyses directed to objective B  
The descriptive statistics were carried out as follows.  
The first step was to study the evolution of hemoglobin each month using parametric 
(Student) and nonparametric (comparing the overall monthly evolution of hemoglobin by 
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the Kruskall-Wallis test) methods followed by bivariate comparisons of each month with the 
next(Mann-Whitney). Although hemoglobin fits a normal distribution we also used 
nonparametric tests to avoid false positive results due to sample size. In this section we 
choose hemoglobin as the dependent variable, not including any other criteria of response. 
This is because the purpose of this section to compare the parameters with hemoglobin, the 
therapeutic target that really determines the quality of life of patients. 
In a second step we use multiple linear regression to obtain a mathematical model that 
relates the levels of hemoglobin with selected parameters. 
The graphic presentation of hemoglobin evolution over time has been made by Box Plot to 
display the median, interquartile distribution, outliers and overlapping. We have also 
represented the means on a bar graph with confidence interval of 95%. 
Finally we applied the same statistical model to the parameters that quantify the iron status: 
serum iron, transferrin, transferrin saturation, ferritin and soluble transferrin receptor. This 
statistical treatment is aimed to check whether iron treatment regimen is optimal, or 
requires changes.  
6. Results 
6.1 Descriptive statistics and groups 
6.1.1 Demography  
42 patients; gender F: 15, M: 27; age: median: 73 years (range: 22 – 88) 
6.1.2 Responses  
79 responses, 97 non responses, 88 not available (no EPO therapy, transplanted, death or 
missing data. (Table 3). 
 Transferrin Saturation 
< 20% >20% 
Ferritin  
ng/ml 




>100 Group 2 (FID) 
33 (13.5%) 
Group 4 (IR) 
198 (80.8%) 
Table 3. Distribution of cases according to groups defined by Young and Chun (2009) 
(see text) 
6.1.3 Iron status 
Applying the criteria of Young and Chun (2009) frequencies of the four groups of iron status 
are: 
- Group 1. - Absolute Iron deficiency (ID) (Ferritin < 100ng/ml and Transferrin 
Saturation < 20%): 5  
- Group 2. - Functional Iron deficiency (FID) (Ferritin ≥ 100ng/ml and Transferrin 
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In addition cases were separated according to iron status classification and compared by 
univariate two-factor ANOVA (factors: iron status group, response) with post-hoc-
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5.2 Statistical analyses directed to objective B  
The descriptive statistics were carried out as follows.  
The first step was to study the evolution of hemoglobin each month using parametric 
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the Kruskall-Wallis test) methods followed by bivariate comparisons of each month with the 
next(Mann-Whitney). Although hemoglobin fits a normal distribution we also used 
nonparametric tests to avoid false positive results due to sample size. In this section we 
choose hemoglobin as the dependent variable, not including any other criteria of response. 
This is because the purpose of this section to compare the parameters with hemoglobin, the 
therapeutic target that really determines the quality of life of patients. 
In a second step we use multiple linear regression to obtain a mathematical model that 
relates the levels of hemoglobin with selected parameters. 
The graphic presentation of hemoglobin evolution over time has been made by Box Plot to 
display the median, interquartile distribution, outliers and overlapping. We have also 
represented the means on a bar graph with confidence interval of 95%. 
Finally we applied the same statistical model to the parameters that quantify the iron status: 
serum iron, transferrin, transferrin saturation, ferritin and soluble transferrin receptor. This 
statistical treatment is aimed to check whether iron treatment regimen is optimal, or 
requires changes.  
6. Results 
6.1 Descriptive statistics and groups 
6.1.1 Demography  
42 patients; gender F: 15, M: 27; age: median: 73 years (range: 22 – 88) 
6.1.2 Responses  
79 responses, 97 non responses, 88 not available (no EPO therapy, transplanted, death or 
missing data. (Table 3). 
 Transferrin Saturation 
< 20% >20% 
Ferritin  
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>100 Group 2 (FID) 
33 (13.5%) 
Group 4 (IR) 
198 (80.8%) 
Table 3. Distribution of cases according to groups defined by Young and Chun (2009) 
(see text) 
6.1.3 Iron status 
Applying the criteria of Young and Chun (2009) frequencies of the four groups of iron status 
are: 
- Group 1. - Absolute Iron deficiency (ID) (Ferritin < 100ng/ml and Transferrin 
Saturation < 20%): 5  
- Group 2. - Functional Iron deficiency (FID) (Ferritin ≥ 100ng/ml and Transferrin 





-  Group 3. - Ferritin < 100ng/ml and Transferrin Saturation ≥ 20% (Iron status is not well 
defined in this group). Transferrin saturation is enough for erythropoiesis, but iron 
stores may be low: 9 
- Group 4. - Iron repletion (IR) (Ferritin > 100ng/ml and Transferrin Saturation ≥ 20%): 198 
6.1.4 Descriptive statistics of all parameters 
The descriptive statistics and comparison with normal distribution is shown in table 4. 






HLR (%) 189 0.825 0.36 0.836 0.062 2.24 n.s. 
HLR# (n/mm3) 189 28.7 12.5 28.6 1.88 66.7 n.s. 
RPI 189 1.55 0.534 1.59 0.12 3.14 n.s. 
RET (%) 192 2.08 0.735 2.13 0.149 5.05 n.s. 
RET# (n/mm3) 192 72.1 24.5 73.2 9.15 150 n.s. 
IRF 189 0.387 0.0757 0.393 0.16 0.56 n.s. 
Hb (g/dL) 224 11.1 1.44 11.1 7.18 14.8 n.s. 
HCT (%) 192 34 4.33 33.9 21.7 45 n.s. 
RBC 103 / mm3) 195 3490 444 3470 2130 4690 n.s. 
Maf 224 10.8 1.6 11 6.54 14.7 n.s. 
RSf 189 0.11 0.00692 0.11 0.09 0.13 n.s. 
MCV (fL) 224 97.3 4.93 97.6 83.8 113 n.s. 
MSCV (fL) 189 95.9 6.04 95.5 83.5 116 n.s. 
MRV (fL) 189 124 11 124 96.3 165 n.s. 
MCH (g/L) 195 31.8 1.83 32.1 26.8 35.8 n.s. 
EPO (IU/L) 238 21.3 39.6 12 1.75 465 p<0.00001 
sTfRFindex 221 0.755 0.247 0.724 0.282 2.02 n.s. 
sTfR (mg/L) 222 1.82 0.498 1.8 0.8 3.2 p=0.046 
Fibrinogen 
(mg/dl) 222 521 121 518 246 993 n.s. 
ESR  
(mm/ first hour) 222 43.2 28.2 35.5 1 142 p=0.0038 
CRP (mg/L) 223 1.73 4.78 0.64 0 38.6 p<0.00001 
IL6 (ng/L) 238 10.5 15.3 6.43 0.6 160 p<0.00001 
Ferritin (ng/ml) 223 376 275 326 24.3 2290 p<0.00001 
Plt (103/mm3) 192 213 56 216 92.5 368 n.s. 
PPV (%) 192 0.178 0.0412 0.175 0.0713 0.288 n.s. 
TfSat (%) 223 33.2 12.3 32.2 9.8 82.8 n.s. 
Iron (g/dL) 223 56.7 22.4 53.5 9.87 198 n.s. 
MCHC (g/dl) 192 32.6 0.723 32.6 31 34.8 n.s. 
MPV (fl) 191 8.46 1.07 8.34 6.13 11.4 n.s. 
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RDW (%) 192 15.8 1.47 15.7 13.2 20.9 n.s. 
@NE 192 66.8 8.09 66.6 46.6 83.9 n.s. 
NE# 192 5 1.61 4.79 1.16 9.74 n.s. 
WBC  
(103/ mm3) 192 7.33 2.2 7.46 0 14.9 n.s. 
VitB12 (pg/ml) 224 534 218 484 180 1180 p=0.025 
RBC Folate 223 723 796 421 107 3670 p<0.00001 
PDW 192 16.7 0.554 16.6 15.6 18.5 n.s. 
ALT (U/L) 222 14.8 12.2 12 1 73 p<0.00001 
GGt (U/L) 222 31.5 38.8 17 4 211 p<0.00001 
RBCFerritin 
(ng/ml of RBC) 224 731 345 638 223 2160 p=0.00023 
Transferrin 
mg/dl 223 175 35.7 169 73.8 351 n.s. 
ATIII (% of 
normal control) 220 101 16.9 101 62 149 n.s. 
Table 4. Descriptive statistics and Kolmogorov-Smirnoff test (n.s. = not significant difference 
from normal distribution)  
All parameters are normally distributed, with the exceptions of Ferritin, EPO, ESR, CRP, 
IL6, Vit B12, RBC, Folate, RBC ferritin, ALT and GGT. In all of these differences with the 
normal distribution are avoided by logarithmic transformation. 
6.1.5 Factorial analysis  
The coefficients given in Table 5 refer to the association of each parameter to one of the 
classes determined by factor analysis. The row-wise maximum relates each parameter to one 
of the 12 classes. Some of the parameters contribute to several components. As an example, 
Maf, which is a product of MCV and Hb, is associated to class 3 (contains Hb) as well as 
class 2 (contains MCV). In a similar manner, WBC is not only associated to Plt and Pct, but 
also to neutrophil-linked parameters NE# and NE%. 
(See Table 5) 
 
Component
1 2 3 4 5 6 7 8 9 10 11 12 
1 
HLR % 0.97     
HLR # 0.97     
RPI 0.94     
RET # 0.94     
RET % 0.93     
IRF 0.65 0.35     
2 
Hb 0.97     
HCT 0.97     
RBC 0.92     





-  Group 3. - Ferritin < 100ng/ml and Transferrin Saturation ≥ 20% (Iron status is not well 
defined in this group). Transferrin saturation is enough for erythropoiesis, but iron 
stores may be low: 9 
- Group 4. - Iron repletion (IR) (Ferritin > 100ng/ml and Transferrin Saturation ≥ 20%): 198 
6.1.4 Descriptive statistics of all parameters 
The descriptive statistics and comparison with normal distribution is shown in table 4. 






HLR (%) 189 0.825 0.36 0.836 0.062 2.24 n.s. 
HLR# (n/mm3) 189 28.7 12.5 28.6 1.88 66.7 n.s. 
RPI 189 1.55 0.534 1.59 0.12 3.14 n.s. 
RET (%) 192 2.08 0.735 2.13 0.149 5.05 n.s. 
RET# (n/mm3) 192 72.1 24.5 73.2 9.15 150 n.s. 
IRF 189 0.387 0.0757 0.393 0.16 0.56 n.s. 
Hb (g/dL) 224 11.1 1.44 11.1 7.18 14.8 n.s. 
HCT (%) 192 34 4.33 33.9 21.7 45 n.s. 
RBC 103 / mm3) 195 3490 444 3470 2130 4690 n.s. 
Maf 224 10.8 1.6 11 6.54 14.7 n.s. 
RSf 189 0.11 0.00692 0.11 0.09 0.13 n.s. 
MCV (fL) 224 97.3 4.93 97.6 83.8 113 n.s. 
MSCV (fL) 189 95.9 6.04 95.5 83.5 116 n.s. 
MRV (fL) 189 124 11 124 96.3 165 n.s. 
MCH (g/L) 195 31.8 1.83 32.1 26.8 35.8 n.s. 
EPO (IU/L) 238 21.3 39.6 12 1.75 465 p<0.00001 
sTfRFindex 221 0.755 0.247 0.724 0.282 2.02 n.s. 
sTfR (mg/L) 222 1.82 0.498 1.8 0.8 3.2 p=0.046 
Fibrinogen 
(mg/dl) 222 521 121 518 246 993 n.s. 
ESR  
(mm/ first hour) 222 43.2 28.2 35.5 1 142 p=0.0038 
CRP (mg/L) 223 1.73 4.78 0.64 0 38.6 p<0.00001 
IL6 (ng/L) 238 10.5 15.3 6.43 0.6 160 p<0.00001 
Ferritin (ng/ml) 223 376 275 326 24.3 2290 p<0.00001 
Plt (103/mm3) 192 213 56 216 92.5 368 n.s. 
PPV (%) 192 0.178 0.0412 0.175 0.0713 0.288 n.s. 
TfSat (%) 223 33.2 12.3 32.2 9.8 82.8 n.s. 
Iron (g/dL) 223 56.7 22.4 53.5 9.87 198 n.s. 
MCHC (g/dl) 192 32.6 0.723 32.6 31 34.8 n.s. 
MPV (fl) 191 8.46 1.07 8.34 6.13 11.4 n.s. 
Iron Deficiency in Hemodialysis Patients – Evaluation of a Combined Treatment with  
Iron Sucrose and Erythropoietin-Alpha: Predictors of Response, Efficacy and Safety 
 
101 
RDW (%) 192 15.8 1.47 15.7 13.2 20.9 n.s. 
@NE 192 66.8 8.09 66.6 46.6 83.9 n.s. 
NE# 192 5 1.61 4.79 1.16 9.74 n.s. 
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(ng/ml of RBC) 224 731 345 638 223 2160 p=0.00023 
Transferrin 
mg/dl 223 175 35.7 169 73.8 351 n.s. 
ATIII (% of 
normal control) 220 101 16.9 101 62 149 n.s. 
Table 4. Descriptive statistics and Kolmogorov-Smirnoff test (n.s. = not significant difference 
from normal distribution)  
All parameters are normally distributed, with the exceptions of Ferritin, EPO, ESR, CRP, 
IL6, Vit B12, RBC, Folate, RBC ferritin, ALT and GGT. In all of these differences with the 
normal distribution are avoided by logarithmic transformation. 
6.1.5 Factorial analysis  
The coefficients given in Table 5 refer to the association of each parameter to one of the 
classes determined by factor analysis. The row-wise maximum relates each parameter to one 
of the 12 classes. Some of the parameters contribute to several components. As an example, 
Maf, which is a product of MCV and Hb, is associated to class 3 (contains Hb) as well as 
class 2 (contains MCV). In a similar manner, WBC is not only associated to Plt and Pct, but 
also to neutrophil-linked parameters NE# and NE%. 
(See Table 5) 
 
Component
1 2 3 4 5 6 7 8 9 10 11 12 
1 
HLR % 0.97     
HLR # 0.97     
RPI 0.94     
RET # 0.94     
RET % 0.93     
IRF 0.65 0.35     
2 
Hb 0.97     
HCT 0.97     
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VHDW    0.75           
-
0.37         
3 
RSf 0.95     
MCV 0.90     
MRV 0.84     
MSCV 0.84     
MCH     0.81         
-
0.47         
4 










0.46   
5 
Fibrinogen 0.83     
ESR (log) 
-
0.33 0.78     
CRP (log) 0.74     
IL6 (log) 0.59 0.43   
Ferritin (log)
-
0.39 0.43 0.40   
-
0.40 
6 Plt 0.94     PPV 0.88     




0.79     
MPV 
-
0.33 0.60     
RDW 0.41 0.55     
9 
NE # 0.35 0.80     
NE % 0.75     
WBC 0.40 0.63     
10 
Vit. B12 (log) 0.77     
RBC Folate 





0.57     
11 
ALT (log) 0.78   






12 Transferrin   0.84 ATIII 0.37   0.53 
Table 5. Factor analysis and correlation matrix.  
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Parameters with column maximum-wise (HLR% in case of class 1, Hb in class 2, Rsf® in 
class 3 and so on) are representative of class in the best manner.  
6.1.6 Functional description of classes 
It is worth noting that each of the classes (selected by factor analysis) contain a group of 
parameters that have a common physiological or pathological role. 
 Class 1 is associated with erythropoietic activity: reticulocytes and reticulocyte indices 
 Class 2 is related to parameters that provide information about the absence, presence or 
severity of anemia 
 Class 3 is related to red cell indices and their derivatives obtained by mathematical 
formulas. They report on the type of anemia. 
 Class 4 is associated with stimulation of erythropoiesis 
 Class 5 is associated with chronic inflammatory disease 
 Class 6 reports on platelets  
 Class 7 is associated with iron status 
 Class 8 is associated with microcytosis and anisocytosis.  
 Class 9 reports on neutrophils. 
 Class 10 reports on vitamin deficiency. 
 Class 11 reports on liver disease. 
 Class 12 reports of acute phase reactants not included in class 5. 
6.1.7 Weekly erythropoietin dose and response to treatment 
(See table 6) 
  Response Total  
EPO doses  No response Response  Significance 
 2000 Count 3 2 5 n.s. 
  % 3.1% 2.5% 2.8%  
 3000 Count 3 2 5 n.s. 
  % 3.1% 2.5% 2.8%  
 4000 Count 10 4 14 n.s. 
  % 10.3% 5.1% 8.0%  
 6000 Count 14 11 25 n.s. 
  % 14.4% 13.9% 14.2%  
 8000 Count 20 18 38 n.s. 
  % 20.6% 22.8% 21.6%  
 12000 Count 18 15 33 n.s. 
  % 18.6% 19.0% 18.8%  
 16000 Count 29 27 56 n.s. 
  % 29.9% 34.2% 31.8%  
Total Count 97 79 176 n.s. 
 % 100.0% 100.0% 100.0%  
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-
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0.79     
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Table 5. Factor analysis and correlation matrix.  
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Parameters with column maximum-wise (HLR% in case of class 1, Hb in class 2, Rsf® in 
class 3 and so on) are representative of class in the best manner.  
6.1.6 Functional description of classes 
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 Class 2 is related to parameters that provide information about the absence, presence or 
severity of anemia 
 Class 3 is related to red cell indices and their derivatives obtained by mathematical 
formulas. They report on the type of anemia. 
 Class 4 is associated with stimulation of erythropoiesis 
 Class 5 is associated with chronic inflammatory disease 
 Class 6 reports on platelets  
 Class 7 is associated with iron status 
 Class 8 is associated with microcytosis and anisocytosis.  
 Class 9 reports on neutrophils. 
 Class 10 reports on vitamin deficiency. 
 Class 11 reports on liver disease. 
 Class 12 reports of acute phase reactants not included in class 5. 
6.1.7 Weekly erythropoietin dose and response to treatment 
(See table 6) 
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EPO doses  No response Response  Significance 
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 3000 Count 3 2 5 n.s. 
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  % 10.3% 5.1% 8.0%  
 6000 Count 14 11 25 n.s. 
  % 14.4% 13.9% 14.2%  
 8000 Count 20 18 38 n.s. 
  % 20.6% 22.8% 21.6%  
 12000 Count 18 15 33 n.s. 
  % 18.6% 19.0% 18.8%  
 16000 Count 29 27 56 n.s. 
  % 29.9% 34.2% 31.8%  
Total Count 97 79 176 n.s. 
 % 100.0% 100.0% 100.0%  





6.1.8 Univariate analysis of selected parameters comparing the groups of iron status 
and split by responders and no-responders 
Table 7 shows statistical analyses of all parameters and their relations with the Iron Status 
classification and State of Response. In this analysis the iron status groups: ID, FID and IR 
are only taken into account. The 9 patients in group 3 have been excluded. ANOVA results 
have been compared with those of the Mann-Whitney test because the number of cases in 
each group is unbalanced. The Mann-Whitney, being nonparametric, is less affected by the 
imbalance. Parameters of the same class of those selected by factor analysis, behave 
similarly. Hb, RET# and sTfR show significant differences because they enter into the 
definition of response. 
Parameters with column maximum are those that best represent their class as detailed above 
(material and methods).  
Parameter Iron Status Response  Effect Response via Mann 
Whitney U-Test 
 
Iron Status Response 
status 
Rsf n.s. n.s.    
MCV n.s. n.s.    
MCH n.s. n.s.    
MSCV n.s. n.s.    
MRV n.s. n.s.    
HLR% n.s. n.s.    
HLR# p=0.033 n.s.    
RET% n.s. n.s.    
RET# n.s. n.s.    
RPI p=0.045 n.s.    
IRF p=0.045 n.s.    
Hb p=0.000 p=0.025 ID, FID < IR Resp<nonresp p=0.0028 
HCt p=0.001 p=0.029 ID < IR Resp<nonresp p=0.07 
RBC p=0.002 p=0.033 ID<IR Resp<nonresp p=0.044 
Maf p=0.000 p=0.039 ID < IR Resp<nonresp p=0.014 
Plt n.s. n.s.    
PPV n.s. n.s.    
WBC n.s. n.s.    
TfRFindex n.s. n.s.    
sTfR p=0.085 n.s. ID<IR   
EPO  n.s. p=0.016 FID: Resp<non resp 
IR: Resp>= non resp 
p=0.011 
ESR n.s. n.s.   
CRP p=0.000 n.s. FID > IR, ID  
IL6 p=0.000 n.s. FID > IR,   
MCHC n.s. n.s.  p=0.0007 
MPV n.s. n.s.   
RDW p=0.031 n.s. FID, ID <IR  
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Ferritin p=0.000 n.s. trivial result  
Iron p=0.000 n.s. trivial result  
TSAT p=0.000 n.s. trivial result  
Vit. B12 n.s. n.s.   
RBC Folate n.s. n.s.   
PDW n.s. n.s.   
ALT n.s. n.s.   
GGT p=0.043 n.s. ID, (FID) > IR  
RBC Ferr n.s. n.s.   
NE# n.s. n.s. ID<IR  
NE% n.s. n.s. ID<IR  
Transferrin p=0.000 n.s. trivial result  
AT III n.s. n.s.   
Table 7. Univariate two-factor ANOVA (Iron Status, Response) and Mann-Witney test. 
Significant differences for iron status are shown in column 3, for response status in column 4 
and their effect in column 5. Parameters that enter into the definition of iron stages are 
logically associated with themselves; therefore we specify "trivial result". 
6.1.9 Description of responses to therapy 
Hereafter "case" means each result (6 per patient) for the referred parameter. 
From 42 patients, 83 cases with EPO-treatment were considered as responses (38.6%). 132 
cases (61.4%) were not responding. Among the responses, 40 (18.6% of 215) fulfilled 1 
criterion of response, 36 cases (16.7%) 2 criteria, 5 cases (2.2%) 3 criteria and 2 cases (0.9%) 4 
criteria. The distribution of responses according to the criteria is as follows: 
 Criterion 1. - 63 cases. (Increase of Hb ≥ 0.5 g/dl in the next control and/or increased of 
Hb in the whole of the following two controls > 0.8 g/dL, under condition that both 
changes are positive)  
 Criterion 2. - 48 cases (Achieve or maintain normal Hb for hemodialysis patients (male: 
12 g/dl, female: 11 g/dl) under two conditions: Hb increase and Reticulocytes >50 x 
109/L)  
 Criterion 3. - 17 cases (Increase of sTfR > 20%, provided that Hb also increases)  
 Criterion 4. -7 cases. (Increase of Ret#>40 x 109/L provided that Hb also increases)  
6.1.10 Parameters predicting response  
Table 8 shows the descriptive statistics and the response to combination therapy with iron 
and erythropoietin. We selected three variables (MCHC, EPO and Hb) with the highest 
levels of significance to determine their predictive value on response to therapy.  
AUC of related ROC for these three parameters are respectively: 0.631 (95% CI: 0.54 - 0.70) 
for Hb, 0.612 (95% CI: 0.58 - 0.73) for EPO, and 0.662 (95% CI 0.57 – 0.73) for MCHC as 
shown in Figure 1, 2 and 3. 
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Significant differences for iron status are shown in column 3, for response status in column 4 
and their effect in column 5. Parameters that enter into the definition of iron stages are 
logically associated with themselves; therefore we specify "trivial result". 
6.1.9 Description of responses to therapy 
Hereafter "case" means each result (6 per patient) for the referred parameter. 
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 Non Response Response  
N Mean SD Med Min Max N Mean SD Med Min Max p 
HLR % 78 0.795 0.372 0.803 0.117 2.24 66 0.897 0.332 0.895 0.256 1.57 0.076 
HLR # 78 27.7 12.2 28.4 4.55 66.7 66 30.8 12.4 31.3 7.7 62 0.143 
RPI 78 1.52 0.517 1.62 0.121 3.14 66 1.65 0.535 1.7 0.589 2.84 0.161 
RET % 80 2.05 0.781 2.13 0.149 5.05 67 2.24 0.66 2.31 0.963 3.71 0.067 
RET # 80 71.6 23.4 74.5 19.8 150 67 76.3 24.8 76.2 29 134 0.287 
IRF 78 0.376 0.078 0.388 0.156 0.52 66 0.395 0.0622 0.396 0.225 0.52 0.226 
Hb 97 11.4 1.32 11.3 8.62 14.8 79 10.7 1.54 10.7 7.18 14.5 0.0028 
HCT 79 34.6 3.93 34.3 26.6 45 68 33.3 4.89 33 21.7 44.8 0.0752 
RBC 81 3540 385 3480 2750 4620 69 3410 502 3340 2130 4690 0.0442 
Maf 97 11.1 1.51 11.3 7.86 14.4 79 10.4 1.69 10.5 6.54 13.8 0.0137 
VHDW  79 7.08 1.32 7.4 4.26 9.69 68 6.7 1.28 6.85 4.04 9.61 0.0505 
RSf 78 0.11 0.006 0.11 0.0967 0.12 66 0.11 0.0076 0.11 0.094 0.134 0.744 
VCM 97 97.4 4.63 97.5 83.8 109 79 97.4 5.11 98.1 85.8 109 0.891 
MSCV 78 95.6 5.76 95.3 83.5 116 66 96.2 6.47 95.8 83.9 111 0.506 
MRV 78 124 8.74 124 105 143 66 125 12.3 123 96.3 165 0.785 
MCH 81 31.9 1.77 32.1 26.8 34.8 69 31.5 1.85 32 27.5 35.1 0.261 
EPO  97 11 11.9 8 1.8 78.6 79 18.4 27.6 10.1 1.1 200 0.0107 
TfR-F 
index 
95 0.761 0.249 0.728 0.366 2.02 79 0.759 0.245 0.725 0.282 1.36 0.885 
sTfR 95 1.85 0.495 1.8 1 3.2 79 1.82 0.512 1.8 0.8 3.1 0.752 
Fibri-
nogen 
96 539 128 526 284 993 79 498 110 487 264 836 0.0296 
ESR 97 44.2 29 35 8 125 78 40 27.9 32 3 142 0.309 
CRP 97 1.89 5.5 0.69 0 38.6 79 1.33 2.93 0.64 0.11 24.3 0.552 
IL-6 97 10.7 20.6 6.15 0.75 160 79 8.14 7.48 6.3 0.6 48.5 0.772 
Ferritin 97 379 250 348 24.3 1940 79 344 211 320 33.2 1160 0.296 
Plt 79 214 57 222 114 327 68 212 57.6 210 114 368 0.892 
PPV 79 0.176 0.042 0.173 0.0919 0.27 68 0.178 0.0397 0.177 0.088 0.288 0.718 
TfSat% 97 33.8 12.3 32.3 11.4 82.8 78 32.5 10.9 32.3 12.6 68.5 0.611 
Iron 97 59.6 25.3 54.1 15.7 198 79 54.1 17.7 53.5 12.2 91.9 0.218 
MCHC 79 32.7 0.662 32.7 31.1 34.8 68 32.3 0.665 32.3 31 34 0.0007 
MPV 78 8.29 1.1 8.3 6.13 11.4 68 8.54 1.02 8.3 6.4 11 0.302 
RDW 79 15.8 1.48 15.6 13.3 20.9 68 15.8 1.47 15.7 13.2 20.8 0.864 
NE % 79 65.9 8.37 66.6 46.6 82.4 68 67.1 8.11 65.1 53.6 83.9 0.503 
NE # 79 4.86 1.59 4.63 2.42 9.74 68 5 1.61 4.89 1.16 8.93 0.424 
WBC 79 7.25 2.13 7.03 0 14.9 68 7.21 2.37 7.62 0 14.1 0.546 
Vit B12 97 525 210 482 184 1160 79 527 199 498 191 1180 0.839 
RBC 
Folate 
96 691 804 318 107 3670 79 787 920 388 109 3500 0.38 
PDW 79 16.7 0.612 16.7 15.6 18.5 68 16.6 0.52 16.6 15.6 17.9 0.516 
ALT 96 13.5 9.99 12 1 56 79 15.8 13.5 13 1 73 0.22 
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GGt 96 30 38.5 16 4 201 79 33.1 39.1 19 5 210 0.286 
RBC Ferr. 97 704 310 632 281 1950 79 698 309 583 230 2010 0.735 
Transfer-
rin 
97 174 31.4 169 79.1 280 79 176 41.5 169 73.8 351 0.811 
ATIII 95 102 15.6 103 68 149 78 103 19 104 65 149 0.724 
Table 8. Descriptive statistics of all variables split by response o no response (from month to 
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Fig. 3. EPO AUC: 0.612 (0.528 – 0.696) 
6.1.11 ROC curves and AUC 
The area under the curve of each of the three variables is too low to be practical in predicting 
response to treatment. So we tried to make a composite model with more prediction power. 
6.1.12 Prediction model 
Based on these results, several models to predict the response on the basis of parameters 
evaluated in this study have been calculated by logistic regression. The optimal model was 
chosen by achieving maximal AUC with a minimum of parameters and taking into account 
practical issues. The best three-parameter combination was RBC, EPO and MCHC 
(AUC=0.72). RBC, belonging to the same class as hemoglobin, slightly improves the AUC 
(+0.1). For this reason the model includes RBC, EPO and MCHC, instead of HB, EPO and 
MCHC. We could not find any other parameter able to increase the power of the predictive 
model. Figure 4 shows the ROC curve of this composite three parameter model. The AUC is 
0.72 (%95 CI: 0.62 – 0.80). (Fig.4.) 
The related formula is: 
 
      
1
1 23 39 1 327 0 838 0 787
1000
respp RBCexp( ( . . log(EPO) . MCHC . * ))
 (2) 
This model, being the best, has relative clinical utility because the AUC is not as high as 
would be desirable. 
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Fig. 4. ROC curve of the combination: RBC, EPO and MCHC (AUC: 0.72 (0.619 – 0.791) 
7. Efficacy and safety  
This section not only tries to verify the effectiveness and safety of treatment but also looks 
for correlations between hemoglobin and other variables. These correlations should not be 
interpreted as predictors of response, since hemoglobin is considered as a whole rather than 
month to month as in the previous section. Therefore we try to find a mathematical model to 
predict hemoglobin levels considering all the time of observation as a whole. For this 
purpose we have selected hemoglobin as a dependent variable. We have also selected 
explicative variables that measure the erythropoietic activity (reticulocytes and soluble 
transferrin receptor), indicators of iron status (serum iron, ferritin, transferrin and 
transferrin saturation), other nutritional factors (vitamin B12 and folic acid) and some 
indicators of acute or chronic inflammation (IL-6 and CRP) that can interfere with iron 
metabolism and erythropoiesis. (Table 9) 
Statistical planning of this section is as follows:  
- Descriptive statistics: means and frequencies 
- Comparative evolution of hemoglobin in the 6 months: ANOVA and nonparametric 
- Statistical comparison of patients with hemoglobin <11g/dl versus≥11g/dl: ANOVA, 
equality of variances and robust tests.  
- Multiple linear regression stepwise forward (hemoglobin as dependent variable and all 
others as explicatory).  
- Variables that did not fit the normal distribution have been replaced by their respective 
logarithms in parametric tests. 
7.1 Descriptive statistics  
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Fig. 4. ROC curve of the combination: RBC, EPO and MCHC (AUC: 0.72 (0.619 – 0.791) 
7. Efficacy and safety  
This section not only tries to verify the effectiveness and safety of treatment but also looks 
for correlations between hemoglobin and other variables. These correlations should not be 
interpreted as predictors of response, since hemoglobin is considered as a whole rather than 
month to month as in the previous section. Therefore we try to find a mathematical model to 
predict hemoglobin levels considering all the time of observation as a whole. For this 
purpose we have selected hemoglobin as a dependent variable. We have also selected 
explicative variables that measure the erythropoietic activity (reticulocytes and soluble 
transferrin receptor), indicators of iron status (serum iron, ferritin, transferrin and 
transferrin saturation), other nutritional factors (vitamin B12 and folic acid) and some 
indicators of acute or chronic inflammation (IL-6 and CRP) that can interfere with iron 
metabolism and erythropoiesis. (Table 9) 
Statistical planning of this section is as follows:  
- Descriptive statistics: means and frequencies 
- Comparative evolution of hemoglobin in the 6 months: ANOVA and nonparametric 
- Statistical comparison of patients with hemoglobin <11g/dl versus≥11g/dl: ANOVA, 
equality of variances and robust tests.  
- Multiple linear regression stepwise forward (hemoglobin as dependent variable and all 
others as explicatory).  
- Variables that did not fit the normal distribution have been replaced by their respective 
logarithms in parametric tests. 
7.1 Descriptive statistics  






 N Min Max Mean S.D. 
EPO 245 1.75 465.12 23.5789 42.74901 
IL-6 245 .60 375.39 15.3838 39.48357 
CRP 243 .05 38.60 2.0386 4.86809 
Hb 245 7.20 14,8 11.0665 1.54600 
HCT 245 21.40 59.50 33.7563 4.62126 
RETICULOCYTE 244 9.10 150.40 73.8156 24.98430 
Fe 244 9.87 197.61 54.8609 22.59088 
TRANSFERRIN 244 73.79 350.58 174.2232 34.89244 
FERRITINE 244 33.20 2290.00 399.6719 292.31897 
sTfR 244 .70 6.61 1.8598 .60920 
B12 245 180.00 1455.00 541.3102 226.92288 
FOLIC 245 1.60 200.00 27.5331 54.87474 
FOLIC-INTRAE 244 85.50 3667.70 700.0311 770.10104 
TSAT 244 8.54 87.09 31.9443 12.69501 
Table 9. Descriptive statistics of variables used in this section 
7.2 Hemoglobin stability 
As shown in table 10, the means of hemoglobin vary from 10.9 to 11.3 during the six months 
follow-up period and remain always within the desired range. The minima of each month 
correspond to different patients, indicating at least a partial recovery of those who have held 
the minimum in any of the previous months. None of the patients exceeded 15 g / dl of 
hemoglobin as can be seen in the Box-Plot (Graph A1). This graph also shows the extreme 
values, which show only 6 out of a total of 245 samples. The evolution of individual patients 
who have had these outliers can be seen in Graph A-2. 
MONTH Mean (g/dl) N Standard deviation Minimum Maximum 
1 10.9689 42 1.53798 7.2 14.3 
2 11.1318 42 1.60113 7.2 14.2 
3 10.9167 42 1.57231 7.2 14.9 
4 10.9350 40 1.38408 7.4 14.6 
5 11.1921 38 1.25383 8.2 13.5 
6 11.2972 36 1.92628 8.1 14.8 
Total 11.0665 245 1.54600 7.2 14.8 
Table 10. Means of hemoglobin for each month during the six month follow-ups 
7.3 Comparative statistics 
7.3.1 Evolution of hemoglobin 
Since hemoglobin fits normal distribution we compared the six month results globally using 
ANOVA with the result that no significant difference could be found (F=0.394, p=0.853).  
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To avoid possible errors due to sample size we have also used a nonparametric test 
(Kruskall-Wallis) with the same result: no significant difference (Chi square 1.473, p = 0.920). 















Fig. 5. Box-Plot of the evolution of Hb during the 6 months of dialysis. Outliers are 
identified with the sample number. Checking the table data we observe that all these 
extreme values come from different patients.  
 
Fig. 6. Individual evolution of the six patients with extreme values. The vertical axis shows 
the values of hemoglobin (g / dl). The X axis shows the months of observation from A (first) 
to F (sixth). Patient 2 was excluded from the trial in the fourth month when the patient had a 
transplant. Patients 3 and 4 remained below 10g/dl of hemoglobin for most of the 
observation period. None of the patients exceeded 15 g/dl of hemoglobin. 
Fig. 7 shows the mean hemoglobin concentration month by month and the error bars for 
95% interval of confidence. The means remain in the range 10.9-11.3 g/dl. No significant 
differences with parametric methods (ANOVA, Student) and nonparametric (Kruskall –
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Error Bars: 95% CI  
Fig. 7. Mean hemoglobin month by month. Error bars indicate confidence intervals of 95% 
7.3.2 Patients with hemoglobin less than 11g/dl compared with those with hemoglobin 
≥ 11g/dl 
In this section we look for differences between the variables using a cutoff of 11 g/ dl of 
hemoglobin. Cases above and below this cutoff are almost balanced (n =117 (47.8%) 
<11g/dl) and n= 128 (52.2%≥ 11g/dl))  
The homogenization of variances tested detected 5 variables with significant differences; 









CRP 4.629 .032 4.416 .037 
RET 1.597 .208 1.584 .209 
Fe 22.626 .000 23.323 .000 
TRANSF .760 .384 .732 .393 
FOLIC-INTRA .441 .507 .435 .510 
TSAT 24.433 .000 24.665 .000 
Log EPO 14.840 .000 14.479 .000 
Log IL-6 9.970 .002 9.813 .002 
Log FERRITINE .862 .354 .834 .362 
Log sTfR 1.316 .252 1.296 .256 
Log B12 .124 .725 .122 .727 
Log FOLIC .013 .908 .013 .909 
SRTf/logFERR .179 .672 .102 .751 
Table 11. Homohenization of variances test using a hemoglobin cutoff of 11g/dl. 
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Table 12 shows the means and standard error of the variables split by an 11g/dl hemoglobin 
cut-off. 
 Mean Std. Error Count p (Welch) 
EPO, Hb<11g/dl 32,316 5,245 117  
EPO, Hb>11 15,563 1,841 128 .000 
iIL-6, Hb<11g/dl 21,233 4,972 117  
iIL-6, Hb>11 10,037 1,512 128 .002 
RCP, Hb<11g/dl 2,742 ,547 115  
RCP, Hb>11 1,406 ,324 128 .037 
Hb, Hb<11g/dl 9,850 ,089 117  
Hb, Hb>11 12,178 ,094 128 .000 
RETIC, Hb<11g/dl 71,695 2,413 116  
RETIC, Hb>11 75,737 2,119 128 .209 
Fe, Hb<11g/dl 47,936 1,661 116  
Fe, Hb>11 61,136 2,171 128 .000 
TRANSFERRIN, Hb<11g/dl 176,270 3,843 116  
TRANSFERRIN, Hb>11 172,369 2,454 128 .393 
FERRITINE, Hb<11g/dl 412,477 32,283 116  
FERRITINE, Hb>11 388,068 20,490 128 .362 
sRTf, Hb<11Hb/dl 1,834 ,065 116  
sRTf, Hb>11 1,883 ,045 128 .256 
B12, Hb<11g/dl 543,487 23,179 117  
B12, Hb>11 539,320 18,008 128 .727 
FOLIC, Hb<11g/dl 30,862 5,583 117  
FOLIC, Hb>11 24,491 4,362 128 .909 
FOLIC-INTRA, Hb<11g/dl 734,179 77,436 117  
FOLIC-INTRA, Hb>11 668,572 62,481 127 .510 
sRTf:logF, Hb<11g/dl ,755 ,028 116  
sRTf:logF, Hb>11 ,761 ,021 128 .751 
TSAT, Hb<11g/dl 27,914 1,068 116  
TSAT, Hb>11 35,596 1,119 128 .000 
Table 12. Means and standard error of the variables split by an 11g/dl hemoglobin cut-off. 
7.3.3 Multiple linear regression 
Since there is no significant difference in monthly hemoglobin we handle all the data 
together. The dependent variable is hemoglobin and the rest explicative. The hematocrit was 
excluded because it is obviously closely related to hemoglobin. For variables that do not fit 
the normal distribution we made a logarithmic transformation. The method used is forward 
stepwise multiple linear regression. In the resulting model only three variables remain: 
serum iron, log soluble transferrin receptor and log EPO. Note that the correlation 
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coefficients t Sig. 
 Steps   B 
Standard 
error Beta zero-order Partial 
1 (constant) 10.109 .251   40.321 .000 
  Fe .018 .004 .259 4.179 .000 
2 (constant) 9.267 .334   27.765 .000 
  Fe .021 .004 .307 4.960 .000 
  Log sRTf 2.672 .721 .229 3.705 .000 
3 (constant) 
(Intercept) 10.396 .413   25.167 .000 
  Fe .018 .004 .261 4.301 .000 
  Log sRTf 3.603 .728 .309 4.952 .000 
  Log EPO -1.053 .241 -.274 -4.363 .000 
Dependent variable: Hb 
Table 13. Forward step-wise multiple regression model. (Dependent variable hemoglobin) 
 
Fig. 8. Serum iron (mg/dl) and transferrin saturation (%) (TSAT). The central horizontal line 
plots the normal transferrin saturation of 30%. All means are above this line except for the 
sixth month. Nevertheless the latter is 28.6%, well above 20%. Error bars show the 
confidence interval 95%. 
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8. Iron, transferrin and saturation 
Fig. 8. shows the serum iron and transferrin saturation for each of the six months of 
observation. The error bars show confidence intervals of 95%. All media, with their 
respective confidence intervals are in the field of 30% saturation of transferrin, enough for 
an adequate iron supply to erythroblasts. However, some individual values are below those 
desirable. Specifically, 33 cases (14.2%) have transferrin saturation less than 20%. 
8.1 Ferritin 
Descriptive statistic for ferritin split by months is shown in table 14. 
 Mean Std. Dev. Std. Error Count Minimum Maximum 
FERRITIN. Total 399.672 292.319 18.714 244 33.200 2290.000 
FERRITIN. A 425.107 325.013 48.450 45 39.900 1952.000 
FERRITIN. B 378.284 249.318 37.586 44 33.200 1314.900 
FERRITIN. C 416.134 247.962 38.725 41 42.600 1159.100 
FERRITIN. D 376.029 317.108 50.139 40 49.400 1940.000 
FERRITIN. E 371.563 219.388 35.589 38 40.000 972.400 
FERRITIN. F 431.210 382.965 63.827 36 109.700 2290.000 
Table 14. Evolution of ferritin during the observation period. Consecutive months are 
















Fig. 9. Mean ferritin (green bars) and transferrin saturation (TSAT) (blue bars). The latter has 
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Fig. 9. Mean ferritin (green bars) and transferrin saturation (TSAT) (blue bars). The latter has 





Mean ferritin is above 300 ng/ml in all cases. This does not necessarily mean that iron stores 
are adequate, as in renal failure and in other chronic diseases ferritin does not measure iron 
stores accurately. In 40 cases, the ferritin is less than 100 ng/ ml. In one case ferritin is above 
2.000 ng/ dl and in six cases over 1.000. The standard deviation is high because ferritin does 
not fit a normal distribution.  
8.2 Soluble transferrin receptor and soluble transferrin receptor/log ferritin index 
























Fig. 10. Evolution of soluble Receptor of Transferrin 
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Error Bars: 95% CI
 
 
Fig. 11. Evolution of sTfR / Log Ferritin index.  
9. Conclusions 
9.1 Predictors of response to therapy 
ANOVA shows significant differences between responders and non-responders for 
hemoglobin, hematocrit, red blood cells, erythropoietin, MCHC and Maf). Nevertheless only 
Hemoglobin (or red blood cells), EPO and MCHC were found to be the best predictors of 
response by multiple regression. However, the AUC of the ROC curves of each of these 
parameters separately is low and therefore its clinical utility is weak. The combination of red 
blood cells, erythropoietin and MCHC results in a mathematical model that significantly 
improves the predictive value of each of these variables, with an AUC of 0.72. (95% 
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This model does not improve with the inclusion of additional variables and has the 
advantage that it only includes routine analytical data, without sophisticated tests. The 
statistical procedure that we have described (factorial analysis, data reduction, logistic 
regression and ROC curves) may be a useful tool for future studies with more patients and 
longer observation which may improve the accuracy of prediction of response. 
9.2 Efficacy and safety 
9.2.1 Hemoglobin 
The mean hemoglobin level for the whole period of observation is X = 11.07g/dl; (SD 1.546; 
n = 245). When comparing the mean hemoglobin of each month, there are no significant 
differences and the small differences that are shown have no clinical significance. Therefore, 
the hemoglobin remains stable throughout the observation period with a mean within the 
desired range. Only six cases have been detected with extreme values (Box-Plot). None of 
the patients exceeded hemoglobin 15g/dl, and only two patients had hemoglobin levels 
persistently below 10g/dl. The cases above and below 11g/dl of hemoglobin are almost 
balanced (n =117 (47.8%) <11g/dl) and n= 128 (52.2%≥ 11g/dl)). These data confirm that this 
protocol maintains stable hemoglobin levels in the planned target. Achieved hemoglobin 
levels are somewhat lower than those recommended in the latest revision of K-DOKI clinical 
guidelines (KDOQI 2007), but conform to those recommended by others (Coyne 
2010)(Akizawa et al. 2008). 
When applying a cutoff of 11g/dl of hemoglobin there are significant differences above and 
below this value for the following parameters: C-reactive protein, serum iron, transferrin 
saturation, erythropoietin, and interleukin 6 (univariate analysis).  
The stepwise multiple regression (with hemoglobin as the dependent variable), allowed us 
to develop a model in which, in the final step, only three parameters remain: serum iron, 
transferrin soluble receptor and erythropoietin (the latter with a negative beta coefficient). In 
this model the constant is 10.396 and the standardized beta coefficients: iron (0.261), log 
soluble transferrin receptor (0.309) and log erythropoietin (-0.274). 
9.2.2 Iron 
Means and standard deviations of the variables that establish the status of iron are as 
follows: serum iron 54.86 ± 22.59, transferrin 174.22 ± 34.89, transferrin saturation 31.94 % ± 
12.70, ferritin 399.67 ± 292.31 and soluble transferrin receptor 1.86 ± 0.61. No significant 
differences were detected for these variables when comparing different months of 
observation.  
Of these variables only the mean serum iron is significantly different (p <0.001) in cases with 
hemoglobin less than 11g/dl (x = 47.93) than in cases with more than 11g/dl hemoglobin  
(x = 61.14). 
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Although the mean transferrin saturation of each month is in the desired range, 33 cases 
(14.2%) had a transferrin saturation of less than 20%. 
The mean index of transferrin soluble receptor / log ferritin is 0.7579 (above the 0.6 cut-off 
for iron deficiency) and the frequency distribution shows that 73.8% of the cases are above 
0.6. These cases are likely to have iron deficiency, according to.(Chen, Hung, and Tarng 
2006b) 
Although the mean transferrin soluble receptor is 1.856 mg/L (less than 2 mg/L cut-off for 
iron deficiency), 37.2% had levels above 2 mg/L. These cases are likely to have iron 
deficiency, according to (Chang et al. 2007) 
Therefore some patients have had iron deficiency at least once during the observation 
period in an amount ranging between 14.2% and 73.8%, depending on whether we use a less 
or more sensitive indicator. 
Therefore, the iron dose should be increased slightly to maintain deposits and availability of 
iron in adequate quantity for normal erythropoiesis. 
10. Discussion 
Predictors of response reported so far are : albumin (Agarwal, Davis, and Smith 2008), 
clinical factors (Bamgbola, Kaskel, and Coco 2009) , (Bistrian and Carey 2000), protocol 
adherence(Chan et al. 2009), soluble receptor of transferrin (Chang et al. 2007; Chen, Hung, 
and Tarng 2006a), low iron stores (low ferritin and low transferrin saturation), malnutrition, 
hyperparathyroidism, and high-turnover bone disease (Kalantar-Zadeh et al. 2009). 
In our model hypo-response to combination therapy with erythropoietin and iron occurs in 
patients with higher hemoglobin (11.4 in non-responders, versus 10.7 in responders), lower 
serum erythropoietin (11 in non-responders versus 18.4 in responders), higher MCHC (32.7 
in non-responders versus 32.3 in responders). To our knowledge this is the first time that 
MCHC is included in a model to predict response to combination therapy with 
erythropoietin and iron in anemia in hemodialysis patients. 
The difference in mean MCHC between responders and non-responders is marginal, but 
statistically significant.  
It may seem odd that a higher level of hemoglobin is a predictor of no response, but can be 
explained by the fact that a level equal to or greater than 12g/dl hemoglobin involves a 
reduction of 50% of the dose of erythropoietin, according to our protocol. In a patient with 
chronic renal failure on hemodialysis serum erythropoietin level depends largely on that 
which is administered as a drug because the endogenous secretion is strongly suppressed. 
Of the three variables in the model, the serum erythropoietin is the most easily adjustable in 
the short term, since it can be achieved by increasing the dose. Although our protocol has 
been shown effective in maintaining a stable mean hemoglobin level of 11g/dl, it is 
insufficient to achieve the target of 12 g/ dl recommended in the latest revision of the K-
DOKI guideline (KDOQI 2007). This trial had been designed before the amendment was 
published. Taking this into account it would be necessary to review the criteria for 
erythropoietin dose reduction conditioned by the level of hemoglobin. The importance of 
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Although the mean transferrin saturation of each month is in the desired range, 33 cases 
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The mean index of transferrin soluble receptor / log ferritin is 0.7579 (above the 0.6 cut-off 
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0.6. These cases are likely to have iron deficiency, according to.(Chen, Hung, and Tarng 
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reduction of 50% of the dose of erythropoietin, according to our protocol. In a patient with 
chronic renal failure on hemodialysis serum erythropoietin level depends largely on that 
which is administered as a drug because the endogenous secretion is strongly suppressed. 
Of the three variables in the model, the serum erythropoietin is the most easily adjustable in 
the short term, since it can be achieved by increasing the dose. Although our protocol has 
been shown effective in maintaining a stable mean hemoglobin level of 11g/dl, it is 
insufficient to achieve the target of 12 g/ dl recommended in the latest revision of the K-
DOKI guideline (KDOQI 2007). This trial had been designed before the amendment was 
published. Taking this into account it would be necessary to review the criteria for 
erythropoietin dose reduction conditioned by the level of hemoglobin. The importance of 





(Mathieu et al. 2008). The last authors describe a cohort of patients in Switzerland with 
stable hemoglobin levels, although slightly higher (mean hemoglobin 11.9 g/dl), than those 
presented in this paper.  
Hemoglobin levels above 13g/dl, although recommended in some instances, have been 
associated with increased mortality. Recently, this increased mortality has been attributed to 
thrombocytosis induced by iron deficiency and therefore appropriate doses of intravenous 
iron could counteract the adverse effect of high doses of erythropoietin (Kalantar-Zadeh et 
al. 2009). However thrombocytosis associated with erythropoietin treatment to achieve high 
levels of hemoglobin can be attributed not only to iron deficiency but also to high doses of 
erythropoietin (Vaziri 2009).These data should be confirmed before raising the target 
hemoglobin level. 
In the last decade hematological cell counters provide new erythrocyte and reticulocyte cell 
indices that are useful for the differential diagnosis of anemia. Some of these indices could 
be useful to establish the status of iron metabolism in the anemia of patients with advanced 
renal disease on hemodialysis and to predict response to treatment. If confirmed, the CBC 
would provide data that would spare more expensive laboratory tests. Unexpectedly, the 
best predictor in terms of this work is MCHC, an erythrocyte index of routine, instead of the 
most innovative. In general the red cell indices were used to assess the iron status rather 
than as predictors of response. Each author recommends the ones they have examined, but 
there is no consensus because the results are variable and generally not confirmed. Some of 
these indices are: reticulocyte hemoglobin equivalent (Ret He) (Brugnara, Schiller, and 
Moran 2006), serum soluble transferrin receptor (Chang et al. 2007), transferrin receptor-
ferritin index (Chen, Hung, and Tarng 2006a), Soluble transferrin receptor and sTfR-F index 
(Choi 2008), soluble transferrin receptor and mean corpuscular hemoglobin (Choi 2007), as 
we have discussed in more detail in the introduction. 
The serum iron is an infrequently used index of iron deficiency. In general, low serum iron 
is unreliable as a marker of iron deficiency because of the wide variation throughout the 
day. Transferrin saturation is generally preferred because in the case of iron deficiency, 
serum transferrin increases while serum iron decreased; but this is not the case in chronic 
renal failure in which both values decrease in parallel and thus the transferrin saturation 
shows little variation. In our patients the standard deviation of serum iron, expressed in 
percentage is 41%, while the same variation for transferrin is only 20%. Despite such a high 
dispersion, serum iron enters the multiple regression model, while transferrin saturation 
does not. Moreover serum iron is the only indicator of iron status with significant mean 
difference when applying a cutoff of 11g/dl hemoglobin. Therefore, although the serum 
iron is not a good indicator of iron status at the individual level, it may be useful in clinical 
trials. 
Therefore we believe that serum iron should be taken into account in the case of anemia of 
chronic kidney disease. 
It is not easy to compare our results with others because the treatment protocol and 
response criteria are different. Moreover there are no randomized clinical trials designed to 
look for safety of treatment with intravenous iron in the long term and it is unclear which of 
the two trends are correct: Increasing the dose of iron to save erythropoietin, or increasing 
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the dose of erythropoietin to diminish the possible adverse effects of iron (Coyne 2010). The 
dilemma is important because high doses of erythropoietin also produce adverse effects. 
The most clear demonstration that increasing the number of patients treated with iron 
results in a decrease in erythropoietin dose in daily clinical practice (not only in clinical 
trials) are shown in the data published by (Hasegawa et al. 2011) . Although the balance 
between iron and erythropoietin therapy is still subject to discussion, it is clear that the 
combination therapy with both drugs reduce morbidity, mortality, hospital admissions and 
costs (Knight et al. 2010). 
In the present trial initial iron dose is 100 mg three times a week intravenously at the end of 
dialysis. The initial dose of erythropoietin is 40 U / K (2,800 U for a person of average 
weight 70K) three times a week.  
In a longitudinal study with data collected in Japan between 1999 and 2006 weekly doses of 
iron (160 mg / month) and erythropoietin (5531 U / week) are lower, but it must also be 
considered that the mean hemoglobin level was lower (10.4 g / dl )(Akizawa et al. 2008). 
(Charytan et al. 2001) using a schedule similar to ours (iron sucrose injection administered 
as 1,000 mg in 10 divided doses by IV push) concludes that this therapy is safe and effective 
for the treatment of iron deficiency in patients with dialysis-associated anemia. 
Iron Sucrose is the most widely iron used in patients with chronic kidney disease, but iron 
dextran of low molecular weight is equally effective (Atalay et al. 2011). 
Several trials compare the costs and effectiveness of treatment of classical formulations of 
iron and erythropoietin with the new ones (some not yet approved for kidney patients) 
(Bhandari 2011)(Cuesta Grueso et al. 2010). Although the efficacy of these new drugs is 
similar to the former ones, there is no conclusive evidence to justify the increased cost of 
new formulations of iron and erythropoietin. In one study ferric carboxymaltose was 
effective in increasing the mean level of hemoglobin from 9.1 to 10.3 g / dl, but at the 
expense of 7.4% of serious adverse effects (Covic and Mircescu 2010). Of the new iron 
preparations only isomaltose iron at doses between 600 and 1,000 mg is cost effective 
compared with iron dextran (Bhandari 2011). 
A comparative study was carried out: one branch with intravenous iron sucrose and the 
other with oral iron succinate. Both showed a positive response but the first one 
demonstrated better results. Although erythropoietin dose was lower in the intravenous 
iron branch, the total cost of both drugs together was higher. Gastrointestinal adverse events 
were higher in the oral branch (Li and Wang 2008). 
Several reports have found that the detection and early treatment of anemia of chronic 
kidney disease with erythropoiesis-stimulating agents improves the quality of life, including 
cognitive and physical performances: memory, sustain attention, energy level, work 
capacity, aerobic capacity, and immune function (Fishbane 2010).  
The alternative to transfusions most often used in patients with anemia of chronic kidney 
disease is erythropoietin and intravenous iron. Combination therapy is even more important 
in patients with anemia and cardio renal disease (Silverberg et al. 2009; Silverberg 2011; 
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indices that are useful for the differential diagnosis of anemia. Some of these indices could 
be useful to establish the status of iron metabolism in the anemia of patients with advanced 
renal disease on hemodialysis and to predict response to treatment. If confirmed, the CBC 
would provide data that would spare more expensive laboratory tests. Unexpectedly, the 
best predictor in terms of this work is MCHC, an erythrocyte index of routine, instead of the 
most innovative. In general the red cell indices were used to assess the iron status rather 
than as predictors of response. Each author recommends the ones they have examined, but 
there is no consensus because the results are variable and generally not confirmed. Some of 
these indices are: reticulocyte hemoglobin equivalent (Ret He) (Brugnara, Schiller, and 
Moran 2006), serum soluble transferrin receptor (Chang et al. 2007), transferrin receptor-
ferritin index (Chen, Hung, and Tarng 2006a), Soluble transferrin receptor and sTfR-F index 
(Choi 2008), soluble transferrin receptor and mean corpuscular hemoglobin (Choi 2007), as 
we have discussed in more detail in the introduction. 
The serum iron is an infrequently used index of iron deficiency. In general, low serum iron 
is unreliable as a marker of iron deficiency because of the wide variation throughout the 
day. Transferrin saturation is generally preferred because in the case of iron deficiency, 
serum transferrin increases while serum iron decreased; but this is not the case in chronic 
renal failure in which both values decrease in parallel and thus the transferrin saturation 
shows little variation. In our patients the standard deviation of serum iron, expressed in 
percentage is 41%, while the same variation for transferrin is only 20%. Despite such a high 
dispersion, serum iron enters the multiple regression model, while transferrin saturation 
does not. Moreover serum iron is the only indicator of iron status with significant mean 
difference when applying a cutoff of 11g/dl hemoglobin. Therefore, although the serum 
iron is not a good indicator of iron status at the individual level, it may be useful in clinical 
trials. 
Therefore we believe that serum iron should be taken into account in the case of anemia of 
chronic kidney disease. 
It is not easy to compare our results with others because the treatment protocol and 
response criteria are different. Moreover there are no randomized clinical trials designed to 
look for safety of treatment with intravenous iron in the long term and it is unclear which of 
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the dose of erythropoietin to diminish the possible adverse effects of iron (Coyne 2010). The 
dilemma is important because high doses of erythropoietin also produce adverse effects. 
The most clear demonstration that increasing the number of patients treated with iron 
results in a decrease in erythropoietin dose in daily clinical practice (not only in clinical 
trials) are shown in the data published by (Hasegawa et al. 2011) . Although the balance 
between iron and erythropoietin therapy is still subject to discussion, it is clear that the 
combination therapy with both drugs reduce morbidity, mortality, hospital admissions and 
costs (Knight et al. 2010). 
In the present trial initial iron dose is 100 mg three times a week intravenously at the end of 
dialysis. The initial dose of erythropoietin is 40 U / K (2,800 U for a person of average 
weight 70K) three times a week.  
In a longitudinal study with data collected in Japan between 1999 and 2006 weekly doses of 
iron (160 mg / month) and erythropoietin (5531 U / week) are lower, but it must also be 
considered that the mean hemoglobin level was lower (10.4 g / dl )(Akizawa et al. 2008). 
(Charytan et al. 2001) using a schedule similar to ours (iron sucrose injection administered 
as 1,000 mg in 10 divided doses by IV push) concludes that this therapy is safe and effective 
for the treatment of iron deficiency in patients with dialysis-associated anemia. 
Iron Sucrose is the most widely iron used in patients with chronic kidney disease, but iron 
dextran of low molecular weight is equally effective (Atalay et al. 2011). 
Several trials compare the costs and effectiveness of treatment of classical formulations of 
iron and erythropoietin with the new ones (some not yet approved for kidney patients) 
(Bhandari 2011)(Cuesta Grueso et al. 2010). Although the efficacy of these new drugs is 
similar to the former ones, there is no conclusive evidence to justify the increased cost of 
new formulations of iron and erythropoietin. In one study ferric carboxymaltose was 
effective in increasing the mean level of hemoglobin from 9.1 to 10.3 g / dl, but at the 
expense of 7.4% of serious adverse effects (Covic and Mircescu 2010). Of the new iron 
preparations only isomaltose iron at doses between 600 and 1,000 mg is cost effective 
compared with iron dextran (Bhandari 2011). 
A comparative study was carried out: one branch with intravenous iron sucrose and the 
other with oral iron succinate. Both showed a positive response but the first one 
demonstrated better results. Although erythropoietin dose was lower in the intravenous 
iron branch, the total cost of both drugs together was higher. Gastrointestinal adverse events 
were higher in the oral branch (Li and Wang 2008). 
Several reports have found that the detection and early treatment of anemia of chronic 
kidney disease with erythropoiesis-stimulating agents improves the quality of life, including 
cognitive and physical performances: memory, sustain attention, energy level, work 
capacity, aerobic capacity, and immune function (Fishbane 2010).  
The alternative to transfusions most often used in patients with anemia of chronic kidney 
disease is erythropoietin and intravenous iron. Combination therapy is even more important 
in patients with anemia and cardio renal disease (Silverberg et al. 2009; Silverberg 2011; 





More than 90 % of end renal disease patients maintained on dialysis respond to traditional 
recombinant human erythropoietin (rHU EPO) or to EPO analogues (biosimilars, 
biogenerics) (Schmid and Schiffl 2010). 
The therapeutic dose of EPO are higher than normal endogenous rates of EPO production in 
healthy subjects, and the amount of IV-iron given may be greater than the amount needed 
for normal erythropoiesis. This increase in erythropoietin and iron needs may be due to 
chronic inflammation and vitamin C deficiency, present in many patients with chronic 
kidney disease (Handelman 2007). The comparison between clinical trials is difficult not 
only for the selection of patients and the different doses of erythropoietin and iron, but also 
for the management of chronic inflammation and replacement of folic acid and vitamins B12 
and C, data that are not always specified.  
The doses of erythropoietin should be considered together with hemoglobin levels and 
resistance to treatment and comorbidities. In patients with chronic renal failure, without 
mention of heart disease, adverse effects are associated with low levels of hemoglobin (<9.5 
g/ dl) despite high doses of erythropoietin (Bradbury et al. 2009), or with therapeutic targets 
of high hemoglobin levels (13.5 to 15 g / dl)(Belonje, de Boer, and Voors 2008) . In patients 
with simultaneous kidney and heart failure, erythropoietin improves cardiac function, even 
if it fails to raise the level of hemoglobin (Belonje, de Boer, and Voors 2008) (Pappas et al. 
2008). To understand the role of erythropoietin it should be noted that its physiological 
effects are beyond the stimulation of erythropoiesis (Diskin et al. 2008). 
Darbepoetin is as effective as epoetin alpha, but at a higher cost (Cuesta Grueso et al. 2010).  
A possible way to save costs would be to give biosimilar erythropoietin rather than original. 
A clinical trial has demonstrated the equivalence of Eprex with GerEpo (biogeneric) in the 
short term, but the short duration of the trial (12 weeks) did not provide any conclusions 
about safety (Goh et al. 2007). 
The current status of new anti-anemic drugs, including their indications and license in 
Europe and USA can be found in (Macdougall and Ashenden 2009). New intravenous iron 
preparations seem promising (Ferumoxytol), as well as erythropoietin with prolonged effect 
(CERA) and peptides that stimulate erythropoiesis by a mechanism different from 
erythropoietin (Hematide). Clinical trials are needed to establish the usefulness of these new 
drugs in patients with chronic kidney disease. 
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1. Introduction 
Iron is an essential element and its correct balance is necessary for good health and normal 
cellular functioning [1]. Hepcidin is the iron-regulatory hormone of hepatic origin. It is a 
defensin-like low-molecular-weight peptide that plays an important role in iron metabolism. 
Hepcidin and its receptor ferroportin play most important role in controlling the dietary 
absorption and tissue distribution of iron. Recently discovered hepcidin molecule has been 
recognized as the main hormone behind the pathogenesis of anemia of chronic disease.  
Maintenance of normal Iron homeostasis in body 
Iron is an important trace element that is crucial for human life. Its main functions include 
structural component of oxygen transportation and storage molecules, and of many 
enzymes. The control of this indispensable but potentially toxic substance is an important 
aspect of human health and disease. Intestinal absorption of dietary iron is a very dynamic 
process where non haem ferric form of iron (Fe3+) is reduced to ferrous form (Fe2+) by 
ferric oxidoreductase "duodenal cytochrome B" (DcytB) for transport across apical brush 
border. Iron is absorbed through the transporter DMT1 (divalent metal transporter 1) also 
called Nramp2 (natural-resistance-associated macrophage protein 2) [2, 3] present in apical 
intestinal epithelial cells. DMT1 mediates transport of non-transferrin bound iron (NTBI) 
along with other divalent metals (Fe2+, Zn2+, Mn2+). This is a proton dependant Fe2+ 
import, therefore conversion of Fe3+ to Fe2+ is necessary. The enterocytes either store the 
iron as ferritin which is accomplished by Fe3+ binding to apoferritin or move to the 
basolateral surface of the cell from where it is transported out by the iron exporter 
ferroportin, reoxidized by hephaestin which is homolog of serum multi-copper oxidase 
ceruloplasmin that oxidizes Fe2+ to Fe3+ and facilitates incorporation of iron into 
transferrin. Iron is then collected by transferrin for distribution to tissues [4].  
Iron transporter, ferroportin is a 571 amino acid long protein that is present in basolateral 
membrane of enterocytes and macrophages and is involved in iron-recycling in senescent 
erythrocytes and reticuloendothelial macrophages. The export is linked to a ferrooxidase. 
Iron in RBCs is phagocytosed by macrophages during recycling of iron from senescent red 
cells, exits the macrophage via ferroportin, assisted by the ferroxidase ceruloplasmin. 
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membrane via Nramp2 (natural resistance-associated macrophage protein) or divalent metal 
transporter1 (DMT1), and incorporate it in ferroproteins, including the storage protein 
ferritin.  
Role of hepcidin in iron metabolism  
Iron is utilized in nearly all cells, large amount of it being present in erythrocytes with lesser 
amounts in myoglobin. Iron is critical to a number of synthetic and enzymatic processes 
with greater requirement during periods of growth. Body plans to conserve iron by 
recycling it from senescent erythrocytes and from other sources. To maintain the 
homeostatic balance, essential mechanisms prevent excessive iron absorption in the 
proximal small intestine and regulate the rate of iron release from macrophages [5]. 
Maintenance of correct iron balance is vital to health. In heme or non-heme proteins, iron is 
involved in vital activities and biochemical reactions. Cell and tissue proliferation and 
immunity are also affected by iron. However, the ability to produce free radicals makes free 
iron a toxic element (Fenton reaction) [1]. 
Fenton reaction: Fe2+ + H2O2  Fe3+ + OH* + OH 
Over past few years immense research has been done and led to identification of a number 
of new proteins involved in iron homeostasis, hepcidin being an important hormone 
involved. Hepcidin acts as a systemic iron-regulatory hormone as it controls iron transport 
from iron-exporting tissues into plasma [6]. Hepcidin inhibits the intestinal absorption [7, 8], 
macrophage release [9, 10] and placental passage [8] of iron. It provides a more functional 
view of iron metabolism and reveals the mechanisms affecting iron status in patients with 
chronic inflammation and anemia. 
Hepatocytes evaluate body iron status and release or down-regulate hepcidin according to 
the iron status of the body, with main function of hepcidin being reduction in plasma iron 
concentration. Hepcidin mRNA moves with the body's iron levels, increasing as they 
increase and decreasing as they decrease [11]. Hepcidin regulates iron uptake constantly on 
a daily basis, to maintain sufficient iron stores for erythropoiesis [12], as well as its feedback 
mechanism to prevent iron overload.  
Hepcidin inhibits the cellular efflux of iron by binding to, and inducing the internalization 
and degradation of, ferroportin, the exclusive iron exporter in iron-transporting cells [6, 13, 
14]. Thus, on one hand hepcidin decreases iron release from the spleen macrophages into 
the plasma and on other hand, it decreases duodenal iron absorption by diminishing the 
effective number of iron exporters on the membrane of enterocytes.  
Hepcidin excess or deficiency might be the causative factor of dysregulation of iron 
homeostasis in hereditary and acquired iron disorders. In ferroportin mutations it has been 
observed that iron accumulates mainly in macrophages and is often combined with anemia 
[15]. It has been observed that hepcidin synthesis is increased by iron loading and decreased 
by anemia and hypoxia [16]. Anemia and hypoxia are associated with a dramatic decrease in 
liver hepcidin gene expression, which may account for the increase in iron release from 
reticuloendothelial cells and increase in iron absorption frequently observed in these 
situations [12]. Several studies have proved that there is local production of hepcidin by 
macrophages [17], cardiomyocytes [18] and fat cells [19], suggesting that hepcidin is 
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involved in different regulatory mechanisms to control iron imbalance. Apart from this, few 
studies have proposed that hepcidin might also directly inhibit erythroid-progenitor 
proliferation and survival [20]. These modifications of hepcidin gene expression further 
suggest a key role for hepcidin in iron homeostasis under various pathophysiological 
conditions, which may support the pharmaceutical use of hepcidin agonists and antagonists 
in various iron homeostasis disorders. 
2. Hepcidin 
2.1 A peptide hormone   
Hepcidin is a small, antimicrobial peptide hormone with a sequence of 25 amino acids which 
is produced by liver in response to inflammatory stimuli & iron overload. Hepcidin was first 
discovered in human urine and serum and later the studies done on the mice models led to 
most of the information on its structure, function expression and regulation. Originally 
hepcidin was isolated from plasma ultrafiltrate [21] and was called liver-expressed 
antimicrobial peptide (LEAP-1). Later when it was isolated from human urine, it was renamed 
as hepatic antimicrobial peptide (HAMP). Currently known as ‘hepcidin’ because of its hepatic 
origin and bactericidal effect in vitro [7], this newly discovered peptide has been established to 
be regulated by inflammation, iron stores, [22] hypoxia and anemia [16].  
Hepcidin is thought to be the primary regulator of iron homeostasis whose production is 
mainly controlled by the erythropoietic activity of the bone-marrow, the body iron stores, 
and presence of inflammation in the body. Hepcidin was discovered accidentally when its 
gene was knocked out in a group of mice and they were noticed to develop iron overload. 
On contrary when hepcidin was over expressed, mouse fetuses died in utero because they 
developed severe hypoferremia thus it indicates that hepcidin may be involved in maternal-
fetal iron transport across placenta [23,24]. It is also proved to be a type II acute phase 
protein [25]. 
2.2 Overview of structure  
Hepcidin exists as precursor protein, a full-length preprohepcidin which comprises of 84 
amino acids (aa). Subsequent to the enzymatic cleavage at the C-terminus, 64 aa long pro-
hepcidin peptide is exported from cytoplasm into the lumen of endoplasmic reticulum 
followed by removal of a 39 aa pro-region peptide by a furin-like proprotein convertase [21, 
7]. The 25 amino acid form is the mature bioactive hepcidin. 
Structural analysis of hepcidin by NMR spectroscopy has revealed that the mature hepcidin 
molecule exists as a simple hairpin structure with disulfide bridges linking the two arms in a 
ladder like configuration. There are four disulfide bonds present between the cysteine 
molecules in the mature hepcidin. The hairpin loop has an indistinct β-sheet structure 
steadied by four disulfide bonds between the two anti-parallel strands. An atypical feature is 
the presence of a cysteine bridge between two adjacent cysteines near the turn of the hairpin 
that might be acting as a vital domain in the activity of the molecule [26]. These specific 
disulfide bonds formed between adjacent cysteines are stressed and might have a greater 
chemical reactivity. Like other antimicrobial peptides, hepcidin displays spatial separation of 
its positively charged hydrophilic side chains from the hydrophobic ones, a characteristic of 
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The predominant form of hepcidin in human urine is 25 aa long (hepcidin-25), along with 
two peptides which are shorter at the amino terminus, hepcidin-22 and hepcidin-20 [7]. Both 
of these isoforms which are truncated at the N-terminus of hepcidin-25 are detectable in 
human serum and urine while 22 aa isoform has been identified only in urine [27] 
suggesting that it may be a urinary degradation product of hepcidin-25 [28]. Recent studies 
have shown that the iron regulating bioactivity is almost exclusively due to the 25 aa 
peptide, signifying that the five N-terminal amino acids are essential for this activity [29, 30]. 
The 25 aa form has been proved to have both antibacterial [7] and antifungal activities [21] 
making hepcidin a member of the family of cysteine rich, cationic, antimicrobial peptides 
(AMP) which includes the defensins and cathelicidins [14] and is responsible for providing 
first line of defense at mucosal barriers [7, 21]. 
2.3 Genetics of hepcidin 
In humans, HAMP is the gene that encodes for hepcidin. Human hepcidin is encoded by a 
0.4–kilobase (kb) mRNA generated from 3 exons of a 2.5-kb gene on chromosome 19q13.1. 
The development of severe iron overload by knocking out the gene in mice suggested that 
hepcidin is involved in iron metabolism [23]. Animal models of iron overload include mice 
deficient in Upstream factor 2 (Usf2) that do not express the antimicrobial peptide hepcidin 
[31]. Constitutive overexpression of hepcidin in HAMP transgenic mice leads to iron-
deficient anemia [8]. These findings indicate a key role for hepcidin in regulation of iron 
absorption in mammals and make HAMP a functional candidate for association with 
juvenile hereditary hemochromatosis that is not linked to 1q. 
2.4 Assay methods 
Various techniques have been employed to measure hepcidin / prohepcidin. Commercially 
available ELISA, dot blot assay using non-commercially available antibodies for the semi-
quantitative measurement of hepcidin in urine [25] and more advanced technologies such as 
surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF 
MS) and liquid chromatography tandem mass spectrometry (LC/MS-MS) [32, 33,34] have 
taken the lead in hepcidin quantification.  
Choice of right sample and a validated and reliable method is still being explored to assay 
levels of hepcidin. Hepcidin has been quantitated in serum as well as urine by various 
techniques although till date urinary hepcidin estimation has been more popular in most of 
the studies. Urinary secretion of hepcidin is under the control of glomerular filtration and 
tubular reabsorption and to some extent local production of hepcidin in renal tissue might 
also contribute towards the urinary hepcidin [35]. In spite of the fact that concentrations of 
urine and serum correlate with each other [36], the use of urine hepcidin measurements 
might be misleading.  
2.5 Regulation of hepcidin and its effects 
Hepcidin is homeostatically regulated by two factors- iron and erythropoietic activity. 
Hepcidin levels are regulated by a feedback mechanism: Iron- increased plasma and stored 
iron stimulate hepcidin production, which in turn blocks dietary iron absorption and further 
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iron loading whereas hepcidin is suppressed in iron deficiency [37], allowing increased 
absorption of dietary iron and replenishment of iron stores. Thus the feedback loop between 
iron and hepcidin ensures that plasma iron concentration is tightly controlled. At the 
cellular level, hepcidin regulates iron by binding with ferroportin. When plasma hepcidin 
concentration is elevated, the rate of hepcidin-ferroportin binding and subsequent 
ferroportin internalization and degradation lead to a decreased release of iron into the 
plasma. Hepcidin transcription implicates numerous proteins through several molecular 
cascades. Major proteins involved are the bone morphogenetic protein (BMP), the 
haemochromatosis protein HFE, TfR2 (Tf receptor 2) and the BMP co-receptor HJV 
(haemojuvelin) and membrane-bound serine protease matriptase 2 (TMPRSS6). Second 
process regulating hepcidin production is the process which consumes most iron, 
erythropoiesis [38]. Increased erythropoietic activity suppresses hepcidin production which 
allows the release of stored iron from macrophages and hepatocytes, and increased iron 
absorption, all resulting in greater supply of iron for hemoglobin synthesis.  
2.6 Role of hepcidin in inflammation 
The discovery of hepcidin regulation by inflammatory mechanisms has greatly increased 
the understanding of anemia caused in chronic inflammatory diseases. During inflammation 
although iron stores tend to increase, but availability of iron from stored forms and 
absorption decreases. Increased iron stores and inflammation induce hepcidin production, 
whereas hypoxia, anemia, and increased erythropoiesis moderates hepcidin synthesis [6, 16, 
39, 40]. The link between inflammation and production of hepcidin by liver is attributed to 
IL-6, produced at sites of inflammation [41]. IL-6 is believed to induce production by 
binding a transcription activator to the hepcidin promoter. Human hepatocytes increase 
hepcidin mRNA in the presence of IL-6 or lipopolysaccharide and in the presence of IL-6 
produced by monocytes exposed to lipopolysaccharide [25]. 
Studies have confirmed that changes in hepcidin expression is not by direct transcriptional 
mechanism but hypoxia-inducible factor (HIF)-1 alpha may down regulate hepcidin or it 
may be mediated by haemojuvelin, which may be increased by the HIF-dependent 
induction of furin activity [42, 43]. In a recent study Nemeth et al have suggested that 
hepcidin is a type II acute-phase protein. Hepcidin peptide was observed to be 100 times 
higher in urine of patients suffering from chronic infections and severe inflammatory 
diseases in contrast to patients with less severe inflammatory disorders [25]. Nicolas et al 
observed in mice models that inflammation from injection of turpentine resulted in 
induction of hepcidin mRNA and decrease in serum iron by 6 times and 2 times respectively 
[16]. The hypoferremic response to turpentine-induced inflammation, a standard 
inflammatory stimulus, was absent in the USF2/hepcidin-deficient mice, indicating that this 
response is fully dependent on hepcidin. In another study by Shike et al it was seen that 
infection with the fish pathogen Streptococcus iniae amplified hepcidin mRNA expression 
4500-fold in white bass liver [44].  
Whereas IL-6 induces hepcidin mRNA other cytokines like IL-1 or tumor necrosis factor 
(TNF-) inhibit it [25]. Recent studies have proposed that inflammation may perpetuate the 
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binding a transcription activator to the hepcidin promoter. Human hepatocytes increase 
hepcidin mRNA in the presence of IL-6 or lipopolysaccharide and in the presence of IL-6 
produced by monocytes exposed to lipopolysaccharide [25]. 
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mechanism but hypoxia-inducible factor (HIF)-1 alpha may down regulate hepcidin or it 
may be mediated by haemojuvelin, which may be increased by the HIF-dependent 
induction of furin activity [42, 43]. In a recent study Nemeth et al have suggested that 
hepcidin is a type II acute-phase protein. Hepcidin peptide was observed to be 100 times 
higher in urine of patients suffering from chronic infections and severe inflammatory 
diseases in contrast to patients with less severe inflammatory disorders [25]. Nicolas et al 
observed in mice models that inflammation from injection of turpentine resulted in 
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[16]. The hypoferremic response to turpentine-induced inflammation, a standard 
inflammatory stimulus, was absent in the USF2/hepcidin-deficient mice, indicating that this 
response is fully dependent on hepcidin. In another study by Shike et al it was seen that 
infection with the fish pathogen Streptococcus iniae amplified hepcidin mRNA expression 
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Whereas IL-6 induces hepcidin mRNA other cytokines like IL-1 or tumor necrosis factor 
(TNF-) inhibit it [25]. Recent studies have proposed that inflammation may perpetuate the 





hepcidin has been found to be elevated in obese women despite iron depletion, suggesting 
that it is responding to inflammation rather than iron status. The source of excess hepcidin 
however was proposed to be liver and not adipose tissue. The iron deficiency of obesity is 
thus a condition of a true body iron deficit rather than maldistribution of iron due to 
inflammation [45].  
2.7 Role of hepcidin in innate immunity  
Role of iron in bacterial growth is well established. Iron is required for bacterial growth and 
trivial to modest increase in iron intake may diminish host resistance to infection [46]. 
Bacterial cells tend to develop various means [47] for acquiring iron in environments where 
very little free iron is available. Iron overload increases the susceptibility to intracellular and 
blood pathogens [48, 49]. In response to bacterial infections, the host has its own 
mechanisms of withholding iron from microbes. These include increasing the production of 
iron binding proteins, reducing dietary iron assimilation, increasing hepatic production of 
hemoglobin and hemin scavengers (haptoglobin and hemopexin, respectively), and the 
release of apolactoferrin from neutrophils to sequester iron at sites of bacterial invasion. 
Conditions under which the level of iron in serum is increased compromise these host 
defenses and thereby predispose the host to invasion from these iron-requiring microbes 
[50]. 
The amphipathic hepcidin contains a motif of numerous cationic residues, well recognized 
in antimicrobial peptides that bind to negatively charged phospholipids on the cytoplasmic 
membranes of many microbes (bacterial, parasitic, and fungal). It has been speculated that 
hepcidin might subsequently disrupt membrane function, penetrate cells in order to damage 
them, or excite an immune response through chemotactic properties. Operating 
downstream of potent cytokines and Toll-like receptors, hepcidin contains potential binding 
sites for transcription factors NF- B, HNF3 and C/EBP in its regulatory region and is thus 
recruited by bacterial lipopolysaccharides and inflammation [21]  
In addition to its direct importance in bacterial growth, excess iron plays a crucial role in 
impairment of the host immune system [51, 52]. Results from different animal models 
indicates that excessive iron may have profound effects on T-cell function, with increased 
CD8+ counts at the expense of reduced CD4+ cell counts and a reduced mitogenic response 
to standard antigens and impaired hypersensitivity responses. Thus it appears that Th1 
responses (cellular immune responses) may be down regulated by excess iron.  
Iron has a direct inhibitory effect on vital gamma interferon-mediated pathways in 
macrophages, such as NO formation (by inhibition of inducible NO synthase), TNF-  
formation, major histocompatibility complex class II expression, and ICAM-1 expression [53, 
54, 55]. As a consequence, gamma interferon pathways become ineffective at destroying 
intracellular pathogens in iron-overloaded macrophages. This has been shown to 
detrimentally affect the immune response to Legionella, Listeria, Ehrlichia, and some viruses, 
where NO is critical [56]. *The identification of NRAMP-1 (natural resistance-associated 
macrophage protein 1)—which both is involved with modulation of iron metabolism in 
macrophages and plays an important role in early-phase macrophage activation and 
therefore in host innate immunity also explains the critical relation between immune 
response and iron [57].  
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Significance of hepcidin as a mediator of innate immunity has been highlighted by Ganz in 
his research. It was observed that hepcidin concentration amplified about 100-fold in the 
urine samples of one of the urine donors who developed a systemic infection [58]. Also its 
composition was seen to resemble that of drosomycin, a 4-disulfide insect defensin 
synthesized in body of drosophila in response to infections. Hepcidin, by its regulatory 
action on iron metabolism may thus be expected to have an important role in immune 
regulation. Hepcidin, by inducing macrophage sequestration of iron, robs bacteria of this 
element. Hepcidin thus provides an uncongenial internal milieu for microbes that 
successfully enter the bloodstream. Microbes require iron for the production of the 
superoxide dismutase that protects them from host oxygen radicals [59, 60].  
2.8 Role of hepcidin in anemia of chronic diseases 
Anemia is frequently associated with a wide variety of chronic infections, inflammatory 
diseases and malignancies. Chronic diseases are characterized with disturbance in iron 
homeostasis leading to anemia, referred to as anemia of chronic diseases. Mild to moderate 
anemia that is usually normocytic, normochromic, later can turn into hypochromic and 
microcytic. Hepcidin is the underlying cause of anemia in such settings. Hepcidin mediated 
anemia i.e, Anemia of Chronic Diseases (ACD) has been referred by a variety of other names 
also like Anemia of Inflammation (AI) and anemia of cancer (in case of malignancy). 
Anemia in patients with chronic infections could not be explained in earlier times though 
Locke et al (1932) had observed that infection was associated with hypoferremia [61]. The 
expression of proteins involved in iron homeostasis is altered by cytokine action although 
its role in anemia of inflammation has not been ascertained [62]. It has been established that 
the inflammatory cytokine IL-6 stimulates synthesis of hepcidin which is responsible for 
most or all of the features of this disorder [58]. It is now seen as a key mediator of 
hypoferremia in inflammation [4, 16, 63]. 
3. Anemia of Chronic Disease (ACD) 
Dysregulated iron metabolism occurs in chronic inflammatory diseases. The immune driven 
anemia due to inflammatory cytokines (IL-1β, TNFα, IFNγ) and impaired erythropoiesis 
leads to anemia of chronic disease (ACD) [64]. Therefore, patients suffering from chronic 
disorders like infection, cancer or an autoimmune disorder often develop ACD. ACD is 
probably the second most common anemia next to anemia due to iron deficiency [65, 66]. It 
has been proved that noninfectious diseases also lead to anemia as observed in chronic 
infections, thus formulating the term ‘anemia of chronic disease’. Hepcidin plays an 
important role in pathogenesis of ACD as it redirects iron from intestinal absorption as well 
as deters its release from macrophages [67].  
A newly identified gene, hemojuvelin is essential for iron homeostasis and is required for 
normal expression of hepcidin in hepatocytes [68]. The laboratory picture of ACD is 
typically characterized by normochromic or mild microcytic anemia with reduced serum 
iron concentrations and transferrin saturation and raised bone marrow iron stores and 
ferritin [69, 70]. The condition is marked by a low reticulocyte count indicating an 
underproduction of red cells. Transferrin concentrations are normal or slightly reduced and 
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3.1 Anemia of inflammation 
Anemia of inflammation is an intricate pattern of anemia encountered in critically ill 
patients. It is characterized by anemia with high ferritin levels and maintenance of iron 
stores in organs [73]. Role of hepcidin in development of anemia of inflammation has been 
explicated by Rivera et al. Stimulation of hepatocytes forms hepcidin, thus preventing 
absorption of iron due to internalization and destruction of ferroportin. Iron gets 
accumulated in the duodenal cells which are shed and recycling of iron is stopped as iron 
is trapped in macrophages. In other words anemia of inflammation can be defined as 
inappropriate preservation of iron in the milieu of anemia [73]. Nemeth et al have showed 
that hepcidin is imperatively linked to inflammatory cytokines [74] and increased 
production of hepcidin by hepatocytes is due to the action of IL-6. Hepcidin thus 
synthesized, negatively regulates intestinal iron absorption and macrophage iron release, 
thus leading to hypoferremia [74, 75]. This is consistent with clinical finding of 
hypoferremia soon after the onset of inflammation. Inflammation-induced hepcidin 
expression might account for iron sequestration within cells of the Reticulo-endothelial 
System (RES).Cytokines thus exert a pivotal role in the control of iron sequestration 
within cells of the RES. A direct inhibitory role for hepcidin on iron release by cells of the 
RES has been proposed but not proven [16]. A potential NF- B-binding site has been 
identified in the promoter region of mouse hepcidin [11. Plasma ferritin is secreted from 
cells of the RES depending on the iron concentration within the cell. High ferritin levels in 
chronic inflammatory conditions result from the reduced uptake of iron into erythroid 
precursors, and may serve as an indicator of how much iron is being deposited within the 
RES [76]. 
3.2 Anemia of cancer 
Anemia is a common occurrence in various malignant conditions. Anemia of cancer is 
referred to as anemia of inflammation when cause is not bleeding or bone marrow 
infiltration or chemotherapy. Tumor cells lead to the occurrence of anemia by either 
infiltrating into the bone marrow [64] or by destroying the erythroid progenitor cells by 
oxidant injury due to free radicals or by producing proinflammatory cytokines [65, 66]. 
Various neoplastic disorders like Hodgkin`s disease, lung and breast carcinoma are 
associated with anemia of cancer. As in chronic inflammatory disorders and infections, 
certain cancers release inflammatory cytokines. Role of hepcidin in pathogenesis of anemia 
by virtue of decreased iron release from macrophages and enterocytes as well as induction 
of its expression by IL-6 is well established [13, 74]. Hepcidin is up-regulated in multiple 
myeloma patients by both IL-6-dependent and IL-6-independent mechanisms and may play 
a role in the anemia of multiple myeloma [77]. Some recent reports indicate ectopic 
production of hepcidin by hepatic adenomas, where severe anemia of cancer was resolved 
after tumor resection [63, 78]. Besides invasion of cancer cells into bone marrow, the anemia 
of cancer worsens by chemotherapy and radiation that damage the bone marrow. 
3.3 Human diseases related to altered hepcidin expression 
In recent years anemia associated with various diseases has been specifically described in 
terms of hepcidin playing a key role in the pathogenesis. Hemochromatosis is one of the 
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most important disease caused by iron dysregulation. Hemochromatosis is characterized by 
continued absorption of dietary iron despite adequate or raised iron stores, with the 
subsequent accumulation of iron in liver and other body tissues. Hereditary 
hemochromatosis (HH) is a condition resulting most commonly from mutation in HFE gene. 
Hemochromatosis protein (HFE) is an atypical major histocompability class I protein, 
located on chromosome 6 [79]. The hemochromatosis (HFE) gene related HH is 
characterized by an inappropriately increased iron absorption, which leads to iron 
accumulation in liver and pancreas. HFE emerges to be involved in the maintenance of body 
iron homeostasis. HFE controls and modulates hepcidin, though its exact role in assessing 
body iron is not very clear. Four main types of HH have been identified and remarkably, 
genes implicated encode for proteins involved in hepcidin synthesis and its interaction with 
ferroportin. Major mutation C282Y causes a conformational change of the HFE protein [80]. 
It is now well known that hepcidin controls iron homeostasis by diminishing cellular iron 
efflux by binding to the transmembrane iron exporter ferroportin on enterocytes and 
macrophages, thus disrupting the function of ferroportin and subsequently inducing its 
internalization [13, 81]. 
HFE is implicated in upstream modulation of the regulation of hepcidin expression as is 
suggested by incongruously low concentrations of hepcidin associated with mutations in 
HFE [77, 82]. Hepcidin concentrations in urine are negatively correlated with the severity of 
HH. It has been proposed that availability of hepcidin measurements in both urine and 
serum, may aid in strategic approach for the treatment [83].  
A few other disorders associated with this type of anemia are thalassemia, Inflammatory 
Bowel Disease (IBD) like Crohn’s disease and celiac disease, Chronic Kidney Disease (CKD), 
rheumatoid arthritis and atherosclerotic lesions like ischemic heart disease.  
Iron overload due to blood transfusions or due to increased iron absorption lead to decrease 
in hepcidin. Murine models of human thalassemia, have also demonstrated decreased 
hepcidin mRNA expression [84]. On one hand the proinflammatory cytokines like IL-6 in 
particular have been observed to have a definitive role in pathogenesis anemias of IBD [85, 
86] and rheumatoid arthritis [87]. IBD is characterized by interplay of inflammatory and 
cytotoxic mechanisms. On the other hand anemia of CKD is predominately driven by 
impaired erythropoietin production, its production being reduced by inflammation [88, 89] 
along with antiproliferative effects of accumulating uremic toxins [90]. Hepcidin production 
is affected by iron status of the body, presence of inflammation, anaemia, hypoxia and 
erythropoietin in CKD [91]. Also several studies have proposed protective effect of 
sustained iron depletion or mild iron deficiency against ischemic heart disease, referred to 
as "iron hypothesis" [92, 93, 94]. Increased retention of iron in macrophages by elevated 
hepcidin and reducing the mobilization of iron from macrophages within atherosclerotic 
plaque might aid in promoting the evolution of atherosclerotic plaque. Low levels of 
hepcidin might result in increased macrophage iron loads promoting uptake of lipids 
through stimulation of expression of the scavenger receptor–1 in macrophages [95]103] and 
causing lipid peroxidation, and evolution of foam cells. Interruption of iron acquisition and 
storage in plaque macrophages by iron restriction or iron chelation inhibit lesion initiation 
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3.4 Future prospects of hepcidin 
Application of hepcidin assay in urine as well as serum has paved way to various studies 
and its use hepcidin as a diagnostic and therapeutic tool. In the recent times knowledge on 
hepcidin, its role in physiological and clinic pathological states has grown tremendously. 
Molecular mechanisms of hepcidin activity amplified our understanding of the regulation of 
iron transport. In fact quantitative assays for serum and urinary hepcidin can lead to 
establish the role of hepcidin, as compared to common parameters, such as serum ferritin 
and transferring saturation [91].  
Hepcidin analysis is being explored by researchers to establish its role with novel tools for 
differential diagnosis, therapeutic regimes and monitoring of disorders of iron metabolism 
in various disease conditions like hereditary hemochromatosis and anemia associated with 
chronic diseases. Role of hepcidin in the pathogenesis of anemia of CKD as well as its effect 
in resistance to erythropoeisis stimulating agents is well established [98]. The potential 
clinical benefits of hepcidin measurement are the improved assessment of functional iron 
status that can be used to assess erythropoietin response and efficacy of iron treatment in 
patients with chronic disease anemias. Since hepcidin inhibits intestinal iron absorption, 
need of oral or parentral iron supplementation can be in such patients can be reviewed by 
evaluation of hepcidin level. Possibility of exploiting hepcidin-lowering or enhancing agents 
may prove to be an effective strategy for curing the main consequences of hepcidinopathies, 
anemia or iron overload, respectively. 
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3.4 Future prospects of hepcidin 
Application of hepcidin assay in urine as well as serum has paved way to various studies 
and its use hepcidin as a diagnostic and therapeutic tool. In the recent times knowledge on 
hepcidin, its role in physiological and clinic pathological states has grown tremendously. 
Molecular mechanisms of hepcidin activity amplified our understanding of the regulation of 
iron transport. In fact quantitative assays for serum and urinary hepcidin can lead to 
establish the role of hepcidin, as compared to common parameters, such as serum ferritin 
and transferring saturation [91].  
Hepcidin analysis is being explored by researchers to establish its role with novel tools for 
differential diagnosis, therapeutic regimes and monitoring of disorders of iron metabolism 
in various disease conditions like hereditary hemochromatosis and anemia associated with 
chronic diseases. Role of hepcidin in the pathogenesis of anemia of CKD as well as its effect 
in resistance to erythropoeisis stimulating agents is well established [98]. The potential 
clinical benefits of hepcidin measurement are the improved assessment of functional iron 
status that can be used to assess erythropoietin response and efficacy of iron treatment in 
patients with chronic disease anemias. Since hepcidin inhibits intestinal iron absorption, 
need of oral or parentral iron supplementation can be in such patients can be reviewed by 
evaluation of hepcidin level. Possibility of exploiting hepcidin-lowering or enhancing agents 
may prove to be an effective strategy for curing the main consequences of hepcidinopathies, 
anemia or iron overload, respectively. 
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1. Introduction  
1.1 Unique features, evolution and life cycle of trypanosomes 
Trypanosomatids comprise a large group of flagellated unicellular protists with free-living 
and parasitic lifestyles. Several members of this family are widely known for being 
vertebrate pathogens of biomedical and veterinary importance. They belong to the order 
Kinetoplastida, which together with the groups Diplonemida (deep-see organisms) and 
Euglenida (photosynthetizing organisms) form the phylum Euglenozoa (Simpson et al., 2006; 
Roger & Simpson, 2009). Kinetoplastids represent one of the most ancient eukaryotic 
lineages that diverged after the acquisition of the mitochondrion and share unique 
biochemical and subcellular features including the nuclear and mitochondrial gene 
expression mechanism, the energy and thiol redox metabolism and the organization of the 
mitochondrial DNA, named kinetoplast, and the compartmentalization of the almost entire 
glycolytic pathway in a peroxisome-like organelle called the glycosome. Phylogenetic 
studies support the theory that hemoflagellate trypanosomes evolved from a free-living 
bodonid that subsequently became an insect parasite, which later gained capacity to adapt 
to mammalian hosts (Adl et al., 2005, 2007; Hamilton et al., 2004; Simpson et al., 2002). An 
early split of the genus Leishmania from the trypanosome taxon together with the existence 
of two well-defined clades within the genus Trypanosoma (the “brucei” clade and the “cruzi” 
clade) are strong evidences that the different lineages of pathogenic trypanosomes have 
evolved independently. Although they share a common ancestor, trypanosomes from the 
“brucei” and “cruzi” clades evolved and are geographically confined to the African and New 
World (South-America and Oceania) continents, respectively. In contrast to members from 
the “cruzi” clade, several lines of evidence indicate that African trypanosomes co-evolved 
with their mammalian hosts and insect vectors (Hamilton et al., 2007; Maslov et al., 1996; 
Stevens et al., 1998; Stevens et al., 2001). Parasitic trypanosomes are naturally transmitted by 
arthropods, e.g. tsetse fly for T. brucei, kissing bug for T. cruzi, and sand fly for Leishmania 
spp. (Fig. 1). Occasionally, bats can also act as vector agents (Dávila & Silva, 2000) and, more 
recently, rats and ticks are discussed as potentially involved in transmission of T. cruzi and 
Leishmania parasites to mammals (Herrera & Urdaneta-Morales, 2001; Colombo et al, 2011; 
Dantas-Torres, 2011). The natural infectious cycle of these parasites is initiated when non-
dividing infective trypanosomes (metacyclic stage) are mechanically introduced in the 
mammal via insect bites or by involuntary deposition of infected feces from insects in the 
mucosa or injured dermis of mammals. Depending on the trypanosomatid species, parasites 
can reside in the host dermis (L. major), infect mucosa (L. brasilienzis and L. amazoniensis) or 
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internal tissues/organs (T. cruzi, L. donovani and L. infantum) or remain in the extracellular 
fluids (i. e., T. brucei ssp.). Inside the mammal hosts, parasites shuttle between proliferative 
and non-proliferative forms. Indeed, the non-proliferative stages play an important role in 
the perpetuation of the life cycle since they are pre-adapted to survive in the poikilothermic 
arthropod (Comini et al., 2011). They are taken up during insect blood meal of an infected 
host and further differentiate to dividing forms. The transformation to the quiescent 
infective stages occurs in the gut (T. cruzi) or salivary glands (T. brucei and Leishmania spp.) 
of the invertebrate. Trypanosomes undergo important metabolic and morphological 
changes to adapt to the growth conditions imposed by the different hosts and environments 
(extracellular medium and cell tissues) they inhabit. Fine tuning of energy metabolism, 
organelle reorganization and dedicated nutrient uptake are some of the mechanisms the 














Fig. 1. Life cycle and diseases caused by trypanosomatids. 
The genus Trypanosoma and Leishmania include species that are pathogenic for mammals. 
The natural cycle of these parasites involves their transmition by different but specific 
arthropods (insect vectors). Inside the host each species exhibit a peculiar tropism for 
different tissues, organs and systems resulting in different pathologies. For instance, T. 
brucei is an extracellar parasite that resides in the host´s bloodstream and cerebrospinal 
fluid; different strains of T. cruzi invade cardiomiocytes or nervous tissue from the digestive 
system; depending on the Leishmania species, the parasites invade the dermis, mucosa or 
internal organs (e. g., spleen). The diseases associated with infection are devastating and 
fatal if left untreated. Human pathogens from the ”brucei“ complex (T. b. rodhesiense and T. b. 
gambiense) cause sleeping sickness or human African trypanosomiasis (HAT; see section1); 
T. b. brucei produces nagana disease of cattle; T. cruzi is the ethiologic agent of Chagas 
disease in Latin-America; L. infantum and L. donovani produces visceral leishmaniasis, L. 
major and L. amazonensis causes cutaneous leishmaniasis, and L. brasiliensis is responsible for 
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a mucocutaneous infection. During their life cycle, the parasites undergo important 
biochemical and ultrastructural remodeling to adapt to the different hosts.The cycle is 
closed when insect feeds on infected mammals. 
1.2 Trypanosomiasis: Disease, burden and treatment 
Different members of the Trypanosomatida family are etiologic agents of highly disabling 
and often fatal diseases of humans and livestock (see Fig. 1). With respect to the parasites 
that are the major focus of this chapter, members from the T. brucei complex are transmitted 
by tsetse flies of the genus Glossina spp., which is found exclusively in equatorial Africa. The 
human pathogens T. b. gambiense and T. b. rodhesiense differ in their geographical 
distribution with the first subspecies being endemic of west and central regions while the 
last is mainly present in east and southern Africa (Barrett et al., 2003).  
HAT present two main clinical phases with compromise of the hematolymphatic system 
(acute phase) and the central nervous system (CNS, chronic phase). The T. b. rhodesiense 
infection develops rapidly as an acute disease that is characterized by a high parasite load, 
severe anemia and thrombocytopenia accompanied by hypertrophy of the 
reticuloendothelial system. If untreated, the pathology evolves to a pancarditis with 
congestive heart failure, pulmonary edema and physiological collapse (Barrett et al., 2003). 
Due to this fast and lethal development, along with the limited sanitary conditions of 
endemic regions, HAT caused by T. b. rhodesiense is usually under-diagnosed explaining - at 
least partly - why 90% of the reported cases of African sleeping sickness are ascribed to T. b. 
gambiense (Birkholtz et al., 2011). In contrast, HAT produced by T. b. gambiense displays a 
more discrete development without characteristic symptoms in the early phase, unless the 
patient develops a generalized lymphadenopathy, which hinders an accurate diagnosis. The 
second stage of HAT starts when the parasites invade internal organs, including the CNS. 
For T. b. rhodesiense and T. b. gambiense this phenomena can take place within few weeks and 
up to years upon infection, respectively. Invasion of the CNS by the parasite is typically 
accompanied by intense headache, sleeping disorders and mental dysfunction, leading to a 
comatose state and sudden death (Barrett et al., 2003). The differential pathogenicity and 
clinical manifestations of both diseases have been formerly explained on the basis of mutual 
host-parasite adaptations that shaped pathogen virulence and host resistance during 
evolution (Fèvre et al., 2006). However, the hypothesis of a co-evolutionary virulence 
attenuation of T. b. gambiense has recently been challenged by studies on phylogenetic 
relationships within the T. brucei taxon (Balmer et al., 2011).  
The World Health Organization (WHO) estimates that sixty million people are at risk of 
infection as a consequence of at least 300 separate active foci in 36 African countries (Jacobs 
et al., 2011), most of them in rural areas of extreme poverty. Around 300,000 people are 
currently infected with trypanosomes and 48,000 of them dye per year (Cavalli & Bolognesi, 
2009). The lack of local human and financial resources combined with the burden of conflicts 
in most of the endemic countries impedes to achieve full control of HAT (Cavalli & Bolognesi, 
2009). However, after continued control programs spanning vector eradication, early diagnosis 
and treatment, and surveillance (Barrett et al., 2003; Cavalli, 2009) the number of annual 
infections fell almost 5- to 7-fold in the last three decades1. Unfortunately, this progress is not 
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accompanied by the development of new chemotherapeutic options (see below) and is 
endangered by the increasing drug resistance of the naturally circulating strains of T. brucei 
ssp. (Cavalli & Bolognesi, 2009; Delespaux  & de Koning, 2007; Jacobs et al., 2011; Matovu et al., 
2001). In addition to HAT, animal trypanosomiasis represents a major problem for the 
agricultural and nutritional development of endemic regions. About ten million square 
kilometers of arable land are infested by tsetse flies (Matovu et al., 2001) capable of 
transmitting T. b. brucei, T. congolense and T. vivax (Nagana-disease) or T. evansi (Surra-disease) 
between domestic and wild (reservoirs) animals. For Africa, the total economic losses due to 
animal trypanosomiasis are estimated to be US$ 4.75 billion per year2. The recent detection of 
members from the “brucei” clade in countries from Asia, Central- and South-America should 
raise alarm considering the serious threat these pathogens entails for the well-developed 
agricultural economies of these regions (Luckins & Dwinger, 2004; Batista et al., 2007, 2009; Da 
Silva et al., 2011; Dávila & Silva, 2000; Mekata et al., 2009).  
Confronted with the lack of prospect for vaccine development against trypanosomiasis, 
chemotherapy remains as the only short- and mid-term therapeutic choice for these 
diseases. Nevertheless, the few drugs currently available against HAT (acute phase: 
pentamidine and suramine, chronic phase: melarsoprol and efluornithine3) are far from 
optimal: most of them were originally developed for veterinary use, lacking safety 
compliance, and present a limited efficacy against late-stage disease (Steverding, 2010). An 
additional drawback associated with the inappropriate use of these drugs lies on the 
emergence of resistance. Unfortunately, pharmaceutical companies are less prone to engage 
and invest in drug discovery and development against diseases that affect the world´s 
poorest people (Barrett et al., 2003; Cavalli & Bolognesi, 2009; Matovu et al., 2001). However, 
in the last years, scientists, policy-makers and non-profit institutions (WHO, TDR, Médecins 
Sans Frontieres, FioCruz Institute, Drugs for Neglected Disease initiative), together with a 
few pharmaceutical companies (Glaxo SmithKline®, Bayer®), have joined efforts to improve 
this situation. As mentioned above, trypanosomes present several unique biochemical and 
biological features that can be exploited for the development of specific therapies. These 
include several organelles (glycosomes, acidocalcisomes, kinetoplast) that are absent in the 
mammalian host, and metabolic pathways and cellular functions that differ significantly 
from host counterparts, namely carbohydrate metabolism, protein and lipid modification, 
thiol-redox metabolism, cell cycle, programmed cell death, etc. (Naula & Burchmore, 2003). 
Despite the obvious indispensability of iron for pathogenic trypanosomatids, the 
mechanisms and components comprising the uptake, storage and usage of this metal have 
been poorly investigated. In the next sections will be reviewed the state-of-the-art regarding 
iron-homeostasis and metabolism in African trypanosomes. 
2. Iron acquisition and homeostasis  
Owing the extracellular and parasitic lifestyle of African trypanosomes, it deems important 
to comment first on the mechanisms and components controlling iron homeostasis in the 
human host. Dietary ferric iron (Fe3+) is reduced to its ferrous form (Fe2+) by a ferrireductase 
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http://www.fao.org/ag/againfo/programmes/en/paat/disease.html 
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present in the membrane of enterocytes, and then incorporated via a divalent metal 
transporter. Cytosolic iron is exported to the circulation from the basolateral membrane of 
enterocytes through ferroportin with the concomitant reoxidation to Fe3+ by the multicopper 
oxidase hephaestin (Kosman, 2010). Iron circulates in plasma bound to the glycoprotein 
transferrin (Tf), which is internalized by cells via a specific transferrin receptor (TfR1) in a 
clathrin-dependent mechanism. In the acidic environment of the endosome Tf, iron and 
TfR1 disassemble. Apo-Tf is released to circulation whereas TfR1 is recycled back to the 
membrane. Fe3+ is exported from the late endosomal vesicle through the concerted action of 
transporters and metalloreductases (Hentze et al., 2010; Kurz et al., 2011). How this “labile 
iron pool” (LIP, Hider & Kong, 2011; Kakhlon & Cabantchik, 2002) is trafficked within the 
cell remains poorly understood (Hentze et al., 2010; Anderson & Vulpe, 2009; Atanasiu et al., 
2007; Hentze et al., 2010; Subramanian et al., 2011). Other major source of iron comprises the 
recycling of heme-iron from senescent erythrocytes, a task carried out by specialized 
macrophages of the reticuloendothelial system known as Kupffer cells (Anderson & Vulpe, 
2009; Schultz et al., 2010). The liver is both the major site for iron storage and also the central 
metabolic regulator. Induced by different stimuli –from iron availability to inflammatory 
stresses– (Zhang & Enns, 2009), hepatocytes produce and secrete a 25-aminoacid hormone, 
hepcidin (Atanasiu et al., 2007), which regulates the levels of systemic iron by a negative-
loop mechanism that involves ferroportin turnover. Intracellular iron homeostasis is 
regulated post-transcriptionally by the iron regulatory protein 1 (IRP1, see section 3.3.3.1). 
The vast majority of iron is dedicated to hemoglobin or myglobin synthesis, but also the 
biogenesis of iron-sulfur (Fe/S) proteins demands this metal. Both processes occur mostly in 
the mitochondria, representing the main subcellular compartment for iron utilization (Levi 
& Rovida, 2009). Iron is stored bound to ferritin heteropolymers, which can hold up to 4500 
Fe3+ atoms (Andrews, 2010). Heme-iron is also essential in mammalian physiology (see 
section 4) but it poses an independent mechanism of absorption that remains mostly 
unsolved (Schultz et al., 2010). As envisaged, iron homeostasis is tightly controlled at several 
levels -from absorption to mobilization and utilization- and in an interdependent manner in 
humans.  
Iron is an essential element also for T. brucei, therefore the parasite has developed 
exceptional mechanisms to guarantee metal supply from a host that (un)intentionally limits 
metal availability in response to infection (see section 5). For example, iron-deficiency 
induced by ferritin upregulation and reduction of iron-transferrin saturation is a classical 
immune-based response mounted during the acute phase of the infection to limit parasite 
proliferation (Chisi et al., 2004). Also the chronic stage is accompanied by a notorious iron 
deprivation (e.g. anemia, see section 5) but, in this case, its origin is a chronic inflammatory 
disorder involving macrophage hyperactivation along with iron accumulation within the 
reticuloendothelial system (Stijlemans et al., 2008). In the bloodstream, trypanosomes 
acquire the metal4 via a high affinity receptor-mediated endocytosis of iron-loaded Tf (see 
Fig. 2; Grab et al., 1992, 1993; Steverding et al., 1995). The trypanosomal Tf receptor (TfR) was 
identified as a heterodimeric complex of proteins encoded by the expression-site-associated-
gene (ESAG) 6 and ESAG 7 (Salmon et al., 1994; Steverding et al., 1995). ESAG 6 and 7 are 
truncated forms of variable surface glycoproteins (VSG) that lack the C-terminal domain, and, 
in the case of ESAG 7, the glycophosphatidylinositol (GPI) anchor. Under normal growth 
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Fig. 2. Working model for iron acquisition and utilization in Trypanosoma brucei.  
Iron is incorporated from the host bloodstream through receptor (TfR) mediated 
internalization of loaded transferrin (Tf, upper left) at the flagellar pocket. In the late 
endosomes, Tf is degraded by a cathepsin B-like protease (CatB) and iron is released to the 
cytosol through the concerted action of a ferric reductase (Fe-RED) and a divalent cation 
transporter (DCT). Once in the cytosol iron is complexed to low molecular mass ligands 
forming the labile iron pool (LIP, see section 2) that probably fuels the synthesis of iron-
dependent enzymes like the glycosomal superoxide dismutase (gFe-SOD) or ribonucleotide 
reductase (RNR), and the biogenesis of cytosolic Fe/S clusters (CIA system, section 3.3.1). 
Mitochondrial Fe/S cluster biogenesis depends on iron imported in a membrane-potential 
dependent (mp) fashion at expenses of the inner membrane carriers Mrs3/4. Mitochondrial 
iron is either incorporated to iron-centered enzymes (e.g. Fe-SOD and trypanosomal 
alternative oxidase, TAO) or participates in Fe/S cluster biogenesis (ISC system, see section 
3.3.1.2). Black letters refer to proteins that have been reported in T. brucei and red letters 
denote components of the iron- and Fe/S cluster metabolism not yet identified in 
trypanosomes but with essential functions in yeast or mammals. CIA proteins are depicted 
in green tones, ISC proteins in orange-brown tones, membrane transporters in purple and Fe 
or Fe/S cluster receiving proteins in grey. Fe and sulfur atoms are shown as red and yellow 
spheres, respectively. Scheme based in Lill & Mühlenhoff, 2008; Hentze et al., 2010 and 
Taylor & Kelly, 2010. 
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conditions the TfR localizes at the flagellar pocket wherefrom bound-transferrin is internalized 
and proteolyticaly degraded in the endolysosome by a cathepsin-B like protease (O’Brien et al., 
2008; Mussmann et al., 2003), which finally releases iron. The relevance of the endocytic 
pathway as the sole source of iron for the parasite was demonstrated using antibodies anti-TfR 
that inhibited growth of T. brucei in vitro (Grab et al., 1992). Expression of TfR in the parasite is 
regulated by iron availability and post-transcriptional control that does not involve the 
IRE/IRP1 system typical for mammals (Fast et al., 1999). Iron starvation induced by iron 
chelators or species-specific transferrins lead to a 3- to 10-fold upregulation in the expression of 
TfR with a concomitant redistribution of the receptor from the flagellar pocket to the entire 
parasite surface (Fast et al., 1999; Mussmann et al., 2004). This, together with the rapid recycling 
of TfR (Kabiri & Steverding, 2000) and gene-specific (in)activation events (van Luenen et al., 
2004) allows trypanosomes to efficiently compete for limiting substrate and withstand iron-
deprivation until a new set of higher affinity TfR is expressed. For instance, sequence 
polymorphisms in ESAG 6 and 7 were proposed to determine the affinities of TfR for 
transferrins from different mammalian species (Bitter et al., 1998) permitting for a rapid 
adaptation of the parasite to distinct hosts. It was also suggested that the TfR repertoire may 
allow the parasite to overcome anti-TfR antibody response by the host (Gerrits et al., 2002). 
However, estimations and studies by Steverding (1998, 2003, 2006) disproved this hypothesis 
and supported the view that high affinity TfRs were evolutionary selected to enable the 
parasite to cope with the diversity of mammalian transferrins (Steverding, 2003, 2006).  
In the aerobic and buffered milieu of the cytosol iron is never free, mostly because it can 
readily produce highly toxic oxygen species through Fenton chemistry (see section 3.2.2), 
but also because the ferric form tends to form insoluble hydroxides. The cellular labile or 
chelatable iron pool is defined as the intracellular pool of redox-active iron that is not 
associated with proteins. LIP comprises ~ 5 % of the total cellular iron and consist of Fe2+ 
and Fe3+ associated with a diverse population of low molecular mass ligands such as organic 
anions (phosphate, citrate, inositol phosphate, etc.), polypeptides such as glutathione (GSH) 
and/or components of membranes (phospholipids, etc; Kakhlon & Cabantchik, 2002). 
Whether this percentage represents the situation in trypanosomes is unknown. The nature 
of the ligand(s) can vary between cells and among different physiological states but recent 
reports support the notion that intracellular GSH (2-5 mM) is the most relevant low 
molecular mass complexing agent in most GSH-dependent organisms (Hider & Kong, 2011; 
Kumar et al., 2011; Mühlenhoff et al., 2010; Overath et al., 1986). The nature of this LIP in 
trypanosomes was never assessed and it is worthy to speculate that trypanothione (T(SH)2, 
see below), and not GSH, will be the relevant physiological ligand. Beyond that T(SH)2 is the 
most abundant intracellular low molecular mass thiol in trypanosomes (Krauth-Siegel & 
Comini, 2008), our working model is supported by experimental evidences showing the 
formation of T(SH)2-Fe and T(SH)2-Fe/S complexes in vitro (Ceylan et al. 2010; Manta et al., 
unpublished, Fig. 2) and by the extensive documentation showing that most thiol-
dependent functions in these organisms evolved to use T(SH)2 and not GSH as cofactor 
(reviewed in Irigoín et al., 2008; Krauth-Siegel and Comini, 2008). How iron enters and exits 
the LIP and which are the proteins involved in this process remain as open questions. 
Recent studies propose a link between the LIP and Fe/S protein metabolism by means of a 
mechanism that involves Fe/S clusters as signalling molecule and cytosolic monothiol 
glutaredoxins as mediators (see section 3.2.1; Kumar et al., 2011; Mühlenhoff et al., 2010). In 
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cofactor for Fe/S cluster assembly) make these proteins exceptional candidates for the 
integration of the cellular iron and Fe/S cluster status with thiol redox status, and as signal 
transducer regulating iron uptake and utilization (Mühlenhoff et al., 2010; Rodriguez-
Manzaneque et al., 2002; Rouhier et al., 2010; Ye et al., 2010). Another important form of 
“low-molecular mass” iron species are the dinitrosyl iron complexes (DNIC, Bosworth et al., 
2009) formed between LIP and low molecular mass thiols when nitric oxide is present 
(Vanin, 2009). This point is addressed in the next section.  
3. Cellular fates of Iron 
Iron is an important redox or structural cofactor of several indispensable proteins of 
trypanosomes. For instance, DNA synthesis, protein translation, oxidant defense and 
cytochrome respiration are important cellular functions that involve the utilization of this 
metal (Taylor & Kelly, 2010).  
In this section we will review the most relevant iron-related molecules and metabolic 
pathways of bloodstream T. brucei. Whenever possible, the components and mechanisms 
employed by the parasite to incorporate different forms of iron onto target molecules will be 
described. Taking advantage of the recent availability of genome sequencing data for the 
most representative species of Trypanosoma (Berriman et al., 2005; El-Sayed et al., 2005; Ivens 
et al., 2005) and the current knowledge of the iron metabolism in model eukaryotes (Hentze 
et al., 2010), we here provide a state-of-the-art view of iron metabolism in African 
trypanosomes.  
3.1 Dinitrosyl iron complexes 
Parasites circulating in host´s bloodstream or inside the phagolysosome of activated 
macrophages are exposed to reactive oxygen and nitrogen species. In both cases, the second 
messenger nitric oxide (•NO) is produced by endothelial or immune cells, which, if not 
neutralized rapidly, can lead to the formation of the highly reactive oxidant peroxynitrite 
(Girard et al., 2005). The effect of •NO and derivatives was studied in T. brucei (Lu et al., 
2011; Steverding et al., 2009; Vincendeau et al., 1992) and T. cruzi (Piacenza et al., 2007; 
Alvarez et al., 2011  and see papers quoted in Irigoín et al., 2008). A recent work by Bocedi et 
al. (2010) demonstrated the formation in vitro of a DNIC involving the parasite specific 
dithiol T(SH)2. Based on the high intracellular concentration of T(SH)2 the authors proposed 
that formation of this complex may play an important role in trapping •NO and, thus, 
preventing the formation of dangerous oxidants. This work raises the possibility for a new 
potential link between iron and low-molecular mass thiols in trypanosomes. 
3.2 Mononuclear iron proteins  
Mononuclear iron proteins can be classified according to their biological function, by Fe centre 
type, by type and number of prosthetic centres, and by sequence similarity. The iron atom is 
usually coordinated by thiolate groups (deprotonated form of cysteine), or the Nδ atoms of 
histidines or the carboxylate anions of acidic residues present in the polypeptide. In these 
proteins the iron provides redox activity and the surrounding aminoacidic and structural 
environment confer the specificity for different substrates. The characteristics and functions of 
a number of iron-centered proteins from trypanosomatids are addressed below.  
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3.2.1 Energy metabolism: Alternative oxidase 
The bloodstream form of the parasite lacks cytochrome activity yet they “respirate” at high 
rates (Priest & Hajduk, 1994). The molecular entity responsible for this is a plant-like 
mitochondrial ubiquinol oxidase (EC 1.10.3.10), known as trypanosomal alternative oxidase 
(TAO; Clarkson et al., 1989). The enzyme is imported into the mitochondrion of bloodstream 
and procyclic parasites by distinct mechanisms involving external ATP supply and inner 
membrane potential, respectively (Williams et al., 2008). It localizes at the outer membrane 
of the organelle where it transfers electrons from ubiquinol to oxygen without proton 
translocation or ATP generation (Chaudhuri et al., 2006), resulting in the reoxidation of 
NADPH produced during glycolysis. TAO genes have been identified in the genome of all 
the subspecies forming the “brucei” clade but are absent in related trypanosomatids such as 
Leishmania spp. or T. cruzi (Chaudhuri et al., 2006; Nakamura et al., 2010). In agreement with 
its metabolic function (NADP/NAPDH-shunt during carbohydrate catabolism), TAO is 
developmentally regulated (Chaudhuri et al., 2002) achieving ~100 times higher levels in 
bloodstream parasites than in procyclic cells (Tsuda et al., 2005; Tyler et al., 1997). The 
essential role of TAO in the physiology of infective T. brucei was recognized early using the 
iron chelator salicyl hydroxamic acid (2-hydroxybenzhydroxamic acid, SHAM) and glycerol 
to alter the metabolic output (Clarkson & Brohn, 1976; Grant & Sargent, 1960). On the other 
hand, recent studies show that TAO plays an important role in preventing oxidant-induced 
programmed cell death of long-slender bloodstream parasites (Tsuda et al., 2005, 2006). This 
antioxidant function of TAO resembles that proposed for the orthologue enzyme from plants 
(Maxwell et al., 1999). In trypanosomes, apoptosis is a highly regulated process deeply 
associated with the accumulation of quiescent parasite forms (short stumpy) in the preparation 
for transmission to the insect vector (Welburn et al., 2006). It is therefore tempting to speculate 
that, at least in bloodstream trypanosomes, TAO might be an important checkpoint connecting 
metabolic status (NADP+/NAPDH ratio) with programmed cell death and differentiation. In 
procyclic forms, TAO has been shown to compensate for a depletion of complex III or IV 
activities in the mitochondrial electron transfer chain (Horváth et al., 2005). Despite this backup 
role in respiration, the enzyme appears to fulfill a yet unknown but essential function in this 
parasite stage (Tsuda et al., 2005; Tyler et al., 1997).  
Although no structures are available for TAO or any other related alternative oxidase, 
current structural models (Moore & Albury, 2008) and proteomic data (Acestor et al., 2009) 
indicate that it is an interfacial membrane protein that interacts with a single leaflet of the 
lipid bilayer, and contains a non-heme di-iron carboxylate center bounded by two highly 
conserved EXXH motifs (Kido et al., 2010a, 2010b). The iron-dependence of TAO was 
established working in vitro with chelating agents and mutant forms of the protein (Ajayi et 
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Aerobic respiration produce partly reduced oxygen intermediates that leak from several 
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3.2.1 Energy metabolism: Alternative oxidase 
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radical is necessary to prevent formation of the most reactive and harmful radical product, 
hydroxyl radical (OH•), which originates from a physiological reaction involving iron and 
known as Fenton reaction5. To accomplish this, all living organisms contain enzymes 
devoted to the O2•- dismutation, called superoxide dismutases (EC 1.15.1.1). There are three 
major families of SODs, depending on the metal cofactor. Most of the cytosolic eukaryotic 
SODs use a bimetallic active site with copper and zinc (CuZn-SODs) while the mitochondria 
harbor a bacterial-related Mg-dependent SOD. In prokaryotes and plastids most of the SODs 
are Fe-dependent (Abreu & Cabelli, 2010).  
Trypanosomes express four different isoforms of SODs (Dufernez et al., 2006; Kabiri & 
Steverding, 2001; Le Trant et al., 1983; Wilkinson et al., 2006) that, in contrast to homologues 
from prokaryotes and eukaryotes, show a restricted metal dependency all of them being Fe-
dependent enzymes (Wilkinson et al., 2006; Bachega et al., 2009). In T. brucei, SOD-A and 
SOD-C localize at the mitochondrion whereas SOD-B1 and SOD-B2 are mostly 
compartmentalized within the glycosome and less abundantly at the cytosol (Dufernez at 
al., 2006). A similar localization was reported for SOD-B enzymes from L. chagasi (Plewes et 
al., 2003). RNAi-mediated knockdown of SOD-A and SOD-C revealed that under normal 
growth conditions the mitochondrial isoforms are dispensable for bloodstream T. brucei 
(Prathalingham et al., 2007; Wilkinson et al., 2006). However, the biological importance of 
SOD-A was put in evidence when parasites depleted in this isoform showed a higher 
sensitivity towards paraquat, an O2•--generating compound (Wilkinson et al., 2006). 
Consistent with a role in oxidant defense for mitochondrial Fe-SOD, transgenic T. cruzi 
overexpressing a mitochondrial isoform was found to be more resistant to fresh human 
serum, a death stimuli mediated by oxidative stress (Piacenza et al., 2007). In contrast, the 
SOD B-type enzymes are indispensable for infective T. brucei grown under normal culture 
conditions (Wilkinson et al., 2006), which poses the question to the glycosomal source of O2•-
, a charged molecule that does not diffuse through lipid membranes. In this respect, 
unwanted O2•- might leak as byproduct from a variety of metabolic activities occurring in 
this organelle, such as glycolysis, oxidation of fatty acids, lipid biosynthesis, and purine 
salvage (Michels et al., 2006). Further dissection of the functional relevance of SOD-B 
isoforms was achieved by means of targeted gene replacement, which demonstrates that 
SOD-B1 and not SOD-B2 is critical to withstand exposure to nifurtimox and benznidazole 
(Prathalingham et al., 2007), two anti-trypanosomal drugs whose mechanism of action 
involves the generation of reactive oxygen intermediates (Maya et al., 2003 and 2007). Also 
the homologue isoforms present in L. chagasi and L. tropica were earlier reported to be 
important for parasite survival in mouse or human macrophages as well as under paraquat 
insult (Plewes et al., 2003; Ghosh et al., 2003). Interestingly, T. brucei SOD-B1 has been shown 
to be developmentally regulated with higher intracellular concentration in proliferating 
stages (Kabiri & Steverding, 2001). This particular expression pattern led the authors to 
propose that the role of SOD-B1 in dividing cells is to counteract the formation of 
superoxide radicals released during the generation of the iron-tyrosyl free-radical centre in 
the small subunit (R2) of ribonucleotide reductase, other iron-containing enzyme (see next 
section). Unexpectedly, a 5- to 8-fold increase in SOD-B1 activity in transgenic T. cruzi was 
accompanied by a significant sensitization of parasites against two pro-oxidant compounds 
namely gentian violet and benznidazole (Temperton et al., 1998). This striking behavior was 
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interpreted as a consequence of an imbalance in the redox homeostasis of the parasite resulting 
from the overexpression of Fe-SOD, a hypothesis that deserves further investigation.  
In summary, trypanosomal SODs diverged from their human homologues by using iron as 
cofactor. They apparently evolved to protect parasites against toxic O2•- produced in the 
glycosomes and/or mitochondrion as a result of sudden changes in metabolism or 
originated from the different environment they live in (e.g., insect midgut, macrophages, 
epithelium, mammal bloodstream).  
3.2.3 Cell proliferation: Ribonucleotide reductase 
Ribonucleotide reductase (RNR, EC 1.17.4.1-2) catalyses the reduction of ribonucleotides to 
deoxyribonucleotides needed for DNA synthesis. There are three different classes of RNR 
being class I the most abundant in eukaryote organisms. Class I RNR are heterotetrameric 
enzymes formed by the association of two related but not identical polypeptides known as 
subunit R1 and R2. The large R1 subunit binds substrates and allosteric effectors, conferring 
specificity and regulatory potential, while the small R2 subunit contains the catalytic center 
composed of two high spin Fe3+ atoms antiferromagnetically coupled to each other through 
a µ-oxo bridge, a highly conserved tyrosine residue and two cysteines (Cotruvo & Stubbe, 
2011). The di-iron center generates a free radical on this catalytic tyrosine through electron 
donation. In a reaction involving several intermediate states, the tyrosine radical attacks the 
nucleotide resulting in reduction of the 2’-OH group of ribonucleoside and the formation of 
a disulfide. Regeneration of active RNR is finally achieved via reduction of this disulfide 
mainly by thioredoxin (Trx), which is subsequently reduced at expenses of NADPH 
(Cotruvo & Stubbe, 2011).  
The biochemical information about parasite RNR is rather limited. Both subunits of RNR 
from T. brucei were cloned, expressed (Dormeyer et al., 1997; Hofer et al., 1997) and 
kinetically characterized (Hofer el al., 1998). The parasite-specific thioredoxin-like 
oxidoreductase tryparedoxin (TXN, Lüdemann et al., 1998) and, in contrast to all other 
RNR from eukaryotes, also the low-molecular weight dithiol T(SH)2 (Dormeyer et al., 
2001) but less likely glutaredoxins (Ceylan et al., 2010) proved to be physiological 
reductants of recombinant RNR. The activity of the enzyme appears to be post-
transcriptionally regulated by a redox mechanism (Dormeyer et al., 2001) and by the 
selective expression of its catalytic subunit R2. For example, whereas the R1 protein is 
actively expressed throughout the whole life cycle of the parasite, the R2 protein is not 
detected in cell cycle-arrested short stumpy trypanosomes (Breidbach et al., 2000). How 
iron is incorporated into the R2 subunit is yet elusive (Cotruvo & Stubbe, 2011). Recent 
findings suggest that, at least in yeast, the di-iron non-heme incorporation into apo-
proteins is tightly related to the Fe/S cluster biogenesis machinery both from the cytosol 
and mitochondria (see section 3.3) (Cotruvo & Stubbe, 2011; Mühlenhoff et al., 2010) and 
in particular to the cytosolic monothiol glutaredoxins (Grx3/4), discussed later in this 
review (see section 3.3.2). In trypanosomes, the only link between iron and RNR came 
from experiments in which parasites treated with the iron chelator deferoxamine (DFX) 
show an extremely reduced [3H]-timidine incorporation, pointing to an essential role of 
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3.2.4 Lipid biosynthesis: Stearoyl-CoA desaturase 
Stearoyl-CoA desaturases (SCD) from eukaryotes are di-iron containing proteins responsible 
for the de novo synthesis of monounsaturated fatty acids from saturated fatty acids. The iron 
is usually coordinated by 8 histidine residues that form the active site (Man et al., 2006). 
They are integral membrane proteins anchored in the endoplasmic reticulum. Recent genetic 
and chemical validation of the orthologue enzyme from T. brucei demonstrated its 
indispensability for in vivo survival of bloodstream forms, as well as for the procyclic stage 
(Alloati et al., 2010, 2011). 
3.3 Iron-sulfur cluster proteins6 
The name iron-sulfur proteins refer to a broad group of proteins. A class of them contains 
mononuclear Fe centers coordinated directly by cysteine residues (e. g., rubredoxins and 
related proteins). A second class ligates a complex between iron and inorganic sulfur 
through side-chain atoms provided mainly by the aminoacid cysteine, or eventually 
histidine or aspartate. These centers are known as Fe/S clusters (Lill & Mühlenhoff, 2008). 
Fe/S centers are ubiquitous inorganic cofactors present in all forms of life and are probably 
the most ancient cofactors and catalysts in the prebiotic world. Among them, the [2Fe-2S] is 
the simplest and most common cluster found in vivo, whereas Fe/S clusters of higher 
complexity require further “maturation” (Lill & Mühlenhoff, 2008; Lill, 2009; Py & Barras, 
2010). In eukaryotes, the list of Fe/S dependent proteins has nearly one hundred members 
(Rouault & Tong, 2005; Ye & Rouault, 2010). In general, this cofactor enables electron 
transfer reactions due to the propensity of the iron atoms to switch between reduced (Fe2+) 
and oxidized (Fe3+) states. In addition, the redox potential of the cluster can be finely tuned 
by the protein environment covering a wide range of potentials, from very reducing (~-500 
mV) to highly oxidizing (~+300 mV) (Lill, 2009; Xu & Møller, 2011). In consequence, Fe/S 
clusters are essential components of the most important biological electron transport chains, 
i.e. photosynthesis and mitochondrial respiration. But the role Fe/S clusters can play in 
proteins goes far beyond their redox properties. For instance, they act as important 
structural or regulatory moieties of some proteins from the DNA metabolism and as 
cofactors in enzymes of the amino acid biosynthesis or Krebs cycle (Lill & Mühlenhoff, 2006; 
Lill, 2009; Netz et al., 2010; Py & Barras, 2010; Ye & Rouault, 2010a, 2010b). 
3.3.1 Biogenesis of iron-sulfur clusters and proteins 
Despite the chemical simplicity of these cofactors, their biosynthesis and insertion into 
apoproteins within the cell requires devoted machineries that are are highly conserved from 
bacteria to humans (Lill & Mühlenhoff, 2006, 2008; Xu & Møller, 2011). In bacteria, there are 
three different systems for the biogenesis of Fe/S proteins, all encoded in specific operons 
and tightly regulated. The “nitrogen fixation” (NIF) system was the first Fe/S cluster 
biogenesis mechanism described and is exclusively dedicated to the maturation of 
nitrogenase enzymes from certain bacterias. On the contrary, the “iron-sulfur cluster” (ISC) 
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of the original contributions. 
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and “sulfur utilization factor” (SUF) systems are widely distributed among bacteria and are 
responsible for the biosynthesis of Fe/S proteins in basal and stressed conditions, 
respectively (Xu & Møller, 2011). The mitochondria and plastids of eukaryotes have 
inherited the ISC and SUF systems, respectively, from ancient symbionts (Balk & Lobréaux, 
2005; Balk & Pilon, 2011; Xu & Møller, 2011). Additionally, maturation of Fe/S cluster 
proteins in eukaryotes can be accomplished in the cytosol by a specific set of proteins that 
constitute the cytosolic iron sulfur cluster assembly (CIA) machinery. In this section we will 
summarize the most relevant aspects of the mitochondrial machinery related to the bacterial 
ISC system, and will introduce the limited information available for the CIA system. Most of 
the reports published stem from studies with the budding yeast Saccharomyces cerevisiae, and 
we will refer to them before describing what is known for Fe/S protein biogenesis in 
trypanosomes (Section 3.3.2).  
The building blocks for the biosynthesis of Fe/S clusters are: iron atoms (in the reduced 
form, Fe2+), sulfide (S2-), reducing power and proteins, which act as scaffolds to assemble the 
Fe/S cluster that is being formed (Py & Barras, 2010; Lill & Mühlenhoff, 2006). Sulfide is 
generated from cysteine by the pyridoxal-5-phosphate-dependent cysteine desulfurase 
(eukaryotic Nfs1 or the bacterial NifS, IscS and SufS). This reaction produces alanine and 
leaves a protein-bound cysteine persulfide intermediate, which is presumably reduced by 
the ferredoxin system (NADPH-dependent ferredoxin reductase and ferredoxin) leading to 
release of S2-. Ferredoxin is a Fe/S protein that in mammals is also known as adrenodoxin, 
an essential component of the thyroid hormone production. Recent studies identified an 
accessory protein, Isd11, that is essential for in vivo Fe/S biogenesis in eukaryotes (Adam et 
al., 2006; Shi et al., 2009; Wiedemann et al., 2006). Isd11 forms a tight complex with Nfs1 that 
renders the cysteine desulfurase active (Xu & Møller, 2011). The iron-carrying protein Yfh1, 
known in humans as frataxin or CyaY in bacteria, participates in the delivery of iron for 
Fe/S cluster biosynthesis but whether this protein is or not the direct iron-carrier is still a 
matter of debate. Frataxin dysfunction is responsible for the most common form of inherited 
ataxia in humans, namely “Friederich ataxia” (Py & Barras, 2010; Lill & Mühlenhoff., 2006, 
2008; Stemmler et al. 2010). The next step involves the transient assembly of the newly 
synthesized Fe/S cluster into “scaffold” proteins. These macromolecules are ubiquitous to 
most living organisms and contain conserved cysteine residues that bind Fe/S clusters in a 
labile manner, allowing the complex to be readily transferred to target proteins. The most 
conserved ones are the U-type scaffold proteins (e.g., bacterial IscU and SufU and eukaryotic 
Isu1), and other include the bacterial NifU, plastid NFU and the A-type scaffolds (e.g., IscA 
and SufA; Lill, 2009; Xu & Møller, 2011), which are supposed to work downstream the U-
type ones or to subrogate their function in specific situations (e.g., heme biosynthesis in 
mammals; Ye & Rouault, 2010b). Whereas the mitochondrial ISC system has more than 15 
proteins identified (Lill & Mühlenhoff, 2008), Nfs1-Ids11, Isu1/Isu2 and Yfh1 are the core 
elements for Fe/S cluster biogenesis in eukaryotic mitochondria (Fig 2; Lill & Mühlenhoff, 
2006).  
The transference of the Fe/S cluster to the target apoprotein is assisted by a set of proteins 
and consumes energy (Amutha et al., 2008; Subramanian et al., 2011). The minimal 
components are: a dedicated chaperone from the HSP70 family termed Ssq1, the DnaJ-like 
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histidine or aspartate. These centers are known as Fe/S clusters (Lill & Mühlenhoff, 2008). 
Fe/S centers are ubiquitous inorganic cofactors present in all forms of life and are probably 
the most ancient cofactors and catalysts in the prebiotic world. Among them, the [2Fe-2S] is 
the simplest and most common cluster found in vivo, whereas Fe/S clusters of higher 
complexity require further “maturation” (Lill & Mühlenhoff, 2008; Lill, 2009; Py & Barras, 
2010). In eukaryotes, the list of Fe/S dependent proteins has nearly one hundred members 
(Rouault & Tong, 2005; Ye & Rouault, 2010). In general, this cofactor enables electron 
transfer reactions due to the propensity of the iron atoms to switch between reduced (Fe2+) 
and oxidized (Fe3+) states. In addition, the redox potential of the cluster can be finely tuned 
by the protein environment covering a wide range of potentials, from very reducing (~-500 
mV) to highly oxidizing (~+300 mV) (Lill, 2009; Xu & Møller, 2011). In consequence, Fe/S 
clusters are essential components of the most important biological electron transport chains, 
i.e. photosynthesis and mitochondrial respiration. But the role Fe/S clusters can play in 
proteins goes far beyond their redox properties. For instance, they act as important 
structural or regulatory moieties of some proteins from the DNA metabolism and as 
cofactors in enzymes of the amino acid biosynthesis or Krebs cycle (Lill & Mühlenhoff, 2006; 
Lill, 2009; Netz et al., 2010; Py & Barras, 2010; Ye & Rouault, 2010a, 2010b). 
3.3.1 Biogenesis of iron-sulfur clusters and proteins 
Despite the chemical simplicity of these cofactors, their biosynthesis and insertion into 
apoproteins within the cell requires devoted machineries that are are highly conserved from 
bacteria to humans (Lill & Mühlenhoff, 2006, 2008; Xu & Møller, 2011). In bacteria, there are 
three different systems for the biogenesis of Fe/S proteins, all encoded in specific operons 
and tightly regulated. The “nitrogen fixation” (NIF) system was the first Fe/S cluster 
biogenesis mechanism described and is exclusively dedicated to the maturation of 
nitrogenase enzymes from certain bacterias. On the contrary, the “iron-sulfur cluster” (ISC) 
                                                                 
6 Due to the high amount of literature on this topic, this section contains mainly quotations to the most 
recent reviews, facilitating further reading for interested lectors. We therefore apologize to the authors 
of the original contributions. 
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and “sulfur utilization factor” (SUF) systems are widely distributed among bacteria and are 
responsible for the biosynthesis of Fe/S proteins in basal and stressed conditions, 
respectively (Xu & Møller, 2011). The mitochondria and plastids of eukaryotes have 
inherited the ISC and SUF systems, respectively, from ancient symbionts (Balk & Lobréaux, 
2005; Balk & Pilon, 2011; Xu & Møller, 2011). Additionally, maturation of Fe/S cluster 
proteins in eukaryotes can be accomplished in the cytosol by a specific set of proteins that 
constitute the cytosolic iron sulfur cluster assembly (CIA) machinery. In this section we will 
summarize the most relevant aspects of the mitochondrial machinery related to the bacterial 
ISC system, and will introduce the limited information available for the CIA system. Most of 
the reports published stem from studies with the budding yeast Saccharomyces cerevisiae, and 
we will refer to them before describing what is known for Fe/S protein biogenesis in 
trypanosomes (Section 3.3.2).  
The building blocks for the biosynthesis of Fe/S clusters are: iron atoms (in the reduced 
form, Fe2+), sulfide (S2-), reducing power and proteins, which act as scaffolds to assemble the 
Fe/S cluster that is being formed (Py & Barras, 2010; Lill & Mühlenhoff, 2006). Sulfide is 
generated from cysteine by the pyridoxal-5-phosphate-dependent cysteine desulfurase 
(eukaryotic Nfs1 or the bacterial NifS, IscS and SufS). This reaction produces alanine and 
leaves a protein-bound cysteine persulfide intermediate, which is presumably reduced by 
the ferredoxin system (NADPH-dependent ferredoxin reductase and ferredoxin) leading to 
release of S2-. Ferredoxin is a Fe/S protein that in mammals is also known as adrenodoxin, 
an essential component of the thyroid hormone production. Recent studies identified an 
accessory protein, Isd11, that is essential for in vivo Fe/S biogenesis in eukaryotes (Adam et 
al., 2006; Shi et al., 2009; Wiedemann et al., 2006). Isd11 forms a tight complex with Nfs1 that 
renders the cysteine desulfurase active (Xu & Møller, 2011). The iron-carrying protein Yfh1, 
known in humans as frataxin or CyaY in bacteria, participates in the delivery of iron for 
Fe/S cluster biosynthesis but whether this protein is or not the direct iron-carrier is still a 
matter of debate. Frataxin dysfunction is responsible for the most common form of inherited 
ataxia in humans, namely “Friederich ataxia” (Py & Barras, 2010; Lill & Mühlenhoff., 2006, 
2008; Stemmler et al. 2010). The next step involves the transient assembly of the newly 
synthesized Fe/S cluster into “scaffold” proteins. These macromolecules are ubiquitous to 
most living organisms and contain conserved cysteine residues that bind Fe/S clusters in a 
labile manner, allowing the complex to be readily transferred to target proteins. The most 
conserved ones are the U-type scaffold proteins (e.g., bacterial IscU and SufU and eukaryotic 
Isu1), and other include the bacterial NifU, plastid NFU and the A-type scaffolds (e.g., IscA 
and SufA; Lill, 2009; Xu & Møller, 2011), which are supposed to work downstream the U-
type ones or to subrogate their function in specific situations (e.g., heme biosynthesis in 
mammals; Ye & Rouault, 2010b). Whereas the mitochondrial ISC system has more than 15 
proteins identified (Lill & Mühlenhoff, 2008), Nfs1-Ids11, Isu1/Isu2 and Yfh1 are the core 
elements for Fe/S cluster biogenesis in eukaryotic mitochondria (Fig 2; Lill & Mühlenhoff, 
2006).  
The transference of the Fe/S cluster to the target apoprotein is assisted by a set of proteins 
and consumes energy (Amutha et al., 2008; Subramanian et al., 2011). The minimal 
components are: a dedicated chaperone from the HSP70 family termed Ssq1, the DnaJ-like 





glutaredoxin (Grx5 in humans and yeast; Fig. 2). The requirement for a glutaredoxin-like 
protein, formerly considered an oxidoreductase (Lillig et al., 2008; Rouhier et al., 2010), in 
Fe/S cluster biogenesis was initially suggested by studies in a yeast Grx5 deletion mutant. 
These cells displayed deficient cluster assembly for at least two Fe/S proteins (aconitase and 
succinate dehydrogenase), leading to impaired respiratory growth and increased sensitivity 
to oxidative stress with accumulation of free iron in the cell (Rodríguez-Manzaneque et al., 
1999 and 2002). Although the precise function of monothiol glutarredoxins within the iron 
metabolism remain to be established, they are critical components of the ISC biosynthetic 
pathway in distantly related organisms such as bacteria (Fernandes et al., 2005), protists 
(Comini et al., 2008) and vertebrates (Xu & Møller, 2011; Ye et al., 2010; Ye & Rouault, 2010b).  
The CIA machinery was first discovered in yeast when seeking for cytosolic proteins 
essential for Fe/S cluster assembly on aconitase (Fig. 2). Nowadays, several components are 
recognized: i) two P-loop NTPases (Cfd1 and Nbp35) that form a stable heterotetrameric 
complex with a [4Fe-4S] cluster bound to the C-terminal region, suggesting a scaffold role 
for cluster assembly; ii) Nar1, a Fe/S-dependent protein related to bacterial iron-containing 
hydrogenases, iii) WD40 β-propeller protein Cia1, which preferentially localizes in the 
nucleus and assists cluster delivery to Nbp35 (Lill & Mühlenhoff, 2008; Sharma et al., 2010; 
Xu & Møller, 2011), and iv) redox components of the CIA machinery (Tah18, Dre2 and 
monothiol glutaredoxins 3 and 4). In yeast, intracellular iron level is sensed by the 
transcription factor Aft1 and requires the regulatory proteins Fra1-Fra2 that interact with the 
cytosolic-nuclear monothiol glutaredoxins Grx3 or Grx4 through the formation of 
heterodimers linked by a Fe/S cluster (Kumánovics et al., 2008; Mühlenhoff et al., 2010; 
Pujol-Carrion et al., 2006). Interestingly, besides the existence of specific and 
compartmentalized machineries, Fe/S cluster biogenesis in the cytosol has been confirmed 
to depend on the mitochondrial system. A still unknown essential compound (noted as “X” 
in Fig. 2) is exported from mitochondria via the inner mitochondrial membrane ATP-
binding cassette (ABC) transporter Atm1 and the intermembrane space protein Erv1, in a 
process that requires GSH (Netz et al., 2010; Sharma et al., 2010; Xu & Møller, 2011). As 
pointed by Ye and Rouault (2010a, 2010b) the next frontier in Fe/S cluster biogenesis will 
consist in unraveling how the monothiol glutaredoxin 5 and ABCB7 transporter are 
involved in the mitochondrial synthesis and export to the cytosol/nucleus of a still 
unknown factor that connects these processes in both compartments. Moreover, it remains 
to be studied how the system operates as a whole (Mühlenhoff et al., 2010; Netz et al., 2010; 
Zhang et al., 2008).  
3.3.2 Biogenesis of iron-sulfur clusters in trypanosomes 
The characterization of the Fe/S biogenesis in trypanosomes was driven by the completion 
of the genome sequencing of three trypanosomatid species (Berriman et al., 2005; El Sayed et 
al., 2005; Ivens et al., 2005). As noted previously, the mitochondrion is a key organelle in 
Fe/S cluster biosynthesis that undergoes important metabolic and morphological changes in 
trypanosomatids, especially in African trypanosomes, during life cycle. For instance, several 
mitochondrial respiratory-chain proteins that depend on these cofactors are 
developmentally synthesized in insect stage parasites (Alfonzo & Lukeš, 2011; Tyler et al, 
1997). Based on sequence comparison with identified Fe/S cluster biogenesis proteins from 
yeast, plants and humans, a number of members of the ISC system are conserved in 
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trypanosomatids (see Fig. 2). Smíd et al. (2006) characterized two major components of this 
machinery present in T. brucei: a cysteine desulfurase (TbIscS2, related to Nfs1) and one U-
type scaffold protein (TbIscU, related to Isu1). Both proteins proved to be essential for the 
mitochondrial biogenesis of Fe/S proteins (Smíd et al., 2006). In agreement with phenotypes 
observed in yeast mutants, down-regulation of TbIscS2 in procyclic parasites by RNAi 
results in inhibition of Fe/S cluster dependent processes both in the mitochondrion and 
cytosol, with a concomitant impairment in ATP production, cellular respiration and growth 
(Smíd et al., 2006; Paris et al., 2009). The occurrence of this protein in the rudimentary 
mitochondrion of bloodstream parasites was still not addressed but appears reasonable 
considering that this stage relies on important Fe/S protein activities (Comini et al., 2008). 
As mentioned above, a stable tricomponent system between Nfs1, Isd11 and IscU have to be 
formed to enable the formation of Fe/S cluster on IscU. An Isd11 homologue is actively 
expressed by both life stages of T. brucei and, as expected, is critical for cytosolic and 
mitochondrial Fe/S cluster biosynthesis in trypanosomes (Paris et al., 2010). A second Nfs-
like gene was identified in T. brucei (Smíd et al., 2006) and characterized as a selenocysteine 
lyase (SLC; Poliak et al., 2010), an enzyme that cleaves selenocysteine into alanine and 
selenium during selenoprotein metabolization. Supporting the experimental evidences on 
the dispensability of the selenoproteome for this parasite (Aeby et al, 2009), down-regulation 
of SLC is not detrimental for T. brucei, at least under cultivation (Poliak et al., 2010). A single-
copy gene with a significant sequence similarity to eukaryotic frataxin was identified in T. 
brucei genome (TbFXN; Long et al., 2008b). Abrogation of frataxin function in the 
mitochondrion of procyclic cells induces a growth-retardation phenotype with a marked 
inhibition of Fe/S-dependent processes, e.g., aconitase activity (Long et al., 2008a, 2008b). 
Interestingly, TbFXN was also identified in the bloodstream form of the parasite but its 
biological relevance was not addressed (Long et al., 2008b). Works with the fission yeast 
indicate that thiolation of tRNA depends on components from the mitochondrial and 
cytosolic ISC systems (Lill & Mühlenhoff, 2006, 2008). A similar link between both pathways 
has recently been disclosed for trypanosomes (Alfonzo & Lukeš, 2011; Bruske et al., 2009). 
More recently, two A-type scaffold proteins from T. brucei were characterized and their 
function rated as essential for the growth and Fe/S cluster metabolism of procyclic but not 
of bloodstream parasites (Long et al., 2011), suggesting specificity for Fe/S protein acceptors 
that are developmentally regulated. The final step in mitochondrial Fe/S cluster biogenesis 
consists in the delivery of the cluster to acceptor proteins, in an ATP-depedent process 
assisted by mitochondrial HSP70 and monothiol glutaredoxins, interestingly, the last being 
Fe/S proteins (Comini et al., 2008; Manta et al., unpublished). Three sequences for putative 
monothiol glutaredoxins, named 1-C-Grx1 to 3, are present in the genome of different 
trypanosomatids (Berriman et al., 2005; El Sayed et al., 2005; Ivens et al., 2005). The proteins 
from T. b. brucei are the best studied so far. 1-C-Grx1 and 1-C-Grx2 localizes at the parasite 
mitochondrion (Filser et al., 2007; Comini et al., 2008; Manta et al. unpublished), whereas 1-C-
Grx3, a hybrid protein containing an N-terminal Trx domain, is probably cytosolic. 1-C-Grx1 
and 1-C-Grx3, but not 1-C-Grx2, are abundant proteins in bloodstream parasites and reach 
maximum levels in stationary phase cultures (Comini et al., 2008). Strikingly, targeting these 
proteins to the mitochondria of S. cerevisiae defective in Grx5 did not rescue the mutant 
phenotype, suggesting the existence of structural or biochemical differences between the 
trypanosomal and eukaryote/prokaryotes orthologues (Filser et al., 2007). Indeed, in vitro all 
three proteins are capable to coordinate an Fe/S cluster at expenses of a protein thiol and 





glutaredoxin (Grx5 in humans and yeast; Fig. 2). The requirement for a glutaredoxin-like 
protein, formerly considered an oxidoreductase (Lillig et al., 2008; Rouhier et al., 2010), in 
Fe/S cluster biogenesis was initially suggested by studies in a yeast Grx5 deletion mutant. 
These cells displayed deficient cluster assembly for at least two Fe/S proteins (aconitase and 
succinate dehydrogenase), leading to impaired respiratory growth and increased sensitivity 
to oxidative stress with accumulation of free iron in the cell (Rodríguez-Manzaneque et al., 
1999 and 2002). Although the precise function of monothiol glutarredoxins within the iron 
metabolism remain to be established, they are critical components of the ISC biosynthetic 
pathway in distantly related organisms such as bacteria (Fernandes et al., 2005), protists 
(Comini et al., 2008) and vertebrates (Xu & Møller, 2011; Ye et al., 2010; Ye & Rouault, 2010b).  
The CIA machinery was first discovered in yeast when seeking for cytosolic proteins 
essential for Fe/S cluster assembly on aconitase (Fig. 2). Nowadays, several components are 
recognized: i) two P-loop NTPases (Cfd1 and Nbp35) that form a stable heterotetrameric 
complex with a [4Fe-4S] cluster bound to the C-terminal region, suggesting a scaffold role 
for cluster assembly; ii) Nar1, a Fe/S-dependent protein related to bacterial iron-containing 
hydrogenases, iii) WD40 β-propeller protein Cia1, which preferentially localizes in the 
nucleus and assists cluster delivery to Nbp35 (Lill & Mühlenhoff, 2008; Sharma et al., 2010; 
Xu & Møller, 2011), and iv) redox components of the CIA machinery (Tah18, Dre2 and 
monothiol glutaredoxins 3 and 4). In yeast, intracellular iron level is sensed by the 
transcription factor Aft1 and requires the regulatory proteins Fra1-Fra2 that interact with the 
cytosolic-nuclear monothiol glutaredoxins Grx3 or Grx4 through the formation of 
heterodimers linked by a Fe/S cluster (Kumánovics et al., 2008; Mühlenhoff et al., 2010; 
Pujol-Carrion et al., 2006). Interestingly, besides the existence of specific and 
compartmentalized machineries, Fe/S cluster biogenesis in the cytosol has been confirmed 
to depend on the mitochondrial system. A still unknown essential compound (noted as “X” 
in Fig. 2) is exported from mitochondria via the inner mitochondrial membrane ATP-
binding cassette (ABC) transporter Atm1 and the intermembrane space protein Erv1, in a 
process that requires GSH (Netz et al., 2010; Sharma et al., 2010; Xu & Møller, 2011). As 
pointed by Ye and Rouault (2010a, 2010b) the next frontier in Fe/S cluster biogenesis will 
consist in unraveling how the monothiol glutaredoxin 5 and ABCB7 transporter are 
involved in the mitochondrial synthesis and export to the cytosol/nucleus of a still 
unknown factor that connects these processes in both compartments. Moreover, it remains 
to be studied how the system operates as a whole (Mühlenhoff et al., 2010; Netz et al., 2010; 
Zhang et al., 2008).  
3.3.2 Biogenesis of iron-sulfur clusters in trypanosomes 
The characterization of the Fe/S biogenesis in trypanosomes was driven by the completion 
of the genome sequencing of three trypanosomatid species (Berriman et al., 2005; El Sayed et 
al., 2005; Ivens et al., 2005). As noted previously, the mitochondrion is a key organelle in 
Fe/S cluster biosynthesis that undergoes important metabolic and morphological changes in 
trypanosomatids, especially in African trypanosomes, during life cycle. For instance, several 
mitochondrial respiratory-chain proteins that depend on these cofactors are 
developmentally synthesized in insect stage parasites (Alfonzo & Lukeš, 2011; Tyler et al, 
1997). Based on sequence comparison with identified Fe/S cluster biogenesis proteins from 
yeast, plants and humans, a number of members of the ISC system are conserved in 
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trypanosomatids (see Fig. 2). Smíd et al. (2006) characterized two major components of this 
machinery present in T. brucei: a cysteine desulfurase (TbIscS2, related to Nfs1) and one U-
type scaffold protein (TbIscU, related to Isu1). Both proteins proved to be essential for the 
mitochondrial biogenesis of Fe/S proteins (Smíd et al., 2006). In agreement with phenotypes 
observed in yeast mutants, down-regulation of TbIscS2 in procyclic parasites by RNAi 
results in inhibition of Fe/S cluster dependent processes both in the mitochondrion and 
cytosol, with a concomitant impairment in ATP production, cellular respiration and growth 
(Smíd et al., 2006; Paris et al., 2009). The occurrence of this protein in the rudimentary 
mitochondrion of bloodstream parasites was still not addressed but appears reasonable 
considering that this stage relies on important Fe/S protein activities (Comini et al., 2008). 
As mentioned above, a stable tricomponent system between Nfs1, Isd11 and IscU have to be 
formed to enable the formation of Fe/S cluster on IscU. An Isd11 homologue is actively 
expressed by both life stages of T. brucei and, as expected, is critical for cytosolic and 
mitochondrial Fe/S cluster biosynthesis in trypanosomes (Paris et al., 2010). A second Nfs-
like gene was identified in T. brucei (Smíd et al., 2006) and characterized as a selenocysteine 
lyase (SLC; Poliak et al., 2010), an enzyme that cleaves selenocysteine into alanine and 
selenium during selenoprotein metabolization. Supporting the experimental evidences on 
the dispensability of the selenoproteome for this parasite (Aeby et al, 2009), down-regulation 
of SLC is not detrimental for T. brucei, at least under cultivation (Poliak et al., 2010). A single-
copy gene with a significant sequence similarity to eukaryotic frataxin was identified in T. 
brucei genome (TbFXN; Long et al., 2008b). Abrogation of frataxin function in the 
mitochondrion of procyclic cells induces a growth-retardation phenotype with a marked 
inhibition of Fe/S-dependent processes, e.g., aconitase activity (Long et al., 2008a, 2008b). 
Interestingly, TbFXN was also identified in the bloodstream form of the parasite but its 
biological relevance was not addressed (Long et al., 2008b). Works with the fission yeast 
indicate that thiolation of tRNA depends on components from the mitochondrial and 
cytosolic ISC systems (Lill & Mühlenhoff, 2006, 2008). A similar link between both pathways 
has recently been disclosed for trypanosomes (Alfonzo & Lukeš, 2011; Bruske et al., 2009). 
More recently, two A-type scaffold proteins from T. brucei were characterized and their 
function rated as essential for the growth and Fe/S cluster metabolism of procyclic but not 
of bloodstream parasites (Long et al., 2011), suggesting specificity for Fe/S protein acceptors 
that are developmentally regulated. The final step in mitochondrial Fe/S cluster biogenesis 
consists in the delivery of the cluster to acceptor proteins, in an ATP-depedent process 
assisted by mitochondrial HSP70 and monothiol glutaredoxins, interestingly, the last being 
Fe/S proteins (Comini et al., 2008; Manta et al., unpublished). Three sequences for putative 
monothiol glutaredoxins, named 1-C-Grx1 to 3, are present in the genome of different 
trypanosomatids (Berriman et al., 2005; El Sayed et al., 2005; Ivens et al., 2005). The proteins 
from T. b. brucei are the best studied so far. 1-C-Grx1 and 1-C-Grx2 localizes at the parasite 
mitochondrion (Filser et al., 2007; Comini et al., 2008; Manta et al. unpublished), whereas 1-C-
Grx3, a hybrid protein containing an N-terminal Trx domain, is probably cytosolic. 1-C-Grx1 
and 1-C-Grx3, but not 1-C-Grx2, are abundant proteins in bloodstream parasites and reach 
maximum levels in stationary phase cultures (Comini et al., 2008). Strikingly, targeting these 
proteins to the mitochondria of S. cerevisiae defective in Grx5 did not rescue the mutant 
phenotype, suggesting the existence of structural or biochemical differences between the 
trypanosomal and eukaryote/prokaryotes orthologues (Filser et al., 2007). Indeed, in vitro all 
three proteins are capable to coordinate an Fe/S cluster at expenses of a protein thiol and 





monoglutathionilspermidine (Comini et al., 2008; Manta et al. unpublished). We observed a 
similar behavior for T. cruzi 1-C-Grx1 (Fleitas et al., unpublished). 1-C-Grx1 is indispensable 
for infective T. brucei with an important function in parasite iron homeostasis and no role in 
protection against oxidants (Comini et al., 2008; Manta et al., unpublished), as previously 
proposed for yeast Grx5 (Rodriguez-Manzaneque et al., 1999). Overexpression of a 
functional apo-mutant of 1-C-Grx1 impairs parasite survival inside an animal host (Manta et 
al., unpublished). Also overexpression of a wildtype form of 1-C-Grx1 was detrimental for 
parasite survival either in vitro (under iron deprivation or oxidative stress conditions) and in 
vivo (mice), indicating that iron homeostasis in African trypanosomes is tightly controlled 
with this protein playing an important role. Altogether, this provides the first evidence for a 
critical physiological role of iron and Fe/S cluster metabolism for T. brucei survival during 
infection. The information concerning Fe/S cluster biogenesis in the cytosol of 
trypanosomes is very scarce. So far, only a putative orthologue of ABCB7 was identified in 
T. brucei genome (Sauvage et al., 2009) and, as outlined above, the occurrence of a putative 
cytosolic monothiol glutaredoxin orthologue of yeast Grx3/Grx4 was described (Smíd et al., 
2006; Filser et al., 2007; Comini et al., 2008). Further investigations are required to establish 
whether trypanosomal 1-C-Grx3 shares a regulatory function on iron- and iron-sulfur-
homeostasis as their yeast counterparts.  
As noted by Long et al. (2011), following the identification of several components of the ISC 
system in T. brucei and owing to the high degree of evolutionary conservation for this 
important pathway it is reasonable to assume a similar complexity for the Fe/S cluster 
assembly machinery in this unicellular eukaryote with respect to that of yeast or even 
human. Nevertheless, certain structural or biochemical specialization in some of it molecular 
components may be envisaged (Filser et al., 2007; Comini et al., 2008; Manta et al., 
unpublished). The regulation of Fe/S biogenesis in trypanosomes is equally unexplored yet. 
Considering the Fe/S metabolic repertoire of each developmental stage of the parasite, it 
makes sense to consider multiple and inter-dependent mechanisms controlling substrate 
supply, Fe/S-biosynthesis and turnover, all important issues that await elucidation. Another 
challenging question raised by Smíd et al. (2006) deals with the identification of the factor(s) 
triggering Fe/S-cluster and -protein synthesis during differentiation. 
3.3.3 Examples of iron-sulfur proteins in trypanosomes 
3.3.3.1 Aconitase 
The enzyme aconitase (EC 4.2.1.3) is an essential component of the mitochondrial 
tricarboxylic acid cycle that catalyzes the reversible conversion of citrate to isocitrate 
through the intermediary formation of the tricarboxylic acid cis-aconitate. Aconitase 
contains an [2Fe-2S] center that acts both in substrate binding and catalytic addition or 
removal of H2O, but not in electron transfer reactions. In addition to this enzymatic activity, 
cytosolic isoforms of apo-aconitase participate in regulation of cellular iron homeostasis, 
therefore, receiving also the name of iron-regulatory proteins (IRP). In its apo-form (non-
cluster bound) aconitase undergoes a conformational change that confers the protein with 
affinity to bind the 3’- or 5’- untranslated regions, known as IRE (iron-response elements), 
present in the mRNA encoding for several proteins related to iron uptake and 
metabolization. Under iron starvation the ratio apo:holo aconitase increases and, hence, IRP 
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activation takes over the post-translational response that triggers iron mobilization, uptake 
and utilization (Hentze et al., 2010).  
As mentioned previously, the bloodstream form of T. brucei possess a rudimentary 
mitochondrion with most enzymes from the Krebs cycle repressed (Saas et al., 2000). In this 
parasite, aconitase is encoded by a single gene whose sequence resembles that of the 
cytosolic isoform of mammalian aconitase (Fast et al., 1999; Saas et al., 2000). The protein 
localizes within both the cytosol and mitochondrion (Saas et al., 2000). While the mRNA 
abundance is almost unaffected during development, the protein content increases several 
times during transformation from dividing to arrested bloodstream form (Overath et al., 
1986), in concordance with the morphological and biochemical events that occur in the 
preparation of the parasite to differentiate to the insect stage (Saas et al., 2000). The protein is 
not essential for infective or procyclic parasites (van Weelden et al., 2003) neither involved in 
the regulation of the transferrin receptor (Fast et al., 1999), as occurs in mammals. Moreover, 
genome survey indicated the absence of sequences with homology to IREs in trypanosomes 
(Berriman et al., 2005; Ivens et al., 2005; El-Sayed et al., 2005), which in principle agrees with 
the low aconitase activity detected in bloodstream parasites and its dispensability for 
procyclic forms. The discovery that insect stage T. brucei does not rely on Krebs cycle for 
pyruvate metabolisation has set a new metabolic paradigm for this parasite species. Despite 
T. brucei aconitase has never been shown in vitro to be a Fe/S-dependent protein, its high 
sequence conservation (Saas et al., 2000) and several biological data supports its Fe/S nature. 
For instance, knockdown of IscS, IscU (Smíd et al., 2006) and Isd11 (Paris et al., 2010) was 
followed by down-regulation of aconitase activity both in the mitochondria and cystosol. 
The final answer for the physiological (in)dispensability of aconitase in infective parasites 
will have to await experiments in animal infection models.  
3.3.3.2 Fumarate hydratases  
Fumarases, also called fumarate hydratases (FHs, E.C. 4.2.1.2), are ubiquitous enzymes that 
catalyze the stereospecific reversible hydration of fumarate to malate. Most prokaryotes and 
eukaryotes express two isoforms of fumarases. In eukaryotes, the mitochondrial isoform is a 
component of the tricarboxylic acid cycle and, hence, central to aerobic respiration. The 
cytosolic isoform is probably involved in the metabolism of fumarate that stem from a 
number of reactions occurring in the cytosol. Two distinct classes of fumarases, class I and 
class II, have been identified so far. The proteins lack sequence homology but are 
functionally related. Class II fumarases (or fumC enzymes) are iron-independent enzymes. 
They occur in several bacteria and in eukaryotes, such as fungi, mammals, and higher 
plants. In contrast, class I fumarases are Fe/S-containing enzymes. Bacteria but also 
unicellular eukaryotes contain class I fumarases. The characterization of two class I 
fumarases in T. brucei revealed that two single copy genes code for mitochondrial and 
cytosolic isoforms that are expressed in procyclic but not in bloodstream parasites (Coustou 
et al., 2006). Simultaneous downregulation of both transcripts was deleterious for the 
viability of procyclic trypanosomes, a phenotype that was counteracted by the addition of 
extracellular fumarate, highlighting the essential and stage-specific role of this metabolite 
(Coustou et al., 2006). Taking into account that secretion of succinate has been described for 





monoglutathionilspermidine (Comini et al., 2008; Manta et al. unpublished). We observed a 
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activation takes over the post-translational response that triggers iron mobilization, uptake 
and utilization (Hentze et al., 2010).  
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(Cazzulo, 1992), the authors proposed the occurrence of FHs in these trypanosomatids. 
Nevertheless, if any, their biochemical importance awaits elucidation. 
4. Heme uptake and utilization  
Heme is an essential cofactor for various proteins. It can perform diverse functions such as 
oxygen transport and storage (hemoglobin and myoglobin), mitochondrial electron 
transport (Complex II–IV), xenobiotic detoxification and steroid metabolism (cytochromes), 
signal transduction (nitric oxide synthases, soluble guanylate cyclases), and regulation of 
antioxidant defense enzymes, since many enzymes like peroxidases, catalases, and the large 
group of cytochrome P450 (CYP450) rely on heme as a prosthetic group. Heme-proteins 
have also been implicated in microRNA processing and microbicide defense (Mochizuki et 
al., 2010; Roberts & Montfort, 2007).  
Heme consists of a cyclic tetrapyrrole ring structure (protoporphyrin IX) that coordinates an 
iron atom which can adopt Fe+3 or Fe+2 oxidation states. Different substitutions over the 
pyrrolic moieties originate the different types of heme (a, b and c; Severance & Hamza, 2009; 
Tripodi et al., 2011). As stated earlier, African trypanosomes are extracellular parasites that 
depend on heme uptake to face their metabolic needs (Fig. 3), thus, the biosynthetic 
pathway operating in the host will be briefly outlined. The complete heme biosynthetic 
pathway involves eight-steps. Although the synthesis of δ-aminolevulinic acid (ALA), the 
first heme precursor, may differ between organisms the remaining seven steps of the 
pathway (from ALA to heme b) are strictly conserved. In most heterotrophic eukaryotes the 
biosynthesis alternates between the mitochondria and the cytosol while in photosynthetic 
organisms heme is exclusively produced in the chloroplasts (Korený et al., 2010). Despite its 
essentiality and versatility, iron and porphyrins are highly toxic to cells due to iron-induced 
pro-oxidant effect on DNA, proteins and membrane lipids. Therefore, its biosynthesis and 
storage is tightly regulated in order to reduce the level of free heme inside the cell. 
Certain organisms lack some components of the biosynthetic pathway from ALA to 
protoporphyrin IX and have developed strategies to obtain heme from other sources. The 
tick Boophilus microplus (Braz et al., 1999), the filarial nematode Brugia malayi (Wo et al., 2009), 
the free-living nematode Caenorhabditis elegans (Rao et al., 2005) and most kinetoplastid 
parasites are examples of eukaryotes that are partially or completely unable to synthesize 
heme despite some of their developmental stages depend on oxidative fosforilation (i.e., 
cytochromes) to obtain energy. The order Kinetoplastida contains species where the 
complete biosynthetic pathway is absent (e.g. most members of the genus Trypanosoma), and 
others, such as Leishmania spp. or Crithidia spp., able to perform only the last three 
biosynthetic steps (Chang et al., 1975; Salzman et al., 1982). Although it is very likely that a 
kinetoplastid’s ancestor harbored a complete set of eukaryotic genes for heme synthesis, 
during evolution these genes have been either lost (e.g. Trypanosoma genus) or subsequently 
rescued from a γ-proteobacterium endosymbiont by horizontal gene transfer, as proposed 
for the non-Trypanosoma trypanosomatids (Korený et al., 2010). As a general consequence, 
trypanosomatids must scavenge heme or precursors from their hosts. At this point, it is 
important to note that there are several species of trypanosomatids that parasitize insects, 
including Herpetomonas roitmani, Crithidia deanei, C. desouzai, C. oncopelti and Blastocrithidia 
 




























Fig. 3. Pathways for heme incorporation and biosynthesis in trypanosomes. 
Although two possible routes for heme internalization have been described in T. cruzi, so far 
none of the putative transporters has been characterized. In T. brucei, hemoglobin (Hb, 
upper left) endocytosis was shown to depend on a haptoglobin-hemoglobin receptor 
(HpHbR) localized at the flagellar pocket (FP) and expressed exclusively in the bloodstream 
form of the parasite. An ABC transporter (ABCG5 in L. major) has been shown to rescue 
heme after lysosomal (L) degradation of Hb. On the other hand, in T. cruzi a non-endocytic 
route was described for free forms of heme (lower part, in green). This is an active process 
mediated by ABC transporters that leads to accumulation of heme inside storage organelles, 
the reservosomes (R). Specific inhibitors for ABC transporters (cyclosporin A, verapamil and 
indomethacin) reduce significantly heme uptake (Peixoto Cupelloa et al., 2011). Intracellular 
parasites endowed with the last three enzymes of heme biosynthesis, such as Leishmania 
spp., are capable to incorporate heme precursors, such as coproporphobilinogen III 
(CPgenIII), which upon transport to the mitochondrial intermembrane space can undergo a 
serie of oxidative reactions leading to the formation of protoporphyrin IX (PPIX) that is 
finally converted into heme by addition of iron through a ferrochelatase (FECH) facing the 
mitochondrial matrix (middle part and insert, orange). Additional subcellular structures and 
biosynthetic components are abbreviated as follows: nucleus (N), kinetoplast (K), 
mitochondrion (M), outer mitochondrial membrane (OMM), inner mitochondrial membrane 
(IMM), coproporphyrinogen oxidase (CPOX), protoporphyrinogen IX (PPgenIX), 
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culicis, which have been found to contain symbiotic bacteria that may supply the protists 
with heme and other essential nutrients (Chang & Trager, 1974). The bacterial symbiotes 
would be subject of regulation by their hosts, hence, functioning as cell organelles rather 
than as independent living entities (Chang et al., 1975).  
Heme’s transport and distribution in trypanosomatids remain elusive. Diffusion across the 
lipid bilayer is hampered for heme due to its anionic carboxylate side-chains. Instead, high 
affinity heme-binding proteins in the cell surface of T. cruzi (Lara et al., 2007), procyclic 
forms of T. brucei (Vanhollebeke et al., 2008) and L. donovani (Campos-Salinas et al., 2011) 
allows for active heme uptake. In T. cruzi epimastigotes, both endocytotic and non-
endocytotic mechanisms of heme internalization have been confirmed. L. donovani can also 
incorporate heme by receptor-mediated endocytosis followed by lysosomal degradation of 
hemoglobin. An ABC transporter localized in membranes of multivesicular structures is 
probably related to intracellular heme trafficking after hemoglobin degradation. Porphyrin 
trafficking in trypanosomatids is yet an uncovered subject but intracellular transport 
appears to involve membrane-bound vesicles as carriers (Severance & Hamza, 1982; Tripodi 
et al., 2011).  
In summary, pathogenic trypanosomatids are auxotrophic for heme and have to adapt their 
heme-dependent metabolic pathways (i.e. biosynthesis of sterols and polyunsaturated fatty 
acids, respiration, oxidative stress response and detoxification) to fluctuations in nutrient 
availability across their life cycle. The most relevant cellular functions requiring heme in 
trypanosomatids are discussed in the next sections.  
4.1 Heme in oxidative defense  
Trypanosomes lack catalase and selenium-dependent glutathione peroxidases but instead 
express two types of trypanothione/tryparedoxin dependent peroxidases to decompose 
endogenous and exogenously produced oxidants (rewieved in Schlecker et al., 2007 and 
Krauth-Siegel & Comini, 2008) and some species have an additional plant-like ascorbate-
dependent hemoperoxidase (APX; Adak & Datta, 2005; Wilkinson et al., 2002a). 
Interestingly, APX is present in intracellular trypanosomatids (T. cruzi and Leishmania spp.) 
but absent in parasites with an extracellular life style in the mammal host, namely T. brucei. 
This feature has been attributed to the major demand for anti-oxidant capacity that 
intracellular parasites need during infection (Wilkinson et al., 2005; Dolai et al., 2009). APX 
localizes to the endoplasmic reticulum (ER; Wilkinson et al., 2002a) and cell membrane (M. 
Hugo et al., personal communication) of T. cruzi and in the intermembrane space of the 
mitochondrial inner membrane in the case of L. major (Dolai et al., 2008). Both enzymes are 
reduced by ascorbate or, alternatively, cytochrome c (Wilkinson et al., 2002a; Dolai et al., 
2008; M. Hugo et al., personal communication). The regeneration of reduced ascorbate 
occurs upon spontaneous reaction of dehydroascorbate with T(SH)2 (Krauth-Siegel & 
Lüdemann, 1996). With respect to the source of ascorbate, in contrast to humans, African 
and American trypanosomes can synthesize this metabolite de novo, a process that takes 
place in the glycosome (Wilkinson et al., 2005). T. cruzi cannot take up ascorbate from the 
environment, as T. brucei does, and therefore relies entirely on its biosynthesis to fuel other 
unknown cellular functions, in addition to oxidant detoxication (Logan et al., 2007). 
The biological role of APX is consistently related to oxidant defense. Overexpression of APX 
in T. cruzi and L. major enhances tolerance against oxidative stress induced by exogenous 
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hydrogen peroxide (Wilkinson et al., 2002a and 2005) and mitochondrial cardiolipin 
oxidation, providing thus protection towards programmed cell death and protein damage 
(Dolai et al., 2008, 2009). This function appears to be redundant with that performed by the 
ER glutathione-like trypanothione-dependent peroxidase of T. cruzi (GPxII; Wilkinson et al., 
2002a) and the mitochondrial trypanothione-dependent peroxiredoxin (mTXNPx) from 
Leishmania spp. However, an explanation for this may lie on different substrate specificities 
(e.g., GpxII reduces fatty acid and phospholipid hydroperoxides; Wilkinson et al., 2002b) or 
the macromolecular targets these enzymes have.  
4.2 Heme in polyunsaturated fatty acids biogenesis 
Fatty acid biosynthesis in trypanosomatids seems to be an essential pathway for the parasite 
life cycle. As stated earlier, differentiation involves dramatic morphological changes in the 
cell and its organelles that certainly require membrane fluidity. The biosynthesis of 
unsaturated fatty acids is another plant-like pathway inherited by trypanosomatids. In this 
respect, lipid desaturation occurs at the methyl end of the molecule, in contrast to mammals, 
in which a double bond is generated at the carboxy end of the molecule.  
T. cruzi and both life stages of T. brucei are able to synthesize fatty acids, although T. brucei 
bloodstream form was formerly thought to depend on lipid uptake from their host. Short 
and medium chain fatty acids are usually synthesized by means of the soluble fatty-acid 
synthetase system and subsequently elongated by the elongase system that resides in the 
ER. T. brucei can elongate fatty acids up to stearate (C18:0). T. cruzi can further elongate C18 
to C24 and C26 fatty acids required in the synthesis of anchors for surface macromolecules. 
The stearate is mainly converted into linoleate (C18:2), which represents near 30% and 40% 
of total fatty acids in T. brucei and T. cruzi, respectively. Moreover, unsaturated fatty acids 
can represent up to 70% of total fatty acid content depending on the parasite species and life 
cycle stage (Alloatti et al., 2010). 
T. brucei oleate desaturase shares high similarity with ∆12 desaturases and, to a lesser extent, 
with ω3 desaturases although the parasite enzyme lacks ω3 desaturase activity. Fatty acid 
desaturases require an electron donor, that can be either ferredoxin in plastids and bacteria 
or cytochrome b5 (cytb5) in the ER, as it is the case for the orthologue from T. brucei (Uttaro, 
2006). Since T. brucei oleate desaturase lacks a consensus sequence for the covalent binding 
of cytb, it has been suggested that electron donation occurs via complex formation with 
another desaturase capable to bind cytb5 (Petrini et al., 2004). The drastic growth defect 
observed upon partial ablation of enzyme activity (even an 8% reduction) by RNAi is a 
strong indication of the essentiality of this pathway for infective parasites (see also section 
3.2.4; Alloatti et al., 2010) 
4.3 Trypanosomes contain unusual single-cys cytochromes 
Cytochromes are heme-containing complexes that participate in many electron transfer 
reactions including oxidative phosphorylation in the respiratory chain (cytochromes type c, 
cytc and cytochromes type c1, cytc1), desaturation of fatty acids or xenobiotic detoxification 
(Comini et al., 2011). In cytc heme is covalently attached through thioether bonds between 
the vinyl groups of the heme and the thiols of two cysteine residues in a conserved CXXCH 
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or cytochrome b5 (cytb5) in the ER, as it is the case for the orthologue from T. brucei (Uttaro, 
2006). Since T. brucei oleate desaturase lacks a consensus sequence for the covalent binding 
of cytb, it has been suggested that electron donation occurs via complex formation with 
another desaturase capable to bind cytb5 (Petrini et al., 2004). The drastic growth defect 
observed upon partial ablation of enzyme activity (even an 8% reduction) by RNAi is a 
strong indication of the essentiality of this pathway for infective parasites (see also section 
3.2.4; Alloatti et al., 2010) 
4.3 Trypanosomes contain unusual single-cys cytochromes 
Cytochromes are heme-containing complexes that participate in many electron transfer 
reactions including oxidative phosphorylation in the respiratory chain (cytochromes type c, 
cytc and cytochromes type c1, cytc1), desaturation of fatty acids or xenobiotic detoxification 
(Comini et al., 2011). In cytc heme is covalently attached through thioether bonds between 
the vinyl groups of the heme and the thiols of two cysteine residues in a conserved CXXCH 





is the best known example of this type of protein. It is located in the intermembrane space 
and transfers electrons from the cytochrome bc1 complex to the cytochrome aa3 oxidase. 
Cytochrome c1 of the bc1 complex (cytochrome reductase) is also a c-type cytochrome. Heme 
coordination by cytc and cytc1 from euglenoids (e.g. the green flagellated algae Euglena 
gracilis) and trypanosomatids occurs through a single thioether bond involving the single 
thiol group from their binding motifs AAQCH and FAPCH, respectively (Priest & Hajduk, 
1994). As another example of a metabolic trait that trypanosomatids share with higher 
plants, plastids contain b6f-type cytochromes with heme covalently attached through a 
single thioether bond (Allen et al., 2004; Tripodi et al., 2011). The biogenesis of holo 
cytochrome c is a catalyzed process that involves different mechanisms and enzymatic 
components that can be grouped into five major systems (Tripodi et al., 2011). The 
cytochrome c maturation machinery employed by kinetoplatids remains unidentified and is 
possibly unique to this and the entire euglenid taxon (Allen et al., 2004; Tripodi et al., 2011). 
Based on the metabolic repertoire of each developmental stage, the relevance of cytochrome 
activity for energy production appears to be restricted to the procyclic form of the parasite.  
4.4 Heme in sterol biogenesis 
Cholesterol, ergosterol and sitosterol are essential structural components of plasma 
membranes from mammals, fungi and plants, respectively. They stabilize membranes, 
determine their fluidity and permeability, and modulate the activity of membrane-bound 
enzymes and ion channels. T. cruzi and T. brucei encode all sterol biosynthetic enzymes, 
including sterol 14-α-demethylase (CYP51), a member of the CYP450 superfamily that 
operates at the initial phase (post-squalene stage) of the pathway that drives the oxidative 
removal of the 14-α-methyl group from the newly cyclized sterol precursors. Azole-based 
compounds, common in antifungal therapies (e.g., posaconazole) proved to be potent 
inhibitors of CYP51 by interacting with the enzyme active site and its prosthetic group 
(Chen et al., 2010). Inhibition of CYP51 leads to accumulation of 14α-methylated sterols, 
which are unable to replace ergosterol in the membrane because of steric hindrance, 
followed by growth arrest and cell death (Lepsheva et al., 2007; Vanden Bosschef et al., 1995). 
In contrast to T. cruzi and Leishmania spp., ergosterol has been thought to be dispensable for 
T. brucei. However, the observation that antifungals are also detrimental for this parasite 
lead to the proposal that sterol derivatives may additionally serve as precursors for 
bioactive molecules that act as regulators of cell cycle and development (Lepsheva et al., 
2007).  
Other CYP450s possess a monooxygenase activity that, upon oxygen activation, catalyzes 
the addition of an oxygen atom into an organic substrate and the reduction of the second 
one to water. After each catalytic cycle, CYPs must be restored to their reduced state by a 
CYP450 reductase (CPR), a NADPH-dependant diflavin (FAD/FMN) enzyme that couple a 
two-electron donor (NADPH) with one-electron acceptors, supplying the electrons one at a 
time. CYPs and CPR are involved in the metabolism of a wide range of endogenous 
compounds and xenobiotics including fatty acids, steroids, drugs, alkanes, polycyclic 
hydrocarbons, insecticides and other environmental contaminants (Murataliev et al., 2004). 
In mammals, there is only one CPR gene. However, T. cruzi and L. major encode three 
different CPR genes (CPR-A, CPR-B and CPR-C), while T. brucei possesses four sequences, 
all of them sharing a high sequence identity. Similar to some higher plant species 
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(Koopmann & Hahlbrock, 1997; Ro et al., 2002; Urban et al., 1997), T. cruzi CPRs are encoded 
by a small gene family, with differential regulation and subcellular localization (Portal et al., 
2008). TcCPR-B is localized mainly in reservosomes, TcCPR-C is mostly found in the ER 
while TcCPR-A displays a more ubiquitous distribution pattern (De Vas et al., 2011). The 
presence of multiple isoforms argues for a well-supported P450-mediated molecular system. 
Portal et al. (2008) showed that CPR-B overexpression in T. cruzi confers increased resistance 
to nifurtimox and, more significantly, to benznidazole. In addition, increased levels of CPRs 
are observed in trypomastigotes, a stage that is particularly exposed to stress during cell 
invasion  supporting a role for CPRs in oxidative stress defense (Portal et al., 2008). 
Moreover, CPR-B and CPR-C overexpression increases the synthesis of ergosterol, with the 
concomitant augmentation in membrane rigidity and decrease in endocytic activity. 
Modification in cell membrane fluidity could result in alteration of drug uptake and, as a 
consequence, in the observed drug resistance (De Vas et al., 2011).  
5. Iron and infection 
As noted in the introductory section, African trypanosomiasis is a parasitic disease of 
medical and veterinary importance that has adverse impact in the health and economical 
development of the sub-Saharian region of Africa (Maudlin, 2006; Stijlemans et al., 2008, 
2010a). Since African trypanosomes multiply predominantly in the bloodstream as extra-
cellular parasites, they are continuously dependent on host nutrient supply and exposed to 
host immune attack. As will be addressed next, the response mounted by the mammalian 
host towards infection includes the activation of both arms of the immune system.  
Beyond the aforementioned clinical outcomes for HAT (Section 1), the most prominent 
immunopathological disease-related feature of trypanosomiasis is anemia. In fact, anemia is 
the major cause of death in bovine trypanosomiasis and an important debilitating symptom 
in HAT (Stijlemans et al., 2008). Anemia of inflammation, also termed anemia of chronic 
disease (ACD), is frequent among patients suffering chronic inflammatory disorders (e. g., 
autoimmune diseases) or chronic infections (Camaschella & Strati, 2010). ACD is the 
consequence of a persistent activated inflammatory immune response and is considered to 
be a defense mechanism where the host establishes an iron “withholding” strategy to limit 
the availability of essential iron for the pathogens (Lalonde & Holbein, 1984; Stijlemans et al., 
2008; Sutak et al., 2008). Stijlemans and coworkers (Stijlemans et al., 2008, 2010a, 2010b; 
Vankrunkelsven et al., 2010) studied the immunological and hematological development of 
T. brucei infection using animal models (cattle and mice). Despite mouse models show 
limitations and artifacts, like the extremely high parasitemia levels reached compared to 
infection in the natural host, they have contributed significantly to our current 
understanding of trypanosomiasis patho-physiology (Magez & Caljon, 2011). The molecular 
mechanism underlying the development of ACD during trypanosomiasis resembles that 
observed in other infectious diseases. Briefly, during the early stage of the infection 
trypanosomes stimulate T-cells to secrete interferon-γ resulting in the activation of 
macrophages (type I cellular immune response) that liberate pro-inflammatory mediators 
like tumor necrosis factor, interleukin (IL) -1, IL-6 and •NO (Stijlemans et al., 2010b). This 
response leads to parasite clearance but also enhances erythrophagocytosis by activated 
macrophages within the spleen and liver (Kupffer cells). At this point it is important to 
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erythrocytes (see Section 2; Hentze et al., 2010). Thus, enhanced removal of red blood cells 
from systemic fluids by the reticuloendothelial system will contribute to deprive host of 
iron. In addition, hepcidin (Section 2) is secreted in response to pro-inflammatory mediators, 
blocking iron release from macrophages and iron intake by enterocytes (Nishimura et al., 
2011), which decreases plasma iron levels and limits host and pathogen accessibility to the 
metal (Taylor & Kelly, 2010). The upregulation of several iron-related molecules (e.g. 
hemooxygenase 1, ferritin and ferroportin) provides additional evidence for the strong type 
I immune response, augmented liver iron-metabolism and accelerated senescence of 
erythrocytes that takes place during trypanosomal infection (Nishimura et al., 2011; 
Omotainse & Anosa, 1992; Stijlemans et al., 2010a; see Section 2). The class of anemia 
originated during the acute phase of trypanosomiasis is a typical non-haematopoietic 
anemia. However, if at the long term the type I response persists, then iron will be 
sequestered intracellularly, resulting in a marked iron deprivation with compromise of 
erythropoiesis and development of ACD (Mwangi et al., 1995; Omotainse & Anosa, 1992; 
Stijlemans et al., 2010b). Despite its adverse effects, if sustained on time, limited iron 
bioavailability can be considered a reasonable host response to control parasitemia (Ganz, 
2009). In the last years, several evidences point to the possibility that the parasite 
deliberately manipulates the mammalian host immune response. Activation of a strong type 
I immune response in early stages of the infection promotes erythrophagocytosis (Igbokwe 
et al., 1994), a strategy that yields abundant iron and lipids (e.g. myristic acid), the last 
needed for GPI biosynthesis and VSG coating (Stijlemans et al., 2010a, 2010b). It is important 
to stress that the trypanosome body is totally covered by a dense GPI-anchored coat of VSGs 
that plays an important protective (physical and immunological barrier) function in 
bloodstream parasites (Comini et al., 2011).  
A large number of microbial pathogens have been reported to affect the morbidity and 
mortality of patients with high iron content, a physiopathological state characterized by the 
presence of non-transferrin bound iron in plasma. Moreover, iron overload due to genetic 
predisposition, therapeutic intervention or nutritional status is known to increase the risk of 
several infections (Kontoghiorghes et al., 2010). It is worth to note that human iron overload 
is common in rural populations inhabiting sub-Saharan regions of Africa, the “tsetse belt”, 
with a high incidence of HAT (Gordeuk, 2002; McNamara et al., 1999). Originally, this 
chronic condition was supposed to be an exclusive consequence of an iron-rich diet based 
on the large consumption of homebrewed beers, but recent studies of pedigrees suggest the 
presence of genetic components (Gordeuk, 2002; Moyo et al., 1998). It remains to be 
investigated whether there is a co-evolutionary development of iron overload and HAT, as 
it is the case for glucose-6-phosphate dehydrogenase deficiency and malaria.  
Considering the well-known role of iron in T. brucei infection and the fact that in vitro iron 
deprivation with chelating agents cause growth retardation of bloodstream T. brucei (Fast et 
al., 1999; Breidbach et al., 2002; Comini et al., 2008), it is surprising the absence of works 
studying the therapeutic potential of iron chelation against T. brucei (Tayor & Kelly, 2010). 
This is not the case for T. cruzi, for which the chelating agent deferoxamine (DFX) proved its 
efficacy to halt replication of intra-macrophage amastigotes (Arantes et al., 2011; Lalonde & 
Holbein, 1984; Jones et al., 1996), and to decrease parasitemia and mortality of infected mice 
(Loo & Lalonde, 1984). However, in contrast to extracellular T. brucei, the possible success of 
chelating therapies against T. cruzi infection are hampered by the intracellular nature of the 
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infective stage of this parasite, which, if not specifically targeted to the pathogen, will imply 
a high dosage or a long-term treatment, both deleterious for the host. Based on the 
demonstration that iron metabolism is crucial for parasite survival in the host (Manta et al., 
unpublished; see section 3.3.2), our group has recently evaluated the therapeutic effect of 
intraperitoneal (i.p.) and oral administration of DFX to T. brucei infected mice. Preliminary 
results show a marked increase in life span of the animal group receiving i.p. treatment (200 
mg/Kg for ~10 days) and almost no side effects (red blood cell and reticulocyte counts) on 
animals treated but non-infected (Manta et al., unpublished). However, DFX displayed a 
cytostatic effect against acute infection by T. brucei, which implies that a successful 
therapeutic regimen will require drug association.  
6. Summary and outlook 
As any other living organism on earth, trypanosomes depend on iron to fulfill critical 
cellular functions (DNA and lipid biosynthesis, oxidant protection and energy generation). 
Their complex life cycle has added an additional problem in the struggle for the supply of 
(micro)nutrients. However, these organisms have developed different strategies and 
mechanisms in order to ensure a physiological iron status within the distinct hosts. 
Moreover, host-parasite co-evolution has resulted in the development of well-balanced 
growth regulation systems, allowing the parasite to survive sufficiently long without killing 
its mammalian host and ensuring an efficient transmission cycle. Interruption of this cycle is 
necessary to abolish the devastating disease these parasites produce to humans and 
livestock. In this respect, the iron metabolism of trypanosomatids should be considered as a 
promising target for effective antiparasitic treatments. Although metal-chelating 
compounds are, obviously, not innocuous to the host, in general they are less toxic than the 
drugs actually used for the treatment of HAT and their side effect is fully reversible upon 
dietary supplementation. In addition, several chelating agents are approved for the 
treatment of human pathologies, some of them are relatively cheap and available for oral 
administration (Sharma & Pancholi, 2010). The risk/benefit assessment for the use of iron 
chelating drugs as antiparasitic therapeutic depends on many factors not addressed yet.  
Moreover, beyond the relevance of iron homeostasis for parasite survival, some components 
of this metabolism and/or iron-, Fe/S cluster- or heme-proteins offer excellent opportunities 
for the design of more specific and efficacious drugs. For instance, the enzymes involved in 
fatty acids biogenesis (oleate desaturase and stearoyl-CoA-desaturase) and sterol 
biosynthesis (CYP51); in defense against oxidants (the plant-like ascorbate peroxidase) and 
xenobiotics (CYP450 reductases); in cell proliferation (ribonucleotide reductase); and in Fe/S 
cluster biogenesis. Alternatively, chemical downregulation of the functions these proteins 
fulfill in the cell can be complemented by the action of first line drugs currently used in 
chemotherapy. A combined therapy would have the advantage of reducing dosage, 
shortening treatment and loweing the possibility for development of drug resistance. The 
specificity of the transferrin receptor is another target to be exploited as an efficient 
mechanism to deliver toxic molecules inside the parasite  
The future prospects look promising in terms of finding novel therapeutic options to fight 
trypanosomiasis. However as depicted in Fig. 2 and Fig. 3, there are still several open 
questions that deserve to be investigated in detail to disclose atomic and functional 
divergences within the components of the parasite and host iron metabolism that can lead to 
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